<bibrecord>
<item-info>
<status state="new" stage="S300" />
<itemidlist>
<ce:doi>10.1007/978-3-031-09518-4_2</ce:doi>
<itemid idtype="TPB-ID">9783031095184</itemid>
</itemidlist>
</item-info>
<head>
<citation-info>
<citation-type code="ch" />
<citation-language xml:lang="ENG" />
<abstract-language xml:lang="ENG" />
<author-keywords>
<author-keyword>Extracellular vesicle</author-keyword>
<author-keyword>Exosome</author-keyword>
<author-keyword>Pre-metastatic niche</author-keyword>
<author-keyword>Metastasis</author-keyword>
<author-keyword>Tumor microenvironment</author-keyword>
<author-keyword>Immune modulation</author-keyword>
<author-keyword>Angiogenesis</author-keyword>
<author-keyword>Vascular permeability</author-keyword>
<author-keyword>Metastatic organotropism</author-keyword>
</author-keywords>
</citation-info>
<citation-title>
<titletext xml:lang="ENG" original="y">Systemic Regulation of Metastatic Disease by Extracellular Vesicles and Particles</titletext>
</citation-title>
<author-group seq="1">
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Wang</ce:surname>
<ce:given-name>Gang</ce:given-name> 
</author>
<author seq="2">
<ce:initials>C.M.</ce:initials> 
<ce:surname>Kenific</ce:surname>
<ce:given-name>Candia M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>G.</ce:initials> 
<ce:surname>Lieberman</ce:surname>
<ce:given-name>Grace</ce:given-name>
</author>
<author seq="4">
<ce:initials>H.</ce:initials> 
<ce:surname>Zhang</ce:surname>
<ce:given-name>Haiying</ce:given-name>
<ce:e-address>haz2005@med.cornell.edu</ce:e-address>
</author>
<author seq="5">
<ce:initials>D.</ce:initials> 
<ce:surname>Lyden</ce:surname>
<ce:given-name>David</ce:given-name>
<ce:e-address>dcl2001@med.cornell.edu</ce:e-address>
</author>
<affiliation>
<organization>Children’s Cancer and Blood Foundation Laboratories</organization>
<organization>Departments of Pediatrics, and Cell and Developmental</organization>
<organization>Biology, Drukier Institute for Children’s Health, Meyer</organization>
<city>New York</city>
<state>New York</state>
<country iso-code="USA" />
<ce:source-text>Children’s Cancer and Blood Foundation Laboratories, Departments of Pediatrics, and Cell and Developmental Biology, Drukier Institute for Children’s Health, Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA</ce:source-text>
</affiliation>
</author-group>
<abstracts>
<abstract xml:lang="ENG" original="y">
<publishercopyright>© Springer Nature Switzerland AG 2022</publishercopyright>
<ce:para>Cancer is a systemic disease that induces functional dysregulation in multiple tissues and organs. The great majority of cancer-related deaths are due to metastasis, a multistep process involving crosstalk between cancer cells and stromal cells and immune cells in pre-metastatic niches (PMNs) at distant organs. As message carriers, extracellular vesicles and particles (EVPs) derived from cancer cells can modulate the phenotype of recipient cells by transferring various biomolecules, including nucleic acids, proteins, metabolites and lipids, thereby contributing to PMN formation and metastasis. In this chapter, we highlight the roles of cancer cell-derived EVPs in metastasis progression, with a focus on PMN establishment.</ce:para>
</abstract>
</abstracts>
<source type="book" country="USA">
<sourcetitle>The Systemic Effects of Advanced Cancer A Textbook on Cancer-Associated Cachexia</sourcetitle>
<sourcetitle-abbrev>The Systemic Effects of Advanced Cancer A Textbook on Cancer-Associated Cachexia</sourcetitle-abbrev>
<isbn type="print" length="13">978-3-031-07272-7</isbn>
<isbn type="electronic" length="13">978-3-031-09518-4</isbn>
<volisspag>
<page-information>
<pages>
<first-page>1</first-page>
<last-page>6</last-page>
</pages>
</page-information>
</volisspag>
<publicationyear first="2022" />
<publicationdate>
<year>2022</year>
<month>01</month>
<day>01</day>
</publicationdate>
<website type="item">
<ce:e-address type="url">https://link.springer.com</ce:e-address>
</website>
<publisher>
<publishername>Springer International Publishing</publishername>
</publisher>
</source>
<enhancement>
<classificationgroup>
<classifications type="ASJC">
<classification>
<classification-code>2700</classification-code>
<classification-code>2400</classification-code>
<classification-code>1300</classification-code>
</classification>
</classifications>
</classificationgroup>
</enhancement>
</head>
<tail>
<bibliography refcount="231">
<reference seq="1">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer:an old disease,a new disease or something in between?Nat.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.R.</ce:initials>
<ce:surname>David</ce:surname>
<ce:given-name>A.R.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.R.</ce:initials>
<ce:surname>Zimmerman</ce:surname>
<ce:given-name>M.R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Rev.Cancer.</ref-sourcetitle>
<ref-publicationyear first="2010" />
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>728</first-page>
<last-page>733</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>David, A.R., Zimmerman, M.R.:Cancer: an old dis- ease, a new disease or something in between? Nat. Rev. Cancer. 10, 728-733 (2010)</ref-fulltext>
<ce:source-text>David, A.R., Zimmerman, M.R.:Cancer: an old dis- ease, a new disease or something in between? Nat. Rev. Cancer. 10, 728-733 (2010)</ce:source-text>
</reference>
<reference seq="2">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer statistics</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.L</ce:initials>
<ce:surname>Siegel</ce:surname>
<ce:given-name>R.L</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.D.</ce:initials>
<ce:surname>Miller</ce:surname>
<ce:given-name>K.D.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Jemal</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>CA Cancer J. Clin</ref-sourcetitle>
<ref-publicationyear first="2020" />
<volisspag>
<volume-issue-number>
<vol-first>70</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>7</first-page>
<last-page>30</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Siegel, R.L., Miller, K.D., Jemal, A .: Cancer statistics, 2020. CA Cancer J. Clin. 70, 7-30 (2020)</ref-fulltext>
<ce:source-text>Siegel, R.L., Miller, K.D., Jemal, A .: Cancer statistics, 2020. CA Cancer J. Clin. 70, 7-30 (2020)</ce:source-text>
</reference>
<reference seq="3">
<ref-info>
<ref-title>
<ref-titletext-english>Emerging biological principles of metastasis.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.W.</ce:initials>
<ce:surname>Lambert</ce:surname>
<ce:given-name>A.W.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.R.</ce:initials>
<ce:surname>Pattabiraman</ce:surname>
<ce:given-name>D.R.</ce:given-name>
</author>
<author seq="3">
<ce:initials> R.A.</ce:initials>
<ce:surname>Weinberg</ce:surname>
<ce:given-name> R.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell.</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>168</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>670</first-page>
<last-page>691</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Lambert, A.W., Pattabiraman, D.R., Weinberg, R.A .: Emerging biological principles of metastasis. Cell. 168, 670-691 (2017)</ref-fulltext>
<ce:source-text>Lambert, A.W., Pattabiraman, D.R., Weinberg, R.A .: Emerging biological principles of metastasis. Cell. 168, 670-691 (2017)</ce:source-text>
</reference>
<reference seq="4">
<ref-info>
<ref-title>
<ref-titletext-english>Surviving at a distance:
organ-specific metastasis.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.C.</ce:initials>
<ce:surname>Obenauf</ce:surname>
<ce:given-name>A.C.</ce:given-name>
</author>
<author seq="">
<ce:initials>J.</ce:initials>
<ce:surname>Massague</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Trends Cancer</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>1</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>76</first-page>
<last-page>91</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>. Obenauf, A.C., Massague, J.: Surviving at a distance: organ-specific metastasis. Trends Cancer. 1, 76–91 (2015) </ref-fulltext>
<ce:source-text>. Obenauf, A.C., Massague, J.: Surviving at a distance: organ-specific metastasis. Trends Cancer. 1, 76–91 (2015) </ce:source-text>
</reference>
<reference seq="5">
<ref-info>
<ref-title>
<ref-titletext-english>Metastatic colonization by circulating tumour cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Massague</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.C.</ce:initials>
<ce:surname>Obenauf</ce:surname>
<ce:given-name>A.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>529</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>298</first-page>
<last-page>306</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Massague, J., Obenauf, A.C.: Metastatic colonization by circulating tumour cells. Nature. 529, 298–306 (2016)</ref-fulltext>
<ce:source-text>Massague, J., Obenauf, A.C.: Metastatic colonization by circulating tumour cells. Nature. 529, 298–306 (2016)</ce:source-text>
</reference>
<reference seq="6">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor metastasis: molecular insights and evolving paradigms.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Valastyan</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.A.</ce:initials>
<ce:surname>Weinberg</ce:surname>
<ce:given-name>R.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell.</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>147</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>275</first-page>
<last-page>292</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Valastyan, S., Weinberg, R.A.: Tumor metastasis: molecular insights and evolving paradigms. Cell. 147, 275–292 (2011)</ref-fulltext>
<ce:source-text>Valastyan, S., Weinberg, R.A.: Tumor metastasis: molecular insights and evolving paradigms. Cell. 147, 275–292 (2011)</ce:source-text>
</reference>
<reference seq="7">
<ref-info>
<ref-title>
<ref-titletext-english>Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. </ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Peinado</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Med.</ref-sourcetitle>
<ref-publicationyear first="2012" />
<volisspag>
<volume-issue-number>
<vol-first>18</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>883</first-page>
<last-page>891</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Peinado, H., et al.: Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat. Med. 18, 883–891 (2012)</ref-fulltext>
<ce:source-text>Peinado, H., et al.: Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat. Med. 18, 883–891 (2012)</ce:source-text>
</reference>
<reference seq="8">
<ref-info>
<ref-title>
<ref-titletext-english>Pancreatic cancer exosomes
initiate pre-metastatic niche formation in the liver.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.</ce:initials>
<ce:surname>Costa-Silva</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Cell Biol</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>17</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>816</first-page>
<last-page>826</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Costa-Silva, B., et al.: Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. Nat. Cell Biol. 17, 816–826 (2015)</ref-fulltext>
<ce:source-text>Costa-Silva, B., et al.: Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. Nat. Cell Biol. 17, 816–826 (2015)</ce:source-text>
</reference>
<reference seq="9">
<ref-info>
<ref-title>
<ref-titletext-english>Tumour exosome integrins determine organotropic metastasis.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Hoshino</ce:surname>
<ce:given-name />
</author>
</ref-authors>
<ref-sourcetitle>Nature.</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>527</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>329</first-page>
<last-page>335</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hoshino, A., et al.: Tumour exosome integrins determine organotropic metastasis. Nature. 527, 329–335 (2015)</ref-fulltext>
<ce:source-text>Hoshino, A., et al.: Tumour exosome integrins determine organotropic metastasis. Nature. 527, 329–335 (2015)</ce:source-text>
</reference>
<reference seq="10">
<ref-info>
<ref-title>
<ref-titletext-english>Tumour exosomal CEMIP protein promotes cancer cell colonization in brain metastasis.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Rodrigues</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Cell Biol</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>21</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1403</first-page>
<last-page>1412</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Rodrigues, G., et al.: Tumour exosomal CEMIP protein promotes cancer cell colonization in brain metastasis. Nat. Cell Biol. 21, 1403–1412 (2019)</ref-fulltext>
<ce:source-text>Rodrigues, G., et al.: Tumour exosomal CEMIP protein promotes cancer cell colonization in brain metastasis. Nat. Cell Biol. 21, 1403–1412 (2019)</ce:source-text>
</reference>
<reference seq="11">
<ref-info>
<ref-title>
<ref-titletext-english>The distribution of secondary growths in cancer of the breast. Lancet.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Paget</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle> Lancet</ref-sourcetitle>
<ref-publicationyear first="1889" />
<volisspag>
<volume-issue-number>
<vol-first>133</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>571</first-page>
<last-page>573</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Paget, S.: The distribution of secondary growths in cancer of the breast. Lancet. 133, 571–573 (1889)</ref-fulltext>
<ce:source-text>Paget, S.: The distribution of secondary growths in cancer of the breast. Lancet. 133, 571–573 (1889)</ce:source-text>
</reference>
<reference seq="12">
<ref-info>
<ref-title>
<ref-titletext-english>: Pre-metastatic niches: organspecific homes for metastases.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Peinado</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Cancer</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>17</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>302</first-page>
<last-page>317</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Peinado, H., et al.: Pre-metastatic niches: organspecific homes for metastases. Nat. Rev. Cancer. 17, 302–317 (2017)</ref-fulltext>
<ce:source-text>Peinado, H., et al.: Pre-metastatic niches: organspecific homes for metastases. Nat. Rev. Cancer. 17, 302–317 (2017)</ce:source-text>
</reference>
<reference seq="13">
<ref-info>
<ref-title>
<ref-titletext-english>VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.N.</ce:initials>
<ce:surname>Kaplan</ce:surname>
<ce:given-name>R.N.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2005" />
<volisspag>
<volume-issue-number>
<vol-first>438</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>820</first-page>
<last-page>827</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kaplan, R.N., et al.: VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature. 438, 820–827 (2005)</ref-fulltext>
<ce:source-text>Kaplan, R.N., et al.: VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature. 438, 820–827 (2005)</ce:source-text>
</reference>
<reference seq="14">
<ref-info>
<ref-title>
<ref-titletext-english>Exosome-mediated metastasis: communication from a distance</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>I.</ce:initials>
<ce:surname>Wortzel</ce:surname>
<ce:given-name>I.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Dror</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>C.M.</ce:initials>
<ce:surname>Kenific</ce:surname>
<ce:given-name>C.M.</ce:given-name>
</author>
<author seq="4">
<ce:initials>D.</ce:initials>
<ce:surname>Lyden</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Dev. Cell</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>49</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>347</first-page>
<last-page>360</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wortzel, I., Dror, S., Kenific, C.M., Lyden, D.: Exosome-mediated metastasis: communication from a distance. Dev. Cell. 49, 347–360 (2019)</ref-fulltext>
<ce:source-text>Wortzel, I., Dror, S., Kenific, C.M., Lyden, D.: Exosome-mediated metastasis: communication from a distance. Dev. Cell. 49, 347–360 (2019)</ce:source-text>
</reference>
<reference seq="15">
<ref-info>
<ref-title>
<ref-titletext-english>Breast cancer cells rely on environmental pyruvate to shape the metastatic niche</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>I.</ce:initials>
<ce:surname>Elia</ce:surname>
<ce:given-name>I.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature.</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>568</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>117</first-page>
<last-page>121</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Elia, I., et al.: Breast cancer cells rely on environmental pyruvate to shape the metastatic niche. Nature. 568, 117–121 (2019)</ref-fulltext>
<ce:source-text>Elia, I., et al.: Breast cancer cells rely on environmental pyruvate to shape the metastatic niche. Nature. 568, 117–121 (2019)</ce:source-text>
</reference>
<reference seq="16">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor exosomal RNAs promote lung pre-metastatic niche formation by activating Alveolar epithelial TLR3 to recruit neutrophils</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Liu</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Cell</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>30</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>243</first-page>
<last-page>256</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Liu, Y., et al.: Tumor exosomal RNAs promote lung pre-metastatic niche formation by activating Alveolar epithelial TLR3 to recruit neutrophils. Cancer Cell. 30, 243–256 (2016)</ref-fulltext>
<ce:source-text>Liu, Y., et al.: Tumor exosomal RNAs promote lung pre-metastatic niche formation by activating Alveolar epithelial TLR3 to recruit neutrophils. Cancer Cell. 30, 243–256 (2016)</ce:source-text>
</reference>
<reference seq="17">
<ref-info>
<ref-title>
<ref-titletext-english>Breast-cancer-secreted miR-122 reprograms glucose metabolism in premetastatic niche to promote metastasis. Nat.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.Y.</ce:initials>
<ce:surname>Fong</ce:surname>
<ce:given-name>M.Y.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Biol</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>17</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>183</first-page>
<last-page>194</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Fong, M.Y., et al.: Breast-cancer-secreted miR-122 reprograms glucose metabolism in premetastatic niche to promote metastasis. Nat. Cell Biol. 17, 183–194 (2015)</ref-fulltext>
<ce:source-text>Fong, M.Y., et al.: Breast-cancer-secreted miR-122 reprograms glucose metabolism in premetastatic niche to promote metastasis. Nat. Cell Biol. 17, 183–194 (2015)</ce:source-text>
</reference>
<reference seq="18">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>W.</ce:initials>
<ce:surname>Zhou</ce:surname>
<ce:given-name>W.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Cell</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>25</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>501</first-page>
<last-page>515</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zhou, W., et al.: Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis. Cancer Cell. 25, 501–515 (2014)</ref-fulltext>
<ce:source-text>Zhou, W., et al.: Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis. Cancer Cell. 25, 501–515 (2014)</ce:source-text>
</reference>
<reference seq="19">
<ref-info>
<ref-title>
<ref-titletext-english>Extracellular vesicles and metastasis. Cold Spring Harb. </ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.E.</ce:initials>
<ce:surname>Wang</ce:surname>
<ce:given-name>S.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Perspect. Med.</ref-sourcetitle>
<ref-publicationyear first="2019" />
</ref-info>
<ref-fulltext>Wang, S.E.: Extracellular vesicles and metastasis. Cold Spring Harb. Perspect. Med. (2019)</ref-fulltext>
<ce:source-text>Wang, S.E.: Extracellular vesicles and metastasis. Cold Spring Harb. Perspect. Med. (2019)</ce:source-text>
</reference>
<reference seq="20">
<ref-info>
<ref-title>
<ref-titletext-english>Thery, C.: Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Mathieu</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>L.</ce:initials>
<ce:surname>Martin-Jaular</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="3">
<ce:initials>G.</ce:initials>
<ce:surname>Lavieu</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Cell Biol.</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>21</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>9</first-page>
<last-page>17</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mathieu, M., Martin-Jaular, L., Lavieu, G., Thery, C.: Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication. Nat. Cell Biol. 21, 9–17 (2019)</ref-fulltext>
<ce:source-text>Mathieu, M., Martin-Jaular, L., Lavieu, G., Thery, C.: Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication. Nat. Cell Biol. 21, 9–17 (2019)</ce:source-text>
</reference>
<reference seq="21">
<ref-info>
<ref-title>
<ref-titletext-english>Identification of distinct nanoparticles and subsets of extracellular vesicles by asymmetric flow field-flow fractionation. </ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Zhang</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Cell Biol</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>20</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>332</first-page>
<last-page>343</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zhang, H., et al.: Identification of distinct nanoparticles and subsets of extracellular vesicles by asymmetric flow field-flow fractionation. Nat. Cell Biol. 20, 332–343 (2018)</ref-fulltext>
<ce:source-text>Zhang, H., et al.: Identification of distinct nanoparticles and subsets of extracellular vesicles by asymmetric flow field-flow fractionation. Nat. Cell Biol. 20, 332–343 (2018)</ce:source-text>
</reference>
<reference seq="22">
<ref-info>
<ref-title>
<ref-titletext-english>Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu. </ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Colombo</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>G.</ce:initials>
<ce:surname>Raposo</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="3">
<ce:initials>C.</ce:initials>
<ce:surname>Thery</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Rev. Cell Dev. Biol</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>30</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>255</first-page>
<last-page>289</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Colombo, M., Raposo, G., Thery, C.: Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu. Rev. Cell Dev. Biol. 30, 255–289 (2014)</ref-fulltext>
<ce:source-text>Colombo, M., Raposo, G., Thery, C.: Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu. Rev. Cell Dev. Biol. 30, 255–289 (2014)</ce:source-text>
</reference>
<reference seq="23">
<ref-info>
<ref-title>
<ref-titletext-english> Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Al-Nedawi</ce:surname>
<ce:given-name />
</author>
</ref-authors>
<ref-sourcetitle>Nat. Cell Biol.</ref-sourcetitle>
<ref-publicationyear first="2008" />
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>619</first-page>
<last-page>624</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Al-Nedawi, K., et al.: Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat. Cell Biol. 10, 619–624 (2008)</ref-fulltext>
<ce:source-text>Al-Nedawi, K., et al.: Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat. Cell Biol. 10, 619–624 (2008)</ce:source-text>
</reference>
<reference seq="24">
<ref-info>
<ref-title>
<ref-titletext-english>Oncosome formation in prostate cancer: association with a region of frequent chromosomal deletion in metastatic disease</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Di Vizio</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Res</ref-sourcetitle>
<ref-publicationyear first="2009" />
<volisspag>
<volume-issue-number>
<vol-first>69</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>5601</first-page>
<last-page>5609</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Di Vizio, D., et al.: Oncosome formation in prostate cancer: association with a region of frequent chromosomal deletion in metastatic disease. Cancer Res. 69, 5601–5609 (2009)</ref-fulltext>
<ce:source-text>Di Vizio, D., et al.: Oncosome formation in prostate cancer: association with a region of frequent chromosomal deletion in metastatic disease. Cancer Res. 69, 5601–5609 (2009)</ce:source-text>
</reference>
<reference seq="25">
<ref-info>
<ref-title>
<ref-titletext-english>Transfer of functional cargo in exomeres.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Q.</ce:initials>
<ce:surname>Zhang</ce:surname>
<ce:given-name>Q.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Rep</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>27</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>940</first-page>
<last-page>954</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>. Zhang, Q., et al.: Transfer of functional cargo in exomeres. Cell Rep. 27, 940–954 e946 (2019)</ref-fulltext>
<ce:source-text>. Zhang, Q., et al.: Transfer of functional cargo in exomeres. Cell Rep. 27, 940–954 e946 (2019)</ce:source-text>
</reference>
<reference seq="26">
<ref-info>
<ref-title>
<ref-titletext-english>The Jeanne Manery-Fisher Memorial Lecture 1991. Maturation of reticulocytes: formation of exosomes as a mechanism for shedding
membrane proteins.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.M.</ce:initials>
<ce:surname>Johnstone</ce:surname>
<ce:given-name>R.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Biochem.Cell Biol. </ref-sourcetitle>
<ref-publicationyear first="1992" />
<volisspag>
<volume-issue-number>
<vol-first>70</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>179</first-page>
<last-page>190</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Johnstone, R.M.: The Jeanne Manery-Fisher Memorial Lecture 1991. Maturation of reticulocytes: formation of exosomes as a mechanism for shedding membrane proteins. Biochem. Cell Biol. 70, 179–190 (1992)</ref-fulltext>
<ce:source-text>Johnstone, R.M.: The Jeanne Manery-Fisher Memorial Lecture 1991. Maturation of reticulocytes: formation of exosomes as a mechanism for shedding membrane proteins. Biochem. Cell Biol. 70, 179–190 (1992)</ce:source-text>
</reference>
<reference seq="27">
<ref-info>
<ref-title>
<ref-titletext-english>Receptor-mediated endocytosis of transferrin and recycling of the transferrin receptor in rat reticulocytes.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Harding</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Heuser</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>P.</ce:initials>
<ce:surname>Stahl</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle />
<ref-publicationyear first="1983" />
<volisspag>
<volume-issue-number>
<vol-first>97</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>329</first-page>
<last-page>339</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Harding, C., Heuser, J., Stahl, P.: Receptor-mediated endocytosis of transferrin and recycling of the transferrin receptor in rat reticulocytes. J. Cell Biol. 97, 329–339 (1983)</ref-fulltext>
<ce:source-text>Harding, C., Heuser, J., Stahl, P.: Receptor-mediated endocytosis of transferrin and recycling of the transferrin receptor in rat reticulocytes. J. Cell Biol. 97, 329–339 (1983)</ce:source-text>
</reference>
<reference seq="28">
<ref-info>
<ref-title>
<ref-titletext-english>Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro: selective externalization of the receptor</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.T.</ce:initials>
<ce:surname>Pan</ce:surname>
<ce:given-name>B.T.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.M.</ce:initials>
<ce:surname>Johnstone</ce:surname>
<ce:given-name>R.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="1983" />
<volisspag>
<volume-issue-number>
<vol-first>33</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>967</first-page>
<last-page>978</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Pan, B.T., Johnstone, R.M.: Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro: selective externalization of the receptor. Cell. 33, 967–978 (1983)</ref-fulltext>
<ce:source-text>Pan, B.T., Johnstone, R.M.: Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro: selective externalization of the receptor. Cell. 33, 967–978 (1983)</ce:source-text>
</reference>
<reference seq="29">
<ref-info>
<ref-title>
<ref-titletext-english>High-resolution proteomic and lipidomic analysis of exosomes and microvesicles from different cell sources</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.A.</ce:initials>
<ce:surname>Haraszti</ce:surname>
<ce:given-name />
</author>
</ref-authors>
<ref-sourcetitle>J Extracell Vesicles. </ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>5</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>32570</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Haraszti, R.A., et al.: High-resolution proteomic and lipidomic analysis of exosomes and microvesicles from different cell sources. J Extracell Vesicles. 5, 32570 (2016)</ref-fulltext>
<ce:source-text>Haraszti, R.A., et al.: High-resolution proteomic and lipidomic analysis of exosomes and microvesicles from different cell sources. J Extracell Vesicles. 5, 32570 (2016)</ce:source-text>
</reference>
<reference seq="30">
<ref-info>
<ref-title>
<ref-titletext-english>T cell exosomes induce cholesterol accumulation in human monocytes via phosphatidylserine receptor.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Zakharova</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Svetlova</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.F.</ce:initials>
<ce:surname>Fomina</ce:surname>
<ce:given-name>A.F.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cell. Physiol</ref-sourcetitle>
<ref-publicationyear first="2007" />
<volisspag>
<volume-issue-number>
<vol-first>212</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>174</first-page>
<last-page>181</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zakharova, L., Svetlova, M., Fomina, A.F.: T cell exosomes induce cholesterol accumulation in human monocytes via phosphatidylserine receptor. J. Cell. Physiol. 212, 174–181 (2007)</ref-fulltext>
<ce:source-text>Zakharova, L., Svetlova, M., Fomina, A.F.: T cell exosomes induce cholesterol accumulation in human monocytes via phosphatidylserine receptor. J. Cell. Physiol. 212, 174–181 (2007)</ce:source-text>
</reference>
<reference seq="31">
<ref-info>
<ref-title>
<ref-titletext-english>Adipocyte extracellular vesicles carry enzymes and fatty acids that stimulate mitochondrial metabolism and remodeling in tumor cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.</ce:initials>
<ce:surname>Clemen</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>EMBO J</ref-sourcetitle>
<ref-publicationyear first="2020" />
<volisspag>
<volume-issue-number>
<vol-first>39</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Clement, E., et al.: Adipocyte extracellular vesicles carry enzymes and fatty acids that stimulate mitochondrial metabolism and remodeling in tumor cells. EMBO J. 39, e102525 (2020)</ref-fulltext>
<ce:source-text>Clement, E., et al.: Adipocyte extracellular vesicles carry enzymes and fatty acids that stimulate mitochondrial metabolism and remodeling in tumor cells. EMBO J. 39, e102525 (2020)</ce:source-text>
</reference>
<reference seq="32">
<ref-info>
<ref-title>
<ref-titletext-english>The role of exosomes in cancer metastasis. Semin</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.B.</ce:initials>
<ce:surname>Steinbichler</ce:surname>
<ce:given-name>T.B.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Dudas</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>H.</ce:initials>
<ce:surname>Riechelmann</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="4">
<ce:initials>I.I.</ce:initials>
<ce:surname>Skvortsova</ce:surname>
<ce:given-name>I.I.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Bio</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>44</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>170</first-page>
<last-page>181</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Steinbichler, T.B., Dudas, J., Riechelmann, H., Skvortsova, I.I.: The role of exosomes in cancer metastasis. Semin. Cancer Biol. 44, 170–181 (2017)</ref-fulltext>
<ce:source-text>Steinbichler, T.B., Dudas, J., Riechelmann, H., Skvortsova, I.I.: The role of exosomes in cancer metastasis. Semin. Cancer Biol. 44, 170–181 (2017)</ce:source-text>
</reference>
<reference seq="33">
<ref-info>
<ref-title>
<ref-titletext-english>Exosome-derived microRNAs in cancer metabolism: possible implications in cancer diagnostics and therapy. </ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Tomasett</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>W.</ce:initials>
<ce:surname>Lee</ce:surname>
<ce:given-name>W.</ce:given-name>
</author>
<author seq="3">
<ce:initials>W.</ce:initials>
<ce:surname>Santarell</ce:surname>
<ce:given-name>W.</ce:given-name>
</author>
<author seq="4">
<ce:initials>J.</ce:initials>
<ce:surname>Neuzil</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Exp. Mol. Med</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>49</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Tomasetti, M., Lee, W., Santarelli, L., Neuzil, J.: Exosome-derived microRNAs in cancer metabolism: possible implications in cancer diagnostics and therapy. Exp. Mol. Med. 49, e285 (2017)</ref-fulltext>
<ce:source-text>Tomasetti, M., Lee, W., Santarelli, L., Neuzil, J.: Exosome-derived microRNAs in cancer metabolism: possible implications in cancer diagnostics and therapy. Exp. Mol. Med. 49, e285 (2017)</ce:source-text>
</reference>
<reference seq="34">
<ref-info>
<ref-title>
<ref-titletext-english>Decoding the biology of exosomes in metastasis.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.</ce:initials>
<ce:surname>Adem</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
<author seq="2">
<ce:initials>P.F.</ce:initials>
<ce:surname>Vieira</ce:surname>
<ce:given-name>P.F.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.A</ce:initials>
<ce:surname>Melo</ce:surname>
<ce:given-name>S.A</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Trends Cancer. </ref-sourcetitle>
<ref-publicationyear first="2020" />
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>20</first-page>
<last-page>30</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Adem, B., Vieira, P.F., Melo, S.A.: Decoding the biology of exosomes in metastasis. Trends Cancer. 6, 20–30 (2020)</ref-fulltext>
<ce:source-text>Adem, B., Vieira, P.F., Melo, S.A.: Decoding the biology of exosomes in metastasis. Trends Cancer. 6, 20–30 (2020)</ce:source-text>
</reference>
<reference seq="35">
<ref-info>
<ref-title>
<ref-titletext-english>The importance of exosomal PDL1 in tumour immune evasion</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Daassi</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.M.</ce:initials>
<ce:surname>Mahoney</ce:surname>
<ce:given-name>K.M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>G.J.</ce:initials>
<ce:surname>Freeman</ce:surname>
<ce:given-name>G.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Immunol</ref-sourcetitle>
<ref-publicationyear first="2020" />
</ref-info>
<ref-fulltext>Daassi, D., Mahoney, K.M., Freeman, G.J.: The importance of exosomal PDL1 in tumour immune evasion. Nat. Rev. Immunol. (2020)</ref-fulltext>
<ce:source-text>Daassi, D., Mahoney, K.M., Freeman, G.J.: The importance of exosomal PDL1 in tumour immune evasion. Nat. Rev. Immunol. (2020)</ce:source-text>
</reference>
<reference seq="36">
<ref-info>
<ref-title>
<ref-titletext-english>Matrix metalloproteinases: regulators of the tumor microenvironment.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Kessenbrock</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="2">
<ce:initials>V.</ce:initials>
<ce:surname>Plaks</ce:surname>
<ce:given-name>V.</ce:given-name>
</author>
<author seq="3">
<ce:initials>Z.</ce:initials>
<ce:surname>Werb</ce:surname>
<ce:given-name>Z.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2010" />
<volisspag>
<volume-issue-number>
<vol-first>141</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>52</first-page>
<last-page>67</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kessenbrock, K., Plaks, V., Werb, Z.: Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 141, 52–67 (2010)</ref-fulltext>
<ce:source-text>Kessenbrock, K., Plaks, V., Werb, Z.: Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 141, 52–67 (2010)</ce:source-text>
</reference>
<reference seq="37">
<ref-info>
<ref-title>
<ref-titletext-english>Urokinase plasminogen activator and gelatinases are associated with membrane vesicles shed by human HT1080 fibrosarcoma cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Ginestra</ce:surname>
<ce:given-name />
</author>
</ref-authors>
<ref-sourcetitle>J. Biol. Chem</ref-sourcetitle>
<ref-publicationyear first="1997" />
<volisspag>
<volume-issue-number>
<vol-first>272</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>17216</first-page>
<last-page>17222</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ginestra, A., et al.: Urokinase plasminogen activator and gelatinases are associated with membrane vesicles shed by human HT1080 fibrosarcoma cells. J. Biol. Chem. 272, 17216–17222 (1997)</ref-fulltext>
<ce:source-text>Ginestra, A., et al.: Urokinase plasminogen activator and gelatinases are associated with membrane vesicles shed by human HT1080 fibrosarcoma cells. J. Biol. Chem. 272, 17216–17222 (1997)</ce:source-text>
</reference>
<reference seq="38">
<ref-info>
<ref-title>
<ref-titletext-english>Selective localization of matrix metalloproteinase 9, beta1 integrins, and human lymphocyte antigen class I molecules on membrane vesicles shed by 8701-BC breast carcinoma cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>V.</ce:initials>
<ce:surname>Dolo</ce:surname>
<ce:given-name>V.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Res</ref-sourcetitle>
<ref-publicationyear first="1998" />
<volisspag>
<volume-issue-number>
<vol-first>58</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>4468</first-page>
<last-page>4474</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Dolo, V., et al.: Selective localization of matrix metalloproteinase 9, beta1 integrins, and human lymphocyte antigen class I molecules on membrane vesicles shed by 8701-BC breast carcinoma cells. Cancer Res. 58, 4468–4474 (1998)</ref-fulltext>
<ce:source-text>Dolo, V., et al.: Selective localization of matrix metalloproteinase 9, beta1 integrins, and human lymphocyte antigen class I molecules on membrane vesicles shed by 8701-BC breast carcinoma cells. Cancer Res. 58, 4468–4474 (1998)</ce:source-text>
</reference>
<reference seq="39">
<ref-info>
<ref-title>
<ref-titletext-english>Hypoxia-induced matrix metalloproteinase-13 expression in exosomes from nasopharyngeal carcinoma enhances metastases</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Shan</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Death Dis</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>382</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Shan, Y., et al.: Hypoxia-induced matrix metalloproteinase-13 expression in exosomes from nasopharyngeal carcinoma enhances metastases. Cell Death Dis. 9, 382 (2018) </ref-fulltext>
<ce:source-text>Shan, Y., et al.: Hypoxia-induced matrix metalloproteinase-13 expression in exosomes from nasopharyngeal carcinoma enhances metastases. Cell Death Dis. 9, 382 (2018) </ce:source-text>
</reference>
<reference seq="40">
<ref-info>
<ref-title>
<ref-titletext-english>Secretion of active membrane type 1 matrix metalloproteinase (MMP-14) into extracellular space in microvesicular exosomes. </ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Hakulinen</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>L.</ce:initials>
<ce:surname>Sankkila</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="3">
<ce:initials>N.</ce:initials>
<ce:surname>Sugiyama</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
<author seq="4">
<ce:initials>K.</ce:initials>
<ce:surname>Lehti</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="5">
<ce:initials>J.</ce:initials>
<ce:surname>Keski-Oja</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle> J. Cell. Biochem</ref-sourcetitle>
<ref-publicationyear first="2010" />
<volisspag>
<volume-issue-number>
<vol-first>105</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1211</first-page>
<last-page>1218</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hakulinen, J., Sankkila, L., Sugiyama, N., Lehti, K., Keski-Oja, J.: Secretion of active membrane type 1 matrix metalloproteinase (MMP-14) into extracellular space in microvesicular exosomes. J. Cell. Biochem. 105, 1211–1218 (2008)</ref-fulltext>
<ce:source-text>Hakulinen, J., Sankkila, L., Sugiyama, N., Lehti, K., Keski-Oja, J.: Secretion of active membrane type 1 matrix metalloproteinase (MMP-14) into extracellular space in microvesicular exosomes. J. Cell. Biochem. 105, 1211–1218 (2008)</ce:source-text>
</reference>
<reference seq="41">
<ref-info>
<ref-title>
<ref-titletext-english>Host matrix modulation by tumor exosomes promotes motility and invasiveness.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>W.</ce:initials>
<ce:surname>Mu</ce:surname>
<ce:given-name>W.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Rana</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Zoller</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Neoplasia</ref-sourcetitle>
<ref-publicationyear first="2013" />
<volisspag>
<volume-issue-number>
<vol-first>15</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>875</first-page>
<last-page>887</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mu, W., Rana, S., Zoller, M.: Host matrix modulation by tumor exosomes promotes motility and invasiveness. Neoplasia. 15, 875–887 (2013)</ref-fulltext>
<ce:source-text>Mu, W., Rana, S., Zoller, M.: Host matrix modulation by tumor exosomes promotes motility and invasiveness. Neoplasia. 15, 875–887 (2013)</ce:source-text>
</reference>
<reference seq="42">
<ref-info>
<ref-title>
<ref-titletext-english>: Extracellular vesicles secreted from cancer cell lines stimulate secretion of MMP-9, IL-6, TGF-beta1 and EMMPRIN. </ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.S</ce:initials>
<ce:surname>Redzic</ce:surname>
<ce:given-name>J.S</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>PLoS One</ref-sourcetitle>
<ref-publicationyear first="2013" />
<ref-text />
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Redzic, J.S., et al.: Extracellular vesicles secreted from cancer cell lines stimulate secretion of MMP-9, IL-6, TGF-beta1 and EMMPRIN. PLoS One. 8, e71225 (2013)</ref-fulltext>
<ce:source-text>Redzic, J.S., et al.: Extracellular vesicles secreted from cancer cell lines stimulate secretion of MMP-9, IL-6, TGF-beta1 and EMMPRIN. PLoS One. 8, e71225 (2013)</ce:source-text>
</reference>
<reference seq="43">
<ref-info>
<ref-title>
<ref-titletext-english>Exosomes from bulk and stem cells from human prostate cancer have a differential microRNA content that contributes cooperatively over local and pre-metastatic niche.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.A.</ce:initials>
<ce:surname>Sanchez</ce:surname>
<ce:given-name>C.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncotarget.</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3993</first-page>
<last-page>4008</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sanchez, C.A., et al.: Exosomes from bulk and stem cells from human prostate cancer have a differential microRNA content that contributes cooperatively over local and pre-metastatic niche. Oncotarget. 7, 3993–4008 (2016)</ref-fulltext>
<ce:source-text>Sanchez, C.A., et al.: Exosomes from bulk and stem cells from human prostate cancer have a differential microRNA content that contributes cooperatively over local and pre-metastatic niche. Oncotarget. 7, 3993–4008 (2016)</ce:source-text>
</reference>
<reference seq="44">
<ref-info>
<ref-title>
<ref-titletext-english>Oncogenic KIT-containing exosomes increase gastrointestinal stromal tumor cell invasion</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Atay</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Proc. Natl. Acad. Sci. USA</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>111</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>711</first-page>
<last-page>716</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Atay, S., et al.: Oncogenic KIT-containing exosomes increase gastrointestinal stromal tumor cell invasion. Proc. Natl. Acad. Sci. USA. 111, 711–716 (2014)</ref-fulltext>
<ce:source-text>Atay, S., et al.: Oncogenic KIT-containing exosomes increase gastrointestinal stromal tumor cell invasion. Proc. Natl. Acad. Sci. USA. 111, 711–716 (2014)</ce:source-text>
</reference>
<reference seq="45">
<ref-info>
<ref-title>
<ref-titletext-english>Alpha-smooth muscle actin expression upregulates fibroblast contractile activity. Mol.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.</ce:initials>
<ce:surname>Hinz</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
<author seq="2">
<ce:initials>G.</ce:initials>
<ce:surname>Celetta</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.J.</ce:initials>
<ce:surname>Tomasek</ce:surname>
<ce:given-name>J.J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>G.</ce:initials>
<ce:surname>Gabbiani</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.</ce:initials>
<ce:surname>Chaponnier</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Biol. Cell</ref-sourcetitle>
<ref-publicationyear first="2001" />
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2730</first-page>
<last-page>2741</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hinz, B., Celetta, G., Tomasek, J.J., Gabbiani, G., Chaponnier, C.: Alpha-smooth muscle actin expression upregulates fibroblast contractile activity. Mol. Biol. Cell. 12, 2730–2741 (2001)</ref-fulltext>
<ce:source-text>Hinz, B., Celetta, G., Tomasek, J.J., Gabbiani, G., Chaponnier, C.: Alpha-smooth muscle actin expression upregulates fibroblast contractile activity. Mol. Biol. Cell. 12, 2730–2741 (2001)</ce:source-text>
</reference>
<reference seq="46">
<ref-info>
<ref-title>
<ref-titletext-english>The biology and function of fibroblasts in cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Kalluri</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Cancer.</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>16</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>582</first-page>
<last-page>598</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kalluri, R.: The biology and function of fibroblasts in cancer. Nat. Rev. Cancer. 16, 582–598 (2016)</ref-fulltext>
<ce:source-text>Kalluri, R.: The biology and function of fibroblasts in cancer. Nat. Rev. Cancer. 16, 582–598 (2016)</ce:source-text>
</reference>
<reference seq="47">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer exosomes trigger fibroblast to myofibroblast differentiation. </ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Webber</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.</ce:initials>
<ce:surname>Steadman</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.D.</ce:initials>
<ce:surname>Mason</ce:surname>
<ce:given-name>M.D.</ce:given-name>
</author>
<author seq="4">
<ce:initials>Z.</ce:initials>
<ce:surname>Tabi</ce:surname>
<ce:given-name />
</author>
<author seq="5">
<ce:initials>A.</ce:initials>
<ce:surname>Clayton</ce:surname>
<ce:given-name />
</author>
</ref-authors>
<ref-sourcetitle>Cancer Res</ref-sourcetitle>
<ref-publicationyear first="2010" />
<volisspag>
<volume-issue-number>
<vol-first>70</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>9621</first-page>
<last-page>9630</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Webber, J., Steadman, R., Mason, M.D., Tabi, Z., Clayton, A.: Cancer exosomes trigger fibroblast to myofibroblast differentiation. Cancer Res. 70, 9621–9630 (2010)</ref-fulltext>
<ce:source-text>Webber, J., Steadman, R., Mason, M.D., Tabi, Z., Clayton, A.: Cancer exosomes trigger fibroblast to myofibroblast differentiation. Cancer Res. 70, 9621–9630 (2010)</ce:source-text>
</reference>
<reference seq="48">
<ref-info>
<ref-title>
<ref-titletext-english>Differentiation of tumourpromoting stromal myofibroblasts by cancer exosomes. </ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.P.</ce:initials>
<ce:surname>Webber</ce:surname>
<ce:given-name>J.P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncogene</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>34</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>290</first-page>
<last-page>302</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>. Webber, J.P., et al.: Differentiation of tumourpromoting stromal myofibroblasts by cancer exosomes. Oncogene. 34, 290–302 (2015) </ref-fulltext>
<ce:source-text>. Webber, J.P., et al.: Differentiation of tumourpromoting stromal myofibroblasts by cancer exosomes. Oncogene. 34, 290–302 (2015) </ce:source-text>
</reference>
<reference seq="49">
<ref-info>
<ref-title>
<ref-titletext-english>Rab27a and Rab27b control different steps of the exosome secretion pathway. Nat.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Ostrowski</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Biol</ref-sourcetitle>
<ref-publicationyear first="2010" />
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>19</first-page>
<last-page>30</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ostrowski, M., et al.: Rab27a and Rab27b control different steps of the exosome secretion pathway. Nat. Cell Biol. 12, 19–30.; sup pp 11-13 (2010)</ref-fulltext>
<ce:source-text>Ostrowski, M., et al.: Rab27a and Rab27b control different steps of the exosome secretion pathway. Nat. Cell Biol. 12, 19–30.; sup pp 11-13 (2010)</ce:source-text>
</reference>
<reference seq="50">
<ref-info>
<ref-title>
<ref-titletext-english>Hepatocellular carcinoma-derived exosomal miRNA-21 contributes to tumor progression by converting hepatocyte stellate cells to cancerassociated fibroblasts.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Zhou</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Exp. Clin. Cancer Res.</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>37</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>324</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zhou, Y., et al.: Hepatocellular carcinoma-derived exosomal miRNA-21 contributes to tumor progression by converting hepatocyte stellate cells to cancerassociated fibroblasts. J. Exp. Clin. Cancer Res. 37, 324 (2018)</ref-fulltext>
<ce:source-text>Zhou, Y., et al.: Hepatocellular carcinoma-derived exosomal miRNA-21 contributes to tumor progression by converting hepatocyte stellate cells to cancerassociated fibroblasts. J. Exp. Clin. Cancer Res. 37, 324 (2018)</ce:source-text>
</reference>
<reference seq="51">
<ref-info>
<ref-title>
<ref-titletext-english> Exosomes released by chronic lymphocytic leukemia cells induce the transition of stromal cells into cancer-associated fibroblasts</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Paggetti</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Blood</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>126</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1106</first-page>
<last-page>1117</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Paggetti, J., et al.: Exosomes released by chronic lymphocytic leukemia cells induce the transition of stromal cells into cancer-associated fibroblasts. Blood. 126, 1106–1117 (2015) </ref-fulltext>
<ce:source-text>Paggetti, J., et al.: Exosomes released by chronic lymphocytic leukemia cells induce the transition of stromal cells into cancer-associated fibroblasts. Blood. 126, 1106–1117 (2015) </ce:source-text>
</reference>
<reference seq="52">
<ref-info>
<ref-title>
<ref-titletext-english>: Cancer exosomes trigger mesenchymal stem cell differentiation into pro-angiogenic and pro-invasive myofibroblasts.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Chowdhury</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncotarget</ref-sourcetitle>
<ref-publicationyear first="2015" />
<ref-text />
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>715</first-page>
<last-page>731</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Chowdhury, R., et al.: Cancer exosomes trigger mesenchymal stem cell differentiation into pro-angiogenic and pro-invasive myofibroblasts. Oncotarget. 6, 715–731 (2015)</ref-fulltext>
<ce:source-text>Chowdhury, R., et al.: Cancer exosomes trigger mesenchymal stem cell differentiation into pro-angiogenic and pro-invasive myofibroblasts. Oncotarget. 6, 715–731 (2015)</ce:source-text>
</reference>
<reference seq="53">
<ref-info>
<ref-title>
<ref-titletext-english>Exosomes from ovarian cancer cells induce adipose tissue-derived mesenchymal stem cells to acquire the physical and functional characteristics of tumor-supporting myofibroblasts</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.A.</ce:initials>
<ce:surname>Cho</ce:surname>
<ce:given-name>J.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Gynecol. Oncol. </ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>123</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>379</first-page>
<last-page>386</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>. Cho, J.A., et al.: Exosomes from ovarian cancer cells induce adipose tissue-derived mesenchymal stem cells to acquire the physical and functional characteristics of tumor-supporting myofibroblasts. Gynecol. Oncol. 123, 379–386 (2011)</ref-fulltext>
<ce:source-text>. Cho, J.A., et al.: Exosomes from ovarian cancer cells induce adipose tissue-derived mesenchymal stem cells to acquire the physical and functional characteristics of tumor-supporting myofibroblasts. Gynecol. Oncol. 123, 379–386 (2011)</ce:source-text>
</reference>
<reference seq="54">
<ref-info>
<ref-title>
<ref-titletext-english>Natural innate and adaptive immunity to cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.D.</ce:initials>
<ce:surname>Vesely</ce:surname>
<ce:given-name>M.D.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.H.</ce:initials>
<ce:surname>Kershaw</ce:surname>
<ce:given-name>M.H.</ce:given-name>
</author>
<author seq="3">
<ce:initials>R.D.</ce:initials>
<ce:surname>Schreiber</ce:surname>
<ce:given-name>R.D.</ce:given-name>
</author>
<author seq="4">
<ce:initials>M.J.</ce:initials>
<ce:surname>Smyth</ce:surname>
<ce:given-name>M.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Annu. Rev. Immunol.</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>29</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>235</first-page>
<last-page>271</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Vesely, M.D., Kershaw, M.H., Schreiber, R.D., Smyth, M.J.: Natural innate and adaptive immunity to cancer. Annu. Rev. Immunol. 29, 235–271 (2011)</ref-fulltext>
<ce:source-text>Vesely, M.D., Kershaw, M.H., Schreiber, R.D., Smyth, M.J.: Natural innate and adaptive immunity to cancer. Annu. Rev. Immunol. 29, 235–271 (2011)</ce:source-text>
</reference>
<reference seq="55">
<ref-info>
<ref-title>
<ref-titletext-english>Concise review: modulating cancer immunity withhematopoietic stem and progenitor cells.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.J.</ce:initials>
<ce:surname>Wildes</ce:surname>
<ce:given-name>T.J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.T.</ce:initials>
<ce:surname>Flores</ce:surname>
<ce:given-name>C.T.</ce:given-name>
</author>
<author seq="3">
<ce:initials>D.A.</ce:initials>
<ce:surname>Mitchell</ce:surname>
<ce:given-name>D.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Stem Cells</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>37</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>166</first-page>
<last-page>175</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wildes, T.J., Flores, C.T., Mitchell, D.A.: Concise review: modulating cancer immunity with hematopoietic stem and progenitor cells. Stem Cells. 37, 166–175 (2019)</ref-fulltext>
<ce:source-text>Wildes, T.J., Flores, C.T., Mitchell, D.A.: Concise review: modulating cancer immunity with hematopoietic stem and progenitor cells. Stem Cells. 37, 166–175 (2019)</ce:source-text>
</reference>
<reference seq="56">
<ref-info>
<ref-title>
<ref-titletext-english>Roles of the immune system in cancer: from tumor initiation to metastatic progression</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Gonzalez</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.</ce:initials>
<ce:surname>Hagerling</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="3">
<ce:initials>Z.</ce:initials>
<ce:surname>Werb</ce:surname>
<ce:given-name>Z.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Genes Dev</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>32</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1267</first-page>
<last-page>1284</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Gonzalez, H., Hagerling, C., Werb, Z.: Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev. 32, 1267–1284 (2018)</ref-fulltext>
<ce:source-text>Gonzalez, H., Hagerling, C., Werb, Z.: Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev. 32, 1267–1284 (2018)</ce:source-text>
</reference>
<reference seq="57">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer-cellintrinsic mechanisms shaping the tumor immune landscape</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.D.</ce:initials>
<ce:surname>Wellenstein</ce:surname>
<ce:given-name>M.D.</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.E.</ce:initials>
<ce:surname>Visser</ce:surname>
<ce:given-name>K.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Immunity</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>48</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>399</first-page>
<last-page>416</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wellenstein, M.D., de Visser, K.E.: Cancer-cellintrinsic mechanisms shaping the tumor immune landscape. Immunity. 48, 399–416 (2018) </ref-fulltext>
<ce:source-text>Wellenstein, M.D., de Visser, K.E.: Cancer-cellintrinsic mechanisms shaping the tumor immune landscape. Immunity. 48, 399–416 (2018) </ce:source-text>
</reference>
<reference seq="58">
<ref-info>
<ref-title>
<ref-titletext-english>: Allele-specific HLA loss and immune escape in lung cancer evolution.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.</ce:initials>
<ce:surname>McGranaha</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell.</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>171</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1259</first-page>
<last-page>1271</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>McGranahan, N., et al.: Allele-specific HLA loss and immune escape in lung cancer evolution. Cell. 171, 1259–1271 e1211 (2017)</ref-fulltext>
<ce:source-text>McGranahan, N., et al.: Allele-specific HLA loss and immune escape in lung cancer evolution. Cell. 171, 1259–1271 e1211 (2017)</ce:source-text>
</reference>
<reference seq="59">
<ref-info>
<ref-title>
<ref-titletext-english>TGFbeta drives immune evasion in genetically reconstituted colon cancer metastasis. </ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.V.F.</ce:initials>
<ce:surname>Tauriello</ce:surname>
<ce:given-name>D.V.F.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature.</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>554</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>538</first-page>
<last-page>543</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Tauriello, D.V.F., et al.: TGFbeta drives immune evasion in genetically reconstituted colon cancer metastasis. Nature. 554, 538–543 (2018)</ref-fulltext>
<ce:source-text>Tauriello, D.V.F., et al.: TGFbeta drives immune evasion in genetically reconstituted colon cancer metastasis. Nature. 554, 538–543 (2018)</ce:source-text>
</reference>
<reference seq="60">
<ref-info>
<ref-title>
<ref-titletext-english>Inflammatory modulation of HSCs: viewing the HSC as a foundation for the immune response. </ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials> K.Y.</ce:initials>
<ce:surname>King</ce:surname>
<ce:given-name> K.Y.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.A.</ce:initials>
<ce:surname>Goodell</ce:surname>
<ce:given-name>M.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Immunol. </ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>11</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>685</first-page>
<last-page>692</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>King, K.Y., Goodell, M.A.: Inflammatory modulation of HSCs: viewing the HSC as a foundation for the immune response. Nat. Rev. Immunol. 11, 685–692 (2011) </ref-fulltext>
<ce:source-text>King, K.Y., Goodell, M.A.: Inflammatory modulation of HSCs: viewing the HSC as a foundation for the immune response. Nat. Rev. Immunol. 11, 685–692 (2011) </ce:source-text>
</reference>
<reference seq="61">
<ref-info>
<ref-title>
<ref-titletext-english> An interferon-driven oxysterol-based defense against tumor-derived extracellular vesicles.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Ortiz</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Cell</ref-sourcetitle>
<ref-publicationyear first="2019" />
<ref-text />
<volisspag>
<volume-issue-number>
<vol-first>35</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>33</first-page>
<last-page>45</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ortiz, A., et al.: An interferon-driven oxysterol-based defense against tumor-derived extracellular vesicles. Cancer Cell. 35, 33–45 e36 (2019)</ref-fulltext>
<ce:source-text>Ortiz, A., et al.: An interferon-driven oxysterol-based defense against tumor-derived extracellular vesicles. Cancer Cell. 35, 33–45 e36 (2019)</ce:source-text>
</reference>
<reference seq="62">
<ref-info>
<ref-title>
<ref-titletext-english>Innate or adaptive immunity? The example of natural killer cells.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.</ce:initials>
<ce:surname>Vivier</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Science</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>331</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>44</first-page>
<last-page>49</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Vivier, E., et al.: Innate or adaptive immunity? The example of natural killer cells. Science. 331, 44–49 (2011)</ref-fulltext>
<ce:source-text>Vivier, E., et al.: Innate or adaptive immunity? The example of natural killer cells. Science. 331, 44–49 (2011)</ce:source-text>
</reference>
<reference seq="63">
<ref-info>
<ref-title>
<ref-titletext-english> AML suppresses hematopoiesis by releasing exosomes that contain microRNAs targeting c-MYB. </ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.I.</ce:initials>
<ce:surname>Hornick</ce:surname>
<ce:given-name>N.I.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Sci.Signal.</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>88</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hornick, N.I., et al.: AML suppresses hematopoiesis by releasing exosomes that contain microRNAs targeting c-MYB. Sci. Signal. 9, ra88 (2016)</ref-fulltext>
<ce:source-text>Hornick, N.I., et al.: AML suppresses hematopoiesis by releasing exosomes that contain microRNAs targeting c-MYB. Sci. Signal. 9, ra88 (2016)</ce:source-text>
</reference>
<reference seq="64">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor exosomes inhibit differentiation of bone marrow dendritic cells.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Yu</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J.Immunol.</ref-sourcetitle>
<ref-publicationyear first="2007" />
<volisspag>
<volume-issue-number>
<vol-first>178</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>6867</first-page>
<last-page>6875</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Yu, S., et al.: Tumor exosomes inhibit differentiation of bone marrow dendritic cells. J. Immunol. 178, 6867–6875 (2007)</ref-fulltext>
<ce:source-text>Yu, S., et al.: Tumor exosomes inhibit differentiation of bone marrow dendritic cells. J. Immunol. 178, 6867–6875 (2007)</ce:source-text>
</reference>
<reference seq="65">
<ref-info>
<ref-title>
<ref-titletext-english>induction of myeloid-derived suppressor cells by tumor exosomes. </ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.</ce:initials>
<ce:surname>Xiang</ce:surname>
<ce:given-name>X.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int.J.Cancer</ref-sourcetitle>
<ref-publicationyear first="2009" />
<volisspag>
<volume-issue-number>
<vol-first>124</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2621</first-page>
<last-page>2633</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Xiang, X., et al.: Induction of myeloid-derived suppressor cells by tumor exosomes. Int. J. Cancer. 124, 2621–2633 (2009)</ref-fulltext>
<ce:source-text>Xiang, X., et al.: Induction of myeloid-derived suppressor cells by tumor exosomes. Int. J. Cancer. 124, 2621–2633 (2009)</ce:source-text>
</reference>
<reference seq="66">
<ref-info>
<ref-title>
<ref-titletext-english>Myeloid-derived suppressor cells. Cancer Immunol.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.I.</ce:initials>
<ce:surname>Gabrilovich</ce:surname>
<ce:given-name>D.I.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Res.</ref-sourcetitle>
<ref-publicationyear first="2017" />
<ref-text />
<volisspag>
<volume-issue-number>
<vol-first>5</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3</first-page>
<last-page>8</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Gabrilovich, D.I.: Myeloid-derived suppressor cells. Cancer Immunol. Res. 5, 3–8 (2017)</ref-fulltext>
<ce:source-text>Gabrilovich, D.I.: Myeloid-derived suppressor cells. Cancer Immunol. Res. 5, 3–8 (2017)</ce:source-text>
</reference>
<reference seq="67">
<ref-info>
<ref-title>
<ref-titletext-english>Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3- dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. </ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Chalmin</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J.Clin.Invest.</ref-sourcetitle>
<ref-publicationyear first="2010" />
<volisspag>
<volume-issue-number>
<vol-first>120</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>457</first-page>
<last-page>471</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Chalmin, F., et al.: Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3- dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J. Clin. Invest. 120, 457–471 (2010)</ref-fulltext>
<ce:source-text>Chalmin, F., et al.: Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3- dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J. Clin. Invest. 120, 457–471 (2010)</ce:source-text>
</reference>
<reference seq="68">
<ref-info>
<ref-title>
<ref-titletext-english>Melanoma extracellular vesicles generate immunosuppressive myeloid cells by upregulating PD-L1 via TLR4 signaling</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>V.</ce:initials>
<ce:surname>Fleming</ce:surname>
<ce:given-name>V.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Res.</ref-sourcetitle>
<ref-publicationyear first="2019" />
<ref-text />
<volisspag>
<volume-issue-number>
<vol-first>79</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>4715</first-page>
<last-page>4728</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Fleming, V., et al.: Melanoma extracellular vesicles generate immunosuppressive myeloid cells by upregulating PD-L1 via TLR4 signaling. Cancer Res. 79, 4715–4728 (2019)</ref-fulltext>
<ce:source-text>Fleming, V., et al.: Melanoma extracellular vesicles generate immunosuppressive myeloid cells by upregulating PD-L1 via TLR4 signaling. Cancer Res. 79, 4715–4728 (2019)</ce:source-text>
</reference>
<reference seq="69">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor-derived microRNAs induce myeloid suppressor cells and predict immunotherapy resistance in melanoma.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>V.</ce:initials>
<ce:surname>Huber</ce:surname>
<ce:given-name>V.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J.Clin.Invest.</ref-sourcetitle>
<ref-publicationyear first="2018" />
<ref-text />
<volisspag>
<volume-issue-number>
<vol-first>128</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>5505</first-page>
<last-page>5516</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Huber, V., et al.: Tumor-derived microRNAs induce myeloid suppressor cells and predict immunotherapy resistance in melanoma. J. Clin. Invest. 128, 5505–5516 (2018)</ref-fulltext>
<ce:source-text>Huber, V., et al.: Tumor-derived microRNAs induce myeloid suppressor cells and predict immunotherapy resistance in melanoma. J. Clin. Invest. 128, 5505–5516 (2018)</ce:source-text>
</reference>
<reference seq="70">
<ref-info>
<ref-title>
<ref-titletext-english>Immunosuppressive effects of hypoxia-induced glioma exosomes through myeloid-derived suppressor cells via the miR-10a/ Rora and miR-21/Pten Pathways</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.</ce:initials>
<ce:surname>Guo</ce:surname>
<ce:given-name />
</author>
</ref-authors>
<ref-sourcetitle>Oncogene</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>37</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>4239</first-page>
<last-page>4259</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Guo, X., et al.: Immunosuppressive effects of hypoxia-induced glioma exosomes through myeloid-derived suppressor cells via the miR-10a/ Rora and miR-21/Pten Pathways. Oncogene. 37, 4239–4259 (2018)</ref-fulltext>
<ce:source-text>Guo, X., et al.: Immunosuppressive effects of hypoxia-induced glioma exosomes through myeloid-derived suppressor cells via the miR-10a/ Rora and miR-21/Pten Pathways. Oncogene. 37, 4239–4259 (2018)</ce:source-text>
</reference>
<reference seq="71">
<ref-info>
<ref-title>
<ref-titletext-english>Akira, S., Uematsu, S., Takeuchi, O.: Pathogen recognition and innate immunity. Cell. 124, 783–801 (2006)</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Akira</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Uematsu</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>O.</ce:initials>
<ce:surname>Takeuchi</ce:surname>
<ce:given-name>O.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle />
<ref-publicationyear first="2006" />
<volisspag>
<volume-issue-number>
<vol-first>124</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>783</first-page>
<last-page>801</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Akira, S., Uematsu, S., Takeuchi, O.: Pathogen recognition and innate immunity. Cell. 124, 783–801 (2006)</ref-fulltext>
<ce:source-text>Akira, S., Uematsu, S., Takeuchi, O.: Pathogen recognition and innate immunity. Cell. 124, 783–801 (2006)</ce:source-text>
</reference>
<reference seq="72">
<ref-info>
<ref-title>
<ref-titletext-english>Macrophages and metabolism in the tumor microenvironment.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>I.</ce:initials>
<ce:surname>Vitale</ce:surname>
<ce:given-name>I.</ce:given-name>
</author>
<author seq="2">
<ce:initials>G.</ce:initials>
<ce:surname>Manic</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="3">
<ce:initials>L.M.</ce:initials>
<ce:surname>Coussens</ce:surname>
<ce:given-name>L.M.</ce:given-name>
</author>
<author seq="4">
<ce:initials>G.</ce:initials>
<ce:surname>Kroemer</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="5">
<ce:initials>L.</ce:initials>
<ce:surname>Galluzzi</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Metab</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>30</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>36</first-page>
<last-page>50</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Vitale, I., Manic, G., Coussens, L.M., Kroemer, G., Galluzzi, L.: Macrophages and metabolism in thetumor microenvironment. Cell Metab. 30, 36–50 (2019)</ref-fulltext>
<ce:source-text>Vitale, I., Manic, G., Coussens, L.M., Kroemer, G., Galluzzi, L.: Macrophages and metabolism in thetumor microenvironment. Cell Metab. 30, 36–50 (2019)</ce:source-text>
</reference>
<reference seq="73">
<ref-info>
<ref-title>
<ref-titletext-english>MicroRNAs bind to toll-like receptors to induce prometastatic inflammatory response</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Fabbri</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle> Proc. Natl. Acad. Sci. USA</ref-sourcetitle>
<ref-publicationyear first="2012" />
<volisspag>
<volume-issue-number>
<vol-first>109</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>. Fabbri, M., et al.: MicroRNAs bind to toll-like receptors to induce prometastatic inflammatory response. Proc. Natl. Acad. Sci. USA. 109, E2110– E2116 (2012)</ref-fulltext>
<ce:source-text>. Fabbri, M., et al.: MicroRNAs bind to toll-like receptors to induce prometastatic inflammatory response. Proc. Natl. Acad. Sci. USA. 109, E2110– E2116 (2012)</ce:source-text>
</reference>
<reference seq="74">
<ref-info>
<ref-title>
<ref-titletext-english>Epithelial ovarian cancer-secreted exosomal miR-222-3p induces polarization of tumor-associated macrophages</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.</ce:initials>
<ce:surname>Ying</ce:surname>
<ce:given-name>X.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncotarget.</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>43076</first-page>
<last-page>43087</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ying, X., et al.: Epithelial ovarian cancer-secreted exosomal miR-222-3p induces polarization of tumor-associated macrophages. Oncotarget. 7, 43076–43087 (2016) </ref-fulltext>
<ce:source-text>Ying, X., et al.: Epithelial ovarian cancer-secreted exosomal miR-222-3p induces polarization of tumor-associated macrophages. Oncotarget. 7, 43076–43087 (2016) </ce:source-text>
</reference>
<reference seq="75">
<ref-info>
<ref-title>
<ref-titletext-english>Mutant p53 cancers reprogram macrophages to tumor supporting macrophages via exosomal miR-1246</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Cooks</ce:surname>
<ce:given-name />
</author>
</ref-authors>
<ref-sourcetitle>Nat.Commun</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>771</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Cooks, T., et al.: Mutant p53 cancers reprogram macrophages to tumor supporting macrophages via exosomal miR-1246. Nat. Commun. 9, 771 (2018)</ref-fulltext>
<ce:source-text>Cooks, T., et al.: Mutant p53 cancers reprogram macrophages to tumor supporting macrophages via exosomal miR-1246. Nat. Commun. 9, 771 (2018)</ce:source-text>
</reference>
<reference seq="76">
<ref-info>
<ref-title>
<ref-titletext-english>Hypoxia-induced tumor exosomes promote M2-like macrophage polarization of infiltrating myeloid cells and microRNA-mediated metabolic shift.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.E.</ce:initials>
<ce:surname>Park</ce:surname>
<ce:given-name>J.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncogene.</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>38</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>5158</first-page>
<last-page>5173</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Park, J.E., et al.: Hypoxia-induced tumor exosomes promote M2-like macrophage polarization of infiltrating myeloid cells and microRNA-mediated metabolic shift. Oncogene. 38, 5158–5173 (2019) </ref-fulltext>
<ce:source-text>Park, J.E., et al.: Hypoxia-induced tumor exosomes promote M2-like macrophage polarization of infiltrating myeloid cells and microRNA-mediated metabolic shift. Oncogene. 38, 5158–5173 (2019) </ce:source-text>
</reference>
<reference seq="77">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer immunotherapy via dendritic cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Palucka</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Banchereau</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Cancer</ref-sourcetitle>
<ref-publicationyear first="2012" />
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>265</first-page>
<last-page>277</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Palucka, K., Banchereau, J.: Cancer immunotherapy via dendritic cells. Nat. Rev. Cancer. 12, 265–277 (2012)</ref-fulltext>
<ce:source-text>Palucka, K., Banchereau, J.: Cancer immunotherapy via dendritic cells. Nat. Rev. Cancer. 12, 265–277 (2012)</ce:source-text>
</reference>
<reference seq="78">
<ref-info>
<ref-title>
<ref-titletext-english>EGFR E746-A750 deletion in lung cancer represses antitumor immunity through the exosome-mediated inhibition of dendritic cells.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Yu</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncogene</ref-sourcetitle>
<ref-publicationyear first="2020" />
</ref-info>
<ref-fulltext>Yu, S., et al.: EGFR E746-A750 deletion in lung cancer represses antitumor immunity through the exosome-mediated inhibition of dendritic cells. Oncogene. (2020)</ref-fulltext>
<ce:source-text>Yu, S., et al.: EGFR E746-A750 deletion in lung cancer represses antitumor immunity through the exosome-mediated inhibition of dendritic cells. Oncogene. (2020)</ce:source-text>
</reference>
<reference seq="79">
<ref-info>
<ref-title>
<ref-titletext-english>Pancreatic cancer-derived exosomes transfer miRNAs to dendritic cells and inhibit RFXAP expression via miR-212-3p</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Ding</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncotarget</ref-sourcetitle>
<ref-publicationyear first="2015" />
<ref-text />
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>29877</first-page>
<last-page>29888</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ding, G., et al.: Pancreatic cancer-derived exosomes transfer miRNAs to dendritic cells and inhibit RFXAP expression via miR-212-3p. Oncotarget. 6, 29877–29888 (2015)</ref-fulltext>
<ce:source-text>Ding, G., et al.: Pancreatic cancer-derived exosomes transfer miRNAs to dendritic cells and inhibit RFXAP expression via miR-212-3p. Oncotarget. 6, 29877–29888 (2015)</ce:source-text>
</reference>
<reference seq="80">
<ref-info>
<ref-title>
<ref-titletext-english>Targeting natural killer cells in cancer immunotherapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Guillerey</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="2">
<ce:initials>N.D.</ce:initials>
<ce:surname>Huntington</ce:surname>
<ce:given-name>N.D.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.J.</ce:initials>
<ce:surname>Smyth</ce:surname>
<ce:given-name>M.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat.Immunol.</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>17</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1025</first-page>
<last-page>1036</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Guillerey, C., Huntington, N.D., Smyth, M.J.: Targeting natural killer cells in cancer immunotherapy. Nat. Immunol. 17, 1025–1036 (2016)</ref-fulltext>
<ce:source-text>Guillerey, C., Huntington, N.D., Smyth, M.J.: Targeting natural killer cells in cancer immunotherapy. Nat. Immunol. 17, 1025–1036 (2016)</ce:source-text>
</reference>
<reference seq="81">
<ref-info>
<ref-title>
<ref-titletext-english> The critical role of the tumor microenvironment in shaping natural killer cellmediated anti-tumor immunity</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Baginska</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Front.Immunol.</ref-sourcetitle>
<ref-publicationyear first="2013" />
<volisspag>
<volume-issue-number>
<vol-first>4</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>490</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Baginska, J., et al.: The critical role of the tumor microenvironment in shaping natural killer cellmediated anti-tumor immunity. Front. Immunol. 4, 490 (2013)</ref-fulltext>
<ce:source-text>Baginska, J., et al.: The critical role of the tumor microenvironment in shaping natural killer cellmediated anti-tumor immunity. Front. Immunol. 4, 490 (2013)</ce:source-text>
</reference>
<reference seq="82">
<ref-info>
<ref-title>
<ref-titletext-english>Altered NKp30, NKp46, NKG2D, and DNAM-1 expression on circulating NK cells is associated with tumor progression in human gastric cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.</ce:initials>
<ce:surname>Han</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J Immunol Res</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>2018</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Han, B., et al.: Altered NKp30, NKp46, NKG2D, and DNAM-1 expression on circulating NK cells is associated with tumor progression in human gastric cancer. J Immunol Res. 2018, 6248590 (2018)</ref-fulltext>
<ce:source-text>Han, B., et al.: Altered NKp30, NKp46, NKG2D, and DNAM-1 expression on circulating NK cells is associated with tumor progression in human gastric cancer. J Immunol Res. 2018, 6248590 (2018)</ce:source-text>
</reference>
<reference seq="83">
<ref-info>
<ref-title>
<ref-titletext-english>TGF-beta inhibits the activation and functions of NK cells by repressing the mTOR pathway.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Viel</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Sci.Signal</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Viel, S., et al.: TGF-beta inhibits the activation and functions of NK cells by repressing the mTOR pathway. Sci. Signal. 9, ra19 (2016)</ref-fulltext>
<ce:source-text>Viel, S., et al.: TGF-beta inhibits the activation and functions of NK cells by repressing the mTOR pathway. Sci. Signal. 9, ra19 (2016)</ce:source-text>
</reference>
<reference seq="84">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor-derived extracellular vesicles inhibit natural killer cell function in pancreatic cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.G.</ce:initials>
<ce:surname>Zhao</ce:surname>
<ce:given-name>J.G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancers</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>11</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>Zhao, J.G., et al.: Tumor-derived extracellular vesicles inhibit natural killer cell function in pancreatic cancer. Cancers. 11 (2019)</first-page>
<last-page>Zhao, J.G., et al.: Tumor-derived extracellular vesicles inhibit natural killer cell function in pancreatic cancer. Cancers. 11 (2019)</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext />
<ce:source-text />
</reference>
<reference seq="85">
<ref-info>
<ref-title>
<ref-titletext-english>Prostate tumor-derived exosomes down-regulate NKG2D expression on natural killer cells and CD8+ T cells: mechanism of immune evasion</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Lundholm</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>PLoS One</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Lundholm, M., et al.: Prostate tumor-derived exosomes down-regulate NKG2D expression on natural killer cells and CD8+ T cells: mechanism of immune evasion. PLoS One. 9, e108925 (2014) </ref-fulltext>
<ce:source-text>Lundholm, M., et al.: Prostate tumor-derived exosomes down-regulate NKG2D expression on natural killer cells and CD8+ T cells: mechanism of immune evasion. PLoS One. 9, e108925 (2014) </ce:source-text>
</reference>
<reference seq="86">
<ref-info>
<ref-title>
<ref-titletext-english>Murine mammary carcinoma exosomes promote tumor growth by suppression of NK cell function.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Liu</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J.Immunol</ref-sourcetitle>
<ref-publicationyear first="2006" />
<volisspag>
<volume-issue-number>
<vol-first>176</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1375</first-page>
<last-page>1385</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Liu, C., et al.: Murine mammary carcinoma exosomes promote tumor growth by suppression of NK cell function. J. Immunol. 176, 1375–1385 (2006)</ref-fulltext>
<ce:source-text>Liu, C., et al.: Murine mammary carcinoma exosomes promote tumor growth by suppression of NK cell function. J. Immunol. 176, 1375–1385 (2006)</ce:source-text>
</reference>
<reference seq="87">
<ref-info>
<ref-title>
<ref-titletext-english>Neutrophils in cancer: neutral no more. </ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.B.</ce:initials>
<ce:surname>Coffelt</ce:surname>
<ce:given-name>S.B.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.D.</ce:initials>
<ce:surname>Wellenstein</ce:surname>
<ce:given-name>M.D.</ce:given-name>
</author>
<author seq="3">
<ce:initials>K.E.</ce:initials>
<ce:surname>de Visser</ce:surname>
<ce:given-name>K.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat.Rev.Cancer.</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>16</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>431</first-page>
<last-page>446</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Coffelt, S.B., Wellenstein, M.D., de Visser, K.E.: Neutrophils in cancer: neutral no more. Nat. Rev. Cancer. 16, 431–446 (2016)</ref-fulltext>
<ce:source-text>Coffelt, S.B., Wellenstein, M.D., de Visser, K.E.: Neutrophils in cancer: neutral no more. Nat. Rev. Cancer. 16, 431–446 (2016)</ce:source-text> </reference>
<reference seq="88">
<ref-info>
<ref-title>
<ref-titletext-english>Granulocyte-colony stimulating
factor promotes lung metastasis through mobilizationof Ly6G+Ly6C+ granulocytes</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Kowanetz</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Proc. Natl. Acad. Sci. USA</ref-sourcetitle>
<ref-publicationyear first="2010" />
<volisspag>
<volume-issue-number>
<vol-first>107</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>21248</first-page>
<last-page>21255</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kowanetz, M., et al.: Granulocyte-colony stimulating factor promotes lung metastasis through mobilizationof Ly6G+Ly6C+ granulocytes. Proc. Natl. Acad. Sci. USA. 107, 21248–21255 (2010)</ref-fulltext>
<ce:source-text>Kowanetz, M., et al.: Granulocyte-colony stimulating factor promotes lung metastasis through mobilizationof Ly6G+Ly6C+ granulocytes. Proc. Natl. Acad. Sci. USA. 107, 21248–21255 (2010)</ce:source-text>
</reference>
<reference seq="89">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor entrained neutrophils inhibit seeding in the premetastatic lung</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Z.</ce:initials>
<ce:surname>Granot</ce:surname>
<ce:given-name>Z.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Cell</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>20</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>300</first-page>
<last-page>314</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Granot, Z., et al.: Tumor entrained neutrophils inhibit seeding in the premetastatic lung. Cancer Cell. 20, 300–314 (2011)</ref-fulltext>
<ce:source-text>Granot, Z., et al.: Tumor entrained neutrophils inhibit seeding in the premetastatic lung. Cancer Cell. 20, 300–314 (2011)</ce:source-text>
</reference>
<reference seq="90">
<ref-info>
<ref-title>
<ref-titletext-english>Intratumoral neutrophils: a poor prognostic factor for hepatocellular carcinoma following resection.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.W.</ce:initials>
<ce:surname>Li</ce:surname>
<ce:given-name>Y.W.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J.Hepatol.</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>54</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>497</first-page>
<last-page>505</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Li, Y.W., et al.: Intratumoral neutrophils: a poor prognostic factor for hepatocellular carcinoma following resection. J. Hepatol. 54, 497–505 (2011)</ref-fulltext>
<ce:source-text>Li, Y.W., et al.: Intratumoral neutrophils: a poor prognostic factor for hepatocellular carcinoma following resection. J. Hepatol. 54, 497–505 (2011)</ce:source-text>
</reference>
<reference seq="91">
<ref-info>
<ref-title>
<ref-titletext-english>The prognostic value of tumorinfiltrating neutrophils in gastric adenocarcinoma after resection. </ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.J.</ce:initials>
<ce:surname>Zhao</ce:surname>
<ce:given-name>J.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>PLoS One</ref-sourcetitle>
<ref-publicationyear first="2012" />
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Zhao, J.J., et al.: The prognostic value of tumorinfiltrating neutrophils in gastric adenocarcinoma after resection. PLoS One. 7, e33655 (2012)</ref-fulltext>
<ce:source-text>Zhao, J.J., et al.: The prognostic value of tumorinfiltrating neutrophils in gastric adenocarcinoma after resection. PLoS One. 7, e33655 (2012)</ce:source-text>
</reference>
<reference seq="92">
<ref-info>
<ref-title>
<ref-titletext-english>Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.K.</ce:initials>
<ce:surname>Jensen</ce:surname>
<ce:given-name>H.K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Oncol</ref-sourcetitle>
<ref-publicationyear first="2009" />
<volisspag>
<volume-issue-number>
<vol-first>27</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>4709</first-page>
<last-page>4717</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Jensen, H.K., et al.: Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma. J. Clin. Oncol. 27, 4709–4717 (2009)</ref-fulltext>
<ce:source-text>Jensen, H.K., et al.: Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma. J. Clin. Oncol. 27, 4709–4717 (2009)</ce:source-text>
</reference>
<reference seq="93">
<ref-info>
<ref-title>
<ref-titletext-english>Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Schmidt</ce:surname>
<ce:given-name />
</author>
</ref-authors>
<ref-sourcetitle>Br. J. Cancer.</ref-sourcetitle>
<ref-publicationyear first="2005" />
<volisspag>
<volume-issue-number>
<vol-first>93</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>273</first-page>
<last-page>278</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Schmidt, H., et al.: Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model. Br. J. Cancer. 93, 273–278 (2005)</ref-fulltext>
<ce:source-text>Schmidt, H., et al.: Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model. Br. J. Cancer. 93, 273–278 (2005)</ce:source-text>
</reference>
<reference seq="94">
<ref-info>
<ref-title>
<ref-titletext-english>Invasive breast cancer reprograms early myeloid differentiation in the bone marrow to generate immunosuppressive neutrophils. </ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.J.</ce:initials>
<ce:surname>Casbon</ce:surname>
<ce:given-name>A.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Proc. Natl. Acad. Sci. USA. </ref-sourcetitle>
<ref-publicationyear first="2015" />
<ref-text />
<volisspag>
<volume-issue-number>
<vol-first>112</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Casbon, A.J., et al.: Invasive breast cancer reprograms early myeloid differentiation in the bone marrow to generate immunosuppressive neutrophils. Proc. Natl. Acad. Sci. USA. 112, E566–E575 (2015)</ref-fulltext>
<ce:source-text>Casbon, A.J., et al.: Invasive breast cancer reprograms early myeloid differentiation in the bone marrow to generate immunosuppressive neutrophils. Proc. Natl. Acad. Sci. USA. 112, E566–E575 (2015)</ce:source-text>
</reference>
<reference seq="95">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.J.</ce:initials>
<ce:surname>Bayne</ce:surname>
<ce:given-name>L.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Cell</ref-sourcetitle>
<ref-publicationyear first="2012" />
<volisspag>
<volume-issue-number>
<vol-first>21</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>822</first-page>
<last-page>835</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Bayne, L.J., et al.: Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell. 21, 822–835 (2012) </ref-fulltext>
<ce:source-text>Bayne, L.J., et al.: Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell. 21, 822–835 (2012) </ce:source-text>
</reference>
<reference seq="96">
<ref-info>
<ref-title>
<ref-titletext-english> IL-17-producing gammadelta T cells and neutrophils conspire to promote breast cancer metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.B.</ce:initials>
<ce:surname>Coffelt</ce:surname>
<ce:given-name>S.B.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>522</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>345</first-page>
<last-page>348</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Coffelt, S.B., et al.: IL-17-producing gammadelta T cells and neutrophils conspire to promote breast cancer metastasis. Nature. 522, 345–348 (2015) </ref-fulltext>
<ce:source-text>Coffelt, S.B., et al.: IL-17-producing gammadelta T cells and neutrophils conspire to promote breast cancer metastasis. Nature. 522, 345–348 (2015) </ce:source-text>
</reference>
<reference seq="97">
<ref-info>
<ref-title>
<ref-titletext-english>CXCL1 is critical for premetastatic niche formation and metastasis in colorectal cancer. </ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Wang</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="2">
<ce:initials>H.</ce:initials>
<ce:surname>Sun</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Wei</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="4">
<ce:initials>B.</ce:initials>
<ce:surname>Cen</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
<author seq="5">
<ce:initials>R.N</ce:initials>
<ce:surname>DuBois</ce:surname>
<ce:given-name>R.N</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Res.</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>77</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3655</first-page>
<last-page>3665</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wang, D., Sun, H., Wei, J., Cen, B., DuBois, R.N.: CXCL1 is critical for premetastatic niche formation and metastasis in colorectal cancer. Cancer Res. 77, 3655–3665 (2017)</ref-fulltext>
<ce:source-text>Wang, D., Sun, H., Wei, J., Cen, B., DuBois, R.N.: CXCL1 is critical for premetastatic niche formation and metastasis in colorectal cancer. Cancer Res. 77, 3655–3665 (2017)</ce:source-text>
</reference>
<reference seq="98">
<ref-info>
<ref-title>
<ref-titletext-english>Tumour-associated neutrophils in patients with cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.E.</ce:initials>
<ce:surname>Shaul</ce:surname>
<ce:given-name>M.E.</ce:given-name>
</author>
<author seq="2">
<ce:initials>Z.G.</ce:initials>
<ce:surname>Fridlender</ce:surname>
<ce:given-name>Z.G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Clin. Oncol.</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>16</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>601</first-page>
<last-page>620</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Shaul, M.E., Fridlender, Z.G.: Tumour-associated neutrophils in patients with cancer. Nat. Rev. Clin. Oncol. 16, 601–620 (2019)</ref-fulltext>
<ce:source-text>Shaul, M.E., Fridlender, Z.G.: Tumour-associated neutrophils in patients with cancer. Nat. Rev. Clin. Oncol. 16, 601–620 (2019)</ce:source-text>
</reference>
<reference seq="99">
<ref-info>
<ref-title>
<ref-titletext-english>Type I IFNs induce anti-tumor polarization of tumor associated neutrophils in mice and human.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Andzinski</ce:surname>
<ce:given-name />
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Cancer</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>138</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1982</first-page>
<last-page>1993</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Andzinski, L., et al.: Type I IFNs induce anti-tumor polarization of tumor associated neutrophils in mice and human. Int. J. Cancer. 138, 1982–1993 (2016)</ref-fulltext>
<ce:source-text>Andzinski, L., et al.: Type I IFNs induce anti-tumor polarization of tumor associated neutrophils in mice and human. Int. J. Cancer. 138, 1982–1993 (2016)</ce:source-text>
</reference>
<reference seq="100">
<ref-info>
<ref-title>
<ref-titletext-english>Polarization of tumorassociated neutrophil phenotype by TGF-beta: “N1” versus “N2” TAN.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Z.G.</ce:initials>
<ce:surname>Fridlender</ce:surname>
<ce:given-name>Z.G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Cell.</ref-sourcetitle>
<ref-publicationyear first="2009" />
<volisspag>
<volume-issue-number>
<vol-first>16</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>183</first-page>
<last-page>194</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Fridlender, Z.G., et al.: Polarization of tumorassociated neutrophil phenotype by TGF-beta: “N1” versus “N2” TAN. Cancer Cell. 16, 183–194 (2009)</ref-fulltext>
<ce:source-text>Fridlender, Z.G., et al.: Polarization of tumorassociated neutrophil phenotype by TGF-beta: “N1” versus “N2” TAN. Cancer Cell. 16, 183–194 (2009)</ce:source-text>
</reference>
<reference seq="101">
<ref-info>
<ref-title>
<ref-titletext-english> Tumor-derived exosomes induce N2 polarization of neutrophils to promote gastric cancer cell migration.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.</ce:initials>
<ce:surname>Zhang</ce:surname>
<ce:given-name>X.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Mol. Cancer</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>17</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>146</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zhang, X., et al.: Tumor-derived exosomes induce N2 polarization of neutrophils to promote gastric cancer cell migration. Mol. Cancer. 17, 146 (2018)</ref-fulltext>
<ce:source-text>Zhang, X., et al.: Tumor-derived exosomes induce N2 polarization of neutrophils to promote gastric cancer cell migration. Mol. Cancer. 17, 146 (2018)</ce:source-text>
</reference>
<reference seq="102">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor stem-like cell-derived exosomal RNAs prime neutrophils for facilitating tumorigenesis of colon cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>W.L.</ce:initials>
<ce:surname>Hwang</ce:surname>
<ce:given-name>W.L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>H.Y.</ce:initials>
<ce:surname>Lan</ce:surname>
<ce:given-name>H.Y.</ce:given-name>
</author>
<author seq="3">
<ce:initials>W.C.</ce:initials>
<ce:surname>Cheng</ce:surname>
<ce:given-name>W.C.</ce:given-name>
</author>
<author seq="4">
<ce:initials>S.C.</ce:initials>
<ce:surname>Huang</ce:surname>
<ce:given-name>S.C.</ce:given-name>
</author>
<author seq="5">
<ce:initials>M.H.</ce:initials>
<ce:surname>Yang</ce:surname>
<ce:given-name>M.H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Hematol. Oncol.</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>10</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hwang, W.L., Lan, H.Y., Cheng, W.C., Huang, S.C., Yang, M.H.: Tumor stem-like cell-derived exosomal RNAs prime neutrophils for facilitating tumorigenesis of colon cancer. J. Hematol. Oncol. 12, 10 (2019)</ref-fulltext>
<ce:source-text>Hwang, W.L., Lan, H.Y., Cheng, W.C., Huang, S.C., Yang, M.H.: Tumor stem-like cell-derived exosomal RNAs prime neutrophils for facilitating tumorigenesis of colon cancer. J. Hematol. Oncol. 12, 10 (2019)</ce:source-text>
</reference>
<reference seq="103">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor-derived exosomes induce the formation of neutrophil extracellular traps: implications for the establishment of cancerassociated thrombosis.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.C.</ce:initials>
<ce:surname>Leal</ce:surname>
<ce:given-name>A.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Sci. Rep</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>6438</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Leal, A.C., et al.: Tumor-derived exosomes induce the formation of neutrophil extracellular traps: implications for the establishment of cancerassociated thrombosis. Sci. Rep. 7, 6438 (2017)</ref-fulltext>
<ce:source-text>Leal, A.C., et al.: Tumor-derived exosomes induce the formation of neutrophil extracellular traps: implications for the establishment of cancerassociated thrombosis. Sci. Rep. 7, 6438 (2017)</ce:source-text>
</reference>
<reference seq="104">
<ref-info>
<ref-title>
<ref-titletext-english>Neutrophil extracellular traps kill bacteria</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>V.</ce:initials>
<ce:surname>Brinkmann</ce:surname>
<ce:given-name>V.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Science</ref-sourcetitle>
<ref-publicationyear first="2004" />
<volisspag>
<volume-issue-number>
<vol-first>303</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1532</first-page>
<last-page>1535</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Brinkmann, V., et al.: Neutrophil extracellular traps kill bacteria. Science. 303, 1532–1535 (2004)</ref-fulltext>
<ce:source-text>Brinkmann, V., et al.: Neutrophil extracellular traps kill bacteria. Science. 303, 1532–1535 (2004)</ce:source-text>
</reference>
<reference seq="105">
<ref-info>
<ref-title>
<ref-titletext-english>Cancers predispose neutrophils to release extracellular DNA traps that contribute tocancer-associated thrombosis. </ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Demers</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Proc. Natl. Acad. Sci. USA</ref-sourcetitle>
<ref-publicationyear first="2012" />
<volisspag>
<volume-issue-number>
<vol-first>109</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>13076</first-page>
<last-page>13081</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Demers, M., et al.: Cancers predispose neutrophils to release extracellular DNA traps that contribute tocancer-associated thrombosis. Proc. Natl. Acad. Sci. USA. 109, 13076–13081 (2012)</ref-fulltext>
<ce:source-text>Demers, M., et al.: Cancers predispose neutrophils to release extracellular DNA traps that contribute tocancer-associated thrombosis. Proc. Natl. Acad. Sci. USA. 109, 13076–13081 (2012)</ce:source-text>
</reference>
<reference seq="106">
<ref-info>
<ref-title>
<ref-titletext-english> Cancer cells induce metastasissupporting neutrophil extracellular DNA traps</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Park</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Sci. Transl. Med.</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>361</first-page>
<last-page>138</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Park, J., et al.: Cancer cells induce metastasissupporting neutrophil extracellular DNA traps. Sci. Transl. Med. 8, 361ra138 (2016)</ref-fulltext>
<ce:source-text>Park, J., et al.: Cancer cells induce metastasissupporting neutrophil extracellular DNA traps. Sci. Transl. Med. 8, 361ra138 (2016)</ce:source-text>
</reference>
<reference seq="107">
<ref-info>
<ref-title>
<ref-titletext-english>Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Cools-Lartigue</ce:surname>
<ce:given-name />
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Invest</ref-sourcetitle>
<ref-publicationyear first="2013" />
</ref-info>
<ref-fulltext>Cools-Lartigue, J., et al.: Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis. J. Clin. Invest. (2013)</ref-fulltext>
<ce:source-text>Cools-Lartigue, J., et al.: Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis. J. Clin. Invest. (2013)</ce:source-text>
</reference>
<reference seq="108">
<ref-info>
<ref-title>
<ref-titletext-english>The origins of vertebrate adaptive immunity</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.W.</ce:initials>
<ce:surname>Litman</ce:surname>
<ce:given-name>G.W.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.P.</ce:initials>
<ce:surname>Rast</ce:surname>
<ce:given-name>J.P.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.D.</ce:initials>
<ce:surname>Fugmann</ce:surname>
<ce:given-name>S.D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Immunol.</ref-sourcetitle>
<ref-publicationyear first="2010" />
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>543</first-page>
<last-page>553</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Litman, G.W., Rast, J.P., Fugmann, S.D.: The origins of vertebrate adaptive immunity. Nat. Rev. Immunol. 10, 543–553 (2010)</ref-fulltext>
<ce:source-text>Litman, G.W., Rast, J.P., Fugmann, S.D.: The origins of vertebrate adaptive immunity. Nat. Rev. Immunol. 10, 543–553 (2010)</ce:source-text>
</reference>
<reference seq="109">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor-derived exosomes promote carcinogenesis of murine oral squamous cell carcinoma. </ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.M.</ce:initials>
<ce:surname>Razzo</ce:surname>
<ce:given-name>B.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Carcinogenesis.</ref-sourcetitle>
<ref-publicationyear first="2019" />
</ref-info>
<ref-fulltext>Razzo, B.M., et al.: Tumor-derived exosomes promote carcinogenesis of murine oral squamous cell carcinoma. Carcinogenesis. (2019)</ref-fulltext>
<ce:source-text>Razzo, B.M., et al.: Tumor-derived exosomes promote carcinogenesis of murine oral squamous cell carcinoma. Carcinogenesis. (2019)</ce:source-text>
</reference>
<reference seq="110">
<ref-info>
<ref-title>
<ref-titletext-english>14-3-3zeta delivered by hepatocellular carcinoma-derived exosomes impaired antitumor function of tumor-infiltrating T lymphocytes.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.</ce:initials>
<ce:surname>Wang</ce:surname>
<ce:given-name>X.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Death Dis. </ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>159</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wang, X., et al.: 14-3-3zeta delivered by hepatocellular carcinoma-derived exosomes impaired antitumor function of tumor-infiltrating T lymphocytes. Cell Death Dis. 9, 159 (2018)</ref-fulltext>
<ce:source-text>Wang, X., et al.: 14-3-3zeta delivered by hepatocellular carcinoma-derived exosomes impaired antitumor function of tumor-infiltrating T lymphocytes. Cell Death Dis. 9, 159 (2018)</ce:source-text>
</reference>
<reference seq="111">
<ref-info>
<ref-title>
<ref-titletext-english>Brain tumor-initiating cells export tenascin-C associated with exosomes to suppress T cell activity.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Mirzaei</ce:surname>
<ce:given-name />
</author>
</ref-authors>
<ref-sourcetitle>Onco. Targets. Ther</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Mirzaei, R., et al.: Brain tumor-initiating cells export tenascin-C associated with exosomes to suppress T cell activity. Onco. Targets. Ther. 7, e1478647 (2018)</ref-fulltext>
<ce:source-text>Mirzaei, R., et al.: Brain tumor-initiating cells export tenascin-C associated with exosomes to suppress T cell activity. Onco. Targets. Ther. 7, e1478647 (2018)</ce:source-text>
</reference>
<reference seq="112">
<ref-info>
<ref-title>
<ref-titletext-english> B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Griss</ce:surname>
<ce:given-name />
</author>
</ref-authors>
<ref-sourcetitle>Nat. Commun</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>4186</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Griss, J., et al.: B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma. Nat. Commun. 10, 4186 (2019)</ref-fulltext>
<ce:source-text>Griss, J., et al.: B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma. Nat. Commun. 10, 4186 (2019)</ce:source-text>
</reference>
<reference seq="113">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor infiltrating B-cells signal functional humoral immune responses in breast cancer.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Garaud</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>JCI Insight.</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>5</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Garaud, S., et al.: Tumor infiltrating B-cells signal functional humoral immune responses in breast cancer. JCI Insight. 5 (2019) </ref-fulltext>
<ce:source-text>Garaud, S., et al.: Tumor infiltrating B-cells signal functional humoral immune responses in breast cancer. JCI Insight. 5 (2019) </ce:source-text>
</reference>
<reference seq="114">
<ref-info>
<ref-title>
<ref-titletext-english>KRAS renaissance(s) in tumor infiltrating B cells in pancreatic cancer.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Q.</ce:initials>
<ce:surname>Meng</ce:surname>
<ce:given-name>Q.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.</ce:initials>
<ce:surname>Valentini</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Rao</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="4">
<ce:initials>M.</ce:initials>
<ce:surname>Maeurer</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Front. Oncol.</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>384</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Meng, Q., Valentini, D., Rao, M., Maeurer, M.: KRAS renaissance(s) in tumor infiltrating B cells in pancreatic cancer. Front. Oncol. 8, 384 (2018)</ref-fulltext>
<ce:source-text>Meng, Q., Valentini, D., Rao, M., Maeurer, M.: KRAS renaissance(s) in tumor infiltrating B cells in pancreatic cancer. Front. Oncol. 8, 384 (2018)</ce:source-text>
</reference>
<reference seq="115">

<ref-info>
<ref-title>
<ref-titletext-english>IL35-producing B cells promote the development of pancreatic neoplasia.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Pylayeva-Gupta</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Discov.</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>546</first-page>
<last-page>559</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Xiao, X., et al.: PD-1hi identifies a novel regulatory B-cell population in human hepatoma that promotes disease progression. Cancer Discov. 6, 546–559 (2016)</ref-fulltext>
<ce:source-text>Xiao, X., et al.: PD-1hi identifies a novel regulatory B-cell population in human hepatoma that promotes disease progression. Cancer Discov. 6, 546–559 (2016)</ce:source-text>
</reference>
<reference seq="116">
<ref-info>
<ref-title>
<ref-titletext-english>PD-1hi identifies a novel regulatory B-cell population in human hepatoma that promotes disease progression</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.</ce:initials>
<ce:surname>Xiao</ce:surname>
<ce:given-name>X.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Discov.</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>546</first-page>
<last-page>559</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Xiao, X., et al.: PD-1hi identifies a novel regulatory B-cell population in human hepatoma that promotes disease progression. Cancer Discov. 6, 546–559 (2016)</ref-fulltext>
<ce:source-text>Xiao, X., et al.: PD-1hi identifies a novel regulatory B-cell population in human hepatoma that promotes disease progression. Cancer Discov. 6, 546–559 (2016)</ce:source-text>
</reference>
<reference seq="117">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor-derived exosomal HMGB1 fosters hepatocellular carcinoma immune evasion by promoting TIM-1(+) regulatory B cell expansion</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Ye</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle> J. Immunother. Cancer.</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>145</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ye, L., et al.: Tumor-derived exosomal HMGB1 fosters hepatocellular carcinoma immune evasion by promoting TIM-1(+) regulatory B cell expansion. J. Immunother. Cancer. 6, 145 (2018)</ref-fulltext>
<ce:source-text>Ye, L., et al.: Tumor-derived exosomal HMGB1 fosters hepatocellular carcinoma immune evasion by promoting TIM-1(+) regulatory B cell expansion. J. Immunother. Cancer. 6, 145 (2018)</ce:source-text>
</reference>
<reference seq="118">
<ref-info>
<ref-title>
<ref-titletext-english>Therapeutics targeting angiogenesis: genetics and epigenetics, extracellular miRNAs and signaling networks (Review). </ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Katoh</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Mol. Med.</ref-sourcetitle>
<ref-publicationyear first="2013" />
<volisspag>
<volume-issue-number>
<vol-first>32</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>763</first-page>
<last-page>767</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Katoh, M.: Therapeutics targeting angiogenesis: genetics and epigenetics, extracellular miRNAs and signaling networks (Review). Int. J. Mol. Med. 32, 763–767 (2013)</ref-fulltext>
<ce:source-text>Katoh, M.: Therapeutics targeting angiogenesis: genetics and epigenetics, extracellular miRNAs and signaling networks (Review). Int. J. Mol. Med. 32, 763–767 (2013)</ce:source-text>
</reference>
<reference seq="119">
<ref-info>
<ref-title>
<ref-titletext-english>Microenvironmental regulation of tumour angiogenesis.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>De Palma</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.</ce:initials>
<ce:surname>Biziato</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="3">
<ce:initials>T.V.</ce:initials>
<ce:surname>Petrova</ce:surname>
<ce:given-name>T.V.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Cancer.</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>17</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>457</first-page>
<last-page>474</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>De Palma, M., Biziato, D., Petrova, T.V.: Microenvironmental regulation of tumour angiogenesis. Nat. Rev. Cancer. 17, 457–474 (2017)</ref-fulltext>
<ce:source-text>De Palma, M., Biziato, D., Petrova, T.V.: Microenvironmental regulation of tumour angiogenesis. Nat. Rev. Cancer. 17, 457–474 (2017)</ce:source-text>
</reference>
<reference seq="120">
<ref-info>
<ref-title>
<ref-titletext-english>Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Sawamiphak</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature.</ref-sourcetitle>
<ref-publicationyear first="2010" />
<volisspag>
<volume-issue-number>
<vol-first>465</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>487</first-page>
<last-page>491</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sawamiphak, S., et al.: Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis. Nature. 465, 487–491 (2010)</ref-fulltext>
<ce:source-text>Sawamiphak, S., et al.: Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis. Nature. 465, 487–491 (2010)</ce:source-text>
</reference>
<reference seq="121">
<ref-info>
<ref-title>
<ref-titletext-english>EPHB2 carried on small extracellular vesicles induces tumor angiogenesis via activation of ephrin reverse signaling</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Sato</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>JCI Insight.</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>4</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Sato, S., et al.: EPHB2 carried on small extracellular vesicles induces tumor angiogenesis via activation of ephrin reverse signaling. JCI Insight. 4 (2019)</ref-fulltext>
<ce:source-text>Sato, S., et al.: EPHB2 carried on small extracellular vesicles induces tumor angiogenesis via activation of ephrin reverse signaling. JCI Insight. 4 (2019)</ce:source-text>
</reference>
<reference seq="122">
<ref-info>
<ref-title>
<ref-titletext-english>Visualization of exosome-mediated miR-210 transfer from hypoxic tumor cells.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.O.</ce:initials>
<ce:surname>Jung</ce:surname>
<ce:given-name>K.O.</ce:given-name>
</author>
<author seq="2">
<ce:initials>H.</ce:initials>
<ce:surname>Youn</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="3">
<ce:initials>C.H.</ce:initials>
<ce:surname>Lee</ce:surname>
<ce:given-name>C.H.</ce:given-name>
</author>
<author seq="4">
<ce:initials>K.W.</ce:initials>
<ce:surname>Kang</ce:surname>
<ce:given-name>K.W.</ce:given-name>
</author>
<author seq="5">
<ce:initials>J.K.</ce:initials>
<ce:surname>Chung</ce:surname>
<ce:given-name>J.K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncotarget</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>9899</first-page>
<last-page>9910</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Jung, K.O., Youn, H., Lee, C.H., Kang, K.W., Chung, J.K.: Visualization of exosome-mediated miR-210 transfer from hypoxic tumor cells. Oncotarget. 8, 9899–9910 (2017)</ref-fulltext>
<ce:source-text>Jung, K.O., Youn, H., Lee, C.H., Kang, K.W., Chung, J.K.: Visualization of exosome-mediated miR-210 transfer from hypoxic tumor cells. Oncotarget. 8, 9899–9910 (2017)</ce:source-text>
</reference>
<reference seq="123">
<ref-info>
<ref-title>
<ref-titletext-english>PTP1b is a physiologic regulator of vascular endothelial growth factor signaling in endothelial cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.A.</ce:initials>
<ce:surname>Lanahan</ce:surname>
<ce:given-name>A.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Circulation.</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>130</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>902</first-page>
<last-page>909</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Lanahan, A.A., et al.: PTP1b is a physiologic regulator of vascular endothelial growth factor signaling in endothelial cells. Circulation. 130, 902–909 (2014)</ref-fulltext>
<ce:source-text>Lanahan, A.A., et al.: PTP1b is a physiologic regulator of vascular endothelial growth factor signaling in endothelial cells. Circulation. 130, 902–909 (2014)</ce:source-text>
</reference>
<reference seq="124">
<ref-info>
<ref-title>
<ref-titletext-english>Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Umezu</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Blood</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>124</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3748</first-page>
<last-page>3757</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Umezu, T., et al.: Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1. Blood. 124, 3748–3757 (2014)</ref-fulltext>
<ce:source-text>Umezu, T., et al.: Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1. Blood. 124, 3748–3757 (2014)</ce:source-text>
</reference>
<reference seq="125">
<ref-info>
<ref-title>
<ref-titletext-english>piRNA-823 delivered by multiple myeloma-derived extracellular vesicles promoted tumorigenesis through re-educating endothelial cells in the tumor environment</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.B.</ce:initials>
<ce:surname>Li</ce:surname>
<ce:given-name>B.B.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncogene</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>38</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>5227</first-page>
<last-page>5238</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Li, B.B., et al.: piRNA-823 delivered by multiple myeloma-derived extracellular vesicles promoted tumorigenesis through re-educating endothelial cells in the tumor environment. Oncogene. 38, 5227–5238 (2019)</ref-fulltext>
<ce:source-text>Li, B.B., et al.: piRNA-823 delivered by multiple myeloma-derived extracellular vesicles promoted tumorigenesis through re-educating endothelial cells in the tumor environment. Oncogene. 38, 5227–5238 (2019)</ce:source-text>
</reference>
<reference seq="126">
<ref-info>
<ref-title>
<ref-titletext-english>Glioblastoma stem-like cells secrete the pro-angiogenic VEGF-A factor in extracellular vesicles</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Treps</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.</ce:initials>
<ce:surname>Perret</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Edmond</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="4">
<ce:initials>D.</ce:initials>
<ce:surname>Ricard</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="5">
<ce:initials>J.</ce:initials>
<ce:surname>Gavard</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Extracell. Vesicles</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Treps, L., Perret, R., Edmond, S., Ricard, D., Gavard, J.: Glioblastoma stem-like cells secrete the pro-angiogenic VEGF-A factor in extracellular vesicles. J. Extracell. Vesicles. 6, 1359479 (2017)</ref-fulltext>
<ce:source-text>Treps, L., Perret, R., Edmond, S., Ricard, D., Gavard, J.: Glioblastoma stem-like cells secrete the pro-angiogenic VEGF-A factor in extracellular vesicles. J. Extracell. Vesicles. 6, 1359479 (2017)</ce:source-text>
</reference>
<reference seq="127">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer-derived small extracellular vesicles promote angiogenesis by heparin-bound, bevacizumab-insensitive VEGF, independent of vesicle uptake</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.Y.</ce:initials>
<ce:surname>Ko</ce:surname>
<ce:given-name>S.Y.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Commun. Biol.</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>2</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>386</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ko, S.Y., et al.: Cancer-derived small extracellular vesicles promote angiogenesis by heparin-bound, bevacizumab-insensitive VEGF, independent of vesicle uptake. Commun. Biol. 2, 386 (2019)</ref-fulltext>
<ce:source-text>Ko, S.Y., et al.: Cancer-derived small extracellular vesicles promote angiogenesis by heparin-bound, bevacizumab-insensitive VEGF, independent of vesicle uptake. Commun. Biol. 2, 386 (2019)</ce:source-text> </reference>
<reference seq="128">
<ref-info>
<ref-title>
<ref-titletext-english>Intravascular survival and extravasation of tumor cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.</ce:initials>
<ce:surname>Strilic</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Offermanns</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Cell</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>32</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>282</first-page>
<last-page>293</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>. Strilic, B., Offermanns, S.: Intravascular survival and extravasation of tumor cells. Cancer Cell. 32, 282–293 (2017)</ref-fulltext>
<ce:source-text>. Strilic, B., Offermanns, S.: Intravascular survival and extravasation of tumor cells. Cancer Cell. 32, 282–293 (2017)</ce:source-text>
</reference>
<reference seq="129">
<ref-info>
<ref-title>
<ref-titletext-english>Circulating and disseminated tumour cells – mechanisms of immune surveillance and escape</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Mohme</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Riethdorf</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>K.</ce:initials>
<ce:surname>Pantel</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Clin. Oncol.</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>14</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>155</first-page>
<last-page>167</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mohme, M., Riethdorf, S., Pantel, K.: Circulating and disseminated tumour cells – mechanisms of immune surveillance and escape. Nat. Rev. Clin. Oncol. 14, 155–167 (2017)</ref-fulltext>
<ce:source-text>Mohme, M., Riethdorf, S., Pantel, K.: Circulating and disseminated tumour cells – mechanisms of immune surveillance and escape. Nat. Rev. Clin. Oncol. 14, 155–167 (2017)</ce:source-text>
</reference>
<reference seq="130">
<ref-info>
<ref-title>
<ref-titletext-english>Extracellular vesicle-transported Semaphorin3A promotes vascular permeability in glioblastoma</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Treps</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncogene</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>35</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2615</first-page>
<last-page>2623</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Treps, L., et al.: Extracellular vesicle-transported Semaphorin3A promotes vascular permeability in glioblastoma. Oncogene. 35, 2615–2623 (2016)</ref-fulltext>
<ce:source-text>Treps, L., et al.: Extracellular vesicle-transported Semaphorin3A promotes vascular permeability in glioblastoma. Oncogene. 35, 2615–2623 (2016)</ce:source-text>
</reference>
<reference seq="131">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer-derived exosomal miR-25-3p promotes pre-metastatic niche formation by inducing vascular permeability and angiogenesis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Z.</ce:initials>
<ce:surname>Zeng</ce:surname>
<ce:given-name>Z.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat.Commun.</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>5395</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zeng, Z., et al.: Cancer-derived exosomal miR-25-3p promotes pre-metastatic niche formation by inducing vascular permeability and angiogenesis. Nat. Commun. 9, 5395 (2018)</ref-fulltext>
<ce:source-text>Zeng, Z., et al.: Cancer-derived exosomal miR-25-3p promotes pre-metastatic niche formation by inducing vascular permeability and angiogenesis. Nat. Commun. 9, 5395 (2018)</ce:source-text>
</reference>
<reference seq="132">
<ref-info>
<ref-title>
<ref-titletext-english>Inhibition of vascular permeability factor/vascular endothelial growth factor-mediated angiogenesis by the Kruppel-like factor KLF2</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Bhattacharya</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J.Biol.Chem.</ref-sourcetitle>
<ref-publicationyear first="2005" />
<volisspag>
<volume-issue-number>
<vol-first>280</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>28848</first-page>
<last-page>28851</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Bhattacharya, R., et al.: Inhibition of vascular permeability factor/vascular endothelial growth factormediated angiogenesis by the Kruppel-like factor KLF2. J. Biol. Chem. 280, 28848–28851 (2005)</ref-fulltext>
<ce:source-text>Bhattacharya, R., et al.: Inhibition of vascular permeability factor/vascular endothelial growth factormediated angiogenesis by the Kruppel-like factor KLF2. J. Biol. Chem. 280, 28848–28851 (2005)</ce:source-text>
</reference>
<reference seq="133">
<ref-info>
<ref-title>
<ref-titletext-english>Kruppel-like factor 4 regulates blood-tumor barrier permeability via ZO-1, occludin and claudin-5</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Ma</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J.Cell.Physiol.</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>229</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>916</first-page>
<last-page>926</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ma, J., et al.: Kruppel-like factor 4 regulates bloodtumor barrier permeability via ZO-1, occludin and claudin-5. J. Cell. Physiol. 229, 916–926 (2014)</ref-fulltext>
<ce:source-text>Ma, J., et al.: Kruppel-like factor 4 regulates bloodtumor barrier permeability via ZO-1, occludin and claudin-5. J. Cell. Physiol. 229, 916–926 (2014)</ce:source-text>
</reference>
<reference seq="134">
<ref-info>
<ref-title>
<ref-titletext-english>Hypoxic lung cancer-secreted exosomal miR-23a increased angiogenesis and vascular permeability by targeting prolyl hydroxylase and tight junction protein ZO-1</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.L.</ce:initials>
<ce:surname>Hsu</ce:surname>
<ce:given-name>Y.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncogene</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>36</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>4929</first-page>
<last-page>4942</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hsu, Y.L., et al.: Hypoxic lung cancer-secreted exosomal miR-23a increased angiogenesis and vascular permeability by targeting prolyl hydroxylase and tight junction protein ZO-1. Oncogene. 36, 4929–4942 (2017) </ref-fulltext>
<ce:source-text>Hsu, Y.L., et al.: Hypoxic lung cancer-secreted exosomal miR-23a increased angiogenesis and vascular permeability by targeting prolyl hydroxylase and tight junction protein ZO-1. Oncogene. 36, 4929–4942 (2017) </ce:source-text>
</reference>
<reference seq="135">
<ref-info>
<ref-title>
<ref-titletext-english>Breast cancer-secreted miR-939 downregulates VE-cadherin and destroys the barrier function of endothelial monolayers</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Di Modica</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Lett.</ref-sourcetitle>
<ref-publicationyear first="2017" />
<ref-text>Breast cancer-secreted miR-939 downregulates VE-cadherin and destroys the barrier function of endothelial monolayers</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>384</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>94</first-page>
<last-page>100</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Di Modica, M., et al.: Breast cancer-secreted miR-939 downregulates VE-cadherin and destroys the barrier function of endothelial monolayers. Cancer Lett. 384, 94–100 (2017)</ref-fulltext>
<ce:source-text>Di Modica, M., et al.: Breast cancer-secreted miR-939 downregulates VE-cadherin and destroys the barrier function of endothelial monolayers. Cancer Lett. 384, 94–100 (2017)</ce:source-text>
</reference>
<reference seq="136">
<ref-info>
<ref-title>
<ref-titletext-english>Hepatoma cell-secreted exosomal microRNA-103 increases vascular permeability and promotes metastasis by targeting junction proteins</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.H.</ce:initials>
<ce:surname>Fang</ce:surname>
<ce:given-name>J.H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Hepatology</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>68</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1459</first-page>
<last-page>1475</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Fang, J.H., et al.: Hepatoma cell-secreted exosomal microRNA-103 increases vascular permeability and promotes metastasis by targeting junction proteins. Hepatology. 68, 1459–1475 (2018)</ref-fulltext>
<ce:source-text>Fang, J.H., et al.: Hepatoma cell-secreted exosomal microRNA-103 increases vascular permeability and promotes metastasis by targeting junction proteins. Hepatology. 68, 1459–1475 (2018)</ce:source-text>
</reference>
<reference seq="137">
<ref-info>
<ref-title>
<ref-titletext-english>Circular RNA IARS (circ-IARS) secreted by pancreatic cancer cells and located within exosomes regulates endothelial monolayer permeability to promote tumor metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Li</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J.Exp.Clin.Cancer Res.</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>37</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Li, J., et al.: Circular RNA IARS (circ-IARS) secreted by pancreatic cancer cells and located within exosomes regulates endothelial monolayer permeability to promote tumor metastasis. J. Exp. Clin. Cancer Res. 37 (2018)</ref-fulltext>
<ce:source-text>Li, J., et al.: Circular RNA IARS (circ-IARS) secreted by pancreatic cancer cells and located within exosomes regulates endothelial monolayer permeability to promote tumor metastasis. J. Exp. Clin. Cancer Res. 37 (2018)</ce:source-text>
</reference>
<reference seq="138">
<ref-info>
<ref-title>
<ref-titletext-english>Natural RNA circles function as efficient microRNA sponges</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.B.</ce:initials>
<ce:surname>Hansen</ce:surname>
<ce:given-name>T.B.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2013" />
<ref-text>Natural RNA circles function as efficient microRNA sponges</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>495</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>384</first-page>
<last-page>388</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hansen, T.B., et al.: Natural RNA circles function as efficient microRNA sponges. Nature. 495, 384–388 (2013) </ref-fulltext>
<ce:source-text>Hansen, T.B., et al.: Natural RNA circles function as efficient microRNA sponges. Nature. 495, 384–388 (2013) </ce:source-text>
</reference>
<reference seq="139">
<ref-info>
<ref-title>
<ref-titletext-english>Organ selectivity for implantation survival and growth of B16 melanoma variant tumor lines</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>I.J.</ce:initials>
<ce:surname>Fidler</ce:surname>
<ce:given-name>I.J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>G.L.</ce:initials>
<ce:surname>Nicolson</ce:surname>
<ce:given-name>G.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J.Natl.Cancer Inst.</ref-sourcetitle>
<ref-publicationyear first="1976" />
<volisspag>
<volume-issue-number>
<vol-first>57</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1199</first-page>
<last-page>1202</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Fidler, I.J., Nicolson, G.L.: Organ selectivity for implantation survival and growth of B16 melanoma variant tumor lines. J. Natl. Cancer Inst. 57, 1199–1202 (1976)</ref-fulltext>
<ce:source-text>Fidler, I.J., Nicolson, G.L.: Organ selectivity for implantation survival and growth of B16 melanoma variant tumor lines. J. Natl. Cancer Inst. 57, 1199–1202 (1976)</ce:source-text>
</reference>
<reference seq="140">
<ref-info>
<ref-title>
<ref-titletext-english>Role of organ selectivity in the determination of metastatic patterns of B16 melanoma</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>I.R.</ce:initials>
<ce:surname>Hart</ce:surname>
<ce:given-name>I.R.</ce:given-name>
</author>
<author seq="2">
<ce:initials>I.J.</ce:initials>
<ce:surname>Fidler</ce:surname>
<ce:given-name>I.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Res.</ref-sourcetitle>
<ref-publicationyear first="1980" />
<volisspag>
<volume-issue-number>
<vol-first>40</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2281</first-page>
<last-page>2287</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hart, I.R., Fidler, I.J.: Role of organ selectivity in the determination of metastatic patterns of B16 melanoma. Cancer Res. 40, 2281–2287 (1980)</ref-fulltext>
<ce:source-text>Hart, I.R., Fidler, I.J.: Role of organ selectivity in the determination of metastatic patterns of B16 melanoma. Cancer Res. 40, 2281–2287 (1980)</ce:source-text>
</reference>
<reference seq="141">
<ref-info>
<ref-title>
<ref-titletext-english>Metastasis organotropism: redefining the congenial soil</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Gao</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Dev. Cell</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>49</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>375</first-page>
<last-page>391</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Gao, Y., et al.: Metastasis organotropism: redefining the congenial soil. Dev. Cell. 49, 375–391 (2019)</ref-fulltext>
<ce:source-text>Gao, Y., et al.: Metastasis organotropism: redefining the congenial soil. Dev. Cell. 49, 375–391 (2019)</ce:source-text>
</reference>
<reference seq="142">
<ref-info>
<ref-title>
<ref-titletext-english>Metastasis: from dissemination to organ-specific colonization</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.X.</ce:initials>
<ce:surname>Nguyen</ce:surname>
<ce:given-name>D.X.</ce:given-name>
</author>
<author seq="2">
<ce:initials>P.D.</ce:initials>
<ce:surname>Bos</ce:surname>
<ce:given-name>P.D.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Massague</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Cancer</ref-sourcetitle>
<ref-publicationyear first="2009" />
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>274</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Nguyen, D.X., Bos, P.D., Massague, J.: Metastasis: from dissemination to organ-specific colonization. Nat. Rev. Cancer. 9, 274–U265 (2009)</ref-fulltext>
<ce:source-text>Nguyen, D.X., Bos, P.D., Massague, J.: Metastasis: from dissemination to organ-specific colonization. Nat. Rev. Cancer. 9, 274–U265 (2009)</ce:source-text>
</reference>
<reference seq="143">
<ref-info>
<ref-title>
<ref-titletext-english>Exosomes released by melanoma cells prepare sentinel lymph nodes for tumor metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.L.</ce:initials>
<ce:surname>Hood</ce:surname>
<ce:given-name>J.L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.S.</ce:initials>
<ce:surname>San</ce:surname>
<ce:given-name>R.S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.A.</ce:initials>
<ce:surname>Wickline</ce:surname>
<ce:given-name>S.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Res.</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>71</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3792</first-page>
<last-page>3801</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hood, J.L., San, R.S., Wickline, S.A.: Exosomes released by melanoma cells prepare sentinel lymph nodes for tumor metastasis. Cancer Res. 71, 3792–3801 (2011)</ref-fulltext>
<ce:source-text>Hood, J.L., San, R.S., Wickline, S.A.: Exosomes released by melanoma cells prepare sentinel lymph nodes for tumor metastasis. Cancer Res. 71, 3792–3801 (2011)</ce:source-text>
</reference>
<reference seq="144">
<ref-info>
<ref-title>
<ref-titletext-english>Molecular mechanism underlying lymphatic metastasis in pancreatic cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Z.</ce:initials>
<ce:surname>Xiao</ce:surname>
<ce:given-name>Z.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Biomed. Res. Int.</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>2014</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Xiao, Z., et al.: Molecular mechanism underlying lymphatic metastasis in pancreatic cancer. Biomed. Res. Int. 2014, 925845 (2014)</ref-fulltext>
<ce:source-text>Xiao, Z., et al.: Molecular mechanism underlying lymphatic metastasis in pancreatic cancer. Biomed. Res. Int. 2014, 925845 (2014)</ce:source-text>
</reference>
<reference seq="145">
<ref-info>
<ref-title>
<ref-titletext-english>SCS macrophages suppress melanoma by restricting tumor-derived vesicle-B cell interactions</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Pucci</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Science</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>352</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>242</first-page>
<last-page>246</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Pucci, F., et al.: SCS macrophages suppress melanoma by restricting tumor-derived vesicle-B cell interactions. Science. 352, 242–246 (2016)</ref-fulltext>
<ce:source-text>Pucci, F., et al.: SCS macrophages suppress melanoma by restricting tumor-derived vesicle-B cell interactions. Science. 352, 242–246 (2016)</ce:source-text>
</reference>
<reference seq="146">
<ref-info>
<ref-title>
<ref-titletext-english>Human melanoma-derived extracellular vesicles regulate dendritic cell maturation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.L.G.</ce:initials>
<ce:surname>Maus</ce:surname>
<ce:given-name>R.L.G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Front. Immunol.</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>358</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Maus, R.L.G., et al.: Human melanoma-derived extracellular vesicles regulate dendritic cell maturation. Front. Immunol. 8, 358 (2017) </ref-fulltext>
<ce:source-text>Maus, R.L.G., et al.: Human melanoma-derived extracellular vesicles regulate dendritic cell maturation. Front. Immunol. 8, 358 (2017) </ce:source-text>
</reference>
<reference seq="147">
<ref-info>
<ref-title>
<ref-titletext-english>Exosomal tumor microRNA modulates premetastatic organ cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Rana</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.</ce:initials>
<ce:surname>Malinowska</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Zoller</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Neoplasia</ref-sourcetitle>
<ref-publicationyear first="2013" />
<volisspag>
<volume-issue-number>
<vol-first>15</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>281</first-page>
<last-page>295</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Rana, S., Malinowska, K., Zoller, M.: Exosomal tumor microRNA modulates premetastatic organ cells. Neoplasia. 15, 281–295 (2013)</ref-fulltext>
<ce:source-text>Rana, S., Malinowska, K., Zoller, M.: Exosomal tumor microRNA modulates premetastatic organ cells. Neoplasia. 15, 281–295 (2013)</ce:source-text>
</reference>
<reference seq="148">
<ref-info>
<ref-title>
<ref-titletext-english>Lymphatic transport of exosomes as a rapid route of information dissemination to the lymph node</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Srinivasan</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>F.O.</ce:initials>
<ce:surname>Vannberg</ce:surname>
<ce:given-name>F.O.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.B.</ce:initials>
<ce:surname>Dixon</ce:surname>
<ce:given-name>J.B.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Sci. Rep.</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>24436</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Srinivasan, S., Vannberg, F.O., Dixon, J.B.: Lymphatic transport of exosomes as a rapid route of information dissemination to the lymph node. Sci. Rep. 6, 24436 (2016)</ref-fulltext>
<ce:source-text>Srinivasan, S., Vannberg, F.O., Dixon, J.B.: Lymphatic transport of exosomes as a rapid route of information dissemination to the lymph node. Sci. Rep. 6, 24436 (2016)</ce:source-text>
</reference>
<reference seq="149">
<ref-info>
<ref-title>
<ref-titletext-english>Exosomal long noncoding RNA LNMAT2 promotes lymphatic metastasis in bladder cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Chen</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Invest.</ref-sourcetitle>
<ref-publicationyear first="2020" />
<volisspag>
<volume-issue-number>
<vol-first>130</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>404</first-page>
<last-page>421</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Chen, C., et al.: Exosomal long noncoding RNA LNMAT2 promotes lymphatic metastasis in bladder cancer. J. Clin. Invest. 130, 404–421 (2020)</ref-fulltext>
<ce:source-text>Chen, C., et al.: Exosomal long noncoding RNA LNMAT2 promotes lymphatic metastasis in bladder cancer. J. Clin. Invest. 130, 404–421 (2020)</ce:source-text>
</reference>
<reference seq="150">
<ref-info>
<ref-title>
<ref-titletext-english>Colorectal cancer exosomes induce lymphatic network remodeling in lymph nodes</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.</ce:initials>
<ce:surname>Sun</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Cancer</ref-sourcetitle>
<ref-publicationyear first="2019" />
<ref-text>Colorectal cancer exosomes induce lymphatic network remodeling in lymph nodes</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>145</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1648</first-page>
<last-page>1659</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sun, B., et al.: Colorectal cancer exosomes induce lymphatic network remodeling in lymph nodes. Int. J. Cancer. 145, 1648–1659 (2019)</ref-fulltext>
<ce:source-text>Sun, B., et al.: Colorectal cancer exosomes induce lymphatic network remodeling in lymph nodes. Int. J. Cancer. 145, 1648–1659 (2019)</ce:source-text>
</reference>
<reference seq="151">
<ref-info>
<ref-title>
<ref-titletext-english>The lymphatic system: integral roles in immunity</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.J.</ce:initials>
<ce:surname>Randolph</ce:surname>
<ce:given-name>G.J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Ivanov</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>B.H.</ce:initials>
<ce:surname>Zinselmeyer</ce:surname>
<ce:given-name>B.H.</ce:given-name>
</author>
<author seq="4">
<ce:initials>J.P.</ce:initials>
<ce:surname>Scallan</ce:surname>
<ce:given-name>J.P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Annu. Rev. Immunol.</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>35</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>31</first-page>
<last-page>52</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Randolph, G.J., Ivanov, S., Zinselmeyer, B.H., Scallan, J.P.: The lymphatic system: integral roles in immunity. Annu. Rev. Immunol. 35, 31–52 (2017)</ref-fulltext>
<ce:source-text>Randolph, G.J., Ivanov, S., Zinselmeyer, B.H., Scallan, J.P.: The lymphatic system: integral roles in immunity. Annu. Rev. Immunol. 35, 31–52 (2017)</ce:source-text>
</reference>
<reference seq="152">
<ref-info>
<ref-title>
<ref-titletext-english>Macrophage immunomodulation by breast cancer-derived exosomes requires toll-like receptor 2-mediated activation of NF-kappaB</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Chow</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Sci. Rep.</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>4</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>5750</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Chow, A., et al.: Macrophage immunomodulation by breast cancer-derived exosomes requires toll-like receptor 2-mediated activation of NF-kappaB. Sci. Rep. 4, 5750 (2014)</ref-fulltext>
<ce:source-text>Chow, A., et al.: Macrophage immunomodulation by breast cancer-derived exosomes requires toll-like receptor 2-mediated activation of NF-kappaB. Sci. Rep. 4, 5750 (2014)</ce:source-text>
</reference>
<reference seq="153">
<ref-info>
<ref-title>
<ref-titletext-english>Melanoma growth and lymph node metastasis is independent of host CD169 expression</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.R.</ce:initials>
<ce:surname>Muhsin-Sharafaldine</ce:surname>
<ce:given-name>M.R.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.C.</ce:initials>
<ce:surname>Saunderson</ce:surname>
<ce:given-name>S.C.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.C.</ce:initials>
<ce:surname>Dunn</ce:surname>
<ce:given-name>A.C.</ce:given-name>
</author>
<author seq="4">
<ce:initials>A.D.</ce:initials>
<ce:surname>McLellan</ce:surname>
<ce:given-name>A.D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Biochem. Biophys. Res. Commun.</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>486</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>965</first-page>
<last-page>970</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Muhsin-Sharafaldine, M.R., Saunderson, S.C., Dunn, A.C., McLellan, A.D.: Melanoma growth and lymph node metastasis is independent of host CD169 expression. Biochem. Biophys. Res. Commun. 486, 965–970 (2017)</ref-fulltext>
<ce:source-text>Muhsin-Sharafaldine, M.R., Saunderson, S.C., Dunn, A.C., McLellan, A.D.: Melanoma growth and lymph node metastasis is independent of host CD169 expression. Biochem. Biophys. Res. Commun. 486, 965–970 (2017)</ce:source-text>
</reference>
<reference seq="154">
<ref-info>
<ref-title>
<ref-titletext-english>Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Skobe</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Med.</ref-sourcetitle>
<ref-publicationyear first="2001" />
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>192</first-page>
<last-page>198</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Skobe, M., et al.: Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat. Med. 7, 192–198 (2001) </ref-fulltext>
<ce:source-text>Skobe, M., et al.: Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat. Med. 7, 192–198 (2001) </ce:source-text>
</reference>
<reference seq="155">
<ref-info>
<ref-title>
<ref-titletext-english>VEGF-D promotes the metastatic spread of tumor cells via the lymphatics</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.A.</ce:initials>
<ce:surname>Stacker</ce:surname>
<ce:given-name>S.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Med.</ref-sourcetitle>
<ref-publicationyear first="2001" />
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>186</first-page>
<last-page>191</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Stacker, S.A., et al.: VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat. Med. 7, 186–191 (2001)</ref-fulltext>
<ce:source-text>Stacker, S.A., et al.: VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat. Med. 7, 186–191 (2001)</ce:source-text>
</reference>
<reference seq="156">
<ref-info>
<ref-title>
<ref-titletext-english>Lymphangiogenesis and lymphatic vessel remodelling in cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.A.</ce:initials>
<ce:surname>Stacker</ce:surname>
<ce:given-name>S.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Cancer</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>14</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>159</first-page>
<last-page>172</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Stacker, S.A., et al.: Lymphangiogenesis and lymphatic vessel remodelling in cancer. Nat. Rev. Cancer. 14, 159–172 (2014)</ref-fulltext>
<ce:source-text>Stacker, S.A., et al.: Lymphangiogenesis and lymphatic vessel remodelling in cancer. Nat. Rev. Cancer. 14, 159–172 (2014)</ce:source-text>
</reference>
<reference seq="157">
<ref-info>
<ref-title>
<ref-titletext-english>Exosomes as a communication tool between the lymphatic system and bladder cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.J.</ce:initials>
<ce:surname>Park</ce:surname>
<ce:given-name>R.J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>Y.J.</ce:initials>
<ce:surname>Hong</ce:surname>
<ce:given-name>Y.J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>Y.</ce:initials>
<ce:surname>Wu</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<author seq="4">
<ce:initials>P.M.</ce:initials>
<ce:surname>Kim</ce:surname>
<ce:given-name>P.M.</ce:given-name>
</author>
<author seq="5">
<ce:initials>Y.K.</ce:initials>
<ce:surname>Hong</ce:surname>
<ce:given-name>Y.K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. Neurourol. J.</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>22</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>220</first-page>
<last-page>224</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Park, R.J., Hong, Y.J., Wu, Y., Kim, P.M., Hong, Y. K.: Exosomes as a communication tool between the lymphatic system and bladder cancer. Int. Neurourol. J. 22, 220–224 (2018)</ref-fulltext>
<ce:source-text>Park, R.J., Hong, Y.J., Wu, Y., Kim, P.M., Hong, Y. K.: Exosomes as a communication tool between the lymphatic system and bladder cancer. Int. Neurourol. J. 22, 220–224 (2018)</ce:source-text>
</reference>
<reference seq="158">
<ref-info>
<ref-title>
<ref-titletext-english>Cervical squamous cell carcinoma-secreted exosomal miR-221-3p promotes lymphangiogenesis and lymphatic metastasis by targeting VASH1</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.F.</ce:initials>
<ce:surname>Zhou</ce:surname>
<ce:given-name>C.F.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncogene</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>38</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1256</first-page>
<last-page>1268</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zhou, C.F., et al.: Cervical squamous cell carcinomasecreted exosomal miR-221-3p promotes lymphangiogenesis and lymphatic metastasis by targeting VASH1. Oncogene. 38, 1256–1268 (2019)</ref-fulltext>
<ce:source-text>Zhou, C.F., et al.: Cervical squamous cell carcinomasecreted exosomal miR-221-3p promotes lymphangiogenesis and lymphatic metastasis by targeting VASH1. Oncogene. 38, 1256–1268 (2019)</ce:source-text>
</reference>
<reference seq="159">
<ref-info>
<ref-title>
<ref-titletext-english>Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.E.</ce:initials>
<ce:surname>Hautmann</ce:surname>
<ce:given-name>R.E.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.C.</ce:initials>
<ce:surname>de Petriconi</ce:surname>
<ce:given-name>R.C.</ce:given-name>
</author>
<author seq="3">
<ce:initials>C.</ce:initials>
<ce:surname>Pfeiffer</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="4">
<ce:initials>B.G.</ce:initials>
<ce:surname>Volkmer</ce:surname>
<ce:given-name>B.G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Eur. Urol.</ref-sourcetitle>
<ref-publicationyear first="2012" />
<volisspag>
<volume-issue-number>
<vol-first>61</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1039</first-page>
<last-page>1047</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hautmann, R.E., de Petriconi, R.C., Pfeiffer, C., Volkmer, B.G.: Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients. Eur. Urol. 61, 1039–1047 (2012)</ref-fulltext>
<ce:source-text>Hautmann, R.E., de Petriconi, R.C., Pfeiffer, C., Volkmer, B.G.: Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients. Eur. Urol. 61, 1039–1047 (2012)</ce:source-text>
</reference>
<reference seq="160">
<ref-info>
<ref-title>
<ref-titletext-english>CD97 promotion of gastric carcinoma lymphatic metastasis is exosome dependent</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Liu</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Gastric Cancer</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>19</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>754</first-page>
<last-page>766</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Liu, D., et al.: CD97 promotion of gastric carcinoma lymphatic metastasis is exosome dependent. Gastric Cancer. 19, 754–766 (2016)</ref-fulltext>
<ce:source-text>Liu, D., et al.: CD97 promotion of gastric carcinoma lymphatic metastasis is exosome dependent. Gastric Cancer. 19, 754–766 (2016)</ce:source-text>
</reference>
<reference seq="161">
<ref-info>
<ref-title>
<ref-titletext-english>Sentinel-node biopsy or nodal observation in melanoma</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.L.</ce:initials>
<ce:surname>Morton</ce:surname>
<ce:given-name>D.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>N. Engl. J. Med.</ref-sourcetitle>
<ref-publicationyear first="2006" />
<volisspag>
<volume-issue-number>
<vol-first>355</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1307</first-page>
<last-page>1317</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Morton, D.L., et al.: Sentinel-node biopsy or nodal observation in melanoma. N. Engl. J. Med. 355, 1307–1317 (2006) </ref-fulltext>
<ce:source-text>Morton, D.L., et al.: Sentinel-node biopsy or nodal observation in melanoma. N. Engl. J. Med. 355, 1307–1317 (2006) </ce:source-text>
</reference>
<reference seq="162">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer volume of lymph node metastasis predicts progression in prostate cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Cheng</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Surg. Pathol.</ref-sourcetitle>
<ref-publicationyear first="1998" />
<volisspag>
<volume-issue-number>
<vol-first>22</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1491</first-page>
<last-page>1500</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Cheng, L., et al.: Cancer volume of lymph node metastasis predicts progression in prostate cancer. Am. J. Surg. Pathol. 22, 1491–1500 (1998)</ref-fulltext>
<ce:source-text>Cheng, L., et al.: Cancer volume of lymph node metastasis predicts progression in prostate cancer. Am. J. Surg. Pathol. 22, 1491–1500 (1998)</ce:source-text>
</reference>
<reference seq="163">
<ref-info>
<ref-title>
<ref-titletext-english>Sulfisoxazole inhibits the secretion of small extracellular vesicles by targeting the endothelin receptor A</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.J.</ce:initials>
<ce:surname>Im</ce:surname>
<ce:given-name>E.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Commun.</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1387</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Im, E.J., et al.: Sulfisoxazole inhibits the secretion of small extracellular vesicles by targeting the endothelin receptor A. Nat. Commun. 10, 1387 (2019)</ref-fulltext>
<ce:source-text>Im, E.J., et al.: Sulfisoxazole inhibits the secretion of small extracellular vesicles by targeting the endothelin receptor A. Nat. Commun. 10, 1387 (2019)</ce:source-text>
</reference>
<reference seq="164">
<ref-info>
<ref-title>
<ref-titletext-english>The lung microenvironment: an important regulator of tumour growth and metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.K.</ce:initials>
<ce:surname>Altorki</ce:surname>
<ce:given-name>N.K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Cancer</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>19</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>9</first-page>
<last-page>31</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Altorki, N.K., et al.: The lung microenvironment: an important regulator of tumour growth and metastasis. Nat. Rev. Cancer. 19, 9–31 (2019)</ref-fulltext>
<ce:source-text>Altorki, N.K., et al.: The lung microenvironment: an important regulator of tumour growth and metastasis. Nat. Rev. Cancer. 19, 9–31 (2019)</ce:source-text>
</reference>
<reference seq="165">
<ref-info>
<ref-title>
<ref-titletext-english>Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.T.</ce:initials>
<ce:surname>Erler</ce:surname>
<ce:given-name>J.T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Cell</ref-sourcetitle>
<ref-publicationyear first="2009" />
<ref-text>Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>15</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>35</first-page>
<last-page>44</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Erler, J.T., et al.: Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell. 15, 35–44 (2009)</ref-fulltext>
<ce:source-text>Erler, J.T., et al.: Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell. 15, 35–44 (2009)</ce:source-text>
</reference>
<reference seq="166">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor-derived exosomal miR-1247-3p induces cancer-associated fibroblast activation to foster lung metastasis of liver cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Fang</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Commun.</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>191</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Fang, T., et al.: Tumor-derived exosomal miR-1247- 3p induces cancer-associated fibroblast activation to foster lung metastasis of liver cancer. Nat. Commun. 9, 191 (2018)</ref-fulltext>
<ce:source-text>Fang, T., et al.: Tumor-derived exosomal miR-1247- 3p induces cancer-associated fibroblast activation to foster lung metastasis of liver cancer. Nat. Commun. 9, 191 (2018)</ce:source-text>
</reference>
<reference seq="167">
<ref-info>
<ref-title>
<ref-titletext-english>The liver</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.</ce:initials>
<ce:surname>Trefts</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Gannon</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>D.H.</ce:initials>
<ce:surname>Wasserman</ce:surname>
<ce:given-name>D.H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Curr. Biol.</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>27</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Trefts, E., Gannon, M., Wasserman, D.H.: The liver. Curr. Biol. 27, R1147–R1151 (2017) </ref-fulltext>
<ce:source-text>Trefts, E., Gannon, M., Wasserman, D.H.: The liver. Curr. Biol. 27, R1147–R1151 (2017) </ce:source-text>
</reference>
<reference seq="168">
<ref-info>
<ref-title>
<ref-titletext-english>Exosome-delivered EGFR regulates liver microenvironment to promote gastric cancer liver metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Zhang</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Commun.</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Zhang, H., et al.: Exosome-delivered EGFR regulates liver microenvironment to promote gastric cancer liver metastasis. Nat. Commun. 8, 15016 (2017)</ref-fulltext>
<ce:source-text>Zhang, H., et al.: Exosome-delivered EGFR regulates liver microenvironment to promote gastric cancer liver metastasis. Nat. Commun. 8, 15016 (2017)</ce:source-text>
</reference>
<reference seq="169">
<ref-info>
<ref-title>
<ref-titletext-english>Colorectal cancer-derived small extracellular vesicles establish an inflammatory premetastatic niche in liver metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Shao</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Carcinogenesis</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>39</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1368</first-page>
<last-page>1379</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Shao, Y., et al.: Colorectal cancer-derived small extracellular vesicles establish an inflammatory premetastatic niche in liver metastasis. Carcinogenesis. 39, 1368–1379 (2018)</ref-fulltext>
<ce:source-text>Shao, Y., et al.: Colorectal cancer-derived small extracellular vesicles establish an inflammatory premetastatic niche in liver metastasis. Carcinogenesis. 39, 1368–1379 (2018)</ce:source-text>
</reference>
<reference seq="170">
<ref-info>
<ref-title>
<ref-titletext-english>Metastasis to bone: causes, consequences and therapeutic opportunities</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.R.</ce:initials>
<ce:surname>Mundy</ce:surname>
<ce:given-name>G.R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Cancer</ref-sourcetitle>
<ref-publicationyear first="2002" />
<volisspag>
<volume-issue-number>
<vol-first>2</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>584</first-page>
<last-page>593</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mundy, G.R.: Metastasis to bone: causes, consequences and therapeutic opportunities. Nat. Rev. Cancer. 2, 584–593 (2002)</ref-fulltext>
<ce:source-text>Mundy, G.R.: Metastasis to bone: causes, consequences and therapeutic opportunities. Nat. Rev. Cancer. 2, 584–593 (2002)</ce:source-text>
</reference>
<reference seq="171">
<ref-info>
<ref-title>
<ref-titletext-english>RANKL-RANK signaling regulates osteoblast differentiation and bone formation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.</ce:initials>
<ce:surname>Cao</ce:surname>
<ce:given-name>X.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Bone Res.</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>35</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Cao, X.: RANKL-RANK signaling regulates osteoblast differentiation and bone formation. Bone Res. 6, 35 (2018)</ref-fulltext>
<ce:source-text>Cao, X.: RANKL-RANK signaling regulates osteoblast differentiation and bone formation. Bone Res. 6, 35 (2018)</ce:source-text>
</reference>
<reference seq="172">
<ref-info>
<ref-title>
<ref-titletext-english>Exosomal release of L-plastin by breast cancer cells facilitates metastatic bone osteolysis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Tiedemann</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Transl. Oncol.</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>462</first-page>
<last-page>474</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Tiedemann, K., et al.: Exosomal release of L-plastin by breast cancer cells facilitates metastatic bone osteolysis. Transl. Oncol. 12, 462–474 (2019) </ref-fulltext>
<ce:source-text>Tiedemann, K., et al.: Exosomal release of L-plastin by breast cancer cells facilitates metastatic bone osteolysis. Transl. Oncol. 12, 462–474 (2019) </ce:source-text>
</reference>
<reference seq="173">
<ref-info>
<ref-title>
<ref-titletext-english>Breast cancer cell-derived exosomal miR-20a-5p promotes the proliferation and differentiation of osteoclasts by targeting SRCIN1</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Guo</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Med.</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>5687</first-page>
<last-page>5701</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Guo, L., et al.: Breast cancer cell-derived exosomal miR-20a-5p promotes the proliferation and differentiation of osteoclasts by targeting SRCIN1. Cancer Med. 8, 5687–5701 (2019)</ref-fulltext>
<ce:source-text>Guo, L., et al.: Breast cancer cell-derived exosomal miR-20a-5p promotes the proliferation and differentiation of osteoclasts by targeting SRCIN1. Cancer Med. 8, 5687–5701 (2019)</ce:source-text>
</reference>
<reference seq="174">
<ref-info>
<ref-title>
<ref-titletext-english>Communication of prostate cancer cells with bone cells via extracellular vesicle RNA; a potential mechanism of metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Probert</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncogene</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>38</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1751</first-page>
<last-page>1763</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Probert, C., et al.: Communication of prostate cancer cells with bone cells via extracellular vesicle RNA; a potential mechanism of metastasis. Oncogene. 38, 1751–1763 (2019)</ref-fulltext>
<ce:source-text>Probert, C., et al.: Communication of prostate cancer cells with bone cells via extracellular vesicle RNA; a potential mechanism of metastasis. Oncogene. 38, 1751–1763 (2019)</ce:source-text>
</reference>
<reference seq="175">
<ref-info>
<ref-title>
<ref-titletext-english>Exosomal miR-141-3p regulates osteoblast activity to promote the osteoblastic metastasis of prostate cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Ye</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncotarget</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>94834</first-page>
<last-page>94849</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ye, Y., et al.: Exosomal miR-141-3p regulates osteoblast activity to promote the osteoblastic metastasis of prostate cancer. Oncotarget. 8, 94834–94849 (2017)</ref-fulltext>
<ce:source-text>Ye, Y., et al.: Exosomal miR-141-3p regulates osteoblast activity to promote the osteoblastic metastasis of prostate cancer. Oncotarget. 8, 94834–94849 (2017)</ce:source-text>
</reference>
<reference seq="176">
<ref-info>
<ref-title>
<ref-titletext-english>Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.L.</ce:initials>
<ce:surname>Lacey</ce:surname>
<ce:given-name>D.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Drug Discov.</ref-sourcetitle>
<ref-publicationyear first="2012" />
<volisspag>
<volume-issue-number>
<vol-first>11</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>401</first-page>
<last-page>419</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Lacey, D.L., et al.: Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat. Rev. Drug Discov. 11, 401–419 (2012)</ref-fulltext>
<ce:source-text>Lacey, D.L., et al.: Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat. Rev. Drug Discov. 11, 401–419 (2012)</ce:source-text>
</reference>
<reference seq="177">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer-secreted hsa-miR-940 induces an osteoblastic phenotype in the bone metastatic microenvironment via targeting ARHGAP1 and FAM134A</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Hashimoto</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Proc. Natl. Acad. Sci. USA</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>115</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2204</first-page>
<last-page>2209</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hashimoto, K., et al.: Cancer-secreted hsa-miR-940 induces an osteoblastic phenotype in the bone metastatic microenvironment via targeting ARHGAP1 and FAM134A. Proc. Natl. Acad. Sci. USA. 115, 2204–2209 (2018)</ref-fulltext>
<ce:source-text>Hashimoto, K., et al.: Cancer-secreted hsa-miR-940 induces an osteoblastic phenotype in the bone metastatic microenvironment via targeting ARHGAP1 and FAM134A. Proc. Natl. Acad. Sci. USA. 115, 2204–2209 (2018)</ce:source-text>
</reference>
<reference seq="178">
<ref-info>
<ref-title>
<ref-titletext-english>Brain metastatic cancer cells release microRNA-181c-containing extracellular vesicles capable of destructing blood-brain barrier</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.</ce:initials>
<ce:surname>Tominaga</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Commun.</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>6716</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Tominaga, N., et al.: Brain metastatic cancer cells release microRNA-181c-containing extracellular vesicles capable of destructing blood-brain barrier. Nat. Commun. 6, 6716 (2015)</ref-fulltext>
<ce:source-text>Tominaga, N., et al.: Brain metastatic cancer cells release microRNA-181c-containing extracellular vesicles capable of destructing blood-brain barrier. Nat. Commun. 6, 6716 (2015)</ce:source-text>
</reference>
<reference seq="179">
<ref-info>
<ref-title>
<ref-titletext-english>Loss of XIST in breast cancer activates MSN-c-Met and reprograms microglia via exosomal miRNA to promote brain metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Xing</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Res.</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>78</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>4316</first-page>
<last-page>4330</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Xing, F., et al.: Loss of XIST in breast cancer activates MSN-c-Met and reprograms microglia via exosomal miRNA to promote brain metastasis. Cancer Res. 78, 4316–4330 (2018)</ref-fulltext>
<ce:source-text>Xing, F., et al.: Loss of XIST in breast cancer activates MSN-c-Met and reprograms microglia via exosomal miRNA to promote brain metastasis. Cancer Res. 78, 4316–4330 (2018)</ce:source-text>
</reference>
<reference seq="180">
<ref-info>
<ref-title>
<ref-titletext-english>Melanoma-derived extracellular vesicles instigate proinflammatory signaling in the metastatic microenvironment</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Gener Lahav</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Cancer</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>145</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2521</first-page>
<last-page>2534</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Gener Lahav, T., et al.: Melanoma-derived extracellular vesicles instigate proinflammatory signaling in the metastatic microenvironment. Int. J. Cancer. 145, 2521–2534 (2019)</ref-fulltext>
<ce:source-text>Gener Lahav, T., et al.: Melanoma-derived extracellular vesicles instigate proinflammatory signaling in the metastatic microenvironment. Int. J. Cancer. 145, 2521–2534 (2019)</ce:source-text>
</reference>
<reference seq="181">
<ref-info>
<ref-title>
<ref-titletext-english>Blood-brain barrier: from physiology to disease and back</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.D.</ce:initials>
<ce:surname>Sweeney</ce:surname>
<ce:given-name>M.D.</ce:given-name>
</author>
<author seq="2">
<ce:initials>Z.</ce:initials>
<ce:surname>Zhao</ce:surname>
<ce:given-name>Z.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Montagne</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="4">
<ce:initials>A.R.</ce:initials>
<ce:surname>Nelson</ce:surname>
<ce:given-name>A.R.</ce:given-name>
</author>
<author seq="5">
<ce:initials>B.V.</ce:initials>
<ce:surname>Zlokovic</ce:surname>
<ce:given-name>B.V.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Physiol. Rev.</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>99</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>21</first-page>
<last-page>78</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sweeney, M.D., Zhao, Z., Montagne, A., Nelson, A. R., Zlokovic, B.V.: Blood-brain barrier: from physiology to disease and back. Physiol. Rev. 99, 21–78 (2019)</ref-fulltext>
<ce:source-text>Sweeney, M.D., Zhao, Z., Montagne, A., Nelson, A. R., Zlokovic, B.V.: Blood-brain barrier: from physiology to disease and back. Physiol. Rev. 99, 21–78 (2019)</ce:source-text>
</reference>
<reference seq="182">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor-derived extracellular vesicles breach the intact blood-brain barrier via transcytosis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Morad</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>ACS Nano</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>13</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>13853</first-page>
<last-page>13865</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Morad, G., et al.: Tumor-derived extracellular vesicles breach the intact blood-brain barrier via transcytosis. ACS Nano. 13, 13853–13865 (2019)</ref-fulltext>
<ce:source-text>Morad, G., et al.: Tumor-derived extracellular vesicles breach the intact blood-brain barrier via transcytosis. ACS Nano. 13, 13853–13865 (2019)</ce:source-text>
</reference>
<reference seq="183">
<ref-info>
<ref-title>
<ref-titletext-english>Brain microvascular endothelial cell exosome-mediated S100A16 up-regulation confers small-cell lung cancer cell survival in brain</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Z.H.</ce:initials>
<ce:surname>Xu</ce:surname>
<ce:given-name>Z.H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>FASEB J.</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>33</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1742</first-page>
<last-page>1757</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Xu, Z.H., et al.: Brain microvascular endothelial cell exosome-mediated S100A16 up-regulation confers small-cell lung cancer cell survival in brain. FASEB J. 33, 1742–1757 (2019)</ref-fulltext>
<ce:source-text>Xu, Z.H., et al.: Brain microvascular endothelial cell exosome-mediated S100A16 up-regulation confers small-cell lung cancer cell survival in brain. FASEB J. 33, 1742–1757 (2019)</ce:source-text>
</reference>
<reference seq="184">
<ref-info>
<ref-title>
<ref-titletext-english>Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Zhang</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>527</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>100</first-page>
<last-page>104</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zhang, L., et al.: Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth. Nature. 527, 100–104 (2015)</ref-fulltext>
<ce:source-text>Zhang, L., et al.: Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth. Nature. 527, 100–104 (2015)</ce:source-text>
</reference>
<reference seq="185">
<ref-info>
<ref-title>
<ref-titletext-english>Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD1 response</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Chen</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>560</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>382</first-page>
<last-page>386</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Chen, G., et al.: Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD1 response. Nature. 560, 382–386 (2018)</ref-fulltext>
<ce:source-text>Chen, G., et al.: Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD1 response. Nature. 560, 382–386 (2018)</ce:source-text>
</reference>
<reference seq="186">
<ref-info>
<ref-title>
<ref-titletext-english>Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Balaj</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Commun.</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>2</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>180</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Balaj, L., et al.: Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences. Nat. Commun. 2, 180 (2011)</ref-fulltext>
<ce:source-text>Balaj, L., et al.: Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences. Nat. Commun. 2, 180 (2011)</ce:source-text>
</reference>
<reference seq="187">
<ref-info>
<ref-title>
<ref-titletext-english>Astrocytes and Glioblastoma cells release exosomes carrying mtDNA</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Guescini</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Genedani</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>V.</ce:initials>
<ce:surname>Stocchi</ce:surname>
<ce:given-name>V.</ce:given-name>
</author>
<author seq="4">
<ce:initials>L.F.</ce:initials>
<ce:surname>Agnati</ce:surname>
<ce:given-name>L.F.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Neural Transm. (Vienna)</ref-sourcetitle>
<ref-publicationyear first="2010" />
<volisspag>
<volume-issue-number>
<vol-first>117</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1</first-page>
<last-page>4</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Guescini, M., Genedani, S., Stocchi, V., Agnati, L.F.: Astrocytes and Glioblastoma cells release exosomes carrying mtDNA. J. Neural Transm. (Vienna). 117, 1–4 (2010) </ref-fulltext>
<ce:source-text>Guescini, M., Genedani, S., Stocchi, V., Agnati, L.F.: Astrocytes and Glioblastoma cells release exosomes carrying mtDNA. J. Neural Transm. (Vienna). 117, 1–4 (2010) </ce:source-text>
</reference>
<reference seq="188">
<ref-info>
<ref-title>
<ref-titletext-english>Double-stranded DNA in exosomes: a novel biomarker in cancer detection</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.K.</ce:initials>
<ce:surname>Thakur</ce:surname>
<ce:given-name>B.K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Res.</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>24</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>766</first-page>
<last-page>769</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Thakur, B.K., et al.: Double-stranded DNA in exosomes: a novel biomarker in cancer detection. Cell Res. 24, 766–769 (2014)</ref-fulltext>
<ce:source-text>Thakur, B.K., et al.: Double-stranded DNA in exosomes: a novel biomarker in cancer detection. Cell Res. 24, 766–769 (2014) </ce:source-text>
</reference>
<reference seq="189">
<ref-info>
<ref-title>
<ref-titletext-english>Exosome DNA: critical regulator of tumor immunity and a diagnostic biomarker</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Sharma</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Johnson</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cell. Physiol.</ref-sourcetitle>
<ref-publicationyear first="2020" />
<volisspag>
<volume-issue-number>
<vol-first>235</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1921</first-page>
<last-page>1932</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sharma, A., Johnson, A.: Exosome DNA: critical regulator of tumor immunity and a diagnostic biomarker. J. Cell. Physiol. 235, 1921–1932 (2020)</ref-fulltext>
<ce:source-text>Sharma, A., Johnson, A.: Exosome DNA: critical regulator of tumor immunity and a diagnostic biomarker. J. Cell. Physiol. 235, 1921–1932 (2020)</ce:source-text>
</reference>
<reference seq="190">
<ref-info>
<ref-title>
<ref-titletext-english>DNA-containing exosomes derived from cancer cells treated with topotecan activate a STING-dependent pathway and reinforce antitumor immunity</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Kitai</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Immunol.</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>198</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1649</first-page>
<last-page>1659</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kitai, Y., et al.: DNA-containing exosomes derived from cancer cells treated with topotecan activate a STING-dependent pathway and reinforce antitumor immunity. J. Immunol. 198, 1649–1659 (2017)</ref-fulltext>
<ce:source-text>Kitai, Y., et al.: DNA-containing exosomes derived from cancer cells treated with topotecan activate a STING-dependent pathway and reinforce antitumor immunity. J. Immunol. 198, 1649–1659 (2017)</ce:source-text>
</reference>
<reference seq="191">
<ref-info>
<ref-title>
<ref-titletext-english>Dendritic cells but not macrophages sense tumor mitochondrial DNA for cross-priming through signal regulatory protein alpha signaling</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.M.</ce:initials>
<ce:surname>Xu</ce:surname>
<ce:given-name>M.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Immunity</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>47</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>363</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Xu, M.M., et al.: Dendritic cells but not macrophages sense tumor mitochondrial DNA for cross-priming through signal regulatory protein alpha signaling. Immunity. 47, 363-+ (2017)</ref-fulltext>
<ce:source-text>Xu, M.M., et al.: Dendritic cells but not macrophages sense tumor mitochondrial DNA for cross-priming through signal regulatory protein alpha signaling. Immunity. 47, 363-+ (2017)</ce:source-text>
</reference>
<reference seq="192">
<ref-info>
<ref-title>
<ref-titletext-english>Metabolomic profiling of extracellular vesicles and alternative normalization methods reveal enriched metabolites and strategies to study prostate cancer-related changes</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Puhka</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Theranostics</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3824</first-page>
<last-page>3841</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Puhka, M., et al.: Metabolomic profiling of extracellular vesicles and alternative normalization methods reveal enriched metabolites and strategies to study prostate cancer-related changes. Theranostics. 7, 3824–3841 (2017)</ref-fulltext>
<ce:source-text>Puhka, M., et al.: Metabolomic profiling of extracellular vesicles and alternative normalization methods reveal enriched metabolites and strategies to study prostate cancer-related changes. Theranostics. 7, 3824–3841 (2017)</ce:source-text>
</reference>
<reference seq="193">
<ref-info>
<ref-title>
<ref-titletext-english>Visualization and tracking of tumour extracellular vesicle delivery and RNA translation using multiplexed reporters</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.P.</ce:initials>
<ce:surname>Lai</ce:surname>
<ce:given-name>C.P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Commun.</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>7029</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Lai, C.P., et al.: Visualization and tracking of tumour extracellular vesicle delivery and RNA translation using multiplexed reporters. Nat. Commun. 6, 7029 (2015)</ref-fulltext>
<ce:source-text>Lai, C.P., et al.: Visualization and tracking of tumour extracellular vesicle delivery and RNA translation using multiplexed reporters. Nat. Commun. 6, 7029 (2015)</ce:source-text>
</reference>
<reference seq="194">
<ref-info>
<ref-title>
<ref-titletext-english>In vivo imaging reveals extracellular vesicle-mediated phenocopying of metastatic behavior</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Zomer</ce:surname>
<ce:given-name />
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>161</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1046</first-page>
<last-page>1057</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zomer, A., et al.: In vivo imaging reveals extracellular vesicle-mediated phenocopying of metastatic behavior. Cell. 161, 1046–1057 (2015)</ref-fulltext>
<ce:source-text>Zomer, A., et al.: In vivo imaging reveals extracellular vesicle-mediated phenocopying of metastatic behavior. Cell. 161, 1046–1057 (2015)</ce:source-text>
</reference>
<reference seq="195">
<ref-info>
<ref-title>
<ref-titletext-english>Studying extracellular vesicle transfer by a Cre-loxP method</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Zomer</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.C.</ce:initials>
<ce:surname>Steenbeek</ce:surname>
<ce:given-name>S.C.</ce:given-name>
</author>
<author seq="3">
<ce:initials>C.</ce:initials>
<ce:surname>Maynard</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="4">
<ce:initials>J.</ce:initials>
<ce:surname>van Rheenen</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Protoc.</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>11</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>87</first-page>
<last-page>101</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zomer, A., Steenbeek, S.C., Maynard, C., van Rheenen, J.: Studying extracellular vesicle transfer by a Cre-loxP method. Nat. Protoc. 11, 87–101 (2016)</ref-fulltext>
<ce:source-text>Zomer, A., Steenbeek, S.C., Maynard, C., van Rheenen, J.: Studying extracellular vesicle transfer by a Cre-loxP method. Nat. Protoc. 11, 87–101 (2016)</ce:source-text>
</reference>
<reference seq="196">
<ref-info>
<ref-title>
<ref-titletext-english>Studying the fate of tumor extracellular vesicles at high spatiotemporal resolution using the zebrafish embryo</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>V.</ce:initials>
<ce:surname>Hyenne</ce:surname>
<ce:given-name>V.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Dev. Cell</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>48</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>554</first-page>
<last-page>572</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hyenne, V., et al.: Studying the fate of tumor extracellular vesicles at high spatiotemporal resolution using the zebrafish embryo. Dev. Cell. 48, 554–572 e557 (2019)</ref-fulltext>
<ce:source-text>Hyenne, V., et al.: Studying the fate of tumor extracellular vesicles at high spatiotemporal resolution using the zebrafish embryo. Dev. Cell. 48, 554–572 e557 (2019)</ce:source-text>
</reference>
<reference seq="197">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer cachexia: mediators, signaling, and metabolic pathways</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.C.</ce:initials>
<ce:surname>Fearon</ce:surname>
<ce:given-name>K.C.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.J.</ce:initials>
<ce:surname>Glass</ce:surname>
<ce:given-name>D.J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>D.C.</ce:initials>
<ce:surname>Guttridge</ce:surname>
<ce:given-name>D.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Metab.</ref-sourcetitle>
<ref-publicationyear first="2012" />
<volisspag>
<volume-issue-number>
<vol-first>16</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>153</first-page>
<last-page>166</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Fearon, K.C., Glass, D.J., Guttridge, D.C.: Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab. 16, 153–166 (2012)</ref-fulltext>
<ce:source-text>Fearon, K.C., Glass, D.J., Guttridge, D.C.: Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab. 16, 153–166 (2012)</ce:source-text>
</reference>
<reference seq="198">
<ref-info>
<ref-title>
<ref-titletext-english>Understanding cachexia as a cancer metabolism syndrome</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.E.</ce:initials>
<ce:surname>Porporato</ce:surname>
<ce:given-name>P.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncogenesis</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>5</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Porporato, P.E.: Understanding cachexia as a cancer metabolism syndrome. Oncogenesis. 5 (2016)</ref-fulltext>
<ce:source-text>Porporato, P.E.: Understanding cachexia as a cancer metabolism syndrome. Oncogenesis. 5 (2016)</ce:source-text>
</reference>
<reference seq="199">
<ref-info>
<ref-title>
<ref-titletext-english>Metastatic cancers promote cachexia through ZIP14 upregulation in skeletal muscle</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Wang</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Med.</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>24</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>770</first-page>
<last-page>781</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wang, G., et al.: Metastatic cancers promote cachexia through ZIP14 upregulation in skeletal muscle. Nat. Med. 24, 770–781 (2018)</ref-fulltext>
<ce:source-text>Wang, G., et al.: Metastatic cancers promote cachexia through ZIP14 upregulation in skeletal muscle. Nat. Med. 24, 770–781 (2018)</ce:source-text>
</reference>
<reference seq="200">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer-associated cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>V.E.</ce:initials>
<ce:surname>Baracos</ce:surname>
<ce:given-name>V.E.</ce:given-name>
</author>
<author seq="2">
<ce:initials>L.</ce:initials>
<ce:surname>Martin</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Korc</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="4">
<ce:initials>D.C.</ce:initials>
<ce:surname>Guttridge</ce:surname>
<ce:given-name>D.C.</ce:given-name>
</author>
<author seq="5">
<ce:initials>K.C.H.</ce:initials>
<ce:surname>Fearon</ce:surname>
<ce:given-name>K.C.H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Dis. Primers</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>4</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>17105</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Baracos, V.E., Martin, L., Korc, M., Guttridge, D.C., Fearon, K.C.H.: Cancer-associated cachexia. Nat. Rev. Dis. Primers. 4, 17105 (2018)</ref-fulltext>
<ce:source-text>Baracos, V.E., Martin, L., Korc, M., Guttridge, D.C., Fearon, K.C.H.: Cancer-associated cachexia. Nat. Rev. Dis. Primers. 4, 17105 (2018)</ce:source-text>
</reference>
<reference seq="201">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer-derived exosome miRNAs induce skeletal muscle wasting by Bcl-2-mediated apoptosis in colon cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Miao</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Mol. Ther. Nucleic Acids</ref-sourcetitle>
<ref-publicationyear first="2021" />
<volisspag>
<volume-issue-number>
<vol-first>24</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>923</first-page>
<last-page>938</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Miao, C., et al.: Cancer-derived exosome miRNAs induce skeletal muscle wasting by Bcl-2-mediated apoptosis in colon cancer cachexia. Mol. Ther. Nucleic Acids. 24, 923–938 (2021) </ref-fulltext>
<ce:source-text>Miao, C., et al.: Cancer-derived exosome miRNAs induce skeletal muscle wasting by Bcl-2-mediated apoptosis in colon cancer cachexia. Mol. Ther. Nucleic Acids. 24, 923–938 (2021) </ce:source-text>
</reference>
<reference seq="202">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor induces muscle wasting in mice through releasing extracellular Hsp70 and Hsp90</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Zhang</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Commun.</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>589</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zhang, G., et al.: Tumor induces muscle wasting in mice through releasing extracellular Hsp70 and Hsp90. Nat. Commun. 8, 589 (2017)</ref-fulltext>
<ce:source-text>Zhang, G., et al.: Tumor induces muscle wasting in mice through releasing extracellular Hsp70 and Hsp90. Nat. Commun. 8, 589 (2017)</ce:source-text>
</reference>
<reference seq="203">
<ref-info>
<ref-title>
<ref-titletext-english>Microvesicles containing miRNAs promote muscle cell death in cancer cachexia via TLR7</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>W.A.</ce:initials>
<ce:surname>He</ce:surname>
<ce:given-name>W.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Proc. Natl. Acad. Sci. USA</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>111</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>4525</first-page>
<last-page>4529</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>He, W.A., et al.: Microvesicles containing miRNAs promote muscle cell death in cancer cachexia via TLR7. Proc. Natl. Acad. Sci. USA. 111, 4525–4529 (2014)</ref-fulltext>
<ce:source-text>He, W.A., et al.: Microvesicles containing miRNAs promote muscle cell death in cancer cachexia via TLR7. Proc. Natl. Acad. Sci. USA. 111, 4525–4529 (2014)</ce:source-text>
</reference>
<reference seq="204">
<ref-info>
<ref-title>
<ref-titletext-english>Pathogenesis of pancreatic cancer exosome-induced lipolysis in adipose tissue</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Sagar</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Gut</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>65</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1165</first-page>
<last-page>1174</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sagar, G., et al.: Pathogenesis of pancreatic cancer exosome-induced lipolysis in adipose tissue. Gut. 65, 1165–1174 (2016)</ref-fulltext>
<ce:source-text>Sagar, G., et al.: Pathogenesis of pancreatic cancer exosome-induced lipolysis in adipose tissue. Gut. 65, 1165–1174 (2016)</ce:source-text>
</reference>
<reference seq="205">
<ref-info>
<ref-title>
<ref-titletext-english>Reduced adipogenesis after lung tumor exosomes priming in human mesenchymal stem cells via TGF-beta signaling pathway</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Wang</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>X.</ce:initials>
<ce:surname>Li</ce:surname>
<ce:given-name>X.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Xu</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="4">
<ce:initials>J.</ce:initials>
<ce:surname>Wang</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="5">
<ce:initials>R.C.</ce:initials>
<ce:surname>Zhao</ce:surname>
<ce:given-name>R.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Mol. Cell. Biochem.</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>435</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>59</first-page>
<last-page>66</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wang, S., Li, X., Xu, M., Wang, J., Zhao, R.C.: Reduced adipogenesis after lung tumor exosomes priming in human mesenchymal stem cells via TGF-beta signaling pathway. Mol. Cell. Biochem. 435, 59–66 (2017)</ref-fulltext>
<ce:source-text>Wang, S., Li, X., Xu, M., Wang, J., Zhao, R.C.: Reduced adipogenesis after lung tumor exosomes priming in human mesenchymal stem cells via TGF-beta signaling pathway. Mol. Cell. Biochem. 435, 59–66 (2017)</ce:source-text>
</reference>
<reference seq="206">
<ref-info>
<ref-title>
<ref-titletext-english>A switch from white to brown fat increases energy expenditure in cancer-associated cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Petruzzelli</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Metab.</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>20</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>433</first-page>
<last-page>447</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Petruzzelli, M., et al.: A switch from white to brown fat increases energy expenditure in cancer-associated cachexia. Cell Metab. 20, 433–447 (2014) </ref-fulltext>
<ce:source-text>Petruzzelli, M., et al.: A switch from white to brown fat increases energy expenditure in cancer-associated cachexia. Cell Metab. 20, 433–447 (2014) </ce:source-text>
</reference>
<reference seq="207">
<ref-info>
<ref-title>
<ref-titletext-english>Tumour-originated exosomal miR-155 triggers cancer-associated cachexia to promote tumour progression</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Q.</ce:initials>
<ce:surname>Wu</ce:surname>
<ce:given-name>Q.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Mol. Cancer</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>17</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>155</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wu, Q., et al.: Tumour-originated exosomal miR-155 triggers cancer-associated cachexia to promote tumour progression. Mol. Cancer. 17, 155 (2018) </ref-fulltext>
<ce:source-text>Wu, Q., et al.: Tumour-originated exosomal miR-155 triggers cancer-associated cachexia to promote tumour progression. Mol. Cancer. 17, 155 (2018)</ce:source-text>
</reference>
<reference seq="208">
<ref-info>
<ref-title>
<ref-titletext-english>Colorectal cancer prompted adipose tissue browning and cancer cachexia through transferring exosomal miR-146b-5p</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>W.J.</ce:initials>
<ce:surname>Di</ce:surname>
<ce:given-name>W.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cell. Physiol.</ref-sourcetitle>
<ref-publicationyear first="2021" />
<volisspag>
<volume-issue-number>
<vol-first>236</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>5399</first-page>
<last-page>5410</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Di, W.J., et al.: Colorectal cancer prompted adipose tissue browning and cancer cachexia through transferring exosomal miR-146b-5p. J. Cell. Physiol. 236, 5399–5410 (2021)</ref-fulltext>
<ce:source-text>Di, W.J., et al.: Colorectal cancer prompted adipose tissue browning and cancer cachexia through transferring exosomal miR-146b-5p. J. Cell. Physiol. 236, 5399–5410 (2021)</ce:source-text>
</reference>
<reference seq="209">
<ref-info>
<ref-title>
<ref-titletext-english>Paraneoplastic syndromes in rheumatology</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.</ce:initials>
<ce:surname>Manger</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
<author seq="2">
<ce:initials>G.</ce:initials>
<ce:surname>Schett</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Rheumatol.</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>662</first-page>
<last-page>670</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Manger, B., Schett, G.: Paraneoplastic syndromes in rheumatology. Nat. Rev. Rheumatol. 10, 662–670 (2014)</ref-fulltext>
<ce:source-text>Manger, B., Schett, G.: Paraneoplastic syndromes in rheumatology. Nat. Rev. Rheumatol. 10, 662–670 (2014)</ce:source-text>
</reference>
<reference seq="210">
<ref-info>
<ref-title>
<ref-titletext-english>Pancreatic cancer-derived exosomes cause paraneoplastic beta-cell dysfunction</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.</ce:initials>
<ce:surname>Javeed</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Clin. Cancer Res.</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>21</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1722</first-page>
<last-page>1733</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Javeed, N., et al.: Pancreatic cancer-derived exosomes cause paraneoplastic beta-cell dysfunction. Clin. Cancer Res. 21, 1722–1733 (2015)</ref-fulltext>
<ce:source-text>Javeed, N., et al.: Pancreatic cancer-derived exosomes cause paraneoplastic beta-cell dysfunction. Clin. Cancer Res. 21, 1722–1733 (2015)</ce:source-text>
</reference>
<reference seq="211">
<ref-info>
<ref-title>
<ref-titletext-english>Intercellular transfer of tissue factor via the uptake of tumor-derived microvesicles</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.G.</ce:initials>
<ce:surname>Lima</ce:surname>
<ce:given-name>L.G.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.C.</ce:initials>
<ce:surname>Leal</ce:surname>
<ce:given-name>A.C.</ce:given-name>
</author>
<author seq="3">
<ce:initials>G.</ce:initials>
<ce:surname>Vargas</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="4">
<ce:initials>I.</ce:initials>
<ce:surname>Porto-Carreiro</ce:surname>
<ce:given-name>I.</ce:given-name>
</author>
<author seq="5">
<ce:initials>R.Q.</ce:initials>
<ce:surname>Monteiro</ce:surname>
<ce:given-name>R.Q.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Thromb. Res.</ref-sourcetitle>
<ref-publicationyear first="2013" />
<volisspag>
<volume-issue-number>
<vol-first>132</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>450</first-page>
<last-page>456</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Lima, L.G., Leal, A.C., Vargas, G., Porto-Carreiro, I., Monteiro, R.Q.: Intercellular transfer of tissue factor via the uptake of tumor-derived microvesicles. Thromb. Res. 132, 450–456 (2013)</ref-fulltext>
<ce:source-text>Lima, L.G., Leal, A.C., Vargas, G., Porto-Carreiro, I., Monteiro, R.Q.: Intercellular transfer of tissue factor via the uptake of tumor-derived microvesicles. Thromb. Res. 132, 450–456 (2013)</ce:source-text>
</reference>
<reference seq="212">
<ref-info>
<ref-title>
<ref-titletext-english>Breast-cancer extracellular vesicles induce platelet activation and aggregation by tissue factor-independent and -dependent mechanisms</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.G.</ce:initials>
<ce:surname>Gomes</ce:surname>
<ce:given-name>F.G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Thromb. Res.</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>159</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>24</first-page>
<last-page>32</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Gomes, F.G., et al.: Breast-cancer extracellular vesicles induce platelet activation and aggregation by tissue factor-independent and -dependent mechanisms. Thromb. Res. 159, 24–32 (2017)</ref-fulltext>
<ce:source-text>Gomes, F.G., et al.: Breast-cancer extracellular vesicles induce platelet activation and aggregation by tissue factor-independent and -dependent mechanisms. Thromb. Res. 159, 24–32 (2017)</ce:source-text>
</reference>
<reference seq="213">
<ref-info>
<ref-title>
<ref-titletext-english>International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.S.</ce:initials>
<ce:surname>Wefel</ce:surname>
<ce:given-name>J.S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Vardy</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>T.</ce:initials>
<ce:surname>Ahles</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="4">
<ce:initials>S.B.</ce:initials>
<ce:surname>Schagen</ce:surname>
<ce:given-name>S.B.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Lancet Oncol.</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>703</first-page>
<last-page>708</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wefel, J.S., Vardy, J., Ahles, T., Schagen, S.B.: International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol. 12, 703–708 (2011)</ref-fulltext>
<ce:source-text>Wefel, J.S., Vardy, J., Ahles, T., Schagen, S.B.: International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol. 12, 703–708 (2011)</ce:source-text>
</reference>
<reference seq="214">
<ref-info>
<ref-title>
<ref-titletext-english>Role of exosomes in cancer-related cognitive impairment</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.Q.</ce:initials>
<ce:surname>Koh</ce:surname>
<ce:given-name>Y.Q.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Mol. Sci.</ref-sourcetitle>
<ref-publicationyear first="2020" />
<volisspag>
<volume-issue-number>
<vol-first>21</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Koh, Y.Q., et al.: Role of exosomes in cancer-related cognitive impairment. Int. J. Mol. Sci. 21 (2020)</ref-fulltext>
<ce:source-text>Koh, Y.Q., et al.: Role of exosomes in cancer-related cognitive impairment. Int. J. Mol. Sci. 21 (2020)</ce:source-text>
</reference>
<reference seq="215">
<ref-info>
<ref-title>
<ref-titletext-english>Ionizing radiation increases the activity of exosomal secretory pathway in MCF-7 human breast cancer cells: a possible way to communicate resistance against radiotherapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.</ce:initials>
<ce:surname>Jabbari</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Nawaz</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Rezaie</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Mol. Sci.</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>20</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Jabbari, N., Nawaz, M., Rezaie, J.: Ionizing radiation increases the activity of exosomal secretory pathway in MCF-7 human breast cancer cells: a possible way to communicate resistance against radiotherapy. Int. J. Mol. Sci. 20 (2019)</ref-fulltext>
<ce:source-text>Jabbari, N., Nawaz, M., Rezaie, J.: Ionizing radiation increases the activity of exosomal secretory pathway in MCF-7 human breast cancer cells: a possible way to communicate resistance against radiotherapy. Int. J. Mol. Sci. 20 (2019)</ce:source-text>
</reference>
<reference seq="216">
<ref-info>
<ref-title>
<ref-titletext-english>Chemotherapy induces secretion of exosomes loaded with heparanase that degrades extracellular matrix and impacts tumor and host cell behavior</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.K.</ce:initials>
<ce:surname>Bandari</ce:surname>
<ce:given-name>S.K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Matrix Biol.</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>65</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>104</first-page>
<last-page>118</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Bandari, S.K., et al.: Chemotherapy induces secretion of exosomes loaded with heparanase that degrades extracellular matrix and impacts tumor and host cell behavior. Matrix Biol. 65, 104–118 (2018)</ref-fulltext>
<ce:source-text>Bandari, S.K., et al.: Chemotherapy induces secretion of exosomes loaded with heparanase that degrades extracellular matrix and impacts tumor and host cell behavior. Matrix Biol. 65, 104–118 (2018)</ce:source-text>
</reference>
<reference seq="217">
<ref-info>
<ref-title>
<ref-titletext-english>Identifying predictors of taxane-induced peripheral neuropathy using mass spectrometry-based proteomics technology</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.I.</ce:initials>
<ce:surname>Chen</ce:surname>
<ce:given-name>E.I.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>PLoS One</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Chen, E.I., et al.: Identifying predictors of taxaneinduced peripheral neuropathy using mass spectrometry-based proteomics technology. PLoS One. 10 (2015)</ref-fulltext>
<ce:source-text>Chen, E.I., et al.: Identifying predictors of taxaneinduced peripheral neuropathy using mass spectrometry-based proteomics technology. PLoS One. 10 (2015)</ce:source-text>
</reference>
<reference seq="218">
<ref-info>
<ref-title>
<ref-titletext-english>Exosomes as a multicomponent biomarker platform in cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>V.S.</ce:initials>
<ce:surname>LeBleu</ce:surname>
<ce:given-name>V.S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.</ce:initials>
<ce:surname>Kalluri</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Trends Cancer</ref-sourcetitle>
<ref-publicationyear first="2020" />
</ref-info>
<ref-fulltext>LeBleu, V.S., Kalluri, R.: Exosomes as a multicomponent biomarker platform in cancer. Trends Cancer. (2020)</ref-fulltext>
<ce:source-text>LeBleu, V.S., Kalluri, R.: Exosomes as a multicomponent biomarker platform in cancer. Trends Cancer. (2020)</ce:source-text>
</reference>
<reference seq="219">
<ref-info>
<ref-title>
<ref-titletext-english>MicroRNAs in serum exosomes as potential biomarkers in clear-cell renal cell carcinoma</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>W.</ce:initials>
<ce:surname>Zhang</ce:surname>
<ce:given-name>W.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Eur. Urol. Focus</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>4</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>412</first-page>
<last-page>419</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zhang, W., et al.: MicroRNAs in serum exosomes as potential biomarkers in clear-cell renal cell carcinoma. Eur. Urol. Focus. 4, 412–419 (2018)</ref-fulltext>
<ce:source-text>Zhang, W., et al.: MicroRNAs in serum exosomes as potential biomarkers in clear-cell renal cell carcinoma. Eur. Urol. Focus. 4, 412–419 (2018)</ce:source-text>
</reference>
<reference seq="220">
<ref-info>
<ref-title>
<ref-titletext-english>Multiparametric plasma EV profiling facilitates diagnosis of pancreatic malignancy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.S.</ce:initials>
<ce:surname>Yang</ce:surname>
<ce:given-name>K.S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Sci. Transl. Med.</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Yang, K.S., et al.: Multiparametric plasma EV profiling facilitates diagnosis of pancreatic malignancy. Sci. Transl. Med. 9 (2017)</ref-fulltext>
<ce:source-text>Yang, K.S., et al.: Multiparametric plasma EV profiling facilitates diagnosis of pancreatic malignancy. Sci. Transl. Med. 9 (2017)</ce:source-text>
</reference>
<reference seq="221">
<ref-info>
<ref-title>
<ref-titletext-english>Progress in exosome isolation techniques</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.</ce:initials>
<ce:surname>Li</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Kaslan</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.H.</ce:initials>
<ce:surname>Lee</ce:surname>
<ce:given-name>S.H.</ce:given-name>
</author>
<author seq="4">
<ce:initials>J.</ce:initials>
<ce:surname>Yao</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="5">
<ce:initials>Z.</ce:initials>
<ce:surname>Gao</ce:surname>
<ce:given-name>Z.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Theranostics</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>789</first-page>
<last-page>804</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Li, P., Kaslan, M., Lee, S.H., Yao, J., Gao, Z.: Progress in exosome isolation techniques. Theranostics. 7, 789–804 (2017)</ref-fulltext>
<ce:source-text>Li, P., Kaslan, M., Lee, S.H., Yao, J., Gao, Z.: Progress in exosome isolation techniques. Theranostics. 7, 789–804 (2017)</ce:source-text>
</reference>
<reference seq="222">
<ref-info>
<ref-title>
<ref-titletext-english>Cardiovascular effects of systemic cancer treatment</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.</ce:initials>
<ce:surname>Senkus</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Jassem</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Treat. Rev.</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>37</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>300</first-page>
<last-page>311</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Senkus, E., Jassem, J.: Cardiovascular effects of systemic cancer treatment. Cancer Treat. Rev. 37, 300–311 (2011)</ref-fulltext>
<ce:source-text>Senkus, E., Jassem, J.: Cardiovascular effects of systemic cancer treatment. Cancer Treat. Rev. 37, 300–311 (2011)</ce:source-text>
</reference>
<reference seq="223">
<ref-info>
<ref-title>
<ref-titletext-english>A paradigm shift in cancer immunotherapy: from enhancement to normalization</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.F.</ce:initials>
<ce:surname>Sanmamed</ce:surname>
<ce:given-name>M.F.</ce:given-name>
</author>
<author seq="2">
<ce:initials>L.</ce:initials>
<ce:surname>Chen</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>175</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>313</first-page>
<last-page>326</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sanmamed, M.F., Chen, L.: A paradigm shift in cancer immunotherapy: from enhancement to normalization. Cell. 175, 313–326 (2018)</ref-fulltext>
<ce:source-text>Sanmamed, M.F., Chen, L.: A paradigm shift in cancer immunotherapy: from enhancement to normalization. Cell. 175, 313–326 (2018)</ce:source-text>
</reference>
<reference seq="224">
<ref-info>
<ref-title>
<ref-titletext-english>Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Chen</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>X.</ce:initials>
<ce:surname>Han</ce:surname>
<ce:given-name>X.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Invest.</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>125</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3384</first-page>
<last-page>3391</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Chen, L., Han, X.: Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J. Clin. Invest. 125, 3384–3391 (2015)</ref-fulltext>
<ce:source-text>Chen, L., Han, X.: Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J. Clin. Invest. 125, 3384–3391 (2015)</ce:source-text>
</reference>
<reference seq="225">
<ref-info>
<ref-title>
<ref-titletext-english>Immune modulation in cancer with antibodies</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.B.</ce:initials>
<ce:surname>Page</ce:surname>
<ce:given-name>D.B.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.A.</ce:initials>
<ce:surname>Postow</ce:surname>
<ce:given-name>M.A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.K.</ce:initials>
<ce:surname>Callahan</ce:surname>
<ce:given-name>M.K.</ce:given-name>
</author>
<author seq="4">
<ce:initials>J.P.</ce:initials>
<ce:surname>Allison</ce:surname>
<ce:given-name>J.P.</ce:given-name>
</author>
<author seq="5">
<ce:initials>J.D.</ce:initials>
<ce:surname>Wolchok</ce:surname>
<ce:given-name>J.D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Annu. Rev. Med.</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>65</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>185</first-page>
<last-page>202</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Page, D.B., Postow, M.A., Callahan, M.K., Allison, J.P., Wolchok, J.D.: Immune modulation in cancer with antibodies. Annu. Rev. Med. 65, 185–202 (2014)</ref-fulltext>
<ce:source-text>Page, D.B., Postow, M.A., Callahan, M.K., Allison, J.P., Wolchok, J.D.: Immune modulation in cancer with antibodies. Annu. Rev. Med. 65, 185–202 (2014)</ce:source-text>
</reference>
<reference seq="226">
<ref-info>
<ref-title>
<ref-titletext-english>Suppression of exosomal PD-L1 induces systemic anti-tumor immunity and memory</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Poggio</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>177</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>414</first-page>
<last-page>427</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Poggio, M., et al.: Suppression of exosomal PD-L1 induces systemic anti-tumor immunity and memory. Cell. 177, 414–427 e413 (2019)</ref-fulltext>
<ce:source-text>Poggio, M., et al.: Suppression of exosomal PD-L1 induces systemic anti-tumor immunity and memory. Cell. 177, 414–427 e413 (2019)</ce:source-text>
</reference>
<reference seq="227">
<ref-info>
<ref-title>
<ref-titletext-english>Engineering exosomes as refined biological nanoplatforms for drug delivery</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.</ce:initials>
<ce:surname>Luan</ce:surname>
<ce:given-name>X.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Acta Pharmacol. Sin.</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>38</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>754</first-page>
<last-page>763</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Luan, X., et al.: Engineering exosomes as refined biological nanoplatforms for drug delivery. Acta Pharmacol. Sin. 38, 754–763 (2017)</ref-fulltext>
<ce:source-text>Luan, X., et al.: Engineering exosomes as refined biological nanoplatforms for drug delivery. Acta Pharmacol. Sin. 38, 754–763 (2017)</ce:source-text>
</reference>
<reference seq="228">
<ref-info>
<ref-title>
<ref-titletext-english>Treatment of brain metastases</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.</ce:initials>
<ce:surname>Lin</ce:surname>
<ce:given-name>X.</ce:given-name>
</author>
<author seq="2">
<ce:initials>L.M.</ce:initials>
<ce:surname>DeAngelis</ce:surname>
<ce:given-name>L.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Oncol.</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>33</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3475</first-page>
<last-page>3484</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Lin, X., DeAngelis, L.M.: Treatment of brain metastases. J. Clin. Oncol. 33, 3475–3484 (2015)</ref-fulltext>
<ce:source-text>Lin, X., DeAngelis, L.M.: Treatment of brain metastases. J. Clin. Oncol. 33, 3475–3484 (2015)</ce:source-text>
</reference>
<reference seq="229">
<ref-info>
<ref-title>
<ref-titletext-english>A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Tian</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Biomaterials</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>35</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2383</first-page>
<last-page>2390</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Tian, Y., et al.: A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. Biomaterials. 35, 2383–2390 (2014)</ref-fulltext>
<ce:source-text>Tian, Y., et al.: A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. Biomaterials. 35, 2383–2390 (2014)</ce:source-text>
</reference>
<reference seq="230">
<ref-info>
<ref-title>
<ref-titletext-english>Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Kamerkar</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>546</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>498</first-page>
<last-page>503</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kamerkar, S., et al.: Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. Nature. 546, 498–503 (2017)</ref-fulltext>
<ce:source-text>Kamerkar, S., et al.: Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. Nature. 546, 498–503 (2017)</ce:source-text>
</reference>
<reference seq="231">
<ref-info>
<ref-title>
<ref-titletext-english>Exosomal formulation of anthocyanidins against multiple cancer types</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Munagala</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Lett.</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>393</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>94</first-page>
<last-page>102</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Munagala, R., et al.: Exosomal formulation of anthocyanidins against multiple cancer types. Cancer Lett. 393, 94–102 (2017)</ref-fulltext>
<ce:source-text>Munagala, R., et al.: Exosomal formulation of anthocyanidins against multiple cancer types. Cancer Lett. 393, 94–102 (2017)</ce:source-text>
</reference>
</bibliography>
</tail>
</bibrecord>
<bibrecord>
<item-info>
<status state="new" stage="S300" />
<itemidlist>
<ce:doi>10.1007/978-3-031-09518-4_3</ce:doi>
<itemid idtype="TPB-ID">9783031095184</itemid>
</itemidlist>
</item-info>
<head>
<citation-info>
<citation-type code="ch" />
<citation-language xml:lang="ENG" />
<abstract-language xml:lang="ENG" />
<author-keywords>
<author-keyword>Bone</author-keyword>
<author-keyword>Muscle</author-keyword>
<author-keyword>TGF-beta</author-keyword>
<author-keyword>Metastasis</author-keyword>
<author-keyword>Crosstalk</author-keyword>
</author-keywords>
</citation-info>
<citation-title>
<titletext xml:lang="ENG" original="y">Bone Metastases: Systemic Regulation and Impact on Host</titletext>
</citation-title>
<author-group seq="1">
<author seq="1">
<ce:initials>S.</ce:initials> 
<ce:surname>Suresh</ce:surname>
<ce:given-name>Sukanya</ce:given-name>
</author>
<author seq="2">
<ce:initials>T.A.</ce:initials> 
<ce:surname>Guise</ce:surname>
<ce:given-name>Theresa A.</ce:given-name>
<ce:e-address>TAGuise@mdanderson.org</ce:e-address>
</author>
<affiliation>
<organization>Department of Endocrine Neoplasia and Hormonal Disorders</organization>
<organization>The University of Texas MD Anderson Cancer Center</organization>
<city>Houston</city>
<state>TX</state>
<country iso-code="USA" />
<ce:source-text>Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.</ce:source-text>
</affiliation>
</author-group>
<abstracts>
<abstract xml:lang="ENG" original="y">
<publishercopyright>© Springer Nature Switzerland AG 2022</publishercopyright>
<ce:para>Advanced cancers frequently metastasize to bone and disrupt normal bone remodeling to cause bone destruction. Bone metastases are incurable and result in significant morbidity: pain, fracture, hypercalcemia, spinal cord compression, and muscle weakness. The associated muscle weakness may occur prior to or in the absence of cachexia. Tumor- induced bone destruction causes the release of growth factors that can fuel tumor progres- sion in bone. These factors can also act sys- temically to cause muscle weakness. The resulting muscle dysfunction adds to cancer- associated morbidity and can increase the risk of falls and fractures in patients with bone metastases. In this review, we discuss the mechanisms by which bone metastases can induce muscle weakness and potential ways to identify and treat cancer-induced systemic dysfunction.</ce:para>
</abstract>
</abstracts>
<source type="book" country="USA">
<sourcetitle>The Systemic Effects of Advanced Cancer A Textbook on Cancer-Associated Cachexia</sourcetitle>
<sourcetitle-abbrev>The Systemic Effects of Advanced Cancer A Textbook on Cancer-Associated Cachexia</sourcetitle-abbrev>
<isbn type="print" length="13">978-3-031-07272-7</isbn>
<isbn type="electronic" length="13">978-3-031-09518-4</isbn>
<volisspag>
<page-information>
<pages>
<first-page>41</first-page>
<last-page>49</last-page>
</pages>
</page-information>
</volisspag>
<publicationyear first="2022" />
<publicationdate>
<year>2022</year>
<month>01</month>
<day>01</day>
</publicationdate>
<website type="item">
<ce:e-address type="url">https://link.springer.com</ce:e-address>
</website>
<publisher>
<publishername>Springer International Publishing</publishername>
</publisher>
</source>
<enhancement>
<classificationgroup>
<classifications type="ASJC">
<classification>
<classification-code>2700</classification-code>
<classification-code>2400</classification-code>
<classification-code>1300</classification-code>
</classification>
</classifications>
</classificationgroup>
</enhancement>
</head>
<tail>
<bibliography refcount="231">
<reference seq="1">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer:an old disease,a new disease or something in between?Nat.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.R.</ce:initials>
<ce:surname>David</ce:surname>
<ce:given-name>A.R.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.R.</ce:initials>
<ce:surname>Zimmerman</ce:surname>
<ce:given-name>M.R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Rev.Cancer.</ref-sourcetitle>
<ref-publicationyear first="2010" />
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>728</first-page>
<last-page>733</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>David, A.R., Zimmerman, M.R.:Cancer: an old dis- ease, a new disease or something in between? Nat. Rev. Cancer. 10, 728-733 (2010)</ref-fulltext>
<ce:source-text>David, A.R., Zimmerman, M.R.:Cancer: an old dis- ease, a new disease or something in between? Nat. Rev. Cancer. 10, 728-733 (2010)</ce:source-text>
</reference>
<reference seq="2">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer statistics</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.L</ce:initials>
<ce:surname>Siegel</ce:surname>
<ce:given-name>R.L</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.D.</ce:initials>
<ce:surname>Miller</ce:surname>
<ce:given-name>K.D.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Jemal</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>CA Cancer J. Clin</ref-sourcetitle>
<ref-publicationyear first="2020" />
<volisspag>
<volume-issue-number>
<vol-first>70</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>7</first-page>
<last-page>30</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Siegel, R.L., Miller, K.D., Jemal, A .: Cancer statistics, 2020. CA Cancer J. Clin. 70, 7-30 (2020)</ref-fulltext>
<ce:source-text>Siegel, R.L., Miller, K.D., Jemal, A .: Cancer statistics, 2020. CA Cancer J. Clin. 70, 7-30 (2020)</ce:source-text>
</reference>
<reference seq="3">
<ref-info>
<ref-title>
<ref-titletext-english>Emerging biological principles of metastasis.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.W.</ce:initials>
<ce:surname>Lambert</ce:surname>
<ce:given-name>A.W.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.R.</ce:initials>
<ce:surname>Pattabiraman</ce:surname>
<ce:given-name>D.R.</ce:given-name>
</author>
<author seq="3">
<ce:initials> R.A.</ce:initials>
<ce:surname>Weinberg</ce:surname>
<ce:given-name> R.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell.</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>168</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>670</first-page>
<last-page>691</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Lambert, A.W., Pattabiraman, D.R., Weinberg, R.A .: Emerging biological principles of metastasis. Cell. 168, 670-691 (2017)</ref-fulltext>
<ce:source-text>Lambert, A.W., Pattabiraman, D.R., Weinberg, R.A .: Emerging biological principles of metastasis. Cell. 168, 670-691 (2017)</ce:source-text>
</reference>
<reference seq="4">
<ref-info>
<ref-title>
<ref-titletext-english>Surviving at a distance:
organ-specific metastasis.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.C.</ce:initials>
<ce:surname>Obenauf</ce:surname>
<ce:given-name>A.C.</ce:given-name>
</author>
<author seq="">
<ce:initials>J.</ce:initials>
<ce:surname>Massague</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Trends Cancer</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>1</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>76</first-page>
<last-page>91</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>. Obenauf, A.C., Massague, J.: Surviving at a distance: organ-specific metastasis. Trends Cancer. 1, 76–91 (2015) </ref-fulltext>
<ce:source-text>. Obenauf, A.C., Massague, J.: Surviving at a distance: organ-specific metastasis. Trends Cancer. 1, 76–91 (2015) </ce:source-text>
</reference>
<reference seq="5">
<ref-info>
<ref-title>
<ref-titletext-english>Metastatic colonization by circulating tumour cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Massague</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.C.</ce:initials>
<ce:surname>Obenauf</ce:surname>
<ce:given-name>A.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>529</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>298</first-page>
<last-page>306</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Massague, J., Obenauf, A.C.: Metastatic colonization by circulating tumour cells. Nature. 529, 298–306 (2016)</ref-fulltext>
<ce:source-text>Massague, J., Obenauf, A.C.: Metastatic colonization by circulating tumour cells. Nature. 529, 298–306 (2016)</ce:source-text>
</reference>
<reference seq="6">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor metastasis: molecular insights and evolving paradigms.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Valastyan</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.A.</ce:initials>
<ce:surname>Weinberg</ce:surname>
<ce:given-name>R.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell.</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>147</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>275</first-page>
<last-page>292</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Valastyan, S., Weinberg, R.A.: Tumor metastasis: molecular insights and evolving paradigms. Cell. 147, 275–292 (2011)</ref-fulltext>
<ce:source-text>Valastyan, S., Weinberg, R.A.: Tumor metastasis: molecular insights and evolving paradigms. Cell. 147, 275–292 (2011)</ce:source-text>
</reference>
<reference seq="7">
<ref-info>
<ref-title>
<ref-titletext-english>Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. </ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Peinado</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Med.</ref-sourcetitle>
<ref-publicationyear first="2012" />
<volisspag>
<volume-issue-number>
<vol-first>18</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>883</first-page>
<last-page>891</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Peinado, H., et al.: Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat. Med. 18, 883–891 (2012)</ref-fulltext>
<ce:source-text>Peinado, H., et al.: Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat. Med. 18, 883–891 (2012)</ce:source-text>
</reference>
<reference seq="8">
<ref-info>
<ref-title>
<ref-titletext-english>Pancreatic cancer exosomes
initiate pre-metastatic niche formation in the liver.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.</ce:initials>
<ce:surname>Costa-Silva</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Cell Biol</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>17</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>816</first-page>
<last-page>826</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Costa-Silva, B., et al.: Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. Nat. Cell Biol. 17, 816–826 (2015)</ref-fulltext>
<ce:source-text>Costa-Silva, B., et al.: Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. Nat. Cell Biol. 17, 816–826 (2015)</ce:source-text>
</reference>
<reference seq="9">
<ref-info>
<ref-title>
<ref-titletext-english>Tumour exosome integrins determine organotropic metastasis.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Hoshino</ce:surname>
<ce:given-name />
</author>
</ref-authors>
<ref-sourcetitle>Nature.</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>527</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>329</first-page>
<last-page>335</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hoshino, A., et al.: Tumour exosome integrins determine organotropic metastasis. Nature. 527, 329–335 (2015)</ref-fulltext>
<ce:source-text>Hoshino, A., et al.: Tumour exosome integrins determine organotropic metastasis. Nature. 527, 329–335 (2015)</ce:source-text>
</reference>
<reference seq="10">
<ref-info>
<ref-title>
<ref-titletext-english>Tumour exosomal CEMIP protein promotes cancer cell colonization in brain metastasis.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Rodrigues</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Cell Biol</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>21</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1403</first-page>
<last-page>1412</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Rodrigues, G., et al.: Tumour exosomal CEMIP protein promotes cancer cell colonization in brain metastasis. Nat. Cell Biol. 21, 1403–1412 (2019)</ref-fulltext>
<ce:source-text>Rodrigues, G., et al.: Tumour exosomal CEMIP protein promotes cancer cell colonization in brain metastasis. Nat. Cell Biol. 21, 1403–1412 (2019)</ce:source-text>
</reference>
<reference seq="11">
<ref-info>
<ref-title>
<ref-titletext-english>The distribution of secondary growths in cancer of the breast. Lancet.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Paget</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle> Lancet</ref-sourcetitle>
<ref-publicationyear first="1889" />
<volisspag>
<volume-issue-number>
<vol-first>133</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>571</first-page>
<last-page>573</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Paget, S.: The distribution of secondary growths in cancer of the breast. Lancet. 133, 571–573 (1889)</ref-fulltext>
<ce:source-text>Paget, S.: The distribution of secondary growths in cancer of the breast. Lancet. 133, 571–573 (1889)</ce:source-text>
</reference>
<reference seq="12">
<ref-info>
<ref-title>
<ref-titletext-english>: Pre-metastatic niches: organspecific homes for metastases.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Peinado</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Cancer</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>17</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>302</first-page>
<last-page>317</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Peinado, H., et al.: Pre-metastatic niches: organspecific homes for metastases. Nat. Rev. Cancer. 17, 302–317 (2017)</ref-fulltext>
<ce:source-text>Peinado, H., et al.: Pre-metastatic niches: organspecific homes for metastases. Nat. Rev. Cancer. 17, 302–317 (2017)</ce:source-text>
</reference>
<reference seq="13">
<ref-info>
<ref-title>
<ref-titletext-english>VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.N.</ce:initials>
<ce:surname>Kaplan</ce:surname>
<ce:given-name>R.N.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2005" />
<volisspag>
<volume-issue-number>
<vol-first>438</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>820</first-page>
<last-page>827</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kaplan, R.N., et al.: VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature. 438, 820–827 (2005)</ref-fulltext>
<ce:source-text>Kaplan, R.N., et al.: VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature. 438, 820–827 (2005)</ce:source-text>
</reference>
<reference seq="14">
<ref-info>
<ref-title>
<ref-titletext-english>Exosome-mediated metastasis: communication from a distance</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>I.</ce:initials>
<ce:surname>Wortzel</ce:surname>
<ce:given-name>I.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Dror</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>C.M.</ce:initials>
<ce:surname>Kenific</ce:surname>
<ce:given-name>C.M.</ce:given-name>
</author>
<author seq="4">
<ce:initials>D.</ce:initials>
<ce:surname>Lyden</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Dev. Cell</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>49</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>347</first-page>
<last-page>360</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wortzel, I., Dror, S., Kenific, C.M., Lyden, D.: Exosome-mediated metastasis: communication from a distance. Dev. Cell. 49, 347–360 (2019)</ref-fulltext>
<ce:source-text>Wortzel, I., Dror, S., Kenific, C.M., Lyden, D.: Exosome-mediated metastasis: communication from a distance. Dev. Cell. 49, 347–360 (2019)</ce:source-text>
</reference>
<reference seq="15">
<ref-info>
<ref-title>
<ref-titletext-english>Breast cancer cells rely on environmental pyruvate to shape the metastatic niche</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>I.</ce:initials>
<ce:surname>Elia</ce:surname>
<ce:given-name>I.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature.</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>568</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>117</first-page>
<last-page>121</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Elia, I., et al.: Breast cancer cells rely on environmental pyruvate to shape the metastatic niche. Nature. 568, 117–121 (2019)</ref-fulltext>
<ce:source-text>Elia, I., et al.: Breast cancer cells rely on environmental pyruvate to shape the metastatic niche. Nature. 568, 117–121 (2019)</ce:source-text>
</reference>
<reference seq="16">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor exosomal RNAs promote lung pre-metastatic niche formation by activating Alveolar epithelial TLR3 to recruit neutrophils</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Liu</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Cell</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>30</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>243</first-page>
<last-page>256</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Liu, Y., et al.: Tumor exosomal RNAs promote lung pre-metastatic niche formation by activating Alveolar epithelial TLR3 to recruit neutrophils. Cancer Cell. 30, 243–256 (2016)</ref-fulltext>
<ce:source-text>Liu, Y., et al.: Tumor exosomal RNAs promote lung pre-metastatic niche formation by activating Alveolar epithelial TLR3 to recruit neutrophils. Cancer Cell. 30, 243–256 (2016)</ce:source-text>
</reference>
<reference seq="17">
<ref-info>
<ref-title>
<ref-titletext-english>Breast-cancer-secreted miR-122 reprograms glucose metabolism in premetastatic niche to promote metastasis. Nat.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.Y.</ce:initials>
<ce:surname>Fong</ce:surname>
<ce:given-name>M.Y.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Biol</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>17</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>183</first-page>
<last-page>194</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Fong, M.Y., et al.: Breast-cancer-secreted miR-122 reprograms glucose metabolism in premetastatic niche to promote metastasis. Nat. Cell Biol. 17, 183–194 (2015)</ref-fulltext>
<ce:source-text>Fong, M.Y., et al.: Breast-cancer-secreted miR-122 reprograms glucose metabolism in premetastatic niche to promote metastasis. Nat. Cell Biol. 17, 183–194 (2015)</ce:source-text>
</reference>
<reference seq="18">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>W.</ce:initials>
<ce:surname>Zhou</ce:surname>
<ce:given-name>W.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Cell</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>25</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>501</first-page>
<last-page>515</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zhou, W., et al.: Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis. Cancer Cell. 25, 501–515 (2014)</ref-fulltext>
<ce:source-text>Zhou, W., et al.: Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis. Cancer Cell. 25, 501–515 (2014)</ce:source-text>
</reference>
<reference seq="19">
<ref-info>
<ref-title>
<ref-titletext-english>Extracellular vesicles and metastasis. Cold Spring Harb. </ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.E.</ce:initials>
<ce:surname>Wang</ce:surname>
<ce:given-name>S.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Perspect. Med.</ref-sourcetitle>
<ref-publicationyear first="2019" />
</ref-info>
<ref-fulltext>Wang, S.E.: Extracellular vesicles and metastasis. Cold Spring Harb. Perspect. Med. (2019)</ref-fulltext>
<ce:source-text>Wang, S.E.: Extracellular vesicles and metastasis. Cold Spring Harb. Perspect. Med. (2019)</ce:source-text>
</reference>
<reference seq="20">
<ref-info>
<ref-title>
<ref-titletext-english>Thery, C.: Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Mathieu</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>L.</ce:initials>
<ce:surname>Martin-Jaular</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="3">
<ce:initials>G.</ce:initials>
<ce:surname>Lavieu</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Cell Biol.</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>21</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>9</first-page>
<last-page>17</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mathieu, M., Martin-Jaular, L., Lavieu, G., Thery, C.: Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication. Nat. Cell Biol. 21, 9–17 (2019)</ref-fulltext>
<ce:source-text>Mathieu, M., Martin-Jaular, L., Lavieu, G., Thery, C.: Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication. Nat. Cell Biol. 21, 9–17 (2019)</ce:source-text>
</reference>
<reference seq="21">
<ref-info>
<ref-title>
<ref-titletext-english>Identification of distinct nanoparticles and subsets of extracellular vesicles by asymmetric flow field-flow fractionation. </ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Zhang</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Cell Biol</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>20</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>332</first-page>
<last-page>343</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zhang, H., et al.: Identification of distinct nanoparticles and subsets of extracellular vesicles by asymmetric flow field-flow fractionation. Nat. Cell Biol. 20, 332–343 (2018)</ref-fulltext>
<ce:source-text>Zhang, H., et al.: Identification of distinct nanoparticles and subsets of extracellular vesicles by asymmetric flow field-flow fractionation. Nat. Cell Biol. 20, 332–343 (2018)</ce:source-text>
</reference>
<reference seq="22">
<ref-info>
<ref-title>
<ref-titletext-english>Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu. </ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Colombo</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>G.</ce:initials>
<ce:surname>Raposo</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="3">
<ce:initials>C.</ce:initials>
<ce:surname>Thery</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Rev. Cell Dev. Biol</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>30</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>255</first-page>
<last-page>289</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Colombo, M., Raposo, G., Thery, C.: Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu. Rev. Cell Dev. Biol. 30, 255–289 (2014)</ref-fulltext>
<ce:source-text>Colombo, M., Raposo, G., Thery, C.: Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu. Rev. Cell Dev. Biol. 30, 255–289 (2014)</ce:source-text>
</reference>
<reference seq="23">
<ref-info>
<ref-title>
<ref-titletext-english> Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Al-Nedawi</ce:surname>
<ce:given-name />
</author>
</ref-authors>
<ref-sourcetitle>Nat. Cell Biol.</ref-sourcetitle>
<ref-publicationyear first="2008" />
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>619</first-page>
<last-page>624</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Al-Nedawi, K., et al.: Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat. Cell Biol. 10, 619–624 (2008)</ref-fulltext>
<ce:source-text>Al-Nedawi, K., et al.: Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat. Cell Biol. 10, 619–624 (2008)</ce:source-text>
</reference>
<reference seq="24">
<ref-info>
<ref-title>
<ref-titletext-english>Oncosome formation in prostate cancer: association with a region of frequent chromosomal deletion in metastatic disease</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Di Vizio</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Res</ref-sourcetitle>
<ref-publicationyear first="2009" />
<volisspag>
<volume-issue-number>
<vol-first>69</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>5601</first-page>
<last-page>5609</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Di Vizio, D., et al.: Oncosome formation in prostate cancer: association with a region of frequent chromosomal deletion in metastatic disease. Cancer Res. 69, 5601–5609 (2009)</ref-fulltext>
<ce:source-text>Di Vizio, D., et al.: Oncosome formation in prostate cancer: association with a region of frequent chromosomal deletion in metastatic disease. Cancer Res. 69, 5601–5609 (2009)</ce:source-text>
</reference>
<reference seq="25">
<ref-info>
<ref-title>
<ref-titletext-english>Transfer of functional cargo in exomeres.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Q.</ce:initials>
<ce:surname>Zhang</ce:surname>
<ce:given-name>Q.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Rep</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>27</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>940</first-page>
<last-page>954</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>. Zhang, Q., et al.: Transfer of functional cargo in exomeres. Cell Rep. 27, 940–954 e946 (2019)</ref-fulltext>
<ce:source-text>. Zhang, Q., et al.: Transfer of functional cargo in exomeres. Cell Rep. 27, 940–954 e946 (2019)</ce:source-text>
</reference>
<reference seq="26">
<ref-info>
<ref-title>
<ref-titletext-english>The Jeanne Manery-Fisher Memorial Lecture 1991. Maturation of reticulocytes: formation of exosomes as a mechanism for shedding
membrane proteins.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.M.</ce:initials>
<ce:surname>Johnstone</ce:surname>
<ce:given-name>R.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Biochem.Cell Biol. </ref-sourcetitle>
<ref-publicationyear first="1992" />
<volisspag>
<volume-issue-number>
<vol-first>70</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>179</first-page>
<last-page>190</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Johnstone, R.M.: The Jeanne Manery-Fisher Memorial Lecture 1991. Maturation of reticulocytes: formation of exosomes as a mechanism for shedding membrane proteins. Biochem. Cell Biol. 70, 179–190 (1992)</ref-fulltext>
<ce:source-text>Johnstone, R.M.: The Jeanne Manery-Fisher Memorial Lecture 1991. Maturation of reticulocytes: formation of exosomes as a mechanism for shedding membrane proteins. Biochem. Cell Biol. 70, 179–190 (1992)</ce:source-text>
</reference>
<reference seq="27">
<ref-info>
<ref-title>
<ref-titletext-english>Receptor-mediated endocytosis of transferrin and recycling of the transferrin receptor in rat reticulocytes.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Harding</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Heuser</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>P.</ce:initials>
<ce:surname>Stahl</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle />
<ref-publicationyear first="1983" />
<volisspag>
<volume-issue-number>
<vol-first>97</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>329</first-page>
<last-page>339</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Harding, C., Heuser, J., Stahl, P.: Receptor-mediated endocytosis of transferrin and recycling of the transferrin receptor in rat reticulocytes. J. Cell Biol. 97, 329–339 (1983)</ref-fulltext>
<ce:source-text>Harding, C., Heuser, J., Stahl, P.: Receptor-mediated endocytosis of transferrin and recycling of the transferrin receptor in rat reticulocytes. J. Cell Biol. 97, 329–339 (1983)</ce:source-text>
</reference>
<reference seq="28">
<ref-info>
<ref-title>
<ref-titletext-english>Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro: selective externalization of the receptor</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.T.</ce:initials>
<ce:surname>Pan</ce:surname>
<ce:given-name>B.T.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.M.</ce:initials>
<ce:surname>Johnstone</ce:surname>
<ce:given-name>R.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="1983" />
<volisspag>
<volume-issue-number>
<vol-first>33</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>967</first-page>
<last-page>978</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Pan, B.T., Johnstone, R.M.: Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro: selective externalization of the receptor. Cell. 33, 967–978 (1983)</ref-fulltext>
<ce:source-text>Pan, B.T., Johnstone, R.M.: Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro: selective externalization of the receptor. Cell. 33, 967–978 (1983)</ce:source-text>
</reference>
<reference seq="29">
<ref-info>
<ref-title>
<ref-titletext-english>High-resolution proteomic and lipidomic analysis of exosomes and microvesicles from different cell sources</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.A.</ce:initials>
<ce:surname>Haraszti</ce:surname>
<ce:given-name />
</author>
</ref-authors>
<ref-sourcetitle>J Extracell Vesicles. </ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>5</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>32570</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Haraszti, R.A., et al.: High-resolution proteomic and lipidomic analysis of exosomes and microvesicles from different cell sources. J Extracell Vesicles. 5, 32570 (2016)</ref-fulltext>
<ce:source-text>Haraszti, R.A., et al.: High-resolution proteomic and lipidomic analysis of exosomes and microvesicles from different cell sources. J Extracell Vesicles. 5, 32570 (2016)</ce:source-text>
</reference>
<reference seq="30">
<ref-info>
<ref-title>
<ref-titletext-english>T cell exosomes induce cholesterol accumulation in human monocytes via phosphatidylserine receptor.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Zakharova</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Svetlova</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.F.</ce:initials>
<ce:surname>Fomina</ce:surname>
<ce:given-name>A.F.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cell. Physiol</ref-sourcetitle>
<ref-publicationyear first="2007" />
<volisspag>
<volume-issue-number>
<vol-first>212</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>174</first-page>
<last-page>181</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zakharova, L., Svetlova, M., Fomina, A.F.: T cell exosomes induce cholesterol accumulation in human monocytes via phosphatidylserine receptor. J. Cell. Physiol. 212, 174–181 (2007)</ref-fulltext>
<ce:source-text>Zakharova, L., Svetlova, M., Fomina, A.F.: T cell exosomes induce cholesterol accumulation in human monocytes via phosphatidylserine receptor. J. Cell. Physiol. 212, 174–181 (2007)</ce:source-text>
</reference>
<reference seq="31">
<ref-info>
<ref-title>
<ref-titletext-english>Adipocyte extracellular vesicles carry enzymes and fatty acids that stimulate mitochondrial metabolism and remodeling in tumor cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.</ce:initials>
<ce:surname>Clemen</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>EMBO J</ref-sourcetitle>
<ref-publicationyear first="2020" />
<volisspag>
<volume-issue-number>
<vol-first>39</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Clement, E., et al.: Adipocyte extracellular vesicles carry enzymes and fatty acids that stimulate mitochondrial metabolism and remodeling in tumor cells. EMBO J. 39, e102525 (2020)</ref-fulltext>
<ce:source-text>Clement, E., et al.: Adipocyte extracellular vesicles carry enzymes and fatty acids that stimulate mitochondrial metabolism and remodeling in tumor cells. EMBO J. 39, e102525 (2020)</ce:source-text>
</reference>
<reference seq="32">
<ref-info>
<ref-title>
<ref-titletext-english>The role of exosomes in cancer metastasis. Semin</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.B.</ce:initials>
<ce:surname>Steinbichler</ce:surname>
<ce:given-name>T.B.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Dudas</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>H.</ce:initials>
<ce:surname>Riechelmann</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="4">
<ce:initials>I.I.</ce:initials>
<ce:surname>Skvortsova</ce:surname>
<ce:given-name>I.I.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Bio</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>44</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>170</first-page>
<last-page>181</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Steinbichler, T.B., Dudas, J., Riechelmann, H., Skvortsova, I.I.: The role of exosomes in cancer metastasis. Semin. Cancer Biol. 44, 170–181 (2017)</ref-fulltext>
<ce:source-text>Steinbichler, T.B., Dudas, J., Riechelmann, H., Skvortsova, I.I.: The role of exosomes in cancer metastasis. Semin. Cancer Biol. 44, 170–181 (2017)</ce:source-text>
</reference>
<reference seq="33">
<ref-info>
<ref-title>
<ref-titletext-english>Exosome-derived microRNAs in cancer metabolism: possible implications in cancer diagnostics and therapy. </ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Tomasett</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>W.</ce:initials>
<ce:surname>Lee</ce:surname>
<ce:given-name>W.</ce:given-name>
</author>
<author seq="3">
<ce:initials>W.</ce:initials>
<ce:surname>Santarell</ce:surname>
<ce:given-name>W.</ce:given-name>
</author>
<author seq="4">
<ce:initials>J.</ce:initials>
<ce:surname>Neuzil</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Exp. Mol. Med</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>49</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Tomasetti, M., Lee, W., Santarelli, L., Neuzil, J.: Exosome-derived microRNAs in cancer metabolism: possible implications in cancer diagnostics and therapy. Exp. Mol. Med. 49, e285 (2017)</ref-fulltext>
<ce:source-text>Tomasetti, M., Lee, W., Santarelli, L., Neuzil, J.: Exosome-derived microRNAs in cancer metabolism: possible implications in cancer diagnostics and therapy. Exp. Mol. Med. 49, e285 (2017)</ce:source-text>
</reference>
<reference seq="34">
<ref-info>
<ref-title>
<ref-titletext-english>Decoding the biology of exosomes in metastasis.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.</ce:initials>
<ce:surname>Adem</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
<author seq="2">
<ce:initials>P.F.</ce:initials>
<ce:surname>Vieira</ce:surname>
<ce:given-name>P.F.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.A</ce:initials>
<ce:surname>Melo</ce:surname>
<ce:given-name>S.A</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Trends Cancer. </ref-sourcetitle>
<ref-publicationyear first="2020" />
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>20</first-page>
<last-page>30</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Adem, B., Vieira, P.F., Melo, S.A.: Decoding the biology of exosomes in metastasis. Trends Cancer. 6, 20–30 (2020)</ref-fulltext>
<ce:source-text>Adem, B., Vieira, P.F., Melo, S.A.: Decoding the biology of exosomes in metastasis. Trends Cancer. 6, 20–30 (2020)</ce:source-text>
</reference>
<reference seq="35">
<ref-info>
<ref-title>
<ref-titletext-english>The importance of exosomal PDL1 in tumour immune evasion</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Daassi</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.M.</ce:initials>
<ce:surname>Mahoney</ce:surname>
<ce:given-name>K.M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>G.J.</ce:initials>
<ce:surname>Freeman</ce:surname>
<ce:given-name>G.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Immunol</ref-sourcetitle>
<ref-publicationyear first="2020" />
</ref-info>
<ref-fulltext>Daassi, D., Mahoney, K.M., Freeman, G.J.: The importance of exosomal PDL1 in tumour immune evasion. Nat. Rev. Immunol. (2020)</ref-fulltext>
<ce:source-text>Daassi, D., Mahoney, K.M., Freeman, G.J.: The importance of exosomal PDL1 in tumour immune evasion. Nat. Rev. Immunol. (2020)</ce:source-text>
</reference>
<reference seq="36">
<ref-info>
<ref-title>
<ref-titletext-english>Matrix metalloproteinases: regulators of the tumor microenvironment.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Kessenbrock</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="2">
<ce:initials>V.</ce:initials>
<ce:surname>Plaks</ce:surname>
<ce:given-name>V.</ce:given-name>
</author>
<author seq="3">
<ce:initials>Z.</ce:initials>
<ce:surname>Werb</ce:surname>
<ce:given-name>Z.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2010" />
<volisspag>
<volume-issue-number>
<vol-first>141</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>52</first-page>
<last-page>67</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kessenbrock, K., Plaks, V., Werb, Z.: Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 141, 52–67 (2010)</ref-fulltext>
<ce:source-text>Kessenbrock, K., Plaks, V., Werb, Z.: Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 141, 52–67 (2010)</ce:source-text>
</reference>
<reference seq="37">
<ref-info>
<ref-title>
<ref-titletext-english>Urokinase plasminogen activator and gelatinases are associated with membrane vesicles shed by human HT1080 fibrosarcoma cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Ginestra</ce:surname>
<ce:given-name />
</author>
</ref-authors>
<ref-sourcetitle>J. Biol. Chem</ref-sourcetitle>
<ref-publicationyear first="1997" />
<volisspag>
<volume-issue-number>
<vol-first>272</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>17216</first-page>
<last-page>17222</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ginestra, A., et al.: Urokinase plasminogen activator and gelatinases are associated with membrane vesicles shed by human HT1080 fibrosarcoma cells. J. Biol. Chem. 272, 17216–17222 (1997)</ref-fulltext>
<ce:source-text>Ginestra, A., et al.: Urokinase plasminogen activator and gelatinases are associated with membrane vesicles shed by human HT1080 fibrosarcoma cells. J. Biol. Chem. 272, 17216–17222 (1997)</ce:source-text>
</reference>
<reference seq="38">
<ref-info>
<ref-title>
<ref-titletext-english>Selective localization of matrix metalloproteinase 9, beta1 integrins, and human lymphocyte antigen class I molecules on membrane vesicles shed by 8701-BC breast carcinoma cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>V.</ce:initials>
<ce:surname>Dolo</ce:surname>
<ce:given-name>V.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Res</ref-sourcetitle>
<ref-publicationyear first="1998" />
<volisspag>
<volume-issue-number>
<vol-first>58</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>4468</first-page>
<last-page>4474</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Dolo, V., et al.: Selective localization of matrix metalloproteinase 9, beta1 integrins, and human lymphocyte antigen class I molecules on membrane vesicles shed by 8701-BC breast carcinoma cells. Cancer Res. 58, 4468–4474 (1998)</ref-fulltext>
<ce:source-text>Dolo, V., et al.: Selective localization of matrix metalloproteinase 9, beta1 integrins, and human lymphocyte antigen class I molecules on membrane vesicles shed by 8701-BC breast carcinoma cells. Cancer Res. 58, 4468–4474 (1998)</ce:source-text>
</reference>
<reference seq="39">
<ref-info>
<ref-title>
<ref-titletext-english>Hypoxia-induced matrix metalloproteinase-13 expression in exosomes from nasopharyngeal carcinoma enhances metastases</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Shan</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Death Dis</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>382</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Shan, Y., et al.: Hypoxia-induced matrix metalloproteinase-13 expression in exosomes from nasopharyngeal carcinoma enhances metastases. Cell Death Dis. 9, 382 (2018) </ref-fulltext>
<ce:source-text>Shan, Y., et al.: Hypoxia-induced matrix metalloproteinase-13 expression in exosomes from nasopharyngeal carcinoma enhances metastases. Cell Death Dis. 9, 382 (2018) </ce:source-text>
</reference>
<reference seq="40">
<ref-info>
<ref-title>
<ref-titletext-english>Secretion of active membrane type 1 matrix metalloproteinase (MMP-14) into extracellular space in microvesicular exosomes. </ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Hakulinen</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>L.</ce:initials>
<ce:surname>Sankkila</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="3">
<ce:initials>N.</ce:initials>
<ce:surname>Sugiyama</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
<author seq="4">
<ce:initials>K.</ce:initials>
<ce:surname>Lehti</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="5">
<ce:initials>J.</ce:initials>
<ce:surname>Keski-Oja</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle> J. Cell. Biochem</ref-sourcetitle>
<ref-publicationyear first="2010" />
<volisspag>
<volume-issue-number>
<vol-first>105</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1211</first-page>
<last-page>1218</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hakulinen, J., Sankkila, L., Sugiyama, N., Lehti, K., Keski-Oja, J.: Secretion of active membrane type 1 matrix metalloproteinase (MMP-14) into extracellular space in microvesicular exosomes. J. Cell. Biochem. 105, 1211–1218 (2008)</ref-fulltext>
<ce:source-text>Hakulinen, J., Sankkila, L., Sugiyama, N., Lehti, K., Keski-Oja, J.: Secretion of active membrane type 1 matrix metalloproteinase (MMP-14) into extracellular space in microvesicular exosomes. J. Cell. Biochem. 105, 1211–1218 (2008)</ce:source-text>
</reference>
<reference seq="41">
<ref-info>
<ref-title>
<ref-titletext-english>Host matrix modulation by tumor exosomes promotes motility and invasiveness.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>W.</ce:initials>
<ce:surname>Mu</ce:surname>
<ce:given-name>W.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Rana</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Zoller</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Neoplasia</ref-sourcetitle>
<ref-publicationyear first="2013" />
<volisspag>
<volume-issue-number>
<vol-first>15</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>875</first-page>
<last-page>887</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mu, W., Rana, S., Zoller, M.: Host matrix modulation by tumor exosomes promotes motility and invasiveness. Neoplasia. 15, 875–887 (2013)</ref-fulltext>
<ce:source-text>Mu, W., Rana, S., Zoller, M.: Host matrix modulation by tumor exosomes promotes motility and invasiveness. Neoplasia. 15, 875–887 (2013)</ce:source-text>
</reference>
<reference seq="42">
<ref-info>
<ref-title>
<ref-titletext-english>: Extracellular vesicles secreted from cancer cell lines stimulate secretion of MMP-9, IL-6, TGF-beta1 and EMMPRIN. </ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.S</ce:initials>
<ce:surname>Redzic</ce:surname>
<ce:given-name>J.S</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>PLoS One</ref-sourcetitle>
<ref-publicationyear first="2013" />
<ref-text />
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Redzic, J.S., et al.: Extracellular vesicles secreted from cancer cell lines stimulate secretion of MMP-9, IL-6, TGF-beta1 and EMMPRIN. PLoS One. 8, e71225 (2013)</ref-fulltext>
<ce:source-text>Redzic, J.S., et al.: Extracellular vesicles secreted from cancer cell lines stimulate secretion of MMP-9, IL-6, TGF-beta1 and EMMPRIN. PLoS One. 8, e71225 (2013)</ce:source-text>
</reference>
<reference seq="43">
<ref-info>
<ref-title>
<ref-titletext-english>Exosomes from bulk and stem cells from human prostate cancer have a differential microRNA content that contributes cooperatively over local and pre-metastatic niche.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.A.</ce:initials>
<ce:surname>Sanchez</ce:surname>
<ce:given-name>C.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncotarget.</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3993</first-page>
<last-page>4008</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sanchez, C.A., et al.: Exosomes from bulk and stem cells from human prostate cancer have a differential microRNA content that contributes cooperatively over local and pre-metastatic niche. Oncotarget. 7, 3993–4008 (2016)</ref-fulltext>
<ce:source-text>Sanchez, C.A., et al.: Exosomes from bulk and stem cells from human prostate cancer have a differential microRNA content that contributes cooperatively over local and pre-metastatic niche. Oncotarget. 7, 3993–4008 (2016)</ce:source-text>
</reference>
<reference seq="44">
<ref-info>
<ref-title>
<ref-titletext-english>Oncogenic KIT-containing exosomes increase gastrointestinal stromal tumor cell invasion</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Atay</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Proc. Natl. Acad. Sci. USA</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>111</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>711</first-page>
<last-page>716</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Atay, S., et al.: Oncogenic KIT-containing exosomes increase gastrointestinal stromal tumor cell invasion. Proc. Natl. Acad. Sci. USA. 111, 711–716 (2014)</ref-fulltext>
<ce:source-text>Atay, S., et al.: Oncogenic KIT-containing exosomes increase gastrointestinal stromal tumor cell invasion. Proc. Natl. Acad. Sci. USA. 111, 711–716 (2014)</ce:source-text>
</reference>
<reference seq="45">
<ref-info>
<ref-title>
<ref-titletext-english>Alpha-smooth muscle actin expression upregulates fibroblast contractile activity. Mol.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.</ce:initials>
<ce:surname>Hinz</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
<author seq="2">
<ce:initials>G.</ce:initials>
<ce:surname>Celetta</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.J.</ce:initials>
<ce:surname>Tomasek</ce:surname>
<ce:given-name>J.J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>G.</ce:initials>
<ce:surname>Gabbiani</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.</ce:initials>
<ce:surname>Chaponnier</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Biol. Cell</ref-sourcetitle>
<ref-publicationyear first="2001" />
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2730</first-page>
<last-page>2741</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hinz, B., Celetta, G., Tomasek, J.J., Gabbiani, G., Chaponnier, C.: Alpha-smooth muscle actin expression upregulates fibroblast contractile activity. Mol. Biol. Cell. 12, 2730–2741 (2001)</ref-fulltext>
<ce:source-text>Hinz, B., Celetta, G., Tomasek, J.J., Gabbiani, G., Chaponnier, C.: Alpha-smooth muscle actin expression upregulates fibroblast contractile activity. Mol. Biol. Cell. 12, 2730–2741 (2001)</ce:source-text>
</reference>
<reference seq="46">
<ref-info>
<ref-title>
<ref-titletext-english>The biology and function of fibroblasts in cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Kalluri</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Cancer.</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>16</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>582</first-page>
<last-page>598</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kalluri, R.: The biology and function of fibroblasts in cancer. Nat. Rev. Cancer. 16, 582–598 (2016)</ref-fulltext>
<ce:source-text>Kalluri, R.: The biology and function of fibroblasts in cancer. Nat. Rev. Cancer. 16, 582–598 (2016)</ce:source-text>
</reference>
<reference seq="47">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer exosomes trigger fibroblast to myofibroblast differentiation. </ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Webber</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.</ce:initials>
<ce:surname>Steadman</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.D.</ce:initials>
<ce:surname>Mason</ce:surname>
<ce:given-name>M.D.</ce:given-name>
</author>
<author seq="4">
<ce:initials>Z.</ce:initials>
<ce:surname>Tabi</ce:surname>
<ce:given-name />
</author>
<author seq="5">
<ce:initials>A.</ce:initials>
<ce:surname>Clayton</ce:surname>
<ce:given-name />
</author>
</ref-authors>
<ref-sourcetitle>Cancer Res</ref-sourcetitle>
<ref-publicationyear first="2010" />
<volisspag>
<volume-issue-number>
<vol-first>70</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>9621</first-page>
<last-page>9630</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Webber, J., Steadman, R., Mason, M.D., Tabi, Z., Clayton, A.: Cancer exosomes trigger fibroblast to myofibroblast differentiation. Cancer Res. 70, 9621–9630 (2010)</ref-fulltext>
<ce:source-text>Webber, J., Steadman, R., Mason, M.D., Tabi, Z., Clayton, A.: Cancer exosomes trigger fibroblast to myofibroblast differentiation. Cancer Res. 70, 9621–9630 (2010)</ce:source-text>
</reference>
<reference seq="48">
<ref-info>
<ref-title>
<ref-titletext-english>Differentiation of tumourpromoting stromal myofibroblasts by cancer exosomes. </ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.P.</ce:initials>
<ce:surname>Webber</ce:surname>
<ce:given-name>J.P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncogene</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>34</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>290</first-page>
<last-page>302</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>. Webber, J.P., et al.: Differentiation of tumourpromoting stromal myofibroblasts by cancer exosomes. Oncogene. 34, 290–302 (2015) </ref-fulltext>
<ce:source-text>. Webber, J.P., et al.: Differentiation of tumourpromoting stromal myofibroblasts by cancer exosomes. Oncogene. 34, 290–302 (2015) </ce:source-text>
</reference>
<reference seq="49">
<ref-info>
<ref-title>
<ref-titletext-english>Rab27a and Rab27b control different steps of the exosome secretion pathway. Nat.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Ostrowski</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Biol</ref-sourcetitle>
<ref-publicationyear first="2010" />
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>19</first-page>
<last-page>30</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ostrowski, M., et al.: Rab27a and Rab27b control different steps of the exosome secretion pathway. Nat. Cell Biol. 12, 19–30.; sup pp 11-13 (2010)</ref-fulltext>
<ce:source-text>Ostrowski, M., et al.: Rab27a and Rab27b control different steps of the exosome secretion pathway. Nat. Cell Biol. 12, 19–30.; sup pp 11-13 (2010)</ce:source-text>
</reference>
<reference seq="50">
<ref-info>
<ref-title>
<ref-titletext-english>Hepatocellular carcinoma-derived exosomal miRNA-21 contributes to tumor progression by converting hepatocyte stellate cells to cancerassociated fibroblasts.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Zhou</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Exp. Clin. Cancer Res.</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>37</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>324</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zhou, Y., et al.: Hepatocellular carcinoma-derived exosomal miRNA-21 contributes to tumor progression by converting hepatocyte stellate cells to cancerassociated fibroblasts. J. Exp. Clin. Cancer Res. 37, 324 (2018)</ref-fulltext>
<ce:source-text>Zhou, Y., et al.: Hepatocellular carcinoma-derived exosomal miRNA-21 contributes to tumor progression by converting hepatocyte stellate cells to cancerassociated fibroblasts. J. Exp. Clin. Cancer Res. 37, 324 (2018)</ce:source-text>
</reference>
<reference seq="51">
<ref-info>
<ref-title>
<ref-titletext-english> Exosomes released by chronic lymphocytic leukemia cells induce the transition of stromal cells into cancer-associated fibroblasts</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Paggetti</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Blood</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>126</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1106</first-page>
<last-page>1117</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Paggetti, J., et al.: Exosomes released by chronic lymphocytic leukemia cells induce the transition of stromal cells into cancer-associated fibroblasts. Blood. 126, 1106–1117 (2015) </ref-fulltext>
<ce:source-text>Paggetti, J., et al.: Exosomes released by chronic lymphocytic leukemia cells induce the transition of stromal cells into cancer-associated fibroblasts. Blood. 126, 1106–1117 (2015) </ce:source-text>
</reference>
<reference seq="52">
<ref-info>
<ref-title>
<ref-titletext-english>: Cancer exosomes trigger mesenchymal stem cell differentiation into pro-angiogenic and pro-invasive myofibroblasts.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Chowdhury</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncotarget</ref-sourcetitle>
<ref-publicationyear first="2015" />
<ref-text />
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>715</first-page>
<last-page>731</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Chowdhury, R., et al.: Cancer exosomes trigger mesenchymal stem cell differentiation into pro-angiogenic and pro-invasive myofibroblasts. Oncotarget. 6, 715–731 (2015)</ref-fulltext>
<ce:source-text>Chowdhury, R., et al.: Cancer exosomes trigger mesenchymal stem cell differentiation into pro-angiogenic and pro-invasive myofibroblasts. Oncotarget. 6, 715–731 (2015)</ce:source-text>
</reference>
<reference seq="53">
<ref-info>
<ref-title>
<ref-titletext-english>Exosomes from ovarian cancer cells induce adipose tissue-derived mesenchymal stem cells to acquire the physical and functional characteristics of tumor-supporting myofibroblasts</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.A.</ce:initials>
<ce:surname>Cho</ce:surname>
<ce:given-name>J.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Gynecol. Oncol. </ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>123</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>379</first-page>
<last-page>386</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>. Cho, J.A., et al.: Exosomes from ovarian cancer cells induce adipose tissue-derived mesenchymal stem cells to acquire the physical and functional characteristics of tumor-supporting myofibroblasts. Gynecol. Oncol. 123, 379–386 (2011)</ref-fulltext>
<ce:source-text>. Cho, J.A., et al.: Exosomes from ovarian cancer cells induce adipose tissue-derived mesenchymal stem cells to acquire the physical and functional characteristics of tumor-supporting myofibroblasts. Gynecol. Oncol. 123, 379–386 (2011)</ce:source-text>
</reference>
<reference seq="54">
<ref-info>
<ref-title>
<ref-titletext-english>Natural innate and adaptive immunity to cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.D.</ce:initials>
<ce:surname>Vesely</ce:surname>
<ce:given-name>M.D.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.H.</ce:initials>
<ce:surname>Kershaw</ce:surname>
<ce:given-name>M.H.</ce:given-name>
</author>
<author seq="3">
<ce:initials>R.D.</ce:initials>
<ce:surname>Schreiber</ce:surname>
<ce:given-name>R.D.</ce:given-name>
</author>
<author seq="4">
<ce:initials>M.J.</ce:initials>
<ce:surname>Smyth</ce:surname>
<ce:given-name>M.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Annu. Rev. Immunol.</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>29</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>235</first-page>
<last-page>271</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Vesely, M.D., Kershaw, M.H., Schreiber, R.D., Smyth, M.J.: Natural innate and adaptive immunity to cancer. Annu. Rev. Immunol. 29, 235–271 (2011)</ref-fulltext>
<ce:source-text>Vesely, M.D., Kershaw, M.H., Schreiber, R.D., Smyth, M.J.: Natural innate and adaptive immunity to cancer. Annu. Rev. Immunol. 29, 235–271 (2011)</ce:source-text>
</reference>
<reference seq="55">
<ref-info>
<ref-title>
<ref-titletext-english>Concise review: modulating cancer immunity withhematopoietic stem and progenitor cells.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.J.</ce:initials>
<ce:surname>Wildes</ce:surname>
<ce:given-name>T.J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.T.</ce:initials>
<ce:surname>Flores</ce:surname>
<ce:given-name>C.T.</ce:given-name>
</author>
<author seq="3">
<ce:initials>D.A.</ce:initials>
<ce:surname>Mitchell</ce:surname>
<ce:given-name>D.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Stem Cells</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>37</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>166</first-page>
<last-page>175</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wildes, T.J., Flores, C.T., Mitchell, D.A.: Concise review: modulating cancer immunity with hematopoietic stem and progenitor cells. Stem Cells. 37, 166–175 (2019)</ref-fulltext>
<ce:source-text>Wildes, T.J., Flores, C.T., Mitchell, D.A.: Concise review: modulating cancer immunity with hematopoietic stem and progenitor cells. Stem Cells. 37, 166–175 (2019)</ce:source-text>
</reference>
<reference seq="56">
<ref-info>
<ref-title>
<ref-titletext-english>Roles of the immune system in cancer: from tumor initiation to metastatic progression</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Gonzalez</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.</ce:initials>
<ce:surname>Hagerling</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="3">
<ce:initials>Z.</ce:initials>
<ce:surname>Werb</ce:surname>
<ce:given-name>Z.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Genes Dev</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>32</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1267</first-page>
<last-page>1284</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Gonzalez, H., Hagerling, C., Werb, Z.: Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev. 32, 1267–1284 (2018)</ref-fulltext>
<ce:source-text>Gonzalez, H., Hagerling, C., Werb, Z.: Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev. 32, 1267–1284 (2018)</ce:source-text>
</reference>
<reference seq="57">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer-cellintrinsic mechanisms shaping the tumor immune landscape</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.D.</ce:initials>
<ce:surname>Wellenstein</ce:surname>
<ce:given-name>M.D.</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.E.</ce:initials>
<ce:surname>Visser</ce:surname>
<ce:given-name>K.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Immunity</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>48</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>399</first-page>
<last-page>416</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wellenstein, M.D., de Visser, K.E.: Cancer-cellintrinsic mechanisms shaping the tumor immune landscape. Immunity. 48, 399–416 (2018) </ref-fulltext>
<ce:source-text>Wellenstein, M.D., de Visser, K.E.: Cancer-cellintrinsic mechanisms shaping the tumor immune landscape. Immunity. 48, 399–416 (2018) </ce:source-text>
</reference>
<reference seq="58">
<ref-info>
<ref-title>
<ref-titletext-english>: Allele-specific HLA loss and immune escape in lung cancer evolution.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.</ce:initials>
<ce:surname>McGranaha</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell.</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>171</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1259</first-page>
<last-page>1271</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>McGranahan, N., et al.: Allele-specific HLA loss and immune escape in lung cancer evolution. Cell. 171, 1259–1271 e1211 (2017)</ref-fulltext>
<ce:source-text>McGranahan, N., et al.: Allele-specific HLA loss and immune escape in lung cancer evolution. Cell. 171, 1259–1271 e1211 (2017)</ce:source-text>
</reference>
<reference seq="59">
<ref-info>
<ref-title>
<ref-titletext-english>TGFbeta drives immune evasion in genetically reconstituted colon cancer metastasis. </ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.V.F.</ce:initials>
<ce:surname>Tauriello</ce:surname>
<ce:given-name>D.V.F.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature.</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>554</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>538</first-page>
<last-page>543</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Tauriello, D.V.F., et al.: TGFbeta drives immune evasion in genetically reconstituted colon cancer metastasis. Nature. 554, 538–543 (2018)</ref-fulltext>
<ce:source-text>Tauriello, D.V.F., et al.: TGFbeta drives immune evasion in genetically reconstituted colon cancer metastasis. Nature. 554, 538–543 (2018)</ce:source-text>
</reference>
<reference seq="60">
<ref-info>
<ref-title>
<ref-titletext-english>Inflammatory modulation of HSCs: viewing the HSC as a foundation for the immune response. </ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials> K.Y.</ce:initials>
<ce:surname>King</ce:surname>
<ce:given-name> K.Y.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.A.</ce:initials>
<ce:surname>Goodell</ce:surname>
<ce:given-name>M.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Immunol. </ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>11</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>685</first-page>
<last-page>692</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>King, K.Y., Goodell, M.A.: Inflammatory modulation of HSCs: viewing the HSC as a foundation for the immune response. Nat. Rev. Immunol. 11, 685–692 (2011) </ref-fulltext>
<ce:source-text>King, K.Y., Goodell, M.A.: Inflammatory modulation of HSCs: viewing the HSC as a foundation for the immune response. Nat. Rev. Immunol. 11, 685–692 (2011) </ce:source-text>
</reference>
<reference seq="61">
<ref-info>
<ref-title>
<ref-titletext-english> An interferon-driven oxysterol-based defense against tumor-derived extracellular vesicles.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Ortiz</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Cell</ref-sourcetitle>
<ref-publicationyear first="2019" />
<ref-text />
<volisspag>
<volume-issue-number>
<vol-first>35</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>33</first-page>
<last-page>45</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ortiz, A., et al.: An interferon-driven oxysterol-based defense against tumor-derived extracellular vesicles. Cancer Cell. 35, 33–45 e36 (2019)</ref-fulltext>
<ce:source-text>Ortiz, A., et al.: An interferon-driven oxysterol-based defense against tumor-derived extracellular vesicles. Cancer Cell. 35, 33–45 e36 (2019)</ce:source-text>
</reference>
<reference seq="62">
<ref-info>
<ref-title>
<ref-titletext-english>Innate or adaptive immunity? The example of natural killer cells.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.</ce:initials>
<ce:surname>Vivier</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Science</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>331</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>44</first-page>
<last-page>49</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Vivier, E., et al.: Innate or adaptive immunity? The example of natural killer cells. Science. 331, 44–49 (2011)</ref-fulltext>
<ce:source-text>Vivier, E., et al.: Innate or adaptive immunity? The example of natural killer cells. Science. 331, 44–49 (2011)</ce:source-text>
</reference>
<reference seq="63">
<ref-info>
<ref-title>
<ref-titletext-english> AML suppresses hematopoiesis by releasing exosomes that contain microRNAs targeting c-MYB. </ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.I.</ce:initials>
<ce:surname>Hornick</ce:surname>
<ce:given-name>N.I.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Sci.Signal.</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>88</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hornick, N.I., et al.: AML suppresses hematopoiesis by releasing exosomes that contain microRNAs targeting c-MYB. Sci. Signal. 9, ra88 (2016)</ref-fulltext>
<ce:source-text>Hornick, N.I., et al.: AML suppresses hematopoiesis by releasing exosomes that contain microRNAs targeting c-MYB. Sci. Signal. 9, ra88 (2016)</ce:source-text>
</reference>
<reference seq="64">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor exosomes inhibit differentiation of bone marrow dendritic cells.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Yu</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J.Immunol.</ref-sourcetitle>
<ref-publicationyear first="2007" />
<volisspag>
<volume-issue-number>
<vol-first>178</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>6867</first-page>
<last-page>6875</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Yu, S., et al.: Tumor exosomes inhibit differentiation of bone marrow dendritic cells. J. Immunol. 178, 6867–6875 (2007)</ref-fulltext>
<ce:source-text>Yu, S., et al.: Tumor exosomes inhibit differentiation of bone marrow dendritic cells. J. Immunol. 178, 6867–6875 (2007)</ce:source-text>
</reference>
<reference seq="65">
<ref-info>
<ref-title>
<ref-titletext-english>induction of myeloid-derived suppressor cells by tumor exosomes. </ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.</ce:initials>
<ce:surname>Xiang</ce:surname>
<ce:given-name>X.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int.J.Cancer</ref-sourcetitle>
<ref-publicationyear first="2009" />
<volisspag>
<volume-issue-number>
<vol-first>124</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2621</first-page>
<last-page>2633</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Xiang, X., et al.: Induction of myeloid-derived suppressor cells by tumor exosomes. Int. J. Cancer. 124, 2621–2633 (2009)</ref-fulltext>
<ce:source-text>Xiang, X., et al.: Induction of myeloid-derived suppressor cells by tumor exosomes. Int. J. Cancer. 124, 2621–2633 (2009)</ce:source-text>
</reference>
<reference seq="66">
<ref-info>
<ref-title>
<ref-titletext-english>Myeloid-derived suppressor cells. Cancer Immunol.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.I.</ce:initials>
<ce:surname>Gabrilovich</ce:surname>
<ce:given-name>D.I.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Res.</ref-sourcetitle>
<ref-publicationyear first="2017" />
<ref-text />
<volisspag>
<volume-issue-number>
<vol-first>5</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3</first-page>
<last-page>8</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Gabrilovich, D.I.: Myeloid-derived suppressor cells. Cancer Immunol. Res. 5, 3–8 (2017)</ref-fulltext>
<ce:source-text>Gabrilovich, D.I.: Myeloid-derived suppressor cells. Cancer Immunol. Res. 5, 3–8 (2017)</ce:source-text>
</reference>
<reference seq="67">
<ref-info>
<ref-title>
<ref-titletext-english>Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3- dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. </ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Chalmin</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J.Clin.Invest.</ref-sourcetitle>
<ref-publicationyear first="2010" />
<volisspag>
<volume-issue-number>
<vol-first>120</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>457</first-page>
<last-page>471</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Chalmin, F., et al.: Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3- dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J. Clin. Invest. 120, 457–471 (2010)</ref-fulltext>
<ce:source-text>Chalmin, F., et al.: Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3- dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J. Clin. Invest. 120, 457–471 (2010)</ce:source-text>
</reference>
<reference seq="68">
<ref-info>
<ref-title>
<ref-titletext-english>Melanoma extracellular vesicles generate immunosuppressive myeloid cells by upregulating PD-L1 via TLR4 signaling</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>V.</ce:initials>
<ce:surname>Fleming</ce:surname>
<ce:given-name>V.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Res.</ref-sourcetitle>
<ref-publicationyear first="2019" />
<ref-text />
<volisspag>
<volume-issue-number>
<vol-first>79</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>4715</first-page>
<last-page>4728</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Fleming, V., et al.: Melanoma extracellular vesicles generate immunosuppressive myeloid cells by upregulating PD-L1 via TLR4 signaling. Cancer Res. 79, 4715–4728 (2019)</ref-fulltext>
<ce:source-text>Fleming, V., et al.: Melanoma extracellular vesicles generate immunosuppressive myeloid cells by upregulating PD-L1 via TLR4 signaling. Cancer Res. 79, 4715–4728 (2019)</ce:source-text>
</reference>
<reference seq="69">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor-derived microRNAs induce myeloid suppressor cells and predict immunotherapy resistance in melanoma.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>V.</ce:initials>
<ce:surname>Huber</ce:surname>
<ce:given-name>V.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J.Clin.Invest.</ref-sourcetitle>
<ref-publicationyear first="2018" />
<ref-text />
<volisspag>
<volume-issue-number>
<vol-first>128</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>5505</first-page>
<last-page>5516</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Huber, V., et al.: Tumor-derived microRNAs induce myeloid suppressor cells and predict immunotherapy resistance in melanoma. J. Clin. Invest. 128, 5505–5516 (2018)</ref-fulltext>
<ce:source-text>Huber, V., et al.: Tumor-derived microRNAs induce myeloid suppressor cells and predict immunotherapy resistance in melanoma. J. Clin. Invest. 128, 5505–5516 (2018)</ce:source-text>
</reference>
<reference seq="70">
<ref-info>
<ref-title>
<ref-titletext-english>Immunosuppressive effects of hypoxia-induced glioma exosomes through myeloid-derived suppressor cells via the miR-10a/ Rora and miR-21/Pten Pathways</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.</ce:initials>
<ce:surname>Guo</ce:surname>
<ce:given-name />
</author>
</ref-authors>
<ref-sourcetitle>Oncogene</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>37</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>4239</first-page>
<last-page>4259</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Guo, X., et al.: Immunosuppressive effects of hypoxia-induced glioma exosomes through myeloid-derived suppressor cells via the miR-10a/ Rora and miR-21/Pten Pathways. Oncogene. 37, 4239–4259 (2018)</ref-fulltext>
<ce:source-text>Guo, X., et al.: Immunosuppressive effects of hypoxia-induced glioma exosomes through myeloid-derived suppressor cells via the miR-10a/ Rora and miR-21/Pten Pathways. Oncogene. 37, 4239–4259 (2018)</ce:source-text>
</reference>
<reference seq="71">
<ref-info>
<ref-title>
<ref-titletext-english>Akira, S., Uematsu, S., Takeuchi, O.: Pathogen recognition and innate immunity. Cell. 124, 783–801 (2006)</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Akira</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Uematsu</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>O.</ce:initials>
<ce:surname>Takeuchi</ce:surname>
<ce:given-name>O.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle />
<ref-publicationyear first="2006" />
<volisspag>
<volume-issue-number>
<vol-first>124</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>783</first-page>
<last-page>801</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Akira, S., Uematsu, S., Takeuchi, O.: Pathogen recognition and innate immunity. Cell. 124, 783–801 (2006)</ref-fulltext>
<ce:source-text>Akira, S., Uematsu, S., Takeuchi, O.: Pathogen recognition and innate immunity. Cell. 124, 783–801 (2006)</ce:source-text>
</reference>
<reference seq="72">
<ref-info>
<ref-title>
<ref-titletext-english>Macrophages and metabolism in the tumor microenvironment.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>I.</ce:initials>
<ce:surname>Vitale</ce:surname>
<ce:given-name>I.</ce:given-name>
</author>
<author seq="2">
<ce:initials>G.</ce:initials>
<ce:surname>Manic</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="3">
<ce:initials>L.M.</ce:initials>
<ce:surname>Coussens</ce:surname>
<ce:given-name>L.M.</ce:given-name>
</author>
<author seq="4">
<ce:initials>G.</ce:initials>
<ce:surname>Kroemer</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="5">
<ce:initials>L.</ce:initials>
<ce:surname>Galluzzi</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Metab</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>30</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>36</first-page>
<last-page>50</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Vitale, I., Manic, G., Coussens, L.M., Kroemer, G., Galluzzi, L.: Macrophages and metabolism in thetumor microenvironment. Cell Metab. 30, 36–50 (2019)</ref-fulltext>
<ce:source-text>Vitale, I., Manic, G., Coussens, L.M., Kroemer, G., Galluzzi, L.: Macrophages and metabolism in thetumor microenvironment. Cell Metab. 30, 36–50 (2019)</ce:source-text>
</reference>
<reference seq="73">
<ref-info>
<ref-title>
<ref-titletext-english>MicroRNAs bind to toll-like receptors to induce prometastatic inflammatory response</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Fabbri</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle> Proc. Natl. Acad. Sci. USA</ref-sourcetitle>
<ref-publicationyear first="2012" />
<volisspag>
<volume-issue-number>
<vol-first>109</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>. Fabbri, M., et al.: MicroRNAs bind to toll-like receptors to induce prometastatic inflammatory response. Proc. Natl. Acad. Sci. USA. 109, E2110– E2116 (2012)</ref-fulltext>
<ce:source-text>. Fabbri, M., et al.: MicroRNAs bind to toll-like receptors to induce prometastatic inflammatory response. Proc. Natl. Acad. Sci. USA. 109, E2110– E2116 (2012)</ce:source-text>
</reference>
<reference seq="74">
<ref-info>
<ref-title>
<ref-titletext-english>Epithelial ovarian cancer-secreted exosomal miR-222-3p induces polarization of tumor-associated macrophages</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.</ce:initials>
<ce:surname>Ying</ce:surname>
<ce:given-name>X.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncotarget.</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>43076</first-page>
<last-page>43087</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ying, X., et al.: Epithelial ovarian cancer-secreted exosomal miR-222-3p induces polarization of tumor-associated macrophages. Oncotarget. 7, 43076–43087 (2016) </ref-fulltext>
<ce:source-text>Ying, X., et al.: Epithelial ovarian cancer-secreted exosomal miR-222-3p induces polarization of tumor-associated macrophages. Oncotarget. 7, 43076–43087 (2016) </ce:source-text>
</reference>
<reference seq="75">
<ref-info>
<ref-title>
<ref-titletext-english>Mutant p53 cancers reprogram macrophages to tumor supporting macrophages via exosomal miR-1246</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Cooks</ce:surname>
<ce:given-name />
</author>
</ref-authors>
<ref-sourcetitle>Nat.Commun</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>771</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Cooks, T., et al.: Mutant p53 cancers reprogram macrophages to tumor supporting macrophages via exosomal miR-1246. Nat. Commun. 9, 771 (2018)</ref-fulltext>
<ce:source-text>Cooks, T., et al.: Mutant p53 cancers reprogram macrophages to tumor supporting macrophages via exosomal miR-1246. Nat. Commun. 9, 771 (2018)</ce:source-text>
</reference>
<reference seq="76">
<ref-info>
<ref-title>
<ref-titletext-english>Hypoxia-induced tumor exosomes promote M2-like macrophage polarization of infiltrating myeloid cells and microRNA-mediated metabolic shift.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.E.</ce:initials>
<ce:surname>Park</ce:surname>
<ce:given-name>J.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncogene.</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>38</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>5158</first-page>
<last-page>5173</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Park, J.E., et al.: Hypoxia-induced tumor exosomes promote M2-like macrophage polarization of infiltrating myeloid cells and microRNA-mediated metabolic shift. Oncogene. 38, 5158–5173 (2019) </ref-fulltext>
<ce:source-text>Park, J.E., et al.: Hypoxia-induced tumor exosomes promote M2-like macrophage polarization of infiltrating myeloid cells and microRNA-mediated metabolic shift. Oncogene. 38, 5158–5173 (2019) </ce:source-text>
</reference>
<reference seq="77">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer immunotherapy via dendritic cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Palucka</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Banchereau</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Cancer</ref-sourcetitle>
<ref-publicationyear first="2012" />
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>265</first-page>
<last-page>277</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Palucka, K., Banchereau, J.: Cancer immunotherapy via dendritic cells. Nat. Rev. Cancer. 12, 265–277 (2012)</ref-fulltext>
<ce:source-text>Palucka, K., Banchereau, J.: Cancer immunotherapy via dendritic cells. Nat. Rev. Cancer. 12, 265–277 (2012)</ce:source-text>
</reference>
<reference seq="78">
<ref-info>
<ref-title>
<ref-titletext-english>EGFR E746-A750 deletion in lung cancer represses antitumor immunity through the exosome-mediated inhibition of dendritic cells.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Yu</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncogene</ref-sourcetitle>
<ref-publicationyear first="2020" />
</ref-info>
<ref-fulltext>Yu, S., et al.: EGFR E746-A750 deletion in lung cancer represses antitumor immunity through the exosome-mediated inhibition of dendritic cells. Oncogene. (2020)</ref-fulltext>
<ce:source-text>Yu, S., et al.: EGFR E746-A750 deletion in lung cancer represses antitumor immunity through the exosome-mediated inhibition of dendritic cells. Oncogene. (2020)</ce:source-text>
</reference>
<reference seq="79">
<ref-info>
<ref-title>
<ref-titletext-english>Pancreatic cancer-derived exosomes transfer miRNAs to dendritic cells and inhibit RFXAP expression via miR-212-3p</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Ding</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncotarget</ref-sourcetitle>
<ref-publicationyear first="2015" />
<ref-text />
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>29877</first-page>
<last-page>29888</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ding, G., et al.: Pancreatic cancer-derived exosomes transfer miRNAs to dendritic cells and inhibit RFXAP expression via miR-212-3p. Oncotarget. 6, 29877–29888 (2015)</ref-fulltext>
<ce:source-text>Ding, G., et al.: Pancreatic cancer-derived exosomes transfer miRNAs to dendritic cells and inhibit RFXAP expression via miR-212-3p. Oncotarget. 6, 29877–29888 (2015)</ce:source-text>
</reference>
<reference seq="80">
<ref-info>
<ref-title>
<ref-titletext-english>Targeting natural killer cells in cancer immunotherapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Guillerey</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="2">
<ce:initials>N.D.</ce:initials>
<ce:surname>Huntington</ce:surname>
<ce:given-name>N.D.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.J.</ce:initials>
<ce:surname>Smyth</ce:surname>
<ce:given-name>M.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat.Immunol.</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>17</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1025</first-page>
<last-page>1036</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Guillerey, C., Huntington, N.D., Smyth, M.J.: Targeting natural killer cells in cancer immunotherapy. Nat. Immunol. 17, 1025–1036 (2016)</ref-fulltext>
<ce:source-text>Guillerey, C., Huntington, N.D., Smyth, M.J.: Targeting natural killer cells in cancer immunotherapy. Nat. Immunol. 17, 1025–1036 (2016)</ce:source-text>
</reference>
<reference seq="81">
<ref-info>
<ref-title>
<ref-titletext-english> The critical role of the tumor microenvironment in shaping natural killer cellmediated anti-tumor immunity</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Baginska</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Front.Immunol.</ref-sourcetitle>
<ref-publicationyear first="2013" />
<volisspag>
<volume-issue-number>
<vol-first>4</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>490</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Baginska, J., et al.: The critical role of the tumor microenvironment in shaping natural killer cellmediated anti-tumor immunity. Front. Immunol. 4, 490 (2013)</ref-fulltext>
<ce:source-text>Baginska, J., et al.: The critical role of the tumor microenvironment in shaping natural killer cellmediated anti-tumor immunity. Front. Immunol. 4, 490 (2013)</ce:source-text>
</reference>
<reference seq="82">
<ref-info>
<ref-title>
<ref-titletext-english>Altered NKp30, NKp46, NKG2D, and DNAM-1 expression on circulating NK cells is associated with tumor progression in human gastric cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.</ce:initials>
<ce:surname>Han</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J Immunol Res</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>2018</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Han, B., et al.: Altered NKp30, NKp46, NKG2D, and DNAM-1 expression on circulating NK cells is associated with tumor progression in human gastric cancer. J Immunol Res. 2018, 6248590 (2018)</ref-fulltext>
<ce:source-text>Han, B., et al.: Altered NKp30, NKp46, NKG2D, and DNAM-1 expression on circulating NK cells is associated with tumor progression in human gastric cancer. J Immunol Res. 2018, 6248590 (2018)</ce:source-text>
</reference>
<reference seq="83">
<ref-info>
<ref-title>
<ref-titletext-english>TGF-beta inhibits the activation and functions of NK cells by repressing the mTOR pathway.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Viel</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Sci.Signal</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Viel, S., et al.: TGF-beta inhibits the activation and functions of NK cells by repressing the mTOR pathway. Sci. Signal. 9, ra19 (2016)</ref-fulltext>
<ce:source-text>Viel, S., et al.: TGF-beta inhibits the activation and functions of NK cells by repressing the mTOR pathway. Sci. Signal. 9, ra19 (2016)</ce:source-text>
</reference>
<reference seq="84">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor-derived extracellular vesicles inhibit natural killer cell function in pancreatic cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.G.</ce:initials>
<ce:surname>Zhao</ce:surname>
<ce:given-name>J.G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancers</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>11</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>Zhao, J.G., et al.: Tumor-derived extracellular vesicles inhibit natural killer cell function in pancreatic cancer. Cancers. 11 (2019)</first-page>
<last-page>Zhao, J.G., et al.: Tumor-derived extracellular vesicles inhibit natural killer cell function in pancreatic cancer. Cancers. 11 (2019)</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext />
<ce:source-text />
</reference>
<reference seq="85">
<ref-info>
<ref-title>
<ref-titletext-english>Prostate tumor-derived exosomes down-regulate NKG2D expression on natural killer cells and CD8+ T cells: mechanism of immune evasion</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Lundholm</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>PLoS One</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Lundholm, M., et al.: Prostate tumor-derived exosomes down-regulate NKG2D expression on natural killer cells and CD8+ T cells: mechanism of immune evasion. PLoS One. 9, e108925 (2014) </ref-fulltext>
<ce:source-text>Lundholm, M., et al.: Prostate tumor-derived exosomes down-regulate NKG2D expression on natural killer cells and CD8+ T cells: mechanism of immune evasion. PLoS One. 9, e108925 (2014) </ce:source-text>
</reference>
<reference seq="86">
<ref-info>
<ref-title>
<ref-titletext-english>Murine mammary carcinoma exosomes promote tumor growth by suppression of NK cell function.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Liu</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J.Immunol</ref-sourcetitle>
<ref-publicationyear first="2006" />
<volisspag>
<volume-issue-number>
<vol-first>176</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1375</first-page>
<last-page>1385</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Liu, C., et al.: Murine mammary carcinoma exosomes promote tumor growth by suppression of NK cell function. J. Immunol. 176, 1375–1385 (2006)</ref-fulltext>
<ce:source-text>Liu, C., et al.: Murine mammary carcinoma exosomes promote tumor growth by suppression of NK cell function. J. Immunol. 176, 1375–1385 (2006)</ce:source-text>
</reference>
<reference seq="87">
<ref-info>
<ref-title>
<ref-titletext-english>Neutrophils in cancer: neutral no more. </ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.B.</ce:initials>
<ce:surname>Coffelt</ce:surname>
<ce:given-name>S.B.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.D.</ce:initials>
<ce:surname>Wellenstein</ce:surname>
<ce:given-name>M.D.</ce:given-name>
</author>
<author seq="3">
<ce:initials>K.E.</ce:initials>
<ce:surname>de Visser</ce:surname>
<ce:given-name>K.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat.Rev.Cancer.</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>16</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>431</first-page>
<last-page>446</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Coffelt, S.B., Wellenstein, M.D., de Visser, K.E.: Neutrophils in cancer: neutral no more. Nat. Rev. Cancer. 16, 431–446 (2016)</ref-fulltext>
<ce:source-text>Coffelt, S.B., Wellenstein, M.D., de Visser, K.E.: Neutrophils in cancer: neutral no more. Nat. Rev. Cancer. 16, 431–446 (2016)</ce:source-text> </reference>
<reference seq="88">
<ref-info>
<ref-title>
<ref-titletext-english>Granulocyte-colony stimulating
factor promotes lung metastasis through mobilizationof Ly6G+Ly6C+ granulocytes</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Kowanetz</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Proc. Natl. Acad. Sci. USA</ref-sourcetitle>
<ref-publicationyear first="2010" />
<volisspag>
<volume-issue-number>
<vol-first>107</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>21248</first-page>
<last-page>21255</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kowanetz, M., et al.: Granulocyte-colony stimulating factor promotes lung metastasis through mobilizationof Ly6G+Ly6C+ granulocytes. Proc. Natl. Acad. Sci. USA. 107, 21248–21255 (2010)</ref-fulltext>
<ce:source-text>Kowanetz, M., et al.: Granulocyte-colony stimulating factor promotes lung metastasis through mobilizationof Ly6G+Ly6C+ granulocytes. Proc. Natl. Acad. Sci. USA. 107, 21248–21255 (2010)</ce:source-text>
</reference>
<reference seq="89">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor entrained neutrophils inhibit seeding in the premetastatic lung</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Z.</ce:initials>
<ce:surname>Granot</ce:surname>
<ce:given-name>Z.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Cell</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>20</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>300</first-page>
<last-page>314</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Granot, Z., et al.: Tumor entrained neutrophils inhibit seeding in the premetastatic lung. Cancer Cell. 20, 300–314 (2011)</ref-fulltext>
<ce:source-text>Granot, Z., et al.: Tumor entrained neutrophils inhibit seeding in the premetastatic lung. Cancer Cell. 20, 300–314 (2011)</ce:source-text>
</reference>
<reference seq="90">
<ref-info>
<ref-title>
<ref-titletext-english>Intratumoral neutrophils: a poor prognostic factor for hepatocellular carcinoma following resection.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.W.</ce:initials>
<ce:surname>Li</ce:surname>
<ce:given-name>Y.W.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J.Hepatol.</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>54</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>497</first-page>
<last-page>505</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Li, Y.W., et al.: Intratumoral neutrophils: a poor prognostic factor for hepatocellular carcinoma following resection. J. Hepatol. 54, 497–505 (2011)</ref-fulltext>
<ce:source-text>Li, Y.W., et al.: Intratumoral neutrophils: a poor prognostic factor for hepatocellular carcinoma following resection. J. Hepatol. 54, 497–505 (2011)</ce:source-text>
</reference>
<reference seq="91">
<ref-info>
<ref-title>
<ref-titletext-english>The prognostic value of tumorinfiltrating neutrophils in gastric adenocarcinoma after resection. </ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.J.</ce:initials>
<ce:surname>Zhao</ce:surname>
<ce:given-name>J.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>PLoS One</ref-sourcetitle>
<ref-publicationyear first="2012" />
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Zhao, J.J., et al.: The prognostic value of tumorinfiltrating neutrophils in gastric adenocarcinoma after resection. PLoS One. 7, e33655 (2012)</ref-fulltext>
<ce:source-text>Zhao, J.J., et al.: The prognostic value of tumorinfiltrating neutrophils in gastric adenocarcinoma after resection. PLoS One. 7, e33655 (2012)</ce:source-text>
</reference>
<reference seq="92">
<ref-info>
<ref-title>
<ref-titletext-english>Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.K.</ce:initials>
<ce:surname>Jensen</ce:surname>
<ce:given-name>H.K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Oncol</ref-sourcetitle>
<ref-publicationyear first="2009" />
<volisspag>
<volume-issue-number>
<vol-first>27</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>4709</first-page>
<last-page>4717</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Jensen, H.K., et al.: Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma. J. Clin. Oncol. 27, 4709–4717 (2009)</ref-fulltext>
<ce:source-text>Jensen, H.K., et al.: Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma. J. Clin. Oncol. 27, 4709–4717 (2009)</ce:source-text>
</reference>
<reference seq="93">
<ref-info>
<ref-title>
<ref-titletext-english>Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Schmidt</ce:surname>
<ce:given-name />
</author>
</ref-authors>
<ref-sourcetitle>Br. J. Cancer.</ref-sourcetitle>
<ref-publicationyear first="2005" />
<volisspag>
<volume-issue-number>
<vol-first>93</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>273</first-page>
<last-page>278</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Schmidt, H., et al.: Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model. Br. J. Cancer. 93, 273–278 (2005)</ref-fulltext>
<ce:source-text>Schmidt, H., et al.: Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model. Br. J. Cancer. 93, 273–278 (2005)</ce:source-text>
</reference>
<reference seq="94">
<ref-info>
<ref-title>
<ref-titletext-english>Invasive breast cancer reprograms early myeloid differentiation in the bone marrow to generate immunosuppressive neutrophils. </ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.J.</ce:initials>
<ce:surname>Casbon</ce:surname>
<ce:given-name>A.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Proc. Natl. Acad. Sci. USA. </ref-sourcetitle>
<ref-publicationyear first="2015" />
<ref-text />
<volisspag>
<volume-issue-number>
<vol-first>112</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Casbon, A.J., et al.: Invasive breast cancer reprograms early myeloid differentiation in the bone marrow to generate immunosuppressive neutrophils. Proc. Natl. Acad. Sci. USA. 112, E566–E575 (2015)</ref-fulltext>
<ce:source-text>Casbon, A.J., et al.: Invasive breast cancer reprograms early myeloid differentiation in the bone marrow to generate immunosuppressive neutrophils. Proc. Natl. Acad. Sci. USA. 112, E566–E575 (2015)</ce:source-text>
</reference>
<reference seq="95">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.J.</ce:initials>
<ce:surname>Bayne</ce:surname>
<ce:given-name>L.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Cell</ref-sourcetitle>
<ref-publicationyear first="2012" />
<volisspag>
<volume-issue-number>
<vol-first>21</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>822</first-page>
<last-page>835</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Bayne, L.J., et al.: Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell. 21, 822–835 (2012) </ref-fulltext>
<ce:source-text>Bayne, L.J., et al.: Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell. 21, 822–835 (2012) </ce:source-text>
</reference>
<reference seq="96">
<ref-info>
<ref-title>
<ref-titletext-english> IL-17-producing gammadelta T cells and neutrophils conspire to promote breast cancer metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.B.</ce:initials>
<ce:surname>Coffelt</ce:surname>
<ce:given-name>S.B.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>522</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>345</first-page>
<last-page>348</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Coffelt, S.B., et al.: IL-17-producing gammadelta T cells and neutrophils conspire to promote breast cancer metastasis. Nature. 522, 345–348 (2015) </ref-fulltext>
<ce:source-text>Coffelt, S.B., et al.: IL-17-producing gammadelta T cells and neutrophils conspire to promote breast cancer metastasis. Nature. 522, 345–348 (2015) </ce:source-text>
</reference>
<reference seq="97">
<ref-info>
<ref-title>
<ref-titletext-english>CXCL1 is critical for premetastatic niche formation and metastasis in colorectal cancer. </ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Wang</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="2">
<ce:initials>H.</ce:initials>
<ce:surname>Sun</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Wei</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="4">
<ce:initials>B.</ce:initials>
<ce:surname>Cen</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
<author seq="5">
<ce:initials>R.N</ce:initials>
<ce:surname>DuBois</ce:surname>
<ce:given-name>R.N</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Res.</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>77</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3655</first-page>
<last-page>3665</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wang, D., Sun, H., Wei, J., Cen, B., DuBois, R.N.: CXCL1 is critical for premetastatic niche formation and metastasis in colorectal cancer. Cancer Res. 77, 3655–3665 (2017)</ref-fulltext>
<ce:source-text>Wang, D., Sun, H., Wei, J., Cen, B., DuBois, R.N.: CXCL1 is critical for premetastatic niche formation and metastasis in colorectal cancer. Cancer Res. 77, 3655–3665 (2017)</ce:source-text>
</reference>
<reference seq="98">
<ref-info>
<ref-title>
<ref-titletext-english>Tumour-associated neutrophils in patients with cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.E.</ce:initials>
<ce:surname>Shaul</ce:surname>
<ce:given-name>M.E.</ce:given-name>
</author>
<author seq="2">
<ce:initials>Z.G.</ce:initials>
<ce:surname>Fridlender</ce:surname>
<ce:given-name>Z.G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Clin. Oncol.</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>16</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>601</first-page>
<last-page>620</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Shaul, M.E., Fridlender, Z.G.: Tumour-associated neutrophils in patients with cancer. Nat. Rev. Clin. Oncol. 16, 601–620 (2019)</ref-fulltext>
<ce:source-text>Shaul, M.E., Fridlender, Z.G.: Tumour-associated neutrophils in patients with cancer. Nat. Rev. Clin. Oncol. 16, 601–620 (2019)</ce:source-text>
</reference>
<reference seq="99">
<ref-info>
<ref-title>
<ref-titletext-english>Type I IFNs induce anti-tumor polarization of tumor associated neutrophils in mice and human.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Andzinski</ce:surname>
<ce:given-name />
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Cancer</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>138</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1982</first-page>
<last-page>1993</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Andzinski, L., et al.: Type I IFNs induce anti-tumor polarization of tumor associated neutrophils in mice and human. Int. J. Cancer. 138, 1982–1993 (2016)</ref-fulltext>
<ce:source-text>Andzinski, L., et al.: Type I IFNs induce anti-tumor polarization of tumor associated neutrophils in mice and human. Int. J. Cancer. 138, 1982–1993 (2016)</ce:source-text>
</reference>
<reference seq="100">
<ref-info>
<ref-title>
<ref-titletext-english>Polarization of tumorassociated neutrophil phenotype by TGF-beta: “N1” versus “N2” TAN.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Z.G.</ce:initials>
<ce:surname>Fridlender</ce:surname>
<ce:given-name>Z.G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Cell.</ref-sourcetitle>
<ref-publicationyear first="2009" />
<volisspag>
<volume-issue-number>
<vol-first>16</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>183</first-page>
<last-page>194</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Fridlender, Z.G., et al.: Polarization of tumorassociated neutrophil phenotype by TGF-beta: “N1” versus “N2” TAN. Cancer Cell. 16, 183–194 (2009)</ref-fulltext>
<ce:source-text>Fridlender, Z.G., et al.: Polarization of tumorassociated neutrophil phenotype by TGF-beta: “N1” versus “N2” TAN. Cancer Cell. 16, 183–194 (2009)</ce:source-text>
</reference>
<reference seq="101">
<ref-info>
<ref-title>
<ref-titletext-english> Tumor-derived exosomes induce N2 polarization of neutrophils to promote gastric cancer cell migration.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.</ce:initials>
<ce:surname>Zhang</ce:surname>
<ce:given-name>X.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Mol. Cancer</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>17</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>146</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zhang, X., et al.: Tumor-derived exosomes induce N2 polarization of neutrophils to promote gastric cancer cell migration. Mol. Cancer. 17, 146 (2018)</ref-fulltext>
<ce:source-text>Zhang, X., et al.: Tumor-derived exosomes induce N2 polarization of neutrophils to promote gastric cancer cell migration. Mol. Cancer. 17, 146 (2018)</ce:source-text>
</reference>
<reference seq="102">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor stem-like cell-derived exosomal RNAs prime neutrophils for facilitating tumorigenesis of colon cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>W.L.</ce:initials>
<ce:surname>Hwang</ce:surname>
<ce:given-name>W.L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>H.Y.</ce:initials>
<ce:surname>Lan</ce:surname>
<ce:given-name>H.Y.</ce:given-name>
</author>
<author seq="3">
<ce:initials>W.C.</ce:initials>
<ce:surname>Cheng</ce:surname>
<ce:given-name>W.C.</ce:given-name>
</author>
<author seq="4">
<ce:initials>S.C.</ce:initials>
<ce:surname>Huang</ce:surname>
<ce:given-name>S.C.</ce:given-name>
</author>
<author seq="5">
<ce:initials>M.H.</ce:initials>
<ce:surname>Yang</ce:surname>
<ce:given-name>M.H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Hematol. Oncol.</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>10</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hwang, W.L., Lan, H.Y., Cheng, W.C., Huang, S.C., Yang, M.H.: Tumor stem-like cell-derived exosomal RNAs prime neutrophils for facilitating tumorigenesis of colon cancer. J. Hematol. Oncol. 12, 10 (2019)</ref-fulltext>
<ce:source-text>Hwang, W.L., Lan, H.Y., Cheng, W.C., Huang, S.C., Yang, M.H.: Tumor stem-like cell-derived exosomal RNAs prime neutrophils for facilitating tumorigenesis of colon cancer. J. Hematol. Oncol. 12, 10 (2019)</ce:source-text>
</reference>
<reference seq="103">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor-derived exosomes induce the formation of neutrophil extracellular traps: implications for the establishment of cancerassociated thrombosis.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.C.</ce:initials>
<ce:surname>Leal</ce:surname>
<ce:given-name>A.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Sci. Rep</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>6438</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Leal, A.C., et al.: Tumor-derived exosomes induce the formation of neutrophil extracellular traps: implications for the establishment of cancerassociated thrombosis. Sci. Rep. 7, 6438 (2017)</ref-fulltext>
<ce:source-text>Leal, A.C., et al.: Tumor-derived exosomes induce the formation of neutrophil extracellular traps: implications for the establishment of cancerassociated thrombosis. Sci. Rep. 7, 6438 (2017)</ce:source-text>
</reference>
<reference seq="104">
<ref-info>
<ref-title>
<ref-titletext-english>Neutrophil extracellular traps kill bacteria</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>V.</ce:initials>
<ce:surname>Brinkmann</ce:surname>
<ce:given-name>V.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Science</ref-sourcetitle>
<ref-publicationyear first="2004" />
<volisspag>
<volume-issue-number>
<vol-first>303</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1532</first-page>
<last-page>1535</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Brinkmann, V., et al.: Neutrophil extracellular traps kill bacteria. Science. 303, 1532–1535 (2004)</ref-fulltext>
<ce:source-text>Brinkmann, V., et al.: Neutrophil extracellular traps kill bacteria. Science. 303, 1532–1535 (2004)</ce:source-text>
</reference>
<reference seq="105">
<ref-info>
<ref-title>
<ref-titletext-english>Cancers predispose neutrophils to release extracellular DNA traps that contribute tocancer-associated thrombosis. </ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Demers</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Proc. Natl. Acad. Sci. USA</ref-sourcetitle>
<ref-publicationyear first="2012" />
<volisspag>
<volume-issue-number>
<vol-first>109</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>13076</first-page>
<last-page>13081</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Demers, M., et al.: Cancers predispose neutrophils to release extracellular DNA traps that contribute tocancer-associated thrombosis. Proc. Natl. Acad. Sci. USA. 109, 13076–13081 (2012)</ref-fulltext>
<ce:source-text>Demers, M., et al.: Cancers predispose neutrophils to release extracellular DNA traps that contribute tocancer-associated thrombosis. Proc. Natl. Acad. Sci. USA. 109, 13076–13081 (2012)</ce:source-text>
</reference>
<reference seq="106">
<ref-info>
<ref-title>
<ref-titletext-english> Cancer cells induce metastasissupporting neutrophil extracellular DNA traps</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Park</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Sci. Transl. Med.</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>361</first-page>
<last-page>138</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Park, J., et al.: Cancer cells induce metastasissupporting neutrophil extracellular DNA traps. Sci. Transl. Med. 8, 361ra138 (2016)</ref-fulltext>
<ce:source-text>Park, J., et al.: Cancer cells induce metastasissupporting neutrophil extracellular DNA traps. Sci. Transl. Med. 8, 361ra138 (2016)</ce:source-text>
</reference>
<reference seq="107">
<ref-info>
<ref-title>
<ref-titletext-english>Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Cools-Lartigue</ce:surname>
<ce:given-name />
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Invest</ref-sourcetitle>
<ref-publicationyear first="2013" />
</ref-info>
<ref-fulltext>Cools-Lartigue, J., et al.: Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis. J. Clin. Invest. (2013)</ref-fulltext>
<ce:source-text>Cools-Lartigue, J., et al.: Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis. J. Clin. Invest. (2013)</ce:source-text>
</reference>
<reference seq="108">
<ref-info>
<ref-title>
<ref-titletext-english>The origins of vertebrate adaptive immunity</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.W.</ce:initials>
<ce:surname>Litman</ce:surname>
<ce:given-name>G.W.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.P.</ce:initials>
<ce:surname>Rast</ce:surname>
<ce:given-name>J.P.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.D.</ce:initials>
<ce:surname>Fugmann</ce:surname>
<ce:given-name>S.D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Immunol.</ref-sourcetitle>
<ref-publicationyear first="2010" />
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>543</first-page>
<last-page>553</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Litman, G.W., Rast, J.P., Fugmann, S.D.: The origins of vertebrate adaptive immunity. Nat. Rev. Immunol. 10, 543–553 (2010)</ref-fulltext>
<ce:source-text>Litman, G.W., Rast, J.P., Fugmann, S.D.: The origins of vertebrate adaptive immunity. Nat. Rev. Immunol. 10, 543–553 (2010)</ce:source-text>
</reference>
<reference seq="109">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor-derived exosomes promote carcinogenesis of murine oral squamous cell carcinoma. </ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.M.</ce:initials>
<ce:surname>Razzo</ce:surname>
<ce:given-name>B.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Carcinogenesis.</ref-sourcetitle>
<ref-publicationyear first="2019" />
</ref-info>
<ref-fulltext>Razzo, B.M., et al.: Tumor-derived exosomes promote carcinogenesis of murine oral squamous cell carcinoma. Carcinogenesis. (2019)</ref-fulltext>
<ce:source-text>Razzo, B.M., et al.: Tumor-derived exosomes promote carcinogenesis of murine oral squamous cell carcinoma. Carcinogenesis. (2019)</ce:source-text>
</reference>
<reference seq="110">
<ref-info>
<ref-title>
<ref-titletext-english>14-3-3zeta delivered by hepatocellular carcinoma-derived exosomes impaired antitumor function of tumor-infiltrating T lymphocytes.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.</ce:initials>
<ce:surname>Wang</ce:surname>
<ce:given-name>X.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Death Dis. </ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>159</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wang, X., et al.: 14-3-3zeta delivered by hepatocellular carcinoma-derived exosomes impaired antitumor function of tumor-infiltrating T lymphocytes. Cell Death Dis. 9, 159 (2018)</ref-fulltext>
<ce:source-text>Wang, X., et al.: 14-3-3zeta delivered by hepatocellular carcinoma-derived exosomes impaired antitumor function of tumor-infiltrating T lymphocytes. Cell Death Dis. 9, 159 (2018)</ce:source-text>
</reference>
<reference seq="111">
<ref-info>
<ref-title>
<ref-titletext-english>Brain tumor-initiating cells export tenascin-C associated with exosomes to suppress T cell activity.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Mirzaei</ce:surname>
<ce:given-name />
</author>
</ref-authors>
<ref-sourcetitle>Onco. Targets. Ther</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Mirzaei, R., et al.: Brain tumor-initiating cells export tenascin-C associated with exosomes to suppress T cell activity. Onco. Targets. Ther. 7, e1478647 (2018)</ref-fulltext>
<ce:source-text>Mirzaei, R., et al.: Brain tumor-initiating cells export tenascin-C associated with exosomes to suppress T cell activity. Onco. Targets. Ther. 7, e1478647 (2018)</ce:source-text>
</reference>
<reference seq="112">
<ref-info>
<ref-title>
<ref-titletext-english> B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Griss</ce:surname>
<ce:given-name />
</author>
</ref-authors>
<ref-sourcetitle>Nat. Commun</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>4186</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Griss, J., et al.: B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma. Nat. Commun. 10, 4186 (2019)</ref-fulltext>
<ce:source-text>Griss, J., et al.: B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma. Nat. Commun. 10, 4186 (2019)</ce:source-text>
</reference>
<reference seq="113">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor infiltrating B-cells signal functional humoral immune responses in breast cancer.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Garaud</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>JCI Insight.</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>5</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Garaud, S., et al.: Tumor infiltrating B-cells signal functional humoral immune responses in breast cancer. JCI Insight. 5 (2019) </ref-fulltext>
<ce:source-text>Garaud, S., et al.: Tumor infiltrating B-cells signal functional humoral immune responses in breast cancer. JCI Insight. 5 (2019) </ce:source-text>
</reference>
<reference seq="114">
<ref-info>
<ref-title>
<ref-titletext-english>KRAS renaissance(s) in tumor infiltrating B cells in pancreatic cancer.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Q.</ce:initials>
<ce:surname>Meng</ce:surname>
<ce:given-name>Q.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.</ce:initials>
<ce:surname>Valentini</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Rao</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="4">
<ce:initials>M.</ce:initials>
<ce:surname>Maeurer</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Front. Oncol.</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>384</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Meng, Q., Valentini, D., Rao, M., Maeurer, M.: KRAS renaissance(s) in tumor infiltrating B cells in pancreatic cancer. Front. Oncol. 8, 384 (2018)</ref-fulltext>
<ce:source-text>Meng, Q., Valentini, D., Rao, M., Maeurer, M.: KRAS renaissance(s) in tumor infiltrating B cells in pancreatic cancer. Front. Oncol. 8, 384 (2018)</ce:source-text>
</reference>
<reference seq="115">

<ref-info>
<ref-title>
<ref-titletext-english>IL35-producing B cells promote the development of pancreatic neoplasia.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Pylayeva-Gupta</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Discov.</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>546</first-page>
<last-page>559</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Xiao, X., et al.: PD-1hi identifies a novel regulatory B-cell population in human hepatoma that promotes disease progression. Cancer Discov. 6, 546–559 (2016)</ref-fulltext>
<ce:source-text>Xiao, X., et al.: PD-1hi identifies a novel regulatory B-cell population in human hepatoma that promotes disease progression. Cancer Discov. 6, 546–559 (2016)</ce:source-text>
</reference>
<reference seq="116">
<ref-info>
<ref-title>
<ref-titletext-english>PD-1hi identifies a novel regulatory B-cell population in human hepatoma that promotes disease progression</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.</ce:initials>
<ce:surname>Xiao</ce:surname>
<ce:given-name>X.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Discov.</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>546</first-page>
<last-page>559</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Xiao, X., et al.: PD-1hi identifies a novel regulatory B-cell population in human hepatoma that promotes disease progression. Cancer Discov. 6, 546–559 (2016)</ref-fulltext>
<ce:source-text>Xiao, X., et al.: PD-1hi identifies a novel regulatory B-cell population in human hepatoma that promotes disease progression. Cancer Discov. 6, 546–559 (2016)</ce:source-text>
</reference>
<reference seq="117">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor-derived exosomal HMGB1 fosters hepatocellular carcinoma immune evasion by promoting TIM-1(+) regulatory B cell expansion</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Ye</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle> J. Immunother. Cancer.</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>145</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ye, L., et al.: Tumor-derived exosomal HMGB1 fosters hepatocellular carcinoma immune evasion by promoting TIM-1(+) regulatory B cell expansion. J. Immunother. Cancer. 6, 145 (2018)</ref-fulltext>
<ce:source-text>Ye, L., et al.: Tumor-derived exosomal HMGB1 fosters hepatocellular carcinoma immune evasion by promoting TIM-1(+) regulatory B cell expansion. J. Immunother. Cancer. 6, 145 (2018)</ce:source-text>
</reference>
<reference seq="118">
<ref-info>
<ref-title>
<ref-titletext-english>Therapeutics targeting angiogenesis: genetics and epigenetics, extracellular miRNAs and signaling networks (Review). </ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Katoh</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Mol. Med.</ref-sourcetitle>
<ref-publicationyear first="2013" />
<volisspag>
<volume-issue-number>
<vol-first>32</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>763</first-page>
<last-page>767</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Katoh, M.: Therapeutics targeting angiogenesis: genetics and epigenetics, extracellular miRNAs and signaling networks (Review). Int. J. Mol. Med. 32, 763–767 (2013)</ref-fulltext>
<ce:source-text>Katoh, M.: Therapeutics targeting angiogenesis: genetics and epigenetics, extracellular miRNAs and signaling networks (Review). Int. J. Mol. Med. 32, 763–767 (2013)</ce:source-text>
</reference>
<reference seq="119">
<ref-info>
<ref-title>
<ref-titletext-english>Microenvironmental regulation of tumour angiogenesis.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>De Palma</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.</ce:initials>
<ce:surname>Biziato</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="3">
<ce:initials>T.V.</ce:initials>
<ce:surname>Petrova</ce:surname>
<ce:given-name>T.V.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Cancer.</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>17</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>457</first-page>
<last-page>474</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>De Palma, M., Biziato, D., Petrova, T.V.: Microenvironmental regulation of tumour angiogenesis. Nat. Rev. Cancer. 17, 457–474 (2017)</ref-fulltext>
<ce:source-text>De Palma, M., Biziato, D., Petrova, T.V.: Microenvironmental regulation of tumour angiogenesis. Nat. Rev. Cancer. 17, 457–474 (2017)</ce:source-text>
</reference>
<reference seq="120">
<ref-info>
<ref-title>
<ref-titletext-english>Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Sawamiphak</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature.</ref-sourcetitle>
<ref-publicationyear first="2010" />
<volisspag>
<volume-issue-number>
<vol-first>465</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>487</first-page>
<last-page>491</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sawamiphak, S., et al.: Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis. Nature. 465, 487–491 (2010)</ref-fulltext>
<ce:source-text>Sawamiphak, S., et al.: Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis. Nature. 465, 487–491 (2010)</ce:source-text>
</reference>
<reference seq="121">
<ref-info>
<ref-title>
<ref-titletext-english>EPHB2 carried on small extracellular vesicles induces tumor angiogenesis via activation of ephrin reverse signaling</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Sato</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>JCI Insight.</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>4</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Sato, S., et al.: EPHB2 carried on small extracellular vesicles induces tumor angiogenesis via activation of ephrin reverse signaling. JCI Insight. 4 (2019)</ref-fulltext>
<ce:source-text>Sato, S., et al.: EPHB2 carried on small extracellular vesicles induces tumor angiogenesis via activation of ephrin reverse signaling. JCI Insight. 4 (2019)</ce:source-text>
</reference>
<reference seq="122">
<ref-info>
<ref-title>
<ref-titletext-english>Visualization of exosome-mediated miR-210 transfer from hypoxic tumor cells.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.O.</ce:initials>
<ce:surname>Jung</ce:surname>
<ce:given-name>K.O.</ce:given-name>
</author>
<author seq="2">
<ce:initials>H.</ce:initials>
<ce:surname>Youn</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
<author seq="3">
<ce:initials>C.H.</ce:initials>
<ce:surname>Lee</ce:surname>
<ce:given-name>C.H.</ce:given-name>
</author>
<author seq="4">
<ce:initials>K.W.</ce:initials>
<ce:surname>Kang</ce:surname>
<ce:given-name>K.W.</ce:given-name>
</author>
<author seq="5">
<ce:initials>J.K.</ce:initials>
<ce:surname>Chung</ce:surname>
<ce:given-name>J.K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncotarget</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>9899</first-page>
<last-page>9910</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Jung, K.O., Youn, H., Lee, C.H., Kang, K.W., Chung, J.K.: Visualization of exosome-mediated miR-210 transfer from hypoxic tumor cells. Oncotarget. 8, 9899–9910 (2017)</ref-fulltext>
<ce:source-text>Jung, K.O., Youn, H., Lee, C.H., Kang, K.W., Chung, J.K.: Visualization of exosome-mediated miR-210 transfer from hypoxic tumor cells. Oncotarget. 8, 9899–9910 (2017)</ce:source-text>
</reference>
<reference seq="123">
<ref-info>
<ref-title>
<ref-titletext-english>PTP1b is a physiologic regulator of vascular endothelial growth factor signaling in endothelial cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.A.</ce:initials>
<ce:surname>Lanahan</ce:surname>
<ce:given-name>A.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Circulation.</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>130</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>902</first-page>
<last-page>909</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Lanahan, A.A., et al.: PTP1b is a physiologic regulator of vascular endothelial growth factor signaling in endothelial cells. Circulation. 130, 902–909 (2014)</ref-fulltext>
<ce:source-text>Lanahan, A.A., et al.: PTP1b is a physiologic regulator of vascular endothelial growth factor signaling in endothelial cells. Circulation. 130, 902–909 (2014)</ce:source-text>
</reference>
<reference seq="124">
<ref-info>
<ref-title>
<ref-titletext-english>Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Umezu</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Blood</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>124</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3748</first-page>
<last-page>3757</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Umezu, T., et al.: Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1. Blood. 124, 3748–3757 (2014)</ref-fulltext>
<ce:source-text>Umezu, T., et al.: Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1. Blood. 124, 3748–3757 (2014)</ce:source-text>
</reference>
<reference seq="125">
<ref-info>
<ref-title>
<ref-titletext-english>piRNA-823 delivered by multiple myeloma-derived extracellular vesicles promoted tumorigenesis through re-educating endothelial cells in the tumor environment</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.B.</ce:initials>
<ce:surname>Li</ce:surname>
<ce:given-name>B.B.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncogene</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>38</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>5227</first-page>
<last-page>5238</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Li, B.B., et al.: piRNA-823 delivered by multiple myeloma-derived extracellular vesicles promoted tumorigenesis through re-educating endothelial cells in the tumor environment. Oncogene. 38, 5227–5238 (2019)</ref-fulltext>
<ce:source-text>Li, B.B., et al.: piRNA-823 delivered by multiple myeloma-derived extracellular vesicles promoted tumorigenesis through re-educating endothelial cells in the tumor environment. Oncogene. 38, 5227–5238 (2019)</ce:source-text>
</reference>
<reference seq="126">
<ref-info>
<ref-title>
<ref-titletext-english>Glioblastoma stem-like cells secrete the pro-angiogenic VEGF-A factor in extracellular vesicles</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Treps</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.</ce:initials>
<ce:surname>Perret</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Edmond</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="4">
<ce:initials>D.</ce:initials>
<ce:surname>Ricard</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="5">
<ce:initials>J.</ce:initials>
<ce:surname>Gavard</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Extracell. Vesicles</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Treps, L., Perret, R., Edmond, S., Ricard, D., Gavard, J.: Glioblastoma stem-like cells secrete the pro-angiogenic VEGF-A factor in extracellular vesicles. J. Extracell. Vesicles. 6, 1359479 (2017)</ref-fulltext>
<ce:source-text>Treps, L., Perret, R., Edmond, S., Ricard, D., Gavard, J.: Glioblastoma stem-like cells secrete the pro-angiogenic VEGF-A factor in extracellular vesicles. J. Extracell. Vesicles. 6, 1359479 (2017)</ce:source-text>
</reference>
<reference seq="127">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer-derived small extracellular vesicles promote angiogenesis by heparin-bound, bevacizumab-insensitive VEGF, independent of vesicle uptake</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.Y.</ce:initials>
<ce:surname>Ko</ce:surname>
<ce:given-name>S.Y.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Commun. Biol.</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>2</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>386</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ko, S.Y., et al.: Cancer-derived small extracellular vesicles promote angiogenesis by heparin-bound, bevacizumab-insensitive VEGF, independent of vesicle uptake. Commun. Biol. 2, 386 (2019)</ref-fulltext>
<ce:source-text>Ko, S.Y., et al.: Cancer-derived small extracellular vesicles promote angiogenesis by heparin-bound, bevacizumab-insensitive VEGF, independent of vesicle uptake. Commun. Biol. 2, 386 (2019)</ce:source-text> </reference>
<reference seq="128">
<ref-info>
<ref-title>
<ref-titletext-english>Intravascular survival and extravasation of tumor cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.</ce:initials>
<ce:surname>Strilic</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Offermanns</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Cell</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>32</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>282</first-page>
<last-page>293</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>. Strilic, B., Offermanns, S.: Intravascular survival and extravasation of tumor cells. Cancer Cell. 32, 282–293 (2017)</ref-fulltext>
<ce:source-text>. Strilic, B., Offermanns, S.: Intravascular survival and extravasation of tumor cells. Cancer Cell. 32, 282–293 (2017)</ce:source-text>
</reference>
<reference seq="129">
<ref-info>
<ref-title>
<ref-titletext-english>Circulating and disseminated tumour cells – mechanisms of immune surveillance and escape</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Mohme</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Riethdorf</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>K.</ce:initials>
<ce:surname>Pantel</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Clin. Oncol.</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>14</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>155</first-page>
<last-page>167</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mohme, M., Riethdorf, S., Pantel, K.: Circulating and disseminated tumour cells – mechanisms of immune surveillance and escape. Nat. Rev. Clin. Oncol. 14, 155–167 (2017)</ref-fulltext>
<ce:source-text>Mohme, M., Riethdorf, S., Pantel, K.: Circulating and disseminated tumour cells – mechanisms of immune surveillance and escape. Nat. Rev. Clin. Oncol. 14, 155–167 (2017)</ce:source-text>
</reference>
<reference seq="130">
<ref-info>
<ref-title>
<ref-titletext-english>Extracellular vesicle-transported Semaphorin3A promotes vascular permeability in glioblastoma</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Treps</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncogene</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>35</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2615</first-page>
<last-page>2623</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Treps, L., et al.: Extracellular vesicle-transported Semaphorin3A promotes vascular permeability in glioblastoma. Oncogene. 35, 2615–2623 (2016)</ref-fulltext>
<ce:source-text>Treps, L., et al.: Extracellular vesicle-transported Semaphorin3A promotes vascular permeability in glioblastoma. Oncogene. 35, 2615–2623 (2016)</ce:source-text>
</reference>
<reference seq="131">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer-derived exosomal miR-25-3p promotes pre-metastatic niche formation by inducing vascular permeability and angiogenesis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Z.</ce:initials>
<ce:surname>Zeng</ce:surname>
<ce:given-name>Z.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat.Commun.</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>5395</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zeng, Z., et al.: Cancer-derived exosomal miR-25-3p promotes pre-metastatic niche formation by inducing vascular permeability and angiogenesis. Nat. Commun. 9, 5395 (2018)</ref-fulltext>
<ce:source-text>Zeng, Z., et al.: Cancer-derived exosomal miR-25-3p promotes pre-metastatic niche formation by inducing vascular permeability and angiogenesis. Nat. Commun. 9, 5395 (2018)</ce:source-text>
</reference>
<reference seq="132">
<ref-info>
<ref-title>
<ref-titletext-english>Inhibition of vascular permeability factor/vascular endothelial growth factor-mediated angiogenesis by the Kruppel-like factor KLF2</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Bhattacharya</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J.Biol.Chem.</ref-sourcetitle>
<ref-publicationyear first="2005" />
<volisspag>
<volume-issue-number>
<vol-first>280</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>28848</first-page>
<last-page>28851</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Bhattacharya, R., et al.: Inhibition of vascular permeability factor/vascular endothelial growth factormediated angiogenesis by the Kruppel-like factor KLF2. J. Biol. Chem. 280, 28848–28851 (2005)</ref-fulltext>
<ce:source-text>Bhattacharya, R., et al.: Inhibition of vascular permeability factor/vascular endothelial growth factormediated angiogenesis by the Kruppel-like factor KLF2. J. Biol. Chem. 280, 28848–28851 (2005)</ce:source-text>
</reference>
<reference seq="133">
<ref-info>
<ref-title>
<ref-titletext-english>Kruppel-like factor 4 regulates blood-tumor barrier permeability via ZO-1, occludin and claudin-5</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Ma</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J.Cell.Physiol.</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>229</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>916</first-page>
<last-page>926</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ma, J., et al.: Kruppel-like factor 4 regulates bloodtumor barrier permeability via ZO-1, occludin and claudin-5. J. Cell. Physiol. 229, 916–926 (2014)</ref-fulltext>
<ce:source-text>Ma, J., et al.: Kruppel-like factor 4 regulates bloodtumor barrier permeability via ZO-1, occludin and claudin-5. J. Cell. Physiol. 229, 916–926 (2014)</ce:source-text>
</reference>
<reference seq="134">
<ref-info>
<ref-title>
<ref-titletext-english>Hypoxic lung cancer-secreted exosomal miR-23a increased angiogenesis and vascular permeability by targeting prolyl hydroxylase and tight junction protein ZO-1</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.L.</ce:initials>
<ce:surname>Hsu</ce:surname>
<ce:given-name>Y.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncogene</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>36</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>4929</first-page>
<last-page>4942</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hsu, Y.L., et al.: Hypoxic lung cancer-secreted exosomal miR-23a increased angiogenesis and vascular permeability by targeting prolyl hydroxylase and tight junction protein ZO-1. Oncogene. 36, 4929–4942 (2017) </ref-fulltext>
<ce:source-text>Hsu, Y.L., et al.: Hypoxic lung cancer-secreted exosomal miR-23a increased angiogenesis and vascular permeability by targeting prolyl hydroxylase and tight junction protein ZO-1. Oncogene. 36, 4929–4942 (2017) </ce:source-text>
</reference>
<reference seq="135">
<ref-info>
<ref-title>
<ref-titletext-english>Breast cancer-secreted miR-939 downregulates VE-cadherin and destroys the barrier function of endothelial monolayers</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Di Modica</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Lett.</ref-sourcetitle>
<ref-publicationyear first="2017" />
<ref-text>Breast cancer-secreted miR-939 downregulates VE-cadherin and destroys the barrier function of endothelial monolayers</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>384</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>94</first-page>
<last-page>100</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Di Modica, M., et al.: Breast cancer-secreted miR-939 downregulates VE-cadherin and destroys the barrier function of endothelial monolayers. Cancer Lett. 384, 94–100 (2017)</ref-fulltext>
<ce:source-text>Di Modica, M., et al.: Breast cancer-secreted miR-939 downregulates VE-cadherin and destroys the barrier function of endothelial monolayers. Cancer Lett. 384, 94–100 (2017)</ce:source-text>
</reference>
<reference seq="136">
<ref-info>
<ref-title>
<ref-titletext-english>Hepatoma cell-secreted exosomal microRNA-103 increases vascular permeability and promotes metastasis by targeting junction proteins</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.H.</ce:initials>
<ce:surname>Fang</ce:surname>
<ce:given-name>J.H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Hepatology</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>68</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1459</first-page>
<last-page>1475</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Fang, J.H., et al.: Hepatoma cell-secreted exosomal microRNA-103 increases vascular permeability and promotes metastasis by targeting junction proteins. Hepatology. 68, 1459–1475 (2018)</ref-fulltext>
<ce:source-text>Fang, J.H., et al.: Hepatoma cell-secreted exosomal microRNA-103 increases vascular permeability and promotes metastasis by targeting junction proteins. Hepatology. 68, 1459–1475 (2018)</ce:source-text>
</reference>
<reference seq="137">
<ref-info>
<ref-title>
<ref-titletext-english>Circular RNA IARS (circ-IARS) secreted by pancreatic cancer cells and located within exosomes regulates endothelial monolayer permeability to promote tumor metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Li</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J.Exp.Clin.Cancer Res.</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>37</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Li, J., et al.: Circular RNA IARS (circ-IARS) secreted by pancreatic cancer cells and located within exosomes regulates endothelial monolayer permeability to promote tumor metastasis. J. Exp. Clin. Cancer Res. 37 (2018)</ref-fulltext>
<ce:source-text>Li, J., et al.: Circular RNA IARS (circ-IARS) secreted by pancreatic cancer cells and located within exosomes regulates endothelial monolayer permeability to promote tumor metastasis. J. Exp. Clin. Cancer Res. 37 (2018)</ce:source-text>
</reference>
<reference seq="138">
<ref-info>
<ref-title>
<ref-titletext-english>Natural RNA circles function as efficient microRNA sponges</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.B.</ce:initials>
<ce:surname>Hansen</ce:surname>
<ce:given-name>T.B.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2013" />
<ref-text>Natural RNA circles function as efficient microRNA sponges</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>495</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>384</first-page>
<last-page>388</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hansen, T.B., et al.: Natural RNA circles function as efficient microRNA sponges. Nature. 495, 384–388 (2013) </ref-fulltext>
<ce:source-text>Hansen, T.B., et al.: Natural RNA circles function as efficient microRNA sponges. Nature. 495, 384–388 (2013) </ce:source-text>
</reference>
<reference seq="139">
<ref-info>
<ref-title>
<ref-titletext-english>Organ selectivity for implantation survival and growth of B16 melanoma variant tumor lines</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>I.J.</ce:initials>
<ce:surname>Fidler</ce:surname>
<ce:given-name>I.J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>G.L.</ce:initials>
<ce:surname>Nicolson</ce:surname>
<ce:given-name>G.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J.Natl.Cancer Inst.</ref-sourcetitle>
<ref-publicationyear first="1976" />
<volisspag>
<volume-issue-number>
<vol-first>57</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1199</first-page>
<last-page>1202</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Fidler, I.J., Nicolson, G.L.: Organ selectivity for implantation survival and growth of B16 melanoma variant tumor lines. J. Natl. Cancer Inst. 57, 1199–1202 (1976)</ref-fulltext>
<ce:source-text>Fidler, I.J., Nicolson, G.L.: Organ selectivity for implantation survival and growth of B16 melanoma variant tumor lines. J. Natl. Cancer Inst. 57, 1199–1202 (1976)</ce:source-text>
</reference>
<reference seq="140">
<ref-info>
<ref-title>
<ref-titletext-english>Role of organ selectivity in the determination of metastatic patterns of B16 melanoma</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>I.R.</ce:initials>
<ce:surname>Hart</ce:surname>
<ce:given-name>I.R.</ce:given-name>
</author>
<author seq="2">
<ce:initials>I.J.</ce:initials>
<ce:surname>Fidler</ce:surname>
<ce:given-name>I.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Res.</ref-sourcetitle>
<ref-publicationyear first="1980" />
<volisspag>
<volume-issue-number>
<vol-first>40</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2281</first-page>
<last-page>2287</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hart, I.R., Fidler, I.J.: Role of organ selectivity in the determination of metastatic patterns of B16 melanoma. Cancer Res. 40, 2281–2287 (1980)</ref-fulltext>
<ce:source-text>Hart, I.R., Fidler, I.J.: Role of organ selectivity in the determination of metastatic patterns of B16 melanoma. Cancer Res. 40, 2281–2287 (1980)</ce:source-text>
</reference>
<reference seq="141">
<ref-info>
<ref-title>
<ref-titletext-english>Metastasis organotropism: redefining the congenial soil</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Gao</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Dev. Cell</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>49</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>375</first-page>
<last-page>391</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Gao, Y., et al.: Metastasis organotropism: redefining the congenial soil. Dev. Cell. 49, 375–391 (2019)</ref-fulltext>
<ce:source-text>Gao, Y., et al.: Metastasis organotropism: redefining the congenial soil. Dev. Cell. 49, 375–391 (2019)</ce:source-text>
</reference>
<reference seq="142">
<ref-info>
<ref-title>
<ref-titletext-english>Metastasis: from dissemination to organ-specific colonization</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.X.</ce:initials>
<ce:surname>Nguyen</ce:surname>
<ce:given-name>D.X.</ce:given-name>
</author>
<author seq="2">
<ce:initials>P.D.</ce:initials>
<ce:surname>Bos</ce:surname>
<ce:given-name>P.D.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Massague</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Cancer</ref-sourcetitle>
<ref-publicationyear first="2009" />
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>274</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Nguyen, D.X., Bos, P.D., Massague, J.: Metastasis: from dissemination to organ-specific colonization. Nat. Rev. Cancer. 9, 274–U265 (2009)</ref-fulltext>
<ce:source-text>Nguyen, D.X., Bos, P.D., Massague, J.: Metastasis: from dissemination to organ-specific colonization. Nat. Rev. Cancer. 9, 274–U265 (2009)</ce:source-text>
</reference>
<reference seq="143">
<ref-info>
<ref-title>
<ref-titletext-english>Exosomes released by melanoma cells prepare sentinel lymph nodes for tumor metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.L.</ce:initials>
<ce:surname>Hood</ce:surname>
<ce:given-name>J.L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.S.</ce:initials>
<ce:surname>San</ce:surname>
<ce:given-name>R.S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.A.</ce:initials>
<ce:surname>Wickline</ce:surname>
<ce:given-name>S.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Res.</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>71</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3792</first-page>
<last-page>3801</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hood, J.L., San, R.S., Wickline, S.A.: Exosomes released by melanoma cells prepare sentinel lymph nodes for tumor metastasis. Cancer Res. 71, 3792–3801 (2011)</ref-fulltext>
<ce:source-text>Hood, J.L., San, R.S., Wickline, S.A.: Exosomes released by melanoma cells prepare sentinel lymph nodes for tumor metastasis. Cancer Res. 71, 3792–3801 (2011)</ce:source-text>
</reference>
<reference seq="144">
<ref-info>
<ref-title>
<ref-titletext-english>Molecular mechanism underlying lymphatic metastasis in pancreatic cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Z.</ce:initials>
<ce:surname>Xiao</ce:surname>
<ce:given-name>Z.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Biomed. Res. Int.</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>2014</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Xiao, Z., et al.: Molecular mechanism underlying lymphatic metastasis in pancreatic cancer. Biomed. Res. Int. 2014, 925845 (2014)</ref-fulltext>
<ce:source-text>Xiao, Z., et al.: Molecular mechanism underlying lymphatic metastasis in pancreatic cancer. Biomed. Res. Int. 2014, 925845 (2014)</ce:source-text>
</reference>
<reference seq="145">
<ref-info>
<ref-title>
<ref-titletext-english>SCS macrophages suppress melanoma by restricting tumor-derived vesicle-B cell interactions</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Pucci</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Science</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>352</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>242</first-page>
<last-page>246</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Pucci, F., et al.: SCS macrophages suppress melanoma by restricting tumor-derived vesicle-B cell interactions. Science. 352, 242–246 (2016)</ref-fulltext>
<ce:source-text>Pucci, F., et al.: SCS macrophages suppress melanoma by restricting tumor-derived vesicle-B cell interactions. Science. 352, 242–246 (2016)</ce:source-text>
</reference>
<reference seq="146">
<ref-info>
<ref-title>
<ref-titletext-english>Human melanoma-derived extracellular vesicles regulate dendritic cell maturation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.L.G.</ce:initials>
<ce:surname>Maus</ce:surname>
<ce:given-name>R.L.G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Front. Immunol.</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>358</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Maus, R.L.G., et al.: Human melanoma-derived extracellular vesicles regulate dendritic cell maturation. Front. Immunol. 8, 358 (2017) </ref-fulltext>
<ce:source-text>Maus, R.L.G., et al.: Human melanoma-derived extracellular vesicles regulate dendritic cell maturation. Front. Immunol. 8, 358 (2017) </ce:source-text>
</reference>
<reference seq="147">
<ref-info>
<ref-title>
<ref-titletext-english>Exosomal tumor microRNA modulates premetastatic organ cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Rana</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.</ce:initials>
<ce:surname>Malinowska</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Zoller</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Neoplasia</ref-sourcetitle>
<ref-publicationyear first="2013" />
<volisspag>
<volume-issue-number>
<vol-first>15</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>281</first-page>
<last-page>295</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Rana, S., Malinowska, K., Zoller, M.: Exosomal tumor microRNA modulates premetastatic organ cells. Neoplasia. 15, 281–295 (2013)</ref-fulltext>
<ce:source-text>Rana, S., Malinowska, K., Zoller, M.: Exosomal tumor microRNA modulates premetastatic organ cells. Neoplasia. 15, 281–295 (2013)</ce:source-text>
</reference>
<reference seq="148">
<ref-info>
<ref-title>
<ref-titletext-english>Lymphatic transport of exosomes as a rapid route of information dissemination to the lymph node</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Srinivasan</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>F.O.</ce:initials>
<ce:surname>Vannberg</ce:surname>
<ce:given-name>F.O.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.B.</ce:initials>
<ce:surname>Dixon</ce:surname>
<ce:given-name>J.B.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Sci. Rep.</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>24436</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Srinivasan, S., Vannberg, F.O., Dixon, J.B.: Lymphatic transport of exosomes as a rapid route of information dissemination to the lymph node. Sci. Rep. 6, 24436 (2016)</ref-fulltext>
<ce:source-text>Srinivasan, S., Vannberg, F.O., Dixon, J.B.: Lymphatic transport of exosomes as a rapid route of information dissemination to the lymph node. Sci. Rep. 6, 24436 (2016)</ce:source-text>
</reference>
<reference seq="149">
<ref-info>
<ref-title>
<ref-titletext-english>Exosomal long noncoding RNA LNMAT2 promotes lymphatic metastasis in bladder cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Chen</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Invest.</ref-sourcetitle>
<ref-publicationyear first="2020" />
<volisspag>
<volume-issue-number>
<vol-first>130</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>404</first-page>
<last-page>421</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Chen, C., et al.: Exosomal long noncoding RNA LNMAT2 promotes lymphatic metastasis in bladder cancer. J. Clin. Invest. 130, 404–421 (2020)</ref-fulltext>
<ce:source-text>Chen, C., et al.: Exosomal long noncoding RNA LNMAT2 promotes lymphatic metastasis in bladder cancer. J. Clin. Invest. 130, 404–421 (2020)</ce:source-text>
</reference>
<reference seq="150">
<ref-info>
<ref-title>
<ref-titletext-english>Colorectal cancer exosomes induce lymphatic network remodeling in lymph nodes</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.</ce:initials>
<ce:surname>Sun</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Cancer</ref-sourcetitle>
<ref-publicationyear first="2019" />
<ref-text>Colorectal cancer exosomes induce lymphatic network remodeling in lymph nodes</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>145</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1648</first-page>
<last-page>1659</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sun, B., et al.: Colorectal cancer exosomes induce lymphatic network remodeling in lymph nodes. Int. J. Cancer. 145, 1648–1659 (2019)</ref-fulltext>
<ce:source-text>Sun, B., et al.: Colorectal cancer exosomes induce lymphatic network remodeling in lymph nodes. Int. J. Cancer. 145, 1648–1659 (2019)</ce:source-text>
</reference>
<reference seq="151">
<ref-info>
<ref-title>
<ref-titletext-english>The lymphatic system: integral roles in immunity</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.J.</ce:initials>
<ce:surname>Randolph</ce:surname>
<ce:given-name>G.J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Ivanov</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>B.H.</ce:initials>
<ce:surname>Zinselmeyer</ce:surname>
<ce:given-name>B.H.</ce:given-name>
</author>
<author seq="4">
<ce:initials>J.P.</ce:initials>
<ce:surname>Scallan</ce:surname>
<ce:given-name>J.P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Annu. Rev. Immunol.</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>35</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>31</first-page>
<last-page>52</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Randolph, G.J., Ivanov, S., Zinselmeyer, B.H., Scallan, J.P.: The lymphatic system: integral roles in immunity. Annu. Rev. Immunol. 35, 31–52 (2017)</ref-fulltext>
<ce:source-text>Randolph, G.J., Ivanov, S., Zinselmeyer, B.H., Scallan, J.P.: The lymphatic system: integral roles in immunity. Annu. Rev. Immunol. 35, 31–52 (2017)</ce:source-text>
</reference>
<reference seq="152">
<ref-info>
<ref-title>
<ref-titletext-english>Macrophage immunomodulation by breast cancer-derived exosomes requires toll-like receptor 2-mediated activation of NF-kappaB</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Chow</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Sci. Rep.</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>4</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>5750</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Chow, A., et al.: Macrophage immunomodulation by breast cancer-derived exosomes requires toll-like receptor 2-mediated activation of NF-kappaB. Sci. Rep. 4, 5750 (2014)</ref-fulltext>
<ce:source-text>Chow, A., et al.: Macrophage immunomodulation by breast cancer-derived exosomes requires toll-like receptor 2-mediated activation of NF-kappaB. Sci. Rep. 4, 5750 (2014)</ce:source-text>
</reference>
<reference seq="153">
<ref-info>
<ref-title>
<ref-titletext-english>Melanoma growth and lymph node metastasis is independent of host CD169 expression</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.R.</ce:initials>
<ce:surname>Muhsin-Sharafaldine</ce:surname>
<ce:given-name>M.R.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.C.</ce:initials>
<ce:surname>Saunderson</ce:surname>
<ce:given-name>S.C.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.C.</ce:initials>
<ce:surname>Dunn</ce:surname>
<ce:given-name>A.C.</ce:given-name>
</author>
<author seq="4">
<ce:initials>A.D.</ce:initials>
<ce:surname>McLellan</ce:surname>
<ce:given-name>A.D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Biochem. Biophys. Res. Commun.</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>486</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>965</first-page>
<last-page>970</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Muhsin-Sharafaldine, M.R., Saunderson, S.C., Dunn, A.C., McLellan, A.D.: Melanoma growth and lymph node metastasis is independent of host CD169 expression. Biochem. Biophys. Res. Commun. 486, 965–970 (2017)</ref-fulltext>
<ce:source-text>Muhsin-Sharafaldine, M.R., Saunderson, S.C., Dunn, A.C., McLellan, A.D.: Melanoma growth and lymph node metastasis is independent of host CD169 expression. Biochem. Biophys. Res. Commun. 486, 965–970 (2017)</ce:source-text>
</reference>
<reference seq="154">
<ref-info>
<ref-title>
<ref-titletext-english>Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Skobe</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Med.</ref-sourcetitle>
<ref-publicationyear first="2001" />
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>192</first-page>
<last-page>198</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Skobe, M., et al.: Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat. Med. 7, 192–198 (2001) </ref-fulltext>
<ce:source-text>Skobe, M., et al.: Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat. Med. 7, 192–198 (2001) </ce:source-text>
</reference>
<reference seq="155">
<ref-info>
<ref-title>
<ref-titletext-english>VEGF-D promotes the metastatic spread of tumor cells via the lymphatics</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.A.</ce:initials>
<ce:surname>Stacker</ce:surname>
<ce:given-name>S.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Med.</ref-sourcetitle>
<ref-publicationyear first="2001" />
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>186</first-page>
<last-page>191</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Stacker, S.A., et al.: VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat. Med. 7, 186–191 (2001)</ref-fulltext>
<ce:source-text>Stacker, S.A., et al.: VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat. Med. 7, 186–191 (2001)</ce:source-text>
</reference>
<reference seq="156">
<ref-info>
<ref-title>
<ref-titletext-english>Lymphangiogenesis and lymphatic vessel remodelling in cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.A.</ce:initials>
<ce:surname>Stacker</ce:surname>
<ce:given-name>S.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Cancer</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>14</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>159</first-page>
<last-page>172</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Stacker, S.A., et al.: Lymphangiogenesis and lymphatic vessel remodelling in cancer. Nat. Rev. Cancer. 14, 159–172 (2014)</ref-fulltext>
<ce:source-text>Stacker, S.A., et al.: Lymphangiogenesis and lymphatic vessel remodelling in cancer. Nat. Rev. Cancer. 14, 159–172 (2014)</ce:source-text>
</reference>
<reference seq="157">
<ref-info>
<ref-title>
<ref-titletext-english>Exosomes as a communication tool between the lymphatic system and bladder cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.J.</ce:initials>
<ce:surname>Park</ce:surname>
<ce:given-name>R.J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>Y.J.</ce:initials>
<ce:surname>Hong</ce:surname>
<ce:given-name>Y.J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>Y.</ce:initials>
<ce:surname>Wu</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<author seq="4">
<ce:initials>P.M.</ce:initials>
<ce:surname>Kim</ce:surname>
<ce:given-name>P.M.</ce:given-name>
</author>
<author seq="5">
<ce:initials>Y.K.</ce:initials>
<ce:surname>Hong</ce:surname>
<ce:given-name>Y.K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. Neurourol. J.</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>22</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>220</first-page>
<last-page>224</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Park, R.J., Hong, Y.J., Wu, Y., Kim, P.M., Hong, Y. K.: Exosomes as a communication tool between the lymphatic system and bladder cancer. Int. Neurourol. J. 22, 220–224 (2018)</ref-fulltext>
<ce:source-text>Park, R.J., Hong, Y.J., Wu, Y., Kim, P.M., Hong, Y. K.: Exosomes as a communication tool between the lymphatic system and bladder cancer. Int. Neurourol. J. 22, 220–224 (2018)</ce:source-text>
</reference>
<reference seq="158">
<ref-info>
<ref-title>
<ref-titletext-english>Cervical squamous cell carcinoma-secreted exosomal miR-221-3p promotes lymphangiogenesis and lymphatic metastasis by targeting VASH1</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.F.</ce:initials>
<ce:surname>Zhou</ce:surname>
<ce:given-name>C.F.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncogene</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>38</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1256</first-page>
<last-page>1268</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zhou, C.F., et al.: Cervical squamous cell carcinomasecreted exosomal miR-221-3p promotes lymphangiogenesis and lymphatic metastasis by targeting VASH1. Oncogene. 38, 1256–1268 (2019)</ref-fulltext>
<ce:source-text>Zhou, C.F., et al.: Cervical squamous cell carcinomasecreted exosomal miR-221-3p promotes lymphangiogenesis and lymphatic metastasis by targeting VASH1. Oncogene. 38, 1256–1268 (2019)</ce:source-text>
</reference>
<reference seq="159">
<ref-info>
<ref-title>
<ref-titletext-english>Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.E.</ce:initials>
<ce:surname>Hautmann</ce:surname>
<ce:given-name>R.E.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.C.</ce:initials>
<ce:surname>de Petriconi</ce:surname>
<ce:given-name>R.C.</ce:given-name>
</author>
<author seq="3">
<ce:initials>C.</ce:initials>
<ce:surname>Pfeiffer</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="4">
<ce:initials>B.G.</ce:initials>
<ce:surname>Volkmer</ce:surname>
<ce:given-name>B.G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Eur. Urol.</ref-sourcetitle>
<ref-publicationyear first="2012" />
<volisspag>
<volume-issue-number>
<vol-first>61</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1039</first-page>
<last-page>1047</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hautmann, R.E., de Petriconi, R.C., Pfeiffer, C., Volkmer, B.G.: Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients. Eur. Urol. 61, 1039–1047 (2012)</ref-fulltext>
<ce:source-text>Hautmann, R.E., de Petriconi, R.C., Pfeiffer, C., Volkmer, B.G.: Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients. Eur. Urol. 61, 1039–1047 (2012)</ce:source-text>
</reference>
<reference seq="160">
<ref-info>
<ref-title>
<ref-titletext-english>CD97 promotion of gastric carcinoma lymphatic metastasis is exosome dependent</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Liu</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Gastric Cancer</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>19</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>754</first-page>
<last-page>766</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Liu, D., et al.: CD97 promotion of gastric carcinoma lymphatic metastasis is exosome dependent. Gastric Cancer. 19, 754–766 (2016)</ref-fulltext>
<ce:source-text>Liu, D., et al.: CD97 promotion of gastric carcinoma lymphatic metastasis is exosome dependent. Gastric Cancer. 19, 754–766 (2016)</ce:source-text>
</reference>
<reference seq="161">
<ref-info>
<ref-title>
<ref-titletext-english>Sentinel-node biopsy or nodal observation in melanoma</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.L.</ce:initials>
<ce:surname>Morton</ce:surname>
<ce:given-name>D.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>N. Engl. J. Med.</ref-sourcetitle>
<ref-publicationyear first="2006" />
<volisspag>
<volume-issue-number>
<vol-first>355</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1307</first-page>
<last-page>1317</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Morton, D.L., et al.: Sentinel-node biopsy or nodal observation in melanoma. N. Engl. J. Med. 355, 1307–1317 (2006) </ref-fulltext>
<ce:source-text>Morton, D.L., et al.: Sentinel-node biopsy or nodal observation in melanoma. N. Engl. J. Med. 355, 1307–1317 (2006) </ce:source-text>
</reference>
<reference seq="162">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer volume of lymph node metastasis predicts progression in prostate cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Cheng</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Surg. Pathol.</ref-sourcetitle>
<ref-publicationyear first="1998" />
<volisspag>
<volume-issue-number>
<vol-first>22</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1491</first-page>
<last-page>1500</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Cheng, L., et al.: Cancer volume of lymph node metastasis predicts progression in prostate cancer. Am. J. Surg. Pathol. 22, 1491–1500 (1998)</ref-fulltext>
<ce:source-text>Cheng, L., et al.: Cancer volume of lymph node metastasis predicts progression in prostate cancer. Am. J. Surg. Pathol. 22, 1491–1500 (1998)</ce:source-text>
</reference>
<reference seq="163">
<ref-info>
<ref-title>
<ref-titletext-english>Sulfisoxazole inhibits the secretion of small extracellular vesicles by targeting the endothelin receptor A</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.J.</ce:initials>
<ce:surname>Im</ce:surname>
<ce:given-name>E.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Commun.</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1387</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Im, E.J., et al.: Sulfisoxazole inhibits the secretion of small extracellular vesicles by targeting the endothelin receptor A. Nat. Commun. 10, 1387 (2019)</ref-fulltext>
<ce:source-text>Im, E.J., et al.: Sulfisoxazole inhibits the secretion of small extracellular vesicles by targeting the endothelin receptor A. Nat. Commun. 10, 1387 (2019)</ce:source-text>
</reference>
<reference seq="164">
<ref-info>
<ref-title>
<ref-titletext-english>The lung microenvironment: an important regulator of tumour growth and metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.K.</ce:initials>
<ce:surname>Altorki</ce:surname>
<ce:given-name>N.K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Cancer</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>19</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>9</first-page>
<last-page>31</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Altorki, N.K., et al.: The lung microenvironment: an important regulator of tumour growth and metastasis. Nat. Rev. Cancer. 19, 9–31 (2019)</ref-fulltext>
<ce:source-text>Altorki, N.K., et al.: The lung microenvironment: an important regulator of tumour growth and metastasis. Nat. Rev. Cancer. 19, 9–31 (2019)</ce:source-text>
</reference>
<reference seq="165">
<ref-info>
<ref-title>
<ref-titletext-english>Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.T.</ce:initials>
<ce:surname>Erler</ce:surname>
<ce:given-name>J.T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Cell</ref-sourcetitle>
<ref-publicationyear first="2009" />
<ref-text>Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>15</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>35</first-page>
<last-page>44</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Erler, J.T., et al.: Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell. 15, 35–44 (2009)</ref-fulltext>
<ce:source-text>Erler, J.T., et al.: Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell. 15, 35–44 (2009)</ce:source-text>
</reference>
<reference seq="166">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor-derived exosomal miR-1247-3p induces cancer-associated fibroblast activation to foster lung metastasis of liver cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Fang</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Commun.</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>191</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Fang, T., et al.: Tumor-derived exosomal miR-1247- 3p induces cancer-associated fibroblast activation to foster lung metastasis of liver cancer. Nat. Commun. 9, 191 (2018)</ref-fulltext>
<ce:source-text>Fang, T., et al.: Tumor-derived exosomal miR-1247- 3p induces cancer-associated fibroblast activation to foster lung metastasis of liver cancer. Nat. Commun. 9, 191 (2018)</ce:source-text>
</reference>
<reference seq="167">
<ref-info>
<ref-title>
<ref-titletext-english>The liver</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.</ce:initials>
<ce:surname>Trefts</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Gannon</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>D.H.</ce:initials>
<ce:surname>Wasserman</ce:surname>
<ce:given-name>D.H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Curr. Biol.</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>27</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Trefts, E., Gannon, M., Wasserman, D.H.: The liver. Curr. Biol. 27, R1147–R1151 (2017) </ref-fulltext>
<ce:source-text>Trefts, E., Gannon, M., Wasserman, D.H.: The liver. Curr. Biol. 27, R1147–R1151 (2017) </ce:source-text>
</reference>
<reference seq="168">
<ref-info>
<ref-title>
<ref-titletext-english>Exosome-delivered EGFR regulates liver microenvironment to promote gastric cancer liver metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Zhang</ce:surname>
<ce:given-name>H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Commun.</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Zhang, H., et al.: Exosome-delivered EGFR regulates liver microenvironment to promote gastric cancer liver metastasis. Nat. Commun. 8, 15016 (2017)</ref-fulltext>
<ce:source-text>Zhang, H., et al.: Exosome-delivered EGFR regulates liver microenvironment to promote gastric cancer liver metastasis. Nat. Commun. 8, 15016 (2017)</ce:source-text>
</reference>
<reference seq="169">
<ref-info>
<ref-title>
<ref-titletext-english>Colorectal cancer-derived small extracellular vesicles establish an inflammatory premetastatic niche in liver metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Shao</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Carcinogenesis</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>39</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1368</first-page>
<last-page>1379</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Shao, Y., et al.: Colorectal cancer-derived small extracellular vesicles establish an inflammatory premetastatic niche in liver metastasis. Carcinogenesis. 39, 1368–1379 (2018)</ref-fulltext>
<ce:source-text>Shao, Y., et al.: Colorectal cancer-derived small extracellular vesicles establish an inflammatory premetastatic niche in liver metastasis. Carcinogenesis. 39, 1368–1379 (2018)</ce:source-text>
</reference>
<reference seq="170">
<ref-info>
<ref-title>
<ref-titletext-english>Metastasis to bone: causes, consequences and therapeutic opportunities</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.R.</ce:initials>
<ce:surname>Mundy</ce:surname>
<ce:given-name>G.R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Cancer</ref-sourcetitle>
<ref-publicationyear first="2002" />
<volisspag>
<volume-issue-number>
<vol-first>2</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>584</first-page>
<last-page>593</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mundy, G.R.: Metastasis to bone: causes, consequences and therapeutic opportunities. Nat. Rev. Cancer. 2, 584–593 (2002)</ref-fulltext>
<ce:source-text>Mundy, G.R.: Metastasis to bone: causes, consequences and therapeutic opportunities. Nat. Rev. Cancer. 2, 584–593 (2002)</ce:source-text>
</reference>
<reference seq="171">
<ref-info>
<ref-title>
<ref-titletext-english>RANKL-RANK signaling regulates osteoblast differentiation and bone formation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.</ce:initials>
<ce:surname>Cao</ce:surname>
<ce:given-name>X.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Bone Res.</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>35</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Cao, X.: RANKL-RANK signaling regulates osteoblast differentiation and bone formation. Bone Res. 6, 35 (2018)</ref-fulltext>
<ce:source-text>Cao, X.: RANKL-RANK signaling regulates osteoblast differentiation and bone formation. Bone Res. 6, 35 (2018)</ce:source-text>
</reference>
<reference seq="172">
<ref-info>
<ref-title>
<ref-titletext-english>Exosomal release of L-plastin by breast cancer cells facilitates metastatic bone osteolysis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Tiedemann</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Transl. Oncol.</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>462</first-page>
<last-page>474</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Tiedemann, K., et al.: Exosomal release of L-plastin by breast cancer cells facilitates metastatic bone osteolysis. Transl. Oncol. 12, 462–474 (2019) </ref-fulltext>
<ce:source-text>Tiedemann, K., et al.: Exosomal release of L-plastin by breast cancer cells facilitates metastatic bone osteolysis. Transl. Oncol. 12, 462–474 (2019) </ce:source-text>
</reference>
<reference seq="173">
<ref-info>
<ref-title>
<ref-titletext-english>Breast cancer cell-derived exosomal miR-20a-5p promotes the proliferation and differentiation of osteoclasts by targeting SRCIN1</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Guo</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Med.</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>5687</first-page>
<last-page>5701</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Guo, L., et al.: Breast cancer cell-derived exosomal miR-20a-5p promotes the proliferation and differentiation of osteoclasts by targeting SRCIN1. Cancer Med. 8, 5687–5701 (2019)</ref-fulltext>
<ce:source-text>Guo, L., et al.: Breast cancer cell-derived exosomal miR-20a-5p promotes the proliferation and differentiation of osteoclasts by targeting SRCIN1. Cancer Med. 8, 5687–5701 (2019)</ce:source-text>
</reference>
<reference seq="174">
<ref-info>
<ref-title>
<ref-titletext-english>Communication of prostate cancer cells with bone cells via extracellular vesicle RNA; a potential mechanism of metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Probert</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncogene</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>38</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1751</first-page>
<last-page>1763</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Probert, C., et al.: Communication of prostate cancer cells with bone cells via extracellular vesicle RNA; a potential mechanism of metastasis. Oncogene. 38, 1751–1763 (2019)</ref-fulltext>
<ce:source-text>Probert, C., et al.: Communication of prostate cancer cells with bone cells via extracellular vesicle RNA; a potential mechanism of metastasis. Oncogene. 38, 1751–1763 (2019)</ce:source-text>
</reference>
<reference seq="175">
<ref-info>
<ref-title>
<ref-titletext-english>Exosomal miR-141-3p regulates osteoblast activity to promote the osteoblastic metastasis of prostate cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Ye</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncotarget</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>94834</first-page>
<last-page>94849</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ye, Y., et al.: Exosomal miR-141-3p regulates osteoblast activity to promote the osteoblastic metastasis of prostate cancer. Oncotarget. 8, 94834–94849 (2017)</ref-fulltext>
<ce:source-text>Ye, Y., et al.: Exosomal miR-141-3p regulates osteoblast activity to promote the osteoblastic metastasis of prostate cancer. Oncotarget. 8, 94834–94849 (2017)</ce:source-text>
</reference>
<reference seq="176">
<ref-info>
<ref-title>
<ref-titletext-english>Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.L.</ce:initials>
<ce:surname>Lacey</ce:surname>
<ce:given-name>D.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Drug Discov.</ref-sourcetitle>
<ref-publicationyear first="2012" />
<volisspag>
<volume-issue-number>
<vol-first>11</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>401</first-page>
<last-page>419</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Lacey, D.L., et al.: Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat. Rev. Drug Discov. 11, 401–419 (2012)</ref-fulltext>
<ce:source-text>Lacey, D.L., et al.: Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat. Rev. Drug Discov. 11, 401–419 (2012)</ce:source-text>
</reference>
<reference seq="177">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer-secreted hsa-miR-940 induces an osteoblastic phenotype in the bone metastatic microenvironment via targeting ARHGAP1 and FAM134A</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Hashimoto</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Proc. Natl. Acad. Sci. USA</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>115</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2204</first-page>
<last-page>2209</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hashimoto, K., et al.: Cancer-secreted hsa-miR-940 induces an osteoblastic phenotype in the bone metastatic microenvironment via targeting ARHGAP1 and FAM134A. Proc. Natl. Acad. Sci. USA. 115, 2204–2209 (2018)</ref-fulltext>
<ce:source-text>Hashimoto, K., et al.: Cancer-secreted hsa-miR-940 induces an osteoblastic phenotype in the bone metastatic microenvironment via targeting ARHGAP1 and FAM134A. Proc. Natl. Acad. Sci. USA. 115, 2204–2209 (2018)</ce:source-text>
</reference>
<reference seq="178">
<ref-info>
<ref-title>
<ref-titletext-english>Brain metastatic cancer cells release microRNA-181c-containing extracellular vesicles capable of destructing blood-brain barrier</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.</ce:initials>
<ce:surname>Tominaga</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Commun.</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>6716</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Tominaga, N., et al.: Brain metastatic cancer cells release microRNA-181c-containing extracellular vesicles capable of destructing blood-brain barrier. Nat. Commun. 6, 6716 (2015)</ref-fulltext>
<ce:source-text>Tominaga, N., et al.: Brain metastatic cancer cells release microRNA-181c-containing extracellular vesicles capable of destructing blood-brain barrier. Nat. Commun. 6, 6716 (2015)</ce:source-text>
</reference>
<reference seq="179">
<ref-info>
<ref-title>
<ref-titletext-english>Loss of XIST in breast cancer activates MSN-c-Met and reprograms microglia via exosomal miRNA to promote brain metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Xing</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Res.</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>78</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>4316</first-page>
<last-page>4330</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Xing, F., et al.: Loss of XIST in breast cancer activates MSN-c-Met and reprograms microglia via exosomal miRNA to promote brain metastasis. Cancer Res. 78, 4316–4330 (2018)</ref-fulltext>
<ce:source-text>Xing, F., et al.: Loss of XIST in breast cancer activates MSN-c-Met and reprograms microglia via exosomal miRNA to promote brain metastasis. Cancer Res. 78, 4316–4330 (2018)</ce:source-text>
</reference>
<reference seq="180">
<ref-info>
<ref-title>
<ref-titletext-english>Melanoma-derived extracellular vesicles instigate proinflammatory signaling in the metastatic microenvironment</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Gener Lahav</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Cancer</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>145</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2521</first-page>
<last-page>2534</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Gener Lahav, T., et al.: Melanoma-derived extracellular vesicles instigate proinflammatory signaling in the metastatic microenvironment. Int. J. Cancer. 145, 2521–2534 (2019)</ref-fulltext>
<ce:source-text>Gener Lahav, T., et al.: Melanoma-derived extracellular vesicles instigate proinflammatory signaling in the metastatic microenvironment. Int. J. Cancer. 145, 2521–2534 (2019)</ce:source-text>
</reference>
<reference seq="181">
<ref-info>
<ref-title>
<ref-titletext-english>Blood-brain barrier: from physiology to disease and back</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.D.</ce:initials>
<ce:surname>Sweeney</ce:surname>
<ce:given-name>M.D.</ce:given-name>
</author>
<author seq="2">
<ce:initials>Z.</ce:initials>
<ce:surname>Zhao</ce:surname>
<ce:given-name>Z.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Montagne</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="4">
<ce:initials>A.R.</ce:initials>
<ce:surname>Nelson</ce:surname>
<ce:given-name>A.R.</ce:given-name>
</author>
<author seq="5">
<ce:initials>B.V.</ce:initials>
<ce:surname>Zlokovic</ce:surname>
<ce:given-name>B.V.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Physiol. Rev.</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>99</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>21</first-page>
<last-page>78</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sweeney, M.D., Zhao, Z., Montagne, A., Nelson, A. R., Zlokovic, B.V.: Blood-brain barrier: from physiology to disease and back. Physiol. Rev. 99, 21–78 (2019)</ref-fulltext>
<ce:source-text>Sweeney, M.D., Zhao, Z., Montagne, A., Nelson, A. R., Zlokovic, B.V.: Blood-brain barrier: from physiology to disease and back. Physiol. Rev. 99, 21–78 (2019)</ce:source-text>
</reference>
<reference seq="182">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor-derived extracellular vesicles breach the intact blood-brain barrier via transcytosis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Morad</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>ACS Nano</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>13</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>13853</first-page>
<last-page>13865</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Morad, G., et al.: Tumor-derived extracellular vesicles breach the intact blood-brain barrier via transcytosis. ACS Nano. 13, 13853–13865 (2019)</ref-fulltext>
<ce:source-text>Morad, G., et al.: Tumor-derived extracellular vesicles breach the intact blood-brain barrier via transcytosis. ACS Nano. 13, 13853–13865 (2019)</ce:source-text>
</reference>
<reference seq="183">
<ref-info>
<ref-title>
<ref-titletext-english>Brain microvascular endothelial cell exosome-mediated S100A16 up-regulation confers small-cell lung cancer cell survival in brain</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Z.H.</ce:initials>
<ce:surname>Xu</ce:surname>
<ce:given-name>Z.H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>FASEB J.</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>33</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1742</first-page>
<last-page>1757</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Xu, Z.H., et al.: Brain microvascular endothelial cell exosome-mediated S100A16 up-regulation confers small-cell lung cancer cell survival in brain. FASEB J. 33, 1742–1757 (2019)</ref-fulltext>
<ce:source-text>Xu, Z.H., et al.: Brain microvascular endothelial cell exosome-mediated S100A16 up-regulation confers small-cell lung cancer cell survival in brain. FASEB J. 33, 1742–1757 (2019)</ce:source-text>
</reference>
<reference seq="184">
<ref-info>
<ref-title>
<ref-titletext-english>Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Zhang</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>527</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>100</first-page>
<last-page>104</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zhang, L., et al.: Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth. Nature. 527, 100–104 (2015)</ref-fulltext>
<ce:source-text>Zhang, L., et al.: Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth. Nature. 527, 100–104 (2015)</ce:source-text>
</reference>
<reference seq="185">
<ref-info>
<ref-title>
<ref-titletext-english>Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD1 response</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Chen</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>560</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>382</first-page>
<last-page>386</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Chen, G., et al.: Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD1 response. Nature. 560, 382–386 (2018)</ref-fulltext>
<ce:source-text>Chen, G., et al.: Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD1 response. Nature. 560, 382–386 (2018)</ce:source-text>
</reference>
<reference seq="186">
<ref-info>
<ref-title>
<ref-titletext-english>Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Balaj</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Commun.</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>2</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>180</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Balaj, L., et al.: Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences. Nat. Commun. 2, 180 (2011)</ref-fulltext>
<ce:source-text>Balaj, L., et al.: Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences. Nat. Commun. 2, 180 (2011)</ce:source-text>
</reference>
<reference seq="187">
<ref-info>
<ref-title>
<ref-titletext-english>Astrocytes and Glioblastoma cells release exosomes carrying mtDNA</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Guescini</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Genedani</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>V.</ce:initials>
<ce:surname>Stocchi</ce:surname>
<ce:given-name>V.</ce:given-name>
</author>
<author seq="4">
<ce:initials>L.F.</ce:initials>
<ce:surname>Agnati</ce:surname>
<ce:given-name>L.F.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Neural Transm. (Vienna)</ref-sourcetitle>
<ref-publicationyear first="2010" />
<volisspag>
<volume-issue-number>
<vol-first>117</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1</first-page>
<last-page>4</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Guescini, M., Genedani, S., Stocchi, V., Agnati, L.F.: Astrocytes and Glioblastoma cells release exosomes carrying mtDNA. J. Neural Transm. (Vienna). 117, 1–4 (2010) </ref-fulltext>
<ce:source-text>Guescini, M., Genedani, S., Stocchi, V., Agnati, L.F.: Astrocytes and Glioblastoma cells release exosomes carrying mtDNA. J. Neural Transm. (Vienna). 117, 1–4 (2010) </ce:source-text>
</reference>
<reference seq="188">
<ref-info>
<ref-title>
<ref-titletext-english>Double-stranded DNA in exosomes: a novel biomarker in cancer detection</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.K.</ce:initials>
<ce:surname>Thakur</ce:surname>
<ce:given-name>B.K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Res.</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>24</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>766</first-page>
<last-page>769</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Thakur, B.K., et al.: Double-stranded DNA in exosomes: a novel biomarker in cancer detection. Cell Res. 24, 766–769 (2014)</ref-fulltext>
<ce:source-text>Thakur, B.K., et al.: Double-stranded DNA in exosomes: a novel biomarker in cancer detection. Cell Res. 24, 766–769 (2014) </ce:source-text>
</reference>
<reference seq="189">
<ref-info>
<ref-title>
<ref-titletext-english>Exosome DNA: critical regulator of tumor immunity and a diagnostic biomarker</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Sharma</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Johnson</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cell. Physiol.</ref-sourcetitle>
<ref-publicationyear first="2020" />
<volisspag>
<volume-issue-number>
<vol-first>235</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1921</first-page>
<last-page>1932</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sharma, A., Johnson, A.: Exosome DNA: critical regulator of tumor immunity and a diagnostic biomarker. J. Cell. Physiol. 235, 1921–1932 (2020)</ref-fulltext>
<ce:source-text>Sharma, A., Johnson, A.: Exosome DNA: critical regulator of tumor immunity and a diagnostic biomarker. J. Cell. Physiol. 235, 1921–1932 (2020)</ce:source-text>
</reference>
<reference seq="190">
<ref-info>
<ref-title>
<ref-titletext-english>DNA-containing exosomes derived from cancer cells treated with topotecan activate a STING-dependent pathway and reinforce antitumor immunity</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Kitai</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Immunol.</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>198</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1649</first-page>
<last-page>1659</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kitai, Y., et al.: DNA-containing exosomes derived from cancer cells treated with topotecan activate a STING-dependent pathway and reinforce antitumor immunity. J. Immunol. 198, 1649–1659 (2017)</ref-fulltext>
<ce:source-text>Kitai, Y., et al.: DNA-containing exosomes derived from cancer cells treated with topotecan activate a STING-dependent pathway and reinforce antitumor immunity. J. Immunol. 198, 1649–1659 (2017)</ce:source-text>
</reference>
<reference seq="191">
<ref-info>
<ref-title>
<ref-titletext-english>Dendritic cells but not macrophages sense tumor mitochondrial DNA for cross-priming through signal regulatory protein alpha signaling</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.M.</ce:initials>
<ce:surname>Xu</ce:surname>
<ce:given-name>M.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Immunity</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>47</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>363</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Xu, M.M., et al.: Dendritic cells but not macrophages sense tumor mitochondrial DNA for cross-priming through signal regulatory protein alpha signaling. Immunity. 47, 363-+ (2017)</ref-fulltext>
<ce:source-text>Xu, M.M., et al.: Dendritic cells but not macrophages sense tumor mitochondrial DNA for cross-priming through signal regulatory protein alpha signaling. Immunity. 47, 363-+ (2017)</ce:source-text>
</reference>
<reference seq="192">
<ref-info>
<ref-title>
<ref-titletext-english>Metabolomic profiling of extracellular vesicles and alternative normalization methods reveal enriched metabolites and strategies to study prostate cancer-related changes</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Puhka</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Theranostics</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3824</first-page>
<last-page>3841</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Puhka, M., et al.: Metabolomic profiling of extracellular vesicles and alternative normalization methods reveal enriched metabolites and strategies to study prostate cancer-related changes. Theranostics. 7, 3824–3841 (2017)</ref-fulltext>
<ce:source-text>Puhka, M., et al.: Metabolomic profiling of extracellular vesicles and alternative normalization methods reveal enriched metabolites and strategies to study prostate cancer-related changes. Theranostics. 7, 3824–3841 (2017)</ce:source-text>
</reference>
<reference seq="193">
<ref-info>
<ref-title>
<ref-titletext-english>Visualization and tracking of tumour extracellular vesicle delivery and RNA translation using multiplexed reporters</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.P.</ce:initials>
<ce:surname>Lai</ce:surname>
<ce:given-name>C.P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Commun.</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>7029</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Lai, C.P., et al.: Visualization and tracking of tumour extracellular vesicle delivery and RNA translation using multiplexed reporters. Nat. Commun. 6, 7029 (2015)</ref-fulltext>
<ce:source-text>Lai, C.P., et al.: Visualization and tracking of tumour extracellular vesicle delivery and RNA translation using multiplexed reporters. Nat. Commun. 6, 7029 (2015)</ce:source-text>
</reference>
<reference seq="194">
<ref-info>
<ref-title>
<ref-titletext-english>In vivo imaging reveals extracellular vesicle-mediated phenocopying of metastatic behavior</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Zomer</ce:surname>
<ce:given-name />
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>161</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1046</first-page>
<last-page>1057</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zomer, A., et al.: In vivo imaging reveals extracellular vesicle-mediated phenocopying of metastatic behavior. Cell. 161, 1046–1057 (2015)</ref-fulltext>
<ce:source-text>Zomer, A., et al.: In vivo imaging reveals extracellular vesicle-mediated phenocopying of metastatic behavior. Cell. 161, 1046–1057 (2015)</ce:source-text>
</reference>
<reference seq="195">
<ref-info>
<ref-title>
<ref-titletext-english>Studying extracellular vesicle transfer by a Cre-loxP method</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Zomer</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.C.</ce:initials>
<ce:surname>Steenbeek</ce:surname>
<ce:given-name>S.C.</ce:given-name>
</author>
<author seq="3">
<ce:initials>C.</ce:initials>
<ce:surname>Maynard</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="4">
<ce:initials>J.</ce:initials>
<ce:surname>van Rheenen</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Protoc.</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>11</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>87</first-page>
<last-page>101</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zomer, A., Steenbeek, S.C., Maynard, C., van Rheenen, J.: Studying extracellular vesicle transfer by a Cre-loxP method. Nat. Protoc. 11, 87–101 (2016)</ref-fulltext>
<ce:source-text>Zomer, A., Steenbeek, S.C., Maynard, C., van Rheenen, J.: Studying extracellular vesicle transfer by a Cre-loxP method. Nat. Protoc. 11, 87–101 (2016)</ce:source-text>
</reference>
<reference seq="196">
<ref-info>
<ref-title>
<ref-titletext-english>Studying the fate of tumor extracellular vesicles at high spatiotemporal resolution using the zebrafish embryo</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>V.</ce:initials>
<ce:surname>Hyenne</ce:surname>
<ce:given-name>V.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Dev. Cell</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>48</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>554</first-page>
<last-page>572</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hyenne, V., et al.: Studying the fate of tumor extracellular vesicles at high spatiotemporal resolution using the zebrafish embryo. Dev. Cell. 48, 554–572 e557 (2019)</ref-fulltext>
<ce:source-text>Hyenne, V., et al.: Studying the fate of tumor extracellular vesicles at high spatiotemporal resolution using the zebrafish embryo. Dev. Cell. 48, 554–572 e557 (2019)</ce:source-text>
</reference>
<reference seq="197">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer cachexia: mediators, signaling, and metabolic pathways</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.C.</ce:initials>
<ce:surname>Fearon</ce:surname>
<ce:given-name>K.C.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.J.</ce:initials>
<ce:surname>Glass</ce:surname>
<ce:given-name>D.J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>D.C.</ce:initials>
<ce:surname>Guttridge</ce:surname>
<ce:given-name>D.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Metab.</ref-sourcetitle>
<ref-publicationyear first="2012" />
<volisspag>
<volume-issue-number>
<vol-first>16</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>153</first-page>
<last-page>166</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Fearon, K.C., Glass, D.J., Guttridge, D.C.: Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab. 16, 153–166 (2012)</ref-fulltext>
<ce:source-text>Fearon, K.C., Glass, D.J., Guttridge, D.C.: Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab. 16, 153–166 (2012)</ce:source-text>
</reference>
<reference seq="198">
<ref-info>
<ref-title>
<ref-titletext-english>Understanding cachexia as a cancer metabolism syndrome</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.E.</ce:initials>
<ce:surname>Porporato</ce:surname>
<ce:given-name>P.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncogenesis</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>5</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Porporato, P.E.: Understanding cachexia as a cancer metabolism syndrome. Oncogenesis. 5 (2016)</ref-fulltext>
<ce:source-text>Porporato, P.E.: Understanding cachexia as a cancer metabolism syndrome. Oncogenesis. 5 (2016)</ce:source-text>
</reference>
<reference seq="199">
<ref-info>
<ref-title>
<ref-titletext-english>Metastatic cancers promote cachexia through ZIP14 upregulation in skeletal muscle</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Wang</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Med.</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>24</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>770</first-page>
<last-page>781</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wang, G., et al.: Metastatic cancers promote cachexia through ZIP14 upregulation in skeletal muscle. Nat. Med. 24, 770–781 (2018)</ref-fulltext>
<ce:source-text>Wang, G., et al.: Metastatic cancers promote cachexia through ZIP14 upregulation in skeletal muscle. Nat. Med. 24, 770–781 (2018)</ce:source-text>
</reference>
<reference seq="200">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer-associated cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>V.E.</ce:initials>
<ce:surname>Baracos</ce:surname>
<ce:given-name>V.E.</ce:given-name>
</author>
<author seq="2">
<ce:initials>L.</ce:initials>
<ce:surname>Martin</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Korc</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="4">
<ce:initials>D.C.</ce:initials>
<ce:surname>Guttridge</ce:surname>
<ce:given-name>D.C.</ce:given-name>
</author>
<author seq="5">
<ce:initials>K.C.H.</ce:initials>
<ce:surname>Fearon</ce:surname>
<ce:given-name>K.C.H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Dis. Primers</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>4</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>17105</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Baracos, V.E., Martin, L., Korc, M., Guttridge, D.C., Fearon, K.C.H.: Cancer-associated cachexia. Nat. Rev. Dis. Primers. 4, 17105 (2018)</ref-fulltext>
<ce:source-text>Baracos, V.E., Martin, L., Korc, M., Guttridge, D.C., Fearon, K.C.H.: Cancer-associated cachexia. Nat. Rev. Dis. Primers. 4, 17105 (2018)</ce:source-text>
</reference>
<reference seq="201">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer-derived exosome miRNAs induce skeletal muscle wasting by Bcl-2-mediated apoptosis in colon cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Miao</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Mol. Ther. Nucleic Acids</ref-sourcetitle>
<ref-publicationyear first="2021" />
<volisspag>
<volume-issue-number>
<vol-first>24</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>923</first-page>
<last-page>938</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Miao, C., et al.: Cancer-derived exosome miRNAs induce skeletal muscle wasting by Bcl-2-mediated apoptosis in colon cancer cachexia. Mol. Ther. Nucleic Acids. 24, 923–938 (2021) </ref-fulltext>
<ce:source-text>Miao, C., et al.: Cancer-derived exosome miRNAs induce skeletal muscle wasting by Bcl-2-mediated apoptosis in colon cancer cachexia. Mol. Ther. Nucleic Acids. 24, 923–938 (2021) </ce:source-text>
</reference>
<reference seq="202">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor induces muscle wasting in mice through releasing extracellular Hsp70 and Hsp90</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Zhang</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Commun.</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>589</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zhang, G., et al.: Tumor induces muscle wasting in mice through releasing extracellular Hsp70 and Hsp90. Nat. Commun. 8, 589 (2017)</ref-fulltext>
<ce:source-text>Zhang, G., et al.: Tumor induces muscle wasting in mice through releasing extracellular Hsp70 and Hsp90. Nat. Commun. 8, 589 (2017)</ce:source-text>
</reference>
<reference seq="203">
<ref-info>
<ref-title>
<ref-titletext-english>Microvesicles containing miRNAs promote muscle cell death in cancer cachexia via TLR7</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>W.A.</ce:initials>
<ce:surname>He</ce:surname>
<ce:given-name>W.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Proc. Natl. Acad. Sci. USA</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>111</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>4525</first-page>
<last-page>4529</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>He, W.A., et al.: Microvesicles containing miRNAs promote muscle cell death in cancer cachexia via TLR7. Proc. Natl. Acad. Sci. USA. 111, 4525–4529 (2014)</ref-fulltext>
<ce:source-text>He, W.A., et al.: Microvesicles containing miRNAs promote muscle cell death in cancer cachexia via TLR7. Proc. Natl. Acad. Sci. USA. 111, 4525–4529 (2014)</ce:source-text>
</reference>
<reference seq="204">
<ref-info>
<ref-title>
<ref-titletext-english>Pathogenesis of pancreatic cancer exosome-induced lipolysis in adipose tissue</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Sagar</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Gut</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>65</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1165</first-page>
<last-page>1174</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sagar, G., et al.: Pathogenesis of pancreatic cancer exosome-induced lipolysis in adipose tissue. Gut. 65, 1165–1174 (2016)</ref-fulltext>
<ce:source-text>Sagar, G., et al.: Pathogenesis of pancreatic cancer exosome-induced lipolysis in adipose tissue. Gut. 65, 1165–1174 (2016)</ce:source-text>
</reference>
<reference seq="205">
<ref-info>
<ref-title>
<ref-titletext-english>Reduced adipogenesis after lung tumor exosomes priming in human mesenchymal stem cells via TGF-beta signaling pathway</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Wang</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>X.</ce:initials>
<ce:surname>Li</ce:surname>
<ce:given-name>X.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Xu</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="4">
<ce:initials>J.</ce:initials>
<ce:surname>Wang</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="5">
<ce:initials>R.C.</ce:initials>
<ce:surname>Zhao</ce:surname>
<ce:given-name>R.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Mol. Cell. Biochem.</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>435</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>59</first-page>
<last-page>66</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wang, S., Li, X., Xu, M., Wang, J., Zhao, R.C.: Reduced adipogenesis after lung tumor exosomes priming in human mesenchymal stem cells via TGF-beta signaling pathway. Mol. Cell. Biochem. 435, 59–66 (2017)</ref-fulltext>
<ce:source-text>Wang, S., Li, X., Xu, M., Wang, J., Zhao, R.C.: Reduced adipogenesis after lung tumor exosomes priming in human mesenchymal stem cells via TGF-beta signaling pathway. Mol. Cell. Biochem. 435, 59–66 (2017)</ce:source-text>
</reference>
<reference seq="206">
<ref-info>
<ref-title>
<ref-titletext-english>A switch from white to brown fat increases energy expenditure in cancer-associated cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Petruzzelli</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Metab.</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>20</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>433</first-page>
<last-page>447</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Petruzzelli, M., et al.: A switch from white to brown fat increases energy expenditure in cancer-associated cachexia. Cell Metab. 20, 433–447 (2014) </ref-fulltext>
<ce:source-text>Petruzzelli, M., et al.: A switch from white to brown fat increases energy expenditure in cancer-associated cachexia. Cell Metab. 20, 433–447 (2014) </ce:source-text>
</reference>
<reference seq="207">
<ref-info>
<ref-title>
<ref-titletext-english>Tumour-originated exosomal miR-155 triggers cancer-associated cachexia to promote tumour progression</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Q.</ce:initials>
<ce:surname>Wu</ce:surname>
<ce:given-name>Q.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Mol. Cancer</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>17</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>155</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wu, Q., et al.: Tumour-originated exosomal miR-155 triggers cancer-associated cachexia to promote tumour progression. Mol. Cancer. 17, 155 (2018) </ref-fulltext>
<ce:source-text>Wu, Q., et al.: Tumour-originated exosomal miR-155 triggers cancer-associated cachexia to promote tumour progression. Mol. Cancer. 17, 155 (2018)</ce:source-text>
</reference>
<reference seq="208">
<ref-info>
<ref-title>
<ref-titletext-english>Colorectal cancer prompted adipose tissue browning and cancer cachexia through transferring exosomal miR-146b-5p</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>W.J.</ce:initials>
<ce:surname>Di</ce:surname>
<ce:given-name>W.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cell. Physiol.</ref-sourcetitle>
<ref-publicationyear first="2021" />
<volisspag>
<volume-issue-number>
<vol-first>236</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>5399</first-page>
<last-page>5410</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Di, W.J., et al.: Colorectal cancer prompted adipose tissue browning and cancer cachexia through transferring exosomal miR-146b-5p. J. Cell. Physiol. 236, 5399–5410 (2021)</ref-fulltext>
<ce:source-text>Di, W.J., et al.: Colorectal cancer prompted adipose tissue browning and cancer cachexia through transferring exosomal miR-146b-5p. J. Cell. Physiol. 236, 5399–5410 (2021)</ce:source-text>
</reference>
<reference seq="209">
<ref-info>
<ref-title>
<ref-titletext-english>Paraneoplastic syndromes in rheumatology</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.</ce:initials>
<ce:surname>Manger</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
<author seq="2">
<ce:initials>G.</ce:initials>
<ce:surname>Schett</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Rheumatol.</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>662</first-page>
<last-page>670</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Manger, B., Schett, G.: Paraneoplastic syndromes in rheumatology. Nat. Rev. Rheumatol. 10, 662–670 (2014)</ref-fulltext>
<ce:source-text>Manger, B., Schett, G.: Paraneoplastic syndromes in rheumatology. Nat. Rev. Rheumatol. 10, 662–670 (2014)</ce:source-text>
</reference>
<reference seq="210">
<ref-info>
<ref-title>
<ref-titletext-english>Pancreatic cancer-derived exosomes cause paraneoplastic beta-cell dysfunction</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.</ce:initials>
<ce:surname>Javeed</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Clin. Cancer Res.</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>21</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1722</first-page>
<last-page>1733</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Javeed, N., et al.: Pancreatic cancer-derived exosomes cause paraneoplastic beta-cell dysfunction. Clin. Cancer Res. 21, 1722–1733 (2015)</ref-fulltext>
<ce:source-text>Javeed, N., et al.: Pancreatic cancer-derived exosomes cause paraneoplastic beta-cell dysfunction. Clin. Cancer Res. 21, 1722–1733 (2015)</ce:source-text>
</reference>
<reference seq="211">
<ref-info>
<ref-title>
<ref-titletext-english>Intercellular transfer of tissue factor via the uptake of tumor-derived microvesicles</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.G.</ce:initials>
<ce:surname>Lima</ce:surname>
<ce:given-name>L.G.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.C.</ce:initials>
<ce:surname>Leal</ce:surname>
<ce:given-name>A.C.</ce:given-name>
</author>
<author seq="3">
<ce:initials>G.</ce:initials>
<ce:surname>Vargas</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<author seq="4">
<ce:initials>I.</ce:initials>
<ce:surname>Porto-Carreiro</ce:surname>
<ce:given-name>I.</ce:given-name>
</author>
<author seq="5">
<ce:initials>R.Q.</ce:initials>
<ce:surname>Monteiro</ce:surname>
<ce:given-name>R.Q.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Thromb. Res.</ref-sourcetitle>
<ref-publicationyear first="2013" />
<volisspag>
<volume-issue-number>
<vol-first>132</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>450</first-page>
<last-page>456</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Lima, L.G., Leal, A.C., Vargas, G., Porto-Carreiro, I., Monteiro, R.Q.: Intercellular transfer of tissue factor via the uptake of tumor-derived microvesicles. Thromb. Res. 132, 450–456 (2013)</ref-fulltext>
<ce:source-text>Lima, L.G., Leal, A.C., Vargas, G., Porto-Carreiro, I., Monteiro, R.Q.: Intercellular transfer of tissue factor via the uptake of tumor-derived microvesicles. Thromb. Res. 132, 450–456 (2013)</ce:source-text>
</reference>
<reference seq="212">
<ref-info>
<ref-title>
<ref-titletext-english>Breast-cancer extracellular vesicles induce platelet activation and aggregation by tissue factor-independent and -dependent mechanisms</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.G.</ce:initials>
<ce:surname>Gomes</ce:surname>
<ce:given-name>F.G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Thromb. Res.</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>159</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>24</first-page>
<last-page>32</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Gomes, F.G., et al.: Breast-cancer extracellular vesicles induce platelet activation and aggregation by tissue factor-independent and -dependent mechanisms. Thromb. Res. 159, 24–32 (2017)</ref-fulltext>
<ce:source-text>Gomes, F.G., et al.: Breast-cancer extracellular vesicles induce platelet activation and aggregation by tissue factor-independent and -dependent mechanisms. Thromb. Res. 159, 24–32 (2017)</ce:source-text>
</reference>
<reference seq="213">
<ref-info>
<ref-title>
<ref-titletext-english>International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.S.</ce:initials>
<ce:surname>Wefel</ce:surname>
<ce:given-name>J.S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Vardy</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="3">
<ce:initials>T.</ce:initials>
<ce:surname>Ahles</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="4">
<ce:initials>S.B.</ce:initials>
<ce:surname>Schagen</ce:surname>
<ce:given-name>S.B.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Lancet Oncol.</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>703</first-page>
<last-page>708</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wefel, J.S., Vardy, J., Ahles, T., Schagen, S.B.: International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol. 12, 703–708 (2011)</ref-fulltext>
<ce:source-text>Wefel, J.S., Vardy, J., Ahles, T., Schagen, S.B.: International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol. 12, 703–708 (2011)</ce:source-text>
</reference>
<reference seq="214">
<ref-info>
<ref-title>
<ref-titletext-english>Role of exosomes in cancer-related cognitive impairment</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.Q.</ce:initials>
<ce:surname>Koh</ce:surname>
<ce:given-name>Y.Q.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Mol. Sci.</ref-sourcetitle>
<ref-publicationyear first="2020" />
<volisspag>
<volume-issue-number>
<vol-first>21</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Koh, Y.Q., et al.: Role of exosomes in cancer-related cognitive impairment. Int. J. Mol. Sci. 21 (2020)</ref-fulltext>
<ce:source-text>Koh, Y.Q., et al.: Role of exosomes in cancer-related cognitive impairment. Int. J. Mol. Sci. 21 (2020)</ce:source-text>
</reference>
<reference seq="215">
<ref-info>
<ref-title>
<ref-titletext-english>Ionizing radiation increases the activity of exosomal secretory pathway in MCF-7 human breast cancer cells: a possible way to communicate resistance against radiotherapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.</ce:initials>
<ce:surname>Jabbari</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Nawaz</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Rezaie</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Mol. Sci.</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>20</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Jabbari, N., Nawaz, M., Rezaie, J.: Ionizing radiation increases the activity of exosomal secretory pathway in MCF-7 human breast cancer cells: a possible way to communicate resistance against radiotherapy. Int. J. Mol. Sci. 20 (2019)</ref-fulltext>
<ce:source-text>Jabbari, N., Nawaz, M., Rezaie, J.: Ionizing radiation increases the activity of exosomal secretory pathway in MCF-7 human breast cancer cells: a possible way to communicate resistance against radiotherapy. Int. J. Mol. Sci. 20 (2019)</ce:source-text>
</reference>
<reference seq="216">
<ref-info>
<ref-title>
<ref-titletext-english>Chemotherapy induces secretion of exosomes loaded with heparanase that degrades extracellular matrix and impacts tumor and host cell behavior</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.K.</ce:initials>
<ce:surname>Bandari</ce:surname>
<ce:given-name>S.K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Matrix Biol.</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>65</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>104</first-page>
<last-page>118</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Bandari, S.K., et al.: Chemotherapy induces secretion of exosomes loaded with heparanase that degrades extracellular matrix and impacts tumor and host cell behavior. Matrix Biol. 65, 104–118 (2018)</ref-fulltext>
<ce:source-text>Bandari, S.K., et al.: Chemotherapy induces secretion of exosomes loaded with heparanase that degrades extracellular matrix and impacts tumor and host cell behavior. Matrix Biol. 65, 104–118 (2018)</ce:source-text>
</reference>
<reference seq="217">
<ref-info>
<ref-title>
<ref-titletext-english>Identifying predictors of taxane-induced peripheral neuropathy using mass spectrometry-based proteomics technology</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.I.</ce:initials>
<ce:surname>Chen</ce:surname>
<ce:given-name>E.I.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>PLoS One</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Chen, E.I., et al.: Identifying predictors of taxaneinduced peripheral neuropathy using mass spectrometry-based proteomics technology. PLoS One. 10 (2015)</ref-fulltext>
<ce:source-text>Chen, E.I., et al.: Identifying predictors of taxaneinduced peripheral neuropathy using mass spectrometry-based proteomics technology. PLoS One. 10 (2015)</ce:source-text>
</reference>
<reference seq="218">
<ref-info>
<ref-title>
<ref-titletext-english>Exosomes as a multicomponent biomarker platform in cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>V.S.</ce:initials>
<ce:surname>LeBleu</ce:surname>
<ce:given-name>V.S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.</ce:initials>
<ce:surname>Kalluri</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Trends Cancer</ref-sourcetitle>
<ref-publicationyear first="2020" />
</ref-info>
<ref-fulltext>LeBleu, V.S., Kalluri, R.: Exosomes as a multicomponent biomarker platform in cancer. Trends Cancer. (2020)</ref-fulltext>
<ce:source-text>LeBleu, V.S., Kalluri, R.: Exosomes as a multicomponent biomarker platform in cancer. Trends Cancer. (2020)</ce:source-text>
</reference>
<reference seq="219">
<ref-info>
<ref-title>
<ref-titletext-english>MicroRNAs in serum exosomes as potential biomarkers in clear-cell renal cell carcinoma</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>W.</ce:initials>
<ce:surname>Zhang</ce:surname>
<ce:given-name>W.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Eur. Urol. Focus</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>4</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>412</first-page>
<last-page>419</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zhang, W., et al.: MicroRNAs in serum exosomes as potential biomarkers in clear-cell renal cell carcinoma. Eur. Urol. Focus. 4, 412–419 (2018)</ref-fulltext>
<ce:source-text>Zhang, W., et al.: MicroRNAs in serum exosomes as potential biomarkers in clear-cell renal cell carcinoma. Eur. Urol. Focus. 4, 412–419 (2018)</ce:source-text>
</reference>
<reference seq="220">
<ref-info>
<ref-title>
<ref-titletext-english>Multiparametric plasma EV profiling facilitates diagnosis of pancreatic malignancy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.S.</ce:initials>
<ce:surname>Yang</ce:surname>
<ce:given-name>K.S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Sci. Transl. Med.</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Yang, K.S., et al.: Multiparametric plasma EV profiling facilitates diagnosis of pancreatic malignancy. Sci. Transl. Med. 9 (2017)</ref-fulltext>
<ce:source-text>Yang, K.S., et al.: Multiparametric plasma EV profiling facilitates diagnosis of pancreatic malignancy. Sci. Transl. Med. 9 (2017)</ce:source-text>
</reference>
<reference seq="221">
<ref-info>
<ref-title>
<ref-titletext-english>Progress in exosome isolation techniques</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.</ce:initials>
<ce:surname>Li</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Kaslan</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.H.</ce:initials>
<ce:surname>Lee</ce:surname>
<ce:given-name>S.H.</ce:given-name>
</author>
<author seq="4">
<ce:initials>J.</ce:initials>
<ce:surname>Yao</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="5">
<ce:initials>Z.</ce:initials>
<ce:surname>Gao</ce:surname>
<ce:given-name>Z.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Theranostics</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>789</first-page>
<last-page>804</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Li, P., Kaslan, M., Lee, S.H., Yao, J., Gao, Z.: Progress in exosome isolation techniques. Theranostics. 7, 789–804 (2017)</ref-fulltext>
<ce:source-text>Li, P., Kaslan, M., Lee, S.H., Yao, J., Gao, Z.: Progress in exosome isolation techniques. Theranostics. 7, 789–804 (2017)</ce:source-text>
</reference>
<reference seq="222">
<ref-info>
<ref-title>
<ref-titletext-english>Cardiovascular effects of systemic cancer treatment</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.</ce:initials>
<ce:surname>Senkus</ce:surname>
<ce:given-name>E.</ce:given-name>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Jassem</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Treat. Rev.</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>37</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>300</first-page>
<last-page>311</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Senkus, E., Jassem, J.: Cardiovascular effects of systemic cancer treatment. Cancer Treat. Rev. 37, 300–311 (2011)</ref-fulltext>
<ce:source-text>Senkus, E., Jassem, J.: Cardiovascular effects of systemic cancer treatment. Cancer Treat. Rev. 37, 300–311 (2011)</ce:source-text>
</reference>
<reference seq="223">
<ref-info>
<ref-title>
<ref-titletext-english>A paradigm shift in cancer immunotherapy: from enhancement to normalization</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.F.</ce:initials>
<ce:surname>Sanmamed</ce:surname>
<ce:given-name>M.F.</ce:given-name>
</author>
<author seq="2">
<ce:initials>L.</ce:initials>
<ce:surname>Chen</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>175</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>313</first-page>
<last-page>326</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sanmamed, M.F., Chen, L.: A paradigm shift in cancer immunotherapy: from enhancement to normalization. Cell. 175, 313–326 (2018)</ref-fulltext>
<ce:source-text>Sanmamed, M.F., Chen, L.: A paradigm shift in cancer immunotherapy: from enhancement to normalization. Cell. 175, 313–326 (2018)</ce:source-text>
</reference>
<reference seq="224">
<ref-info>
<ref-title>
<ref-titletext-english>Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Chen</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>X.</ce:initials>
<ce:surname>Han</ce:surname>
<ce:given-name>X.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Invest.</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>125</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3384</first-page>
<last-page>3391</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Chen, L., Han, X.: Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J. Clin. Invest. 125, 3384–3391 (2015)</ref-fulltext>
<ce:source-text>Chen, L., Han, X.: Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J. Clin. Invest. 125, 3384–3391 (2015)</ce:source-text>
</reference>
<reference seq="225">
<ref-info>
<ref-title>
<ref-titletext-english>Immune modulation in cancer with antibodies</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.B.</ce:initials>
<ce:surname>Page</ce:surname>
<ce:given-name>D.B.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.A.</ce:initials>
<ce:surname>Postow</ce:surname>
<ce:given-name>M.A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.K.</ce:initials>
<ce:surname>Callahan</ce:surname>
<ce:given-name>M.K.</ce:given-name>
</author>
<author seq="4">
<ce:initials>J.P.</ce:initials>
<ce:surname>Allison</ce:surname>
<ce:given-name>J.P.</ce:given-name>
</author>
<author seq="5">
<ce:initials>J.D.</ce:initials>
<ce:surname>Wolchok</ce:surname>
<ce:given-name>J.D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Annu. Rev. Med.</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>65</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>185</first-page>
<last-page>202</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Page, D.B., Postow, M.A., Callahan, M.K., Allison, J.P., Wolchok, J.D.: Immune modulation in cancer with antibodies. Annu. Rev. Med. 65, 185–202 (2014)</ref-fulltext>
<ce:source-text>Page, D.B., Postow, M.A., Callahan, M.K., Allison, J.P., Wolchok, J.D.: Immune modulation in cancer with antibodies. Annu. Rev. Med. 65, 185–202 (2014)</ce:source-text>
</reference>
<reference seq="226">
<ref-info>
<ref-title>
<ref-titletext-english>Suppression of exosomal PD-L1 induces systemic anti-tumor immunity and memory</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Poggio</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>177</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>414</first-page>
<last-page>427</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Poggio, M., et al.: Suppression of exosomal PD-L1 induces systemic anti-tumor immunity and memory. Cell. 177, 414–427 e413 (2019)</ref-fulltext>
<ce:source-text>Poggio, M., et al.: Suppression of exosomal PD-L1 induces systemic anti-tumor immunity and memory. Cell. 177, 414–427 e413 (2019)</ce:source-text>
</reference>
<reference seq="227">
<ref-info>
<ref-title>
<ref-titletext-english>Engineering exosomes as refined biological nanoplatforms for drug delivery</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.</ce:initials>
<ce:surname>Luan</ce:surname>
<ce:given-name>X.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Acta Pharmacol. Sin.</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>38</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>754</first-page>
<last-page>763</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Luan, X., et al.: Engineering exosomes as refined biological nanoplatforms for drug delivery. Acta Pharmacol. Sin. 38, 754–763 (2017)</ref-fulltext>
<ce:source-text>Luan, X., et al.: Engineering exosomes as refined biological nanoplatforms for drug delivery. Acta Pharmacol. Sin. 38, 754–763 (2017)</ce:source-text>
</reference>
<reference seq="228">
<ref-info>
<ref-title>
<ref-titletext-english>Treatment of brain metastases</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.</ce:initials>
<ce:surname>Lin</ce:surname>
<ce:given-name>X.</ce:given-name>
</author>
<author seq="2">
<ce:initials>L.M.</ce:initials>
<ce:surname>DeAngelis</ce:surname>
<ce:given-name>L.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Oncol.</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>33</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3475</first-page>
<last-page>3484</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Lin, X., DeAngelis, L.M.: Treatment of brain metastases. J. Clin. Oncol. 33, 3475–3484 (2015)</ref-fulltext>
<ce:source-text>Lin, X., DeAngelis, L.M.: Treatment of brain metastases. J. Clin. Oncol. 33, 3475–3484 (2015)</ce:source-text>
</reference>
<reference seq="229">
<ref-info>
<ref-title>
<ref-titletext-english>A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Tian</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Biomaterials</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>35</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2383</first-page>
<last-page>2390</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Tian, Y., et al.: A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. Biomaterials. 35, 2383–2390 (2014)</ref-fulltext>
<ce:source-text>Tian, Y., et al.: A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. Biomaterials. 35, 2383–2390 (2014)</ce:source-text>
</reference>
<reference seq="230">
<ref-info>
<ref-title>
<ref-titletext-english>Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Kamerkar</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>546</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>498</first-page>
<last-page>503</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kamerkar, S., et al.: Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. Nature. 546, 498–503 (2017)</ref-fulltext>
<ce:source-text>Kamerkar, S., et al.: Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. Nature. 546, 498–503 (2017)</ce:source-text>
</reference>
<reference seq="231">
<ref-info>
<ref-title>
<ref-titletext-english>Exosomal formulation of anthocyanidins against multiple cancer types</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Munagala</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Lett.</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>393</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>94</first-page>
<last-page>102</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Munagala, R., et al.: Exosomal formulation of anthocyanidins against multiple cancer types. Cancer Lett. 393, 94–102 (2017)</ref-fulltext>
<ce:source-text>Munagala, R., et al.: Exosomal formulation of anthocyanidins against multiple cancer types. Cancer Lett. 393, 94–102 (2017)</ce:source-text>
</reference>
</bibliography>
</tail>
</bibrecord>
<bibrecord>
<item-info>
<status state="new" stage="S300" />
<itemidlist>
<ce:doi>10.1007/978-3-031-09518-4_4</ce:doi>
<itemid idtype="TPB-ID">9783031095184</itemid>
</itemidlist>
</item-info>
<head>
<citation-info>
<citation-type code="ch" />
<citation-language xml:lang="ENG" />
<abstract-language xml:lang="ENG" />
<author-keywords>
<author-keyword>Cancer metastasis</author-keyword>
<author-keyword>Epithelial-mesenchymal transition</author-keyword>
<author-keyword>Metastatic niche</author-keyword>
<author-keyword>Colonization</author-keyword>
<author-keyword>Dormancy</author-keyword>
<author-keyword>Immunotherapy</author-keyword>
<author-keyword>Cancer metabolism</author-keyword>
</author-keywords>
</citation-info>
<citation-title>
<titletext xml:lang="ENG" original="y">Targeting Metastatic Disease: Challenges and New Opportunities</titletext>
</citation-title>
<author-group seq="1">
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Hu</ce:surname>
<ce:given-name>Haitian</ce:given-name>
</author>
<author seq="2">
<ce:initials>H.</ce:initials>
<ce:surname>Zheng</ce:surname>
<ce:given-name>Hanqiu</ce:given-name>
</author>
<affiliation>
<organization>Department of Basic Medical Sciences</organization>
<organization>School of Medicine</organization>
<organization>Tsinghua University</organization>
<city>Beijing</city>
<country iso-code="CHN" />
<ce:source-text>Department of Basic Medical Sciences, School of Medicine, Tsinghua University, Beijing, China</ce:source-text>
</affiliation>
</author-group>
<author-group seq="2">
<author seq="1">
<ce:initials>Z.</ce:initials>
<ce:surname>Hu</ce:surname>
<ce:given-name>Zeping</ce:given-name>
</author>
<affiliation>
<organization>School of Pharmaceutical Sciences</organization>
<organization>Tsinghua University</organization>
<city>Beijing</city>
<country iso-code="CHN" />
<ce:source-text>School of Pharmaceutical Sciences, Tsinghua University, Beijing, China</ce:source-text>
</affiliation>
</author-group>
<abstracts>
<abstract xml:lang="ENG" original="y">
<publishercopyright>© Springer Nature Switzerland AG 2022</publishercopyright>
<ce:para>Metastasis is the major cause of cancerassociated deaths in most cancers. Research in the past two decades revealed the complexity of metastasis process. Metastasis involved not only tumor-intrinsic signaling, but often their interactions with tumor microenvironment composed of extracellular matrix and stromal cells including fibroblast, endothelial cells, macrophages etc. Tumor immune environment and cancer metabolism shunting also contribute to metastasis cascade. Lagging this mechanistic understanding of metastatic cascade is the scarce of effective therapeutic options specifically designed for metastatic patients. A few successful treatment examples include bisphosphonate and denosumab against bone metastasis, immune checkpoint inhibitors for certain metastatic cancer patients. In this chapter, we will discuss the approved therapeutic agents and procedures for metastatic patients and discuss the current progress on metastasis research that could shed light upon future drug development.</ce:para>
</abstract>
</abstracts>
<source type="book" country="USA">
<sourcetitle>The Systemic Effects of Advanced Cancer: A Textbook on Cancer-Associated Cachexia</sourcetitle>
<sourcetitle-abbrev>The Systemic Effects of Advanced Cancer: A Textbook on Cancer-Associated Cachexia</sourcetitle-abbrev>
<isbn type="print" length="13">9783031072727</isbn>
<isbn type="electronic" length="13">9783031095184</isbn>
<volisspag>
<page-information>
<pages>
<first-page>51</first-page>
<last-page>68</last-page>
</pages>
</page-information>
</volisspag>
<publicationyear first="2022" />
<publicationdate>
<year>2022</year>
<month>09</month>
<day>21</day>
</publicationdate>
<website type="item">
<ce:e-address type="url">https://link.springer.com/</ce:e-address>
</website>
<publisher>
<publishername>Springer International Publishing</publishername>
</publisher>
</source>
<enhancement>
<classificationgroup>
<classifications type="ASJC">
<classification>
<classification-code>2700</classification-code>
<classification-code>2400</classification-code>
<classification-code>1300</classification-code>
</classification>
</classifications>
</classificationgroup>
</enhancement>
</head>
<tail>
<bibliography refcount="72">
<reference seq="1">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer statistics, 2020</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.L.</ce:initials>
<ce:surname>Siegel</ce:surname>
<ce:given-name>R.L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>K.D.</ce:initials>
<ce:surname>Miller</ce:surname>
<ce:given-name>K.D.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Jemal</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>CA Cancer J. Clin</ref-sourcetitle>
<ref-publicationyear first="2020" />
<volisspag>
<volume-issue-number>
<vol-first>70</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>7</first-page>
<last-page>30</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Siegel, R.L., Miller, K.D., Jemal, A.: Cancer statistics, 2020. CA Cancer J. Clin. 70(1), 7–30 (2020)</ref-fulltext>
<ce:source-text>Siegel, R.L., Miller, K.D., Jemal, A.: Cancer statistics, 2020. CA Cancer J. Clin. 70(1), 7–30 (2020)</ce:source-text>
</reference>
<reference seq="2">
<ref-info>
<ref-title>
<ref-titletext-english>Cytokines and advanced cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.J.</ce:initials>
<ce:surname>Dunlop</ce:surname>
<ce:given-name>R.J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.W.</ce:initials>
<ce:surname>Campbell</ce:surname>
<ce:given-name>C.W.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Pain Symptom Manag</ref-sourcetitle>
<ref-publicationyear first="2000" />
<volisspag>
<volume-issue-number>
<vol-first>20</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>214</first-page>
<last-page>232</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Dunlop, R.J., Campbell, C.W.: Cytokines and advanced cancer. J. Pain Symptom Manag. 20(3), 214–232 (2000)</ref-fulltext>
<ce:source-text>Dunlop, R.J., Campbell, C.W.: Cytokines and advanced cancer. J. Pain Symptom Manag. 20(3), 214–232 (2000)</ce:source-text>
</reference>
<reference seq="3">
<ref-info>
<ref-authors>
<author seq="1">
<ce:initials>R.E.</ce:initials>
<ce:surname>Coleman</ce:surname>
<ce:given-name>R.E.</ce:given-name>
</author>
<et-al />
</ref-authors>
<ref-sourcetitle>Bone Metastases. Nat. Rev. Dis. Primers.</ref-sourcetitle>
<ref-publicationyear first="2020" />
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>83</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Coleman, R.E., et al.: Bone metastases. Nat. Rev. Dis. Primers. 6(1), 83 (2020)</ref-fulltext>
<ce:source-text>Coleman, R.E., et al.: Bone metastases. Nat. Rev. Dis. Primers. 6(1), 83 (2020)</ce:source-text>
</reference>
<reference seq="4">
<ref-info>
<ref-title>
<ref-titletext-english>Incidence of bone metastases in patients with solid tumors: Analysis of oncology electronic medical records in the United States</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.K.</ce:initials>
<ce:surname>Hernandez</ce:surname>
<ce:given-name>R.K.</ce:given-name>
</author>
<et-al />
</ref-authors>
<ref-sourcetitle>BMC Cancer</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>18</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>44</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hernandez, R.K., et al.: Incidence of bone metastases in patients with solid tumors: Analysis of oncology electronic medical records in the United States. BMC Cancer. 18(1), 44 (2018)</ref-fulltext>
<ce:source-text>Hernandez, R.K., et al.: Incidence of bone metastases in patients with solid tumors: Analysis of oncology electronic medical records in the United States. BMC Cancer. 18(1), 44 (2018)</ce:source-text>
</reference>
<reference seq="5">
<ref-info>
<ref-title>
<ref-titletext-english>Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.E.</ce:initials>
<ce:surname>Coleman</ce:surname>
<ce:given-name>R.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Res</ref-sourcetitle>
<ref-publicationyear first="2006" />
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
<iss-first>20</iss-first>
<part>Part 2</part>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Coleman, R.E.: Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin. Cancer Res. 12(20 Pt 2), 6243s–6249s (2006)</ref-fulltext>
<ce:source-text>Coleman, R.E.: Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin. Cancer Res. 12(20 Pt 2), 6243s–6249s (2006)</ce:source-text>
</reference>
<reference seq="6">
<ref-info>
<ref-title>
<ref-titletext-english>Pathogenesis of myeloma bone disease</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.D.</ce:initials>
<ce:surname>Roodman</ce:surname>
<ce:given-name>G.D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cell. Biochem</ref-sourcetitle>
<ref-publicationyear first="2010" />
<volisspag>
<volume-issue-number>
<vol-first>109</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>283</first-page>
<last-page>291</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Roodman, G.D.: Pathogenesis of myeloma bone disease. J. Cell. Biochem. 109(2), 283–291 (2010)</ref-fulltext>
<ce:source-text>Roodman, G.D.: Pathogenesis of myeloma bone disease. J. Cell. Biochem. 109(2), 283–291 (2010)</ce:source-text>
</reference>
<reference seq="7">
<ref-info>
<ref-title>
<ref-titletext-english>Skeletal complications of malignancy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.E.</ce:initials>
<ce:surname>Coleman</ce:surname>
<ce:given-name>R.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer</ref-sourcetitle>
<ref-publicationyear first="1997" />
<volisspag>
<volume-issue-number>
<vol-first>80</vol-first>
<iss-first>8</iss-first>
<suppl>Supplement</suppl>
</volume-issue-number>
<page-information>
<pages>
<first-page>1588</first-page>
<last-page>1594</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Coleman, R.E.: Skeletal complications of malignancy. Cancer. 80(8 Suppl), 1588–1594 (1997)</ref-fulltext>
<ce:source-text>Coleman, R.E.: Skeletal complications of malignancy. Cancer. 80(8 Suppl), 1588–1594 (1997)</ce:source-text>
</reference>
<reference seq="8">
<ref-info>
<ref-title>
<ref-titletext-english>The distribution of secondary growths in cancer of the breast. 1889</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Paget</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Metastasis Rev</ref-sourcetitle>
<ref-publicationyear first="1989" />
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>98</first-page>
<last-page>101</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Paget, S.: The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev. 8(2), 98–101 (1989)</ref-fulltext>
<ce:source-text>Paget, S.: The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev. 8(2), 98–101 (1989)</ce:source-text>
</reference>
<reference seq="9">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer to bone: A fatal attraction</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.N.</ce:initials>
<ce:surname>Weilbaecher</ce:surname>
<ce:given-name>K.N.</ce:given-name>
</author>
<author seq="2">
<ce:initials>T.A.</ce:initials>
<ce:surname>Guise</ce:surname>
<ce:given-name>T.A.</ce:given-name>
</author>
<author seq="3">
<ce:initials>L.K.</ce:initials>
<ce:surname>McCauley</ce:surname>
<ce:given-name>L.K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Cancer</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>11</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>411</first-page>
<last-page>425</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Weilbaecher, K.N., Guise, T.A., McCauley, L.K.: Cancer to bone: A fatal attraction. Nat. Rev. Cancer. 11(6), 411–425 (2011)</ref-fulltext>
<ce:source-text>Weilbaecher, K.N., Guise, T.A., McCauley, L.K.: Cancer to bone: A fatal attraction. Nat. Rev. Cancer. 11(6), 411–425 (2011)</ce:source-text>
</reference>
<reference seq="10">
<ref-info>
<ref-title>
<ref-titletext-english>Understanding the bone in cancer metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Fornetti</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>A.L.</ce:initials>
<ce:surname>Welm</ce:surname>
<ce:given-name>A.L.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.A.</ce:initials>
<ce:surname>Stewart</ce:surname>
<ce:given-name>S.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Bone Miner. Res</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>33</vol-first>
<iss-first>12</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2099</first-page>
<last-page>2113</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Fornetti, J., Welm, A.L., Stewart, S.A.: Understanding the bone in cancer metastasis. J. Bone Miner. Res. 33(12), 2099–2113 (2018)</ref-fulltext>
<ce:source-text>Fornetti, J., Welm, A.L., Stewart, S.A.: Understanding the bone in cancer metastasis. J. Bone Miner. Res. 33(12), 2099–2113 (2018)</ce:source-text>
</reference>
<reference seq="11">
<ref-info>
<ref-title>
<ref-titletext-english>Cellular and molecular mechanisms of bone remodeling</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.J.</ce:initials>
<ce:surname>Raggatt</ce:surname>
<ce:given-name>L.J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>N.C.</ce:initials>
<ce:surname>Partridge</ce:surname>
<ce:given-name>N.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Biol. Chem</ref-sourcetitle>
<ref-publicationyear first="2010" />
<volisspag>
<volume-issue-number>
<vol-first>285</vol-first>
<iss-first>33</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>25103</first-page>
<last-page>25108</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Raggatt, L.J., Partridge, N.C.: Cellular and molecular mechanisms of bone remodeling. J. Biol. Chem. 285(33), 25103–25108 (2010)</ref-fulltext>
<ce:source-text>Raggatt, L.J., Partridge, N.C.: Cellular and molecular mechanisms of bone remodeling. J. Biol. Chem. 285(33), 25103–25108 (2010)</ce:source-text>
</reference>
<reference seq="12">
<ref-info>
<ref-title>
<ref-titletext-english>Breast cancer cells interact with osteoblasts to support osteoclast formation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.J.</ce:initials>
<ce:surname>Thomas</ce:surname>
<ce:given-name>R.J.</ce:given-name>
</author>
<et-al />
</ref-authors>
<ref-sourcetitle>Endocrinology</ref-sourcetitle>
<ref-publicationyear first="1999" />
<volisspag>
<volume-issue-number>
<vol-first>140</vol-first>
<iss-first>10</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>4451</first-page>
<last-page>4458</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Thomas, R.J., et al.: Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology. 140(10), 4451–4458 (1999)</ref-fulltext>
<ce:source-text>Thomas, R.J., et al.: Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology. 140(10), 4451–4458 (1999)</ce:source-text>
</reference>
<reference seq="13">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.</ce:initials>
<ce:surname>Sethi</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
<et-al />
</ref-authors>
<ref-sourcetitle>Cancer Cell</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>19</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>192</first-page>
<last-page>205</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sethi, N., et al.: Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. Cancer Cell. 19(2), 192–205 (2011)</ref-fulltext>
<ce:source-text>Sethi, N., et al.: Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. Cancer Cell. 19(2), 192–205 (2011)</ce:source-text>
</reference>
<reference seq="14">
<ref-info>
<ref-title>
<ref-titletext-english>TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.J.</ce:initials>
<ce:surname>Yin</ce:surname>
<ce:given-name>J.J.</ce:given-name>
</author>
<et-al />
</ref-authors>
<ref-sourcetitle>J. Clin. Invest</ref-sourcetitle>
<ref-publicationyear first="1999" />
<volisspag>
<volume-issue-number>
<vol-first>103</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>197</first-page>
<last-page>206</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Yin, J.J., et al.: TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J. Clin. Invest. 103(2), 197–206 (1999)</ref-fulltext>
<ce:source-text>Yin, J.J., et al.: TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J. Clin. Invest. 103(2), 197–206 (1999)</ce:source-text>
</reference>
<reference seq="15">
<ref-info>
<ref-title>
<ref-titletext-english>Metastasis to bone: Causes, consequences and therapeutic opportunities</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.R.</ce:initials>
<ce:surname>Mundy</ce:surname>
<ce:given-name>G.R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Cancer</ref-sourcetitle>
<ref-publicationyear first="2002" />
<volisspag>
<volume-issue-number>
<vol-first>2</vol-first>
<iss-first>8</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>584</first-page>
<last-page>593</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mundy, G.R.: Metastasis to bone: Causes, consequences and therapeutic opportunities. Nat. Rev. Cancer. 2(8), 584–593 (2002)</ref-fulltext>
<ce:source-text>Mundy, G.R.: Metastasis to bone: Causes, consequences and therapeutic opportunities. Nat. Rev. Cancer. 2(8), 584–593 (2002)</ce:source-text>
</reference>
<reference seq="16">
<ref-info>
<ref-title>
<ref-titletext-english>Therapeutic strategies to target TGF-beta in the treatment of bone metastases</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.T.</ce:initials>
<ce:surname>Buijs</ce:surname>
<ce:given-name>J.T.</ce:given-name>
</author>
<author seq="2">
<ce:initials>P.</ce:initials>
<ce:surname>Juarez</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
<author seq="3">
<ce:initials>T.A.</ce:initials>
<ce:surname>Guise</ce:surname>
<ce:given-name>T.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Curr. Pharm. Biotechnol</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
<iss-first>12</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2121</first-page>
<last-page>2137</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Buijs, J.T., Juarez, P., Guise, T.A.: Therapeutic strategies to target TGF-beta in the treatment of bone metastases. Curr. Pharm. Biotechnol. 12(12), 2121–2137 (2011)</ref-fulltext>
<ce:source-text>Buijs, J.T., Juarez, P., Guise, T.A.: Therapeutic strategies to target TGF-beta in the treatment of bone metastases. Curr. Pharm. Biotechnol. 12(12), 2121–2137 (2011)</ce:source-text>
</reference>
<reference seq="17">
<ref-info>
<ref-title>
<ref-titletext-english>Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized, double-blind study</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.T.</ce:initials>
<ce:surname>Stopeck</ce:surname>
<ce:given-name>A.T.</ce:given-name>
</author>
<et-al />
</ref-authors>
<ref-sourcetitle>J. Clin. Oncol</ref-sourcetitle>
<ref-publicationyear first="2010" />
<volisspag>
<volume-issue-number>
<vol-first>28</vol-first>
<iss-first>35</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>5132</first-page>
<last-page>5139</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Stopeck, A.T., et al.: Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized, double-blind study. J. Clin. Oncol. 28(35), 5132–5139 (2010)</ref-fulltext>
<ce:source-text>Stopeck, A.T., et al.: Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized, double-blind study. J. Clin. Oncol. 28(35), 5132–5139 (2010)</ce:source-text>
</reference>
<reference seq="18">
<ref-info>
<ref-title>
<ref-titletext-english>Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.N.</ce:initials>
<ce:surname>Hortobagyi</ce:surname>
<ce:given-name>G.N.</ce:given-name>
</author>
<et-al />
</ref-authors>
<ref-sourcetitle>N. Engl. J. Med</ref-sourcetitle>
<ref-publicationyear first="1996" />
<volisspag>
<volume-issue-number>
<vol-first>335</vol-first>
<iss-first>24</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1785</first-page>
<last-page>1791</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hortobagyi, G.N., et al.: Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N. Engl. J. Med. 335(24), 1785–1791 (1996)</ref-fulltext>
<ce:source-text>Hortobagyi, G.N., et al.: Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N. Engl. J. Med. 335(24), 1785–1791 (1996)</ce:source-text>
</reference>
<reference seq="19">
<ref-info>
<ref-title>
<ref-titletext-english>Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.R.</ce:initials>
<ce:surname>Berenson</ce:surname>
<ce:given-name>J.R.</ce:given-name>
</author>
<et-al />
</ref-authors>
<ref-sourcetitle>N. Engl. J. Med</ref-sourcetitle>
<ref-publicationyear first="1996" />
<volisspag>
<volume-issue-number>
<vol-first>334</vol-first>
<iss-first>8</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>488</first-page>
<last-page>493</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Berenson, J.R., et al.: Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N. Engl. J. Med. 334(8), 488–493 (1996)</ref-fulltext>
<ce:source-text>Berenson, J.R., et al.: Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N. Engl. J. Med. 334(8), 488–493 (1996)</ce:source-text>
</reference>
<reference seq="20">
<ref-info>
<ref-title>
<ref-titletext-english>Imaging characteristic analysis of metastatic spine lesions from breast, prostate, lung, and renal cell carcinomas for surgical planning: Osteolytic versus osteoblastic</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.A.</ce:initials>
<ce:surname>Reddington</ce:surname>
<ce:given-name>J.A.</ce:given-name>
</author>
<et-al />
</ref-authors>
<ref-sourcetitle>Surg. Neurol. Int</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
<suppl>Supplement 13</suppl>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Reddington, J.A., et al.: Imaging characteristic analysis of metastatic spine lesions from breast, prostate, lung, and renal cell carcinomas for surgical planning: osteolytic versus osteoblastic. Surg. Neurol. Int. 7(Suppl 13), S361–S365 (2016)</ref-fulltext>
<ce:source-text>Reddington, J.A., et al.: Imaging characteristic analysis of metastatic spine lesions from breast, prostate, lung, and renal cell carcinomas for surgical planning: osteolytic versus osteoblastic. Surg. Neurol. Int. 7(Suppl 13), S361–S365 (2016)</ce:source-text>
</reference>
<reference seq="21">
<ref-info>
<ref-title>
<ref-titletext-english>Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.E.</ce:initials>
<ce:surname>Brown</ce:surname>
<ce:given-name>J.E.</ce:given-name>
</author>
<et-al />
</ref-authors>
<ref-sourcetitle>J. Natl. Cancer Inst</ref-sourcetitle>
<ref-publicationyear first="2005" />
<volisspag>
<volume-issue-number>
<vol-first>97</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>59</first-page>
<last-page>69</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Brown, J.E., et al.: Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J. Natl. Cancer Inst. 97(1), 59–69 (2005)</ref-fulltext>
<ce:source-text>Brown, J.E., et al.: Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J. Natl. Cancer Inst. 97(1), 59–69 (2005)</ce:source-text>
</reference>
<reference seq="22">
<ref-info>
<ref-title>
<ref-titletext-english>Usefulness of radium-223 in patients with bone metastases</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.</ce:initials>
<ce:surname>Gupta</ce:surname>
<ce:given-name>N.</ce:given-name>
</author>
<et-al />
</ref-authors>
<ref-sourcetitle>Proc. (Bayl. Univ. Med. Cent.).</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>30</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>424</first-page>
<last-page>426</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Gupta, N., et al.: Usefulness of radium-223 in patients with bone metastases. Proc. (Bayl. Univ. Med. Cent.). 30(4), 424–426 (2017)</ref-fulltext>
<ce:source-text>Gupta, N., et al.: Usefulness of radium-223 in patients with bone metastases. Proc. (Bayl. Univ. Med. Cent.). 30(4), 424–426 (2017)</ce:source-text>
</reference>
<reference seq="23">
<ref-info>
<ref-title>
<ref-titletext-english>Bone morphogenetic protein 6 in skeletal metastases from prostate cancer and other common human malignancies</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.</ce:initials>
<ce:surname>Autzen</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
<et-al />
</ref-authors>
<ref-sourcetitle>Br. J. Cancer</ref-sourcetitle>
<ref-publicationyear first="1998" />
<volisspag>
<volume-issue-number>
<vol-first>78</vol-first>
<iss-first>9</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1219</first-page>
<last-page>1223</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Autzen, P., et al.: Bone morphogenetic protein 6 in skeletal metastases from prostate cancer and other common human malignancies. Br. J. Cancer. 78(9), 1219–1223 (1998)</ref-fulltext>
<ce:source-text>Autzen, P., et al.: Bone morphogenetic protein 6 in skeletal metastases from prostate cancer and other common human malignancies. Br. J. Cancer. 78(9), 1219–1223 (1998)</ce:source-text>
</reference>
<reference seq="24">
<ref-info>
<ref-title>
<ref-titletext-english>A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.J.</ce:initials>
<ce:surname>Yin</ce:surname>
<ce:given-name>J.J.</ce:given-name>
</author>
<et-al />
</ref-authors>
<ref-sourcetitle>Proc. Natl. Acad. Sci. USA</ref-sourcetitle>
<ref-publicationyear first="2003" />
<volisspag>
<volume-issue-number>
<vol-first>100</vol-first>
<iss-first>19</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>10954</first-page>
<last-page>10959</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Yin, J.J., et al.: A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc. Natl. Acad. Sci. USA. 100(19), 10954–10959 (2003)</ref-fulltext>
<ce:source-text>Yin, J.J., et al.: A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc. Natl. Acad. Sci. USA. 100(19), 10954–10959 (2003)</ce:source-text>
</reference>
<reference seq="25">
<ref-info>
<ref-title>
<ref-titletext-english>Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.B.</ce:initials>
<ce:surname>Nelson</ce:surname>
<ce:given-name>J.B.</ce:given-name>
</author>
<et-al />
</ref-authors>
<ref-sourcetitle>Nat. Med</ref-sourcetitle>
<ref-publicationyear first="1995" />
<volisspag>
<volume-issue-number>
<vol-first>1</vol-first>
<iss-first>9</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>944</first-page>
<last-page>949</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Nelson, J.B., et al.: Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat. Med. 1(9), 944–949 (1995)</ref-fulltext>
<ce:source-text>Nelson, J.B., et al.: Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat. Med. 1(9), 944–949 (1995)</ce:source-text>
</reference>
<reference seq="26">
<ref-info>
<ref-title>
<ref-titletext-english>Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.F.</ce:initials>
<ce:surname>Shariat</ce:surname>
<ce:given-name>S.F.</ce:given-name>
</author>
<et-al />
</ref-authors>
<ref-sourcetitle>J. Clin. Oncol</ref-sourcetitle>
<ref-publicationyear first="2001" />
<volisspag>
<volume-issue-number>
<vol-first>19</vol-first>
<iss-first>11</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2856</first-page>
<last-page>2864</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Shariat, S.F., et al.: Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy. J. Clin. Oncol. 19(11), 2856–2864 (2001)</ref-fulltext>
<ce:source-text>Shariat, S.F., et al.: Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy. J. Clin. Oncol. 19(11), 2856–2864 (2001)</ce:source-text>
</reference>
<reference seq="27">
<ref-info>
<ref-title>
<ref-titletext-english>Differences in tumor microenvironment dictate T helper lineage polarization and response to immune checkpoint therapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Jiao</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<et-al />
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>179</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1177</first-page>
<last-page>1190</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Jiao, S., et al.: Differences in tumor microenvironment dictate T helper lineage polarization and response to immune checkpoint therapy. Cell. 179(5), 1177–1190 e13 (2019)</ref-fulltext>
<ce:source-text>Jiao, S., et al.: Differences in tumor microenvironment dictate T helper lineage polarization and response to immune checkpoint therapy. Cell. 179(5), 1177–1190 e13 (2019)</ce:source-text>
</reference>
<reference seq="28">
<ref-info>
<ref-title>
<ref-titletext-english>Osteoblasts in prostate cancer metastasis to bone</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.J.</ce:initials>
<ce:surname>Logothetis</ce:surname>
<ce:given-name>C.J.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.H.</ce:initials>
<ce:surname>Lin</ce:surname>
<ce:given-name>S.H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Cancer</ref-sourcetitle>
<ref-publicationyear first="2005" />
<volisspag>
<volume-issue-number>
<vol-first>5</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>21</first-page>
<last-page>28</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Logothetis, C.J., Lin, S.H.: Osteoblasts in prostate cancer metastasis to bone. Nat. Rev. Cancer. 5(1), 21–28 (2005)</ref-fulltext>
<ce:source-text>Logothetis, C.J., Lin, S.H.: Osteoblasts in prostate cancer metastasis to bone. Nat. Rev. Cancer. 5(1), 21–28 (2005)</ce:source-text>
</reference>
<reference seq="29">
<ref-info>
<ref-title>
<ref-titletext-english>Enhanced expression of parathyroid hormone-related protein in prostate cancer as compared with benign prostatic hyperplasia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Asadi</ce:surname>
<ce:given-name>F.</ce:given-name>
</author>
<et-al />
</ref-authors>
<ref-sourcetitle>Hum. Pathol</ref-sourcetitle>
<ref-publicationyear first="1996" />
<volisspag>
<volume-issue-number>
<vol-first>27</vol-first>
<iss-first>12</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1319</first-page>
<last-page>1323</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Asadi, F., et al.: Enhanced expression of parathyroid hormone-related protein in prostate cancer as compared with benign prostatic hyperplasia. Hum. Pathol. 27(12), 1319–1323 (1996)</ref-fulltext>
<ce:source-text>Asadi, F., et al.: Enhanced expression of parathyroid hormone-related protein in prostate cancer as compared with benign prostatic hyperplasia. Hum. Pathol. 27(12), 1319–1323 (1996)</ce:source-text>
</reference>
<reference seq="30">
<ref-info>
<ref-title>
<ref-titletext-english>A N-terminal PTHrP peptide fragment void of a PTH/PTHrP-receptor binding domain activates cardiac ET(A) receptors</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.D.</ce:initials>
<ce:surname>Schluter</ce:surname>
<ce:given-name>K.D.</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.</ce:initials>
<ce:surname>Katzer</ce:surname>
<ce:given-name>C.</ce:given-name>
</author>
<author seq="3">
<ce:initials>H.M.</ce:initials>
<ce:surname>Piper</ce:surname>
<ce:given-name>H.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Br. J. Pharmacol</ref-sourcetitle>
<ref-publicationyear first="2001" />
<volisspag>
<volume-issue-number>
<vol-first>132</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>427</first-page>
<last-page>432</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Schluter, K.D., Katzer, C., Piper, H.M.: A N-terminal PTHrP peptide fragment void of a PTH/PTHrP-receptor binding domain activates cardiac ET(A) receptors. Br. J. Pharmacol. 132(2), 427–432 (2001)</ref-fulltext>
<ce:source-text>Schluter, K.D., Katzer, C., Piper, H.M.: A N-terminal PTHrP peptide fragment void of a PTH/PTHrP-receptor binding domain activates cardiac ET(A) receptors. Br. J. Pharmacol. 132(2), 427–432 (2001)</ce:source-text>
</reference>
<reference seq="31">
<ref-info>
<ref-title>
<ref-titletext-english>Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone microenvironment in vivo</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.D.</ce:initials>
<ce:surname>Ottewell</ce:surname>
<ce:given-name>P.D.</ce:given-name>
</author>
<et-al />
</ref-authors>
<ref-sourcetitle>Clin. Cancer Res</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>20</vol-first>
<iss-first>11</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2922</first-page>
<last-page>2932</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ottewell, P.D., et al.: Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone microenvironment in vivo. Clin. Cancer Res. 20(11), 2922–2932 (2014)</ref-fulltext>
<ce:source-text>Ottewell, P.D., et al.: Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone microenvironment in vivo. Clin. Cancer Res. 20(11), 2922–2932 (2014)</ce:source-text>
</reference>
<reference seq="32">
<ref-info>
<ref-title>
<ref-titletext-english>Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.E.</ce:initials>
<ce:surname>Wright</ce:surname>
<ce:given-name>L.E.</ce:given-name>
</author>
<et-al />
</ref-authors>
<ref-sourcetitle>Oncotarget</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>8406</first-page>
<last-page>8419</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wright, L.E., et al.: Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo. Oncotarget. 8(5), 8406–8419 (2017)</ref-fulltext>
<ce:source-text>Wright, L.E., et al.: Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo. Oncotarget. 8(5), 8406–8419 (2017)</ce:source-text>
</reference>
<reference seq="33">
<ref-info>
<ref-title>
<ref-titletext-english>Castration-induced bone loss triggers growth of disseminated prostate cancer cells in bone</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.D.</ce:initials>
<ce:surname>Ottewell</ce:surname>
<ce:given-name>P.D.</ce:given-name>
</author>
<et-al />
</ref-authors>
<ref-sourcetitle>Endocr. Relat. Cancer</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>21</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>769</first-page>
<last-page>781</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ottewell, P.D., et al.: Castration-induced bone loss triggers growth of disseminated prostate cancer cells in bone. Endocr. Relat. Cancer. 21(5), 769–781 (2014)</ref-fulltext>
<ce:source-text>Ottewell, P.D., et al.: Castration-induced bone loss triggers growth of disseminated prostate cancer cells in bone. Endocr. Relat. Cancer. 21(5), 769–781 (2014)</ce:source-text>
</reference>
<reference seq="34">
<ref-info>
<ref-title>
<ref-titletext-english>Understanding cachexia in the context of metastatic progression</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.K.</ce:initials>
<ce:surname>Biswas</ce:surname>
<ce:given-name>A.K.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Acharyya</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Cancer</ref-sourcetitle>
<ref-publicationyear first="2020" />
<volisspag>
<volume-issue-number>
<vol-first>20</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>274</first-page>
<last-page>284</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Biswas, A.K., Acharyya, S.: Understanding cachexia in the context of metastatic progression. Nat. Rev. Cancer. 20(5), 274–284 (2020)</ref-fulltext>
<ce:source-text>Biswas, A.K., Acharyya, S.: Understanding cachexia in the context of metastatic progression. Nat. Rev. Cancer. 20(5), 274–284 (2020)</ce:source-text>
</reference>
<reference seq="35">
<ref-info>
<ref-title>
<ref-titletext-english>Definition and classification of cancer cachexia: An international consensus</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Fearon</ce:surname>
<ce:given-name>K.</ce:given-name>
</author>
<et-al />
</ref-authors>
<ref-sourcetitle>Lancet Oncol</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>489</first-page>
<last-page>495</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Fearon, K., et al.: Definition and classification of cancer cachexia: An international consensus. Lancet Oncol. 12(5), 489–495 (2011)</ref-fulltext>
<ce:source-text>Fearon, K., et al.: Definition and classification of cancer cachexia: An international consensus. Lancet Oncol. 12(5), 489–495 (2011)</ce:source-text>
</reference>
<reference seq="36">
<ref-info>
<ref-title>
<ref-titletext-english>Prevalence, incidence and clinical impact of cachexia: Facts and numbers-update 2014</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>von Haehling</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.D.</ce:initials>
<ce:surname>Anker</ce:surname>
<ce:given-name>S.D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>5</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>261</first-page>
<last-page>263</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>von Haehling, S., Anker, S.D.: Prevalence, incidence and clinical impact of cachexia: facts and numbers-update 2014. J. Cachexia. Sarcopenia Muscle. 5(4), 261–263 (2014)</ref-fulltext>
<ce:source-text>von Haehling, S., Anker, S.D.: Prevalence, incidence and clinical impact of cachexia: facts and numbers-update 2014. J. Cachexia. Sarcopenia Muscle. 5(4), 261–263 (2014)</ce:source-text>
</reference>
<reference seq="37">
<ref-info>
<ref-title>
<ref-titletext-english>An epidemiological survey of cachexia in advanced cancer patients and analysis on its diagnostic and treatment status</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Sun</ce:surname>
<ce:given-name>L.</ce:given-name>
</author>
<author seq="2">
<ce:initials>X.Q.</ce:initials>
<ce:surname>Quan</ce:surname>
<ce:given-name>X.Q.</ce:given-name>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Yu</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nutr. Cancer</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>67</vol-first>
<iss-first>7</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1056</first-page>
<last-page>1062</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sun, L., Quan, X.Q., Yu, S.: An epidemiological survey of cachexia in advanced cancer patients and analysis on its diagnostic and treatment status. Nutr. Cancer. 67(7), 1056–1062 (2015)</ref-fulltext>
<ce:source-text>Sun, L., Quan, X.Q., Yu, S.: An epidemiological survey of cachexia in advanced cancer patients and analysis on its diagnostic and treatment status. Nutr. Cancer. 67(7), 1056–1062 (2015)</ce:source-text>
</reference>
<reference seq="38">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer-associated cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>V.E.</ce:initials>
<ce:surname>Baracos</ce:surname>
<ce:given-name>V.E.</ce:given-name>
</author>
<et-al />
</ref-authors>
<ref-sourcetitle>Nat. Rev. Dis. Primers</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>4</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>17105</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Baracos, V.E., et al.: Cancer-associated cachexia. Nat. Rev. Dis. Primers. 4, 17105 (2018)</ref-fulltext>
<ce:source-text>Baracos, V.E., et al.: Cancer-associated cachexia. Nat. Rev. Dis. Primers. 4, 17105 (2018)</ce:source-text>
</reference>
<reference seq="39">
<ref-info>
<ref-title>
<ref-titletext-english>Skeletal muscle mass and muscle strength in relation to lower-extremity performance in older men and women</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Visser</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<et-al />
</ref-authors>
<ref-sourcetitle>J. Am. Geriatr. Soc</ref-sourcetitle>
<ref-publicationyear first="2000" />
<volisspag>
<volume-issue-number>
<vol-first>48</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>381</first-page>
<last-page>386</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Visser, M., et al.: Skeletal muscle mass and muscle strength in relation to lower-extremity performance in older men and women. J. Am. Geriatr. Soc. 48(4), 381–386 (2000)</ref-fulltext>
<ce:source-text>Visser, M., et al.: Skeletal muscle mass and muscle strength in relation to lower-extremity performance in older men and women. J. Am. Geriatr. Soc. 48(4), 381–386 (2000)</ce:source-text>
</reference>
<reference seq="40">
<ref-info>
<ref-title>
<ref-titletext-english>Strength, but not muscle mass, is associated with mortality in the health, aging and body composition study cohort</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.B.</ce:initials>
<ce:surname>Newman</ce:surname>
<ce:given-name>A.B.</ce:given-name>
</author>
<et-al />
</ref-authors>
<ref-sourcetitle>J. Gerontol. A Biol. Sci. Med. Sci</ref-sourcetitle>
<ref-publicationyear first="2006" />
<volisspag>
<volume-issue-number>
<vol-first>61</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>72</first-page>
<last-page>77</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Newman, A.B., et al.: Strength, but not muscle mass, is associated with mortality in the health, aging and body composition study cohort. J. Gerontol. A Biol. Sci. Med. Sci. 61(1), 72–77 (2006)</ref-fulltext>
<ce:source-text>Newman, A.B., et al.: Strength, but not muscle mass, is associated with mortality in the health, aging and body composition study cohort. J. Gerontol. A Biol. Sci. Med. Sci. 61(1), 72–77 (2006)</ce:source-text>
</reference>
<reference seq="41">
<ref-info>
<ref-title>
<ref-titletext-english>The loss of skeletal muscle strength, mass, and quality in older adults: The health, aging and body composition study</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.H.</ce:initials>
<ce:surname>Goodpaster</ce:surname>
<ce:given-name>B.H.</ce:given-name>
</author>
<et-al />
</ref-authors>
<ref-sourcetitle>J. Gerontol. a Biol. Sci. Med. Sci</ref-sourcetitle>
<ref-publicationyear first="2006" />
<volisspag>
<volume-issue-number>
<vol-first>61</vol-first>
<iss-first>10</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1059</first-page>
<last-page>1064</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Goodpaster, B.H., et al.: The loss of skeletal muscle strength, mass, and quality in older adults: The health, aging and body composition study. J. Gerontol. A Biol. Sci. Med. Sci. 61(10), 1059–1064 (2006)</ref-fulltext>
<ce:source-text>Goodpaster, B.H., et al.: The loss of skeletal muscle strength, mass, and quality in older adults: The health, aging and body composition study. J. Gerontol. A Biol. Sci. Med. Sci. 61(10), 1059–1064 (2006)</ce:source-text>
</reference>
<reference seq="42">
<ref-info>
<ref-title>
<ref-titletext-english>Muscle strength in breast cancer patients receiving different treatment regimes</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>O.</ce:initials>
<ce:surname>Klassen</ce:surname>
<ce:given-name>O.</ce:given-name>
</author>
<et-al />
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>305</first-page>
<last-page>316</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Klassen, O., et al.: Muscle strength in breast cancer patients receiving different treatment regimes. J. Cachexia. Sarcopenia Muscle. 8(2), 305–316 (2017)</ref-fulltext>
<ce:source-text>Klassen, O., et al.: Muscle strength in breast cancer patients receiving different treatment regimes. J. Cachexia. Sarcopenia Muscle. 8(2), 305–316 (2017)</ce:source-text>
</reference>
<reference seq="43">
<ref-info>
<ref-title>
<ref-titletext-english>Physical activity and fitness in women with metastatic breast cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Yee</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<et-al />
</ref-authors>
<ref-sourcetitle>J. Cancer Surviv</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>647</first-page>
<last-page>656</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Yee, J., et al.: Physical activity and fitness in women with metastatic breast cancer. J. Cancer Surviv. 8(4), 647–656 (2014)</ref-fulltext>
<ce:source-text>Yee, J., et al.: Physical activity and fitness in women with metastatic breast cancer. J. Cancer Surviv. 8(4), 647–656 (2014)</ce:source-text>
</reference>
<reference seq="44">
<ref-info>
<ref-title>
<ref-titletext-english>Impact of primary breast cancer therapy on energetic capacity and body composition. Breast Cancer Res</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.J.</ce:initials>
<ce:surname>Ballinger</ce:surname>
<ce:given-name>T.J.</ce:given-name>
</author>
<et-al />
</ref-authors>
<ref-sourcetitle>Treat</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>172</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>445</first-page>
<last-page>452</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ballinger, T.J., et al.: Impact of primary breast cancer therapy on energetic capacity and body composition. Breast Cancer Res. Treat. 172(2), 445–452 (2018)</ref-fulltext>
<ce:source-text>Ballinger, T.J., et al.: Impact of primary breast cancer therapy on energetic capacity and body composition. Breast Cancer Res. Treat. 172(2), 445–452 (2018)</ce:source-text>
</reference>
<reference seq="45">
<ref-info>
<ref-title>
<ref-titletext-english>Correlation between muscle mass and handgrip strength in digestive cancer patients undergoing chemotherapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Moreau</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<et-al />
</ref-authors>
<ref-sourcetitle>Cancer Med</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>8</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3677</first-page>
<last-page>3684</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Moreau, J., et al.: Correlation between muscle mass and handgrip strength in digestive cancer patients undergoing chemotherapy. Cancer Med. 8(8), 3677–3684 (2019)</ref-fulltext>
<ce:source-text>Moreau, J., et al.: Correlation between muscle mass and handgrip strength in digestive cancer patients undergoing chemotherapy. Cancer Med. 8(8), 3677–3684 (2019)</ce:source-text>
</reference>
<reference seq="46">
<ref-info>
<ref-title>
<ref-titletext-english>Reduced muscle strength and functional performance in men with prostate cancer undergoing androgen suppression: A comprehensive cross-sectional investigation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.A.</ce:initials>
<ce:surname>Galvao</ce:surname>
<ce:given-name>D.A.</ce:given-name>
</author>
<et-al />
</ref-authors>
<ref-sourcetitle>Prostate Cancer Prostatic Dis</ref-sourcetitle>
<ref-publicationyear first="2009" />
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>198</first-page>
<last-page>203</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Galvao, D.A., et al.: Reduced muscle strength and functional performance in men with prostate cancer undergoing androgen suppression: A comprehensive cross-sectional investigation. Prostate Cancer Prostatic Dis. 12(2), 198–203 (2009)</ref-fulltext>
<ce:source-text>Galvao, D.A., et al.: Reduced muscle strength and functional performance in men with prostate cancer undergoing androgen suppression: A comprehensive cross-sectional investigation. Prostate Cancer Prostatic Dis. 12(2), 198–203 (2009)</ce:source-text>
</reference>
<reference seq="47">
<ref-info>
<ref-title>
<ref-titletext-english>Loss of skeletal muscle during systemic chemotherapy is prognostic of poor survival in patients with foregut cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.E.</ce:initials>
<ce:surname>Daly</ce:surname>
<ce:given-name>L.E.</ce:given-name>
</author>
<et-al />
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>315</first-page>
<last-page>325</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Daly, L.E., et al.: Loss of skeletal muscle during systemic chemotherapy is prognostic of poor survival in patients with foregut cancer. J. Cachexia. Sarcopenia Muscle. 9(2), 315–325 (2018)</ref-fulltext>
<ce:source-text>Daly, L.E., et al.: Loss of skeletal muscle during systemic chemotherapy is prognostic of poor survival in patients with foregut cancer. J. Cachexia. Sarcopenia Muscle. 9(2), 315–325 (2018)</ce:source-text>
</reference>
<reference seq="48">
<ref-info>
<ref-title>
<ref-titletext-english>Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: Results from a placebo-controlled study</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Antoun</ce:surname>
<ce:given-name>S.</ce:given-name>
</author>
<et-al />
</ref-authors>
<ref-sourcetitle>J. Clin. Oncol</ref-sourcetitle>
<ref-publicationyear first="2010" />
<volisspag>
<volume-issue-number>
<vol-first>28</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1054</first-page>
<last-page>1060</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Antoun, S., et al.: Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study. J. Clin. Oncol. 28(6), 1054–1060 (2010)</ref-fulltext>
<ce:source-text>Antoun, S., et al.: Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study. J. Clin. Oncol. 28(6), 1054–1060 (2010)</ce:source-text>
</reference>
<reference seq="49">
<ref-info>
<ref-title>
<ref-titletext-english>Chronic treatment with multi-kinase inhibitors causes differential toxicities on skeletal and cardiac muscles</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.R.</ce:initials>
<ce:surname>Huot</ce:surname>
<ce:given-name>J.R.</ce:given-name>
</author>
<et-al />
</ref-authors>
<ref-sourcetitle>Cancers (Basel)</ref-sourcetitle>
<ref-publicationyear first="2019" />
<volisspag>
<volume-issue-number>
<vol-first>11</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Huot, J.R., et al., Chronic treatment with multi-kinase inhibitors causes differential toxicities on skeletal and cardiac muscles. Cancers (Basel), 2019. 11(4)</ref-fulltext>
<ce:source-text>Huot, J.R., et al., Chronic treatment with multi-kinase inhibitors causes differential toxicities on skeletal and cardiac muscles. Cancers (Basel), 2019. 11(4)</ce:source-text>
</reference>
<reference seq="50">
<ref-info>
<ref-title>
<ref-titletext-english>Zoledronic acid improves muscle function in healthy mice treated with chemotherapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.A.</ce:initials>
<ce:surname>Hain</ce:surname>
<ce:given-name>B.A.</ce:given-name>
</author>
<et-al />
</ref-authors>
<ref-sourcetitle>J. Bone Miner. Res</ref-sourcetitle>
<ref-publicationyear first="2020" />
<volisspag>
<volume-issue-number>
<vol-first>35</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>368</first-page>
<last-page>381</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hain, B.A., et al.: Zoledronic acid improves muscle function in healthy mice treated with chemotherapy. J. Bone Miner. Res. 35(2), 368–381 (2020)</ref-fulltext>
<ce:source-text>Hain, B.A., et al.: Zoledronic acid improves muscle function in healthy mice treated with chemotherapy. J. Bone Miner. Res. 35(2), 368–381 (2020)</ce:source-text>
</reference>
<reference seq="51">
<ref-info>
<ref-title>
<ref-titletext-english>Skeletal muscle Ca(2+) mishandling: Another effect of bone-to-muscle signaling</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.N.</ce:initials>
<ce:surname>Regan</ce:surname>
<ce:given-name>J.N.</ce:given-name>
</author>
<author seq="2">
<ce:initials>D.L.</ce:initials>
<ce:surname>Waning</ce:surname>
<ce:given-name>D.L.</ce:given-name>
</author>
<author seq="3">
<ce:initials>T.A.</ce:initials>
<ce:surname>Guise</ce:surname>
<ce:given-name>T.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Semin. Cell Dev. Biol</ref-sourcetitle>
<ref-publicationyear first="2016" />
<volisspag>
<volume-issue-number>
<vol-first>49</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>24</first-page>
<last-page>29</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Regan, J.N., Waning, D.L., Guise, T.A.: Skeletal muscle Ca(2+) mishandling: Another effect of bone-to-muscle signaling. Semin. Cell Dev. Biol. 49, 24–29 (2016)</ref-fulltext>
<ce:source-text>Regan, J.N., Waning, D.L., Guise, T.A.: Skeletal muscle Ca(2+) mishandling: Another effect of bone-to-muscle signaling. Semin. Cell Dev. Biol. 49, 24–29 (2016)</ce:source-text>
</reference>
<reference seq="52">
<ref-info>
<ref-title>
<ref-titletext-english>Endocrine regulation of energy metabolism by the skeleton</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.K.</ce:initials>
<ce:surname>Lee</ce:surname>
<ce:given-name>N.K.</ce:given-name>
</author>
<et-al />
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2007" />
<volisspag>
<volume-issue-number>
<vol-first>130</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>456</first-page>
<last-page>469</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Lee, N.K., et al.: Endocrine regulation of energy metabolism by the skeleton. Cell. 130(3), 456–469 (2007)</ref-fulltext>
<ce:source-text>Lee, N.K., et al.: Endocrine regulation of energy metabolism by the skeleton. Cell. 130(3), 456–469 (2007)</ce:source-text>
</reference>
<reference seq="53">
<ref-info>
<ref-title>
<ref-titletext-english>Circulating undercarboxylated osteocalcin as estimator of cardiovascular and type 2 diabetes risk in metabolic syndrome patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.</ce:initials>
<ce:surname>Riquelme-Gallego</ce:surname>
<ce:given-name>B.</ce:given-name>
</author>
<et-al />
</ref-authors>
<ref-sourcetitle>Sci. Rep</ref-sourcetitle>
<ref-publicationyear first="2020" />
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1840</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Riquelme-Gallego, B., et al.: Circulating undercarboxylated osteocalcin as estimator of cardiovascular and type 2 diabetes risk in metabolic syndrome patients. Sci. Rep. 10(1), 1840 (2020)</ref-fulltext>
<ce:source-text>Riquelme-Gallego, B., et al.: Circulating undercarboxylated osteocalcin as estimator of cardiovascular and type 2 diabetes risk in metabolic syndrome patients. Sci. Rep. 10(1), 1840 (2020)</ce:source-text>
</reference>
<reference seq="54">
<ref-info>
<ref-title>
<ref-titletext-english>Undercarboxylated osteocalcin, muscle strength and indices of bone health in older women</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>I.</ce:initials>
<ce:surname>Levinger</ce:surname>
<ce:given-name>I.</ce:given-name>
</author>
<et-al />
</ref-authors>
<ref-sourcetitle>Bone</ref-sourcetitle>
<ref-publicationyear first="2014" />
<volisspag>
<volume-issue-number>
<vol-first>64</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>8</first-page>
<last-page>12</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Levinger, I., et al.: Undercarboxylated osteocalcin, muscle strength and indices of bone health in older women. Bone. 64, 8–12 (2014)</ref-fulltext>
<ce:source-text>Levinger, I., et al.: Undercarboxylated osteocalcin, muscle strength and indices of bone health in older women. Bone. 64, 8–12 (2014)</ce:source-text>
</reference>
<reference seq="55">
<ref-info>
<ref-title>
<ref-titletext-english>Mechanisms of IGF-1-mediated regulation of skeletal muscle hypertrophy and atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Yoshida</ce:surname>
<ce:given-name>T.</ce:given-name>
</author>
<author seq="2">
<ce:initials>P.</ce:initials>
<ce:surname>Delafontaine</ce:surname>
<ce:given-name>P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2020" />
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
<iss-first>9</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Yoshida, T., Delafontaine, P.: Mechanisms of IGF-1-mediated regulation of skeletal muscle hypertrophy and atrophy. Cell. 9(9) (2020)</ref-fulltext>
<ce:source-text>Yoshida, T., Delafontaine, P.: Mechanisms of IGF-1-mediated regulation of skeletal muscle hypertrophy and atrophy. Cell. 9(9) (2020)</ce:source-text>
</reference>
<reference seq="56">
<ref-info>
<ref-title>
<ref-titletext-english>BMP signaling controls muscle mass</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Sartori</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
<et-al />
</ref-authors>
<ref-sourcetitle>Nat. Genet</ref-sourcetitle>
<ref-publicationyear first="2013" />
<volisspag>
<volume-issue-number>
<vol-first>45</vol-first>
<iss-first>11</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1309</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sartori, R., et al.: BMP signaling controls muscle mass. Nat. Genet. 45(11), 1309 (2013)</ref-fulltext>
<ce:source-text>Sartori, R., et al.: BMP signaling controls muscle mass. Nat. Genet. 45(11), 1309 (2013)</ce:source-text>
</reference>
<reference seq="57">
<ref-info>
<ref-title>
<ref-titletext-english>TGF-beta inhibits muscle differentiation through functional repression of myogenic transcription factors by Smad3</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Liu</ce:surname>
<ce:given-name>D.</ce:given-name>
</author>
<author seq="2">
<ce:initials>B.L.</ce:initials>
<ce:surname>Black</ce:surname>
<ce:given-name>B.L.</ce:given-name>
</author>
<author seq="3">
<ce:initials>R.</ce:initials>
<ce:surname>Derynck</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Genes Dev</ref-sourcetitle>
<ref-publicationyear first="2001" />
<volisspag>
<volume-issue-number>
<vol-first>15</vol-first>
<iss-first>22</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2950</first-page>
<last-page>2966</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Liu, D., Black, B.L., Derynck, R.: TGF-beta inhibits muscle differentiation through functional repression of myogenic transcription factors by Smad3. Genes Dev. 15(22), 2950–2966 (2001)</ref-fulltext>
<ce:source-text>Liu, D., Black, B.L., Derynck, R.: TGF-beta inhibits muscle differentiation through functional repression of myogenic transcription factors by Smad3. Genes Dev. 15(22), 2950–2966 (2001)</ce:source-text>
</reference>
<reference seq="58">
<ref-info>
<ref-title>
<ref-titletext-english>Conditional expression of TGF-beta1 in skeletal muscles causes endomysial fibrosis and myofibers atrophy</ref-titletext-english>
</ref-title>
<itemidlist>
<itemid idtype="ARTNUM">e79356</itemid>
</itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Narola</ce:surname>
<ce:given-name>J.</ce:given-name>
</author>
<et-al />
</ref-authors>
<ref-sourcetitle>Plos One</ref-sourcetitle>
<ref-publicationyear first="2013" />
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>11</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Narola, J., et al.: Conditional expression of TGF-beta1 in skeletal muscles causes endomysial fibrosis and myofibers atrophy. PLoS One. 8(11), e79356 (2013)</ref-fulltext>
<ce:source-text>Narola, J., et al.: Conditional expression of TGF-beta1 in skeletal muscles causes endomysial fibrosis and myofibers atrophy. PLoS One. 8(11), e79356 (2013)</ce:source-text>
</reference>
<reference seq="59">
<ref-info>
<ref-title>
<ref-titletext-english>Transforming growth factor-beta induces skeletal muscle atrophy and fibrosis through the induction of atrogin-1 and scleraxis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.L.</ce:initials>
<ce:surname>Mendias</ce:surname>
<ce:given-name>C.L.</ce:given-name>
</author>
<et-al />
</ref-authors>
<ref-sourcetitle>Muscle Nerve</ref-sourcetitle>
<ref-publicationyear first="2012" />
<volisspag>
<volume-issue-number>
<vol-first>45</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>55</first-page>
<last-page>59</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mendias, C.L., et al.: Transforming growth factor-beta induces skeletal muscle atrophy and fibrosis through the induction of atrogin-1 and scleraxis. Muscle Nerve. 45(1), 55–59 (2012)</ref-fulltext>
<ce:source-text>Mendias, C.L., et al.: Transforming growth factor-beta induces skeletal muscle atrophy and fibrosis through the induction of atrogin-1 and scleraxis. Muscle Nerve. 45(1), 55–59 (2012)</ce:source-text>
</reference>
<reference seq="60">
<ref-info>
<ref-title>
<ref-titletext-english>Aberrant repair and fibrosis development in skeletal muscle. Skelet</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.J.</ce:initials>
<ce:surname>Mann</ce:surname>
<ce:given-name>C.J.</ce:given-name>
</author>
<et-al />
</ref-authors>
<ref-sourcetitle>Muscle</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>1</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>21</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mann, C.J., et al.: Aberrant repair and fibrosis development in skeletal muscle. Skelet. Muscle. 1(1), 21 (2011)</ref-fulltext>
<ce:source-text>Mann, C.J., et al.: Aberrant repair and fibrosis development in skeletal muscle. Skelet. Muscle. 1(1), 21 (2011)</ce:source-text>
</reference>
<reference seq="61">
<ref-info>
<ref-title>
<ref-titletext-english>Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.E.</ce:initials>
<ce:surname>Benny Klimek</ce:surname>
<ce:given-name>M.E.</ce:given-name>
</author>
<et-al />
</ref-authors>
<ref-sourcetitle>Biochem. Biophys. Res. Commun</ref-sourcetitle>
<ref-publicationyear first="2010" />
<volisspag>
<volume-issue-number>
<vol-first>391</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1548</first-page>
<last-page>1554</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Benny Klimek, M.E., et al.: Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia. Biochem. Biophys. Res. Commun. 391(3), 1548–1554 (2010)</ref-fulltext>
<ce:source-text>Benny Klimek, M.E., et al.: Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia. Biochem. Biophys. Res. Commun. 391(3), 1548–1554 (2010)</ce:source-text>
</reference>
<reference seq="62">
<ref-info>
<ref-title>
<ref-titletext-english>Specific targeting of TGF-beta family ligands demonstrates distinct roles in the regulation of muscle mass in health and disease</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.L.</ce:initials>
<ce:surname>Chen</ce:surname>
<ce:given-name>J.L.</ce:given-name>
</author>
<et-al />
</ref-authors>
<ref-sourcetitle>Proc. Natl. Acad. Sci. USA</ref-sourcetitle>
<ref-publicationyear first="2017" />
<volisspag>
<volume-issue-number>
<vol-first>114</vol-first>
<iss-first>26</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Chen, J.L., et al.: Specific targeting of TGF-beta family ligands demonstrates distinct roles in the regulation of muscle mass in health and disease. Proc. Natl. Acad. Sci. USA. 114(26), E5266–E5275 (2017)</ref-fulltext>
<ce:source-text>Chen, J.L., et al.: Specific targeting of TGF-beta family ligands demonstrates distinct roles in the regulation of muscle mass in health and disease. Proc. Natl. Acad. Sci. USA. 114(26), E5266–E5275 (2017)</ce:source-text>
</reference>
<reference seq="63">
<ref-info>
<ref-title>
<ref-titletext-english>Proteolysis of latent transforming growth factor-beta (TGF-beta)-binding protein-1 by osteoclasts. A cellular mechanism for release of TGF-beta from bone matrix</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.L.</ce:initials>
<ce:surname>Dallas</ce:surname>
<ce:given-name>S.L.</ce:given-name>
</author>
<et-al />
</ref-authors>
<ref-sourcetitle>J. Biol. Chem</ref-sourcetitle>
<ref-publicationyear first="2002" />
<volisspag>
<volume-issue-number>
<vol-first>277</vol-first>
<iss-first>24</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>21352</first-page>
<last-page>21360</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Dallas, S.L., et al.: Proteolysis of latent transforming growth factor-beta (TGF-beta)-binding protein-1 by osteoclasts. A cellular mechanism for release of TGF-beta from bone matrix. J. Biol. Chem. 277(24), 21352–21360 (2002)</ref-fulltext>
<ce:source-text>Dallas, S.L., et al.: Proteolysis of latent transforming growth factor-beta (TGF-beta)-binding protein-1 by osteoclasts. A cellular mechanism for release of TGF-beta from bone matrix. J. Biol. Chem. 277(24), 21352–21360 (2002)</ce:source-text>
</reference>
<reference seq="64">
<ref-info>
<ref-title>
<ref-titletext-english>TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Tang</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<et-al />
</ref-authors>
<ref-sourcetitle>Nat. Med</ref-sourcetitle>
<ref-publicationyear first="2009" />
<volisspag>
<volume-issue-number>
<vol-first>15</vol-first>
<iss-first>7</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>757</first-page>
<last-page>765</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Tang, Y., et al.: TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat. Med. 15(7), 757–765 (2009)</ref-fulltext>
<ce:source-text>Tang, Y., et al.: TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat. Med. 15(7), 757–765 (2009)</ce:source-text>
</reference>
<reference seq="65">
<ref-info>
<ref-title>
<ref-titletext-english>Increased expression of TGF-beta 2 in osteoblasts results in an osteoporosis-like phenotype</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Erlebacher</ce:surname>
<ce:given-name>A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.</ce:initials>
<ce:surname>Derynck</ce:surname>
<ce:given-name>R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cell Biol</ref-sourcetitle>
<ref-publicationyear first="1996" />
<volisspag>
<volume-issue-number>
<vol-first>132</vol-first>
<iss-first>1</iss-first>
<iss-last>2</iss-last>
</volume-issue-number>
<page-information>
<pages>
<first-page>195</first-page>
<last-page>210</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Erlebacher, A., Derynck, R.: Increased expression of TGF-beta 2 in osteoblasts results in an osteoporosis-like phenotype. J. Cell Biol. 132(1–2), 195–210 (1996)</ref-fulltext>
<ce:source-text>Erlebacher, A., Derynck, R.: Increased expression of TGF-beta 2 in osteoblasts results in an osteoporosis-like phenotype. J. Cell Biol. 132(1–2), 195–210 (1996)</ce:source-text>
</reference>
<reference seq="66">
<ref-info>
<ref-title>
<ref-titletext-english>Pharmacologic inhibition of the TGF-beta type I receptor kinase has anabolic and anti-catabolic effects on bone</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.S.</ce:initials>
<ce:surname>Mohammad</ce:surname>
<ce:given-name>K.S.</ce:given-name>
</author>
<et-al />
</ref-authors>
<ref-sourcetitle>Plos One</ref-sourcetitle>
<ref-publicationyear first="2009" />
<volisspag>
<volume-issue-number>
<vol-first>4</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Mohammad, K.S., et al.: Pharmacologic inhibition of the TGF-beta type I receptor kinase has anabolic and anti-catabolic effects on bone. PLoS One. 4(4), e5275 (2009)</ref-fulltext>
<ce:source-text>Mohammad, K.S., et al.: Pharmacologic inhibition of the TGF-beta type I receptor kinase has anabolic and anti-catabolic effects on bone. PLoS One. 4(4), e5275 (2009)</ce:source-text>
</reference>
<reference seq="67">
<ref-info>
<ref-title>
<ref-titletext-english>Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Kang</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<et-al />
</ref-authors>
<ref-sourcetitle>Proc. Natl. Acad. Sci. USA</ref-sourcetitle>
<ref-publicationyear first="2005" />
<volisspag>
<volume-issue-number>
<vol-first>102</vol-first>
<iss-first>39</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>13909</first-page>
<last-page>13914</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kang, Y., et al.: Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc. Natl. Acad. Sci. USA. 102(39), 13909–13914 (2005)</ref-fulltext>
<ce:source-text>Kang, Y., et al.: Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc. Natl. Acad. Sci. USA. 102(39), 13909–13914 (2005)</ce:source-text>
</reference>
<reference seq="68">
<ref-info>
<ref-title>
<ref-titletext-english>A multigenic program mediating breast cancer metastasis to bone</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Kang</ce:surname>
<ce:given-name>Y.</ce:given-name>
</author>
<et-al />
</ref-authors>
<ref-sourcetitle>Cancer Cell</ref-sourcetitle>
<ref-publicationyear first="2003" />
<volisspag>
<volume-issue-number>
<vol-first>3</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>537</first-page>
<last-page>549</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kang, Y., et al.: A multigenic program mediating breast cancer metastasis to bone. Cancer Cell. 3(6), 537–549 (2003)</ref-fulltext>
<ce:source-text>Kang, Y., et al.: A multigenic program mediating breast cancer metastasis to bone. Cancer Cell. 3(6), 537–549 (2003)</ce:source-text>
</reference>
<reference seq="69">
<ref-info>
<ref-title>
<ref-titletext-english>Imaging transforming growth factor-beta signaling dynamics and therapeutic response in breast cancer bone metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Korpal</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
<et-al />
</ref-authors>
<ref-sourcetitle>Nat. Med</ref-sourcetitle>
<ref-publicationyear first="2009" />
<volisspag>
<volume-issue-number>
<vol-first>15</vol-first>
<iss-first>8</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>960</first-page>
<last-page>966</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Korpal, M., et al.: Imaging transforming growth factor-beta signaling dynamics and therapeutic response in breast cancer bone metastasis. Nat. Med. 15(8), 960–966 (2009)</ref-fulltext>
<ce:source-text>Korpal, M., et al.: Imaging transforming growth factor-beta signaling dynamics and therapeutic response in breast cancer bone metastasis. Nat. Med. 15(8), 960–966 (2009)</ce:source-text>
</reference>
<reference seq="70">
<ref-info>
<ref-title>
<ref-titletext-english>Excess TGF-beta mediates muscle weakness associated with bone metastases in mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.L.</ce:initials>
<ce:surname>Waning</ce:surname>
<ce:given-name>D.L.</ce:given-name>
</author>
<et-al />
</ref-authors>
<ref-sourcetitle>Nat. Med</ref-sourcetitle>
<ref-publicationyear first="2015" />
<volisspag>
<volume-issue-number>
<vol-first>21</vol-first>
<iss-first>11</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1262</first-page>
<last-page>1271</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Waning, D.L., et al.: Excess TGF-beta mediates muscle weakness associated with bone metastases in mice. Nat. Med. 21(11), 1262–1271 (2015)</ref-fulltext>
<ce:source-text>Waning, D.L., et al.: Excess TGF-beta mediates muscle weakness associated with bone metastases in mice. Nat. Med. 21(11), 1262–1271 (2015)</ce:source-text>
</reference>
<reference seq="71">
<ref-info>
<ref-title>
<ref-titletext-english>Ryanodine receptor oxidation causes intracellular calcium leak and muscle weakness in aging</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.C.</ce:initials>
<ce:surname>Andersson</ce:surname>
<ce:given-name>D.C.</ce:given-name>
</author>
<et-al />
</ref-authors>
<ref-sourcetitle>Cell Metab</ref-sourcetitle>
<ref-publicationyear first="2011" />
<volisspag>
<volume-issue-number>
<vol-first>14</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>196</first-page>
<last-page>207</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Andersson, D.C., et al.: Ryanodine receptor oxidation causes intracellular calcium leak and muscle weakness in aging. Cell Metab. 14(2), 196–207 (2011)</ref-fulltext>
<ce:source-text>Andersson, D.C., et al.: Ryanodine receptor oxidation causes intracellular calcium leak and muscle weakness in aging. Cell Metab. 14(2), 196–207 (2011)</ce:source-text>
</reference>
<reference seq="72">
<ref-info>
<ref-title>
<ref-titletext-english>Metastatic cancers promote cachexia through ZIP14 upregulation in skeletal muscle</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Wang</ce:surname>
<ce:given-name>G.</ce:given-name>
</author>
<et-al />
</ref-authors>
<ref-sourcetitle>Nat. Med</ref-sourcetitle>
<ref-publicationyear first="2018" />
<volisspag>
<volume-issue-number>
<vol-first>24</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>770</first-page>
<last-page>781</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wang, G., et al.: Metastatic cancers promote cachexia through ZIP14 upregulation in skeletal muscle. Nat. Med. 24(6), 770–781 (2018)</ref-fulltext>
<ce:source-text>Wang, G., et al.: Metastatic cancers promote cachexia through ZIP14 upregulation in skeletal muscle. Nat. Med. 24(6), 770–781 (2018)</ce:source-text>
</reference>
</bibliography>
</tail>
</bibrecord>
<bibrecord>
<item-info>
<status state="new" stage="S300" />
<itemidlist>
<ce:doi>10.1007/978-3-031-09518-4_8</ce:doi>
<itemid idtype="TPB-ID">9783031095184</itemid>
</itemidlist>
</item-info>
<head>
<citation-info>
<citation-type code="ch" />
<citation-language xml:lang="ENG" />
<abstract-language xml:lang="ENG" />
<author-keywords>
<author-keyword>Chemotherapy</author-keyword>
<author-keyword>Skeletal muscle</author-keyword>
<author-keyword>Cachexia</author-keyword>
<author-keyword>Muscle weakness</author-keyword>
</author-keywords>
</citation-info>
<citation-title>
<titletext xml:lang="ENG" original="y">Therapy-Induced Toxicities Associated with the Onset of Cachexia</titletext>
</citation-title>
<author-group seq="1">
<author seq="1">
<ce:initials>J.R.</ce:initials> 
<ce:surname>Huot</ce:surname>
<ce:given-name>Joshua R.</ce:given-name>
</author>
<affiliation>
<organization>Department of Pediatrics</organization>
<organization>the Hollings Cancer Center</organization>
<organization>Medical University of South Carolina</organization>
<state>Indianapolis</state>
<country iso-code="USA" />
<ce:source-text>Department of Surgery, Indiana University School of Medicine, Indianapolis, IN, USA</ce:source-text>
</affiliation>
</author-group>
<author-group seq="2">
<author seq="1">
<ce:initials>F.</ce:initials> 
<ce:surname>Pin</ce:surname>
<ce:given-name>Fabrizio</ce:given-name>
</author>
<affiliation>
<organization>Department of Anatomy</organization>
<organization>Indiana University School of Medicine</organization>
<state>Indianapolis</state>
<country iso-code="USA" />
<ce:source-text>Department of Anatomy, Cell Biology and Physiology, Indiana University School of Medicine, Indianapolis, IN, USA.</ce:source-text>
</affiliation>
</author-group>
<author-group seq="3">
<author seq="1">
<ce:initials>A.</ce:initials> 
<ce:surname>Bonetto</ce:surname>
<ce:given-name>Andrea</ce:given-name>
<ce:e-address>andrea.bonetto@cuanschutz.edu</ce:e-address>
</author>
<affiliation>
<organization>Department of Surgery</organization>
<organization>Indiana University School of Medicine</organization>
<organization>Department of Anatomy</organization>
<state>Indianapolis</state>
<country iso-code="USA" />
<ce:source-text>Department of Surgery, Indiana University School of Medicine, Indianapolis, IN, USA Department of Anatomy, Cell Biology and Physiology, Indiana University School of Medicine, Indianapolis, IN, USA Department of Otolaryngology – Head and Neck Surgery, Indiana University School of Medicine, Indianapolis, IN, USA Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, IN, USA Indiana Center for Musculoskeletal Health, Indiana University School of Medicine, Indianapolis, IN, USA Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA</ce:source-text>
</affiliation>
</author-group>
<abstracts>
<abstract xml:lang="ENG" original="y">
<publishercopyright>© Springer Nature Switzerland AG 2022</publishercopyright>
<ce:para>Cancer is the second-leading cause of death worldwide. Notably, 40% of all patients suffer from cachexia, a debilitating muscle wasting syndrome that represents one of the primary causes of death in advanced cancer patients. Despite their known side effects, such as vomiting, anorexia, mucositis, neuropathy, musculoskeletal and metabolic alterations, chemotherapy treatments are the most effec- tive and extensively used strategies against cancer. Moreover, chemotherapeutic agents may participate in and even exacerbate the pathophysiological alterations driving cachexia. Indeed, skeletal muscle atrophy and cardiac abnormalities occurring as a conse- quence of chemotherapy administration can worsen the response to anticancer therapies, reduce physical activity and severely impede the quality of life in cancer patients. Hence, chemotherapy-induced cachexia has recently emerged as a critical clinical problem impacting outcomes and overall survival in cancer patients. Here, we review some of the mechanism(s) through which chemother- apeutics induce musculoskeletal deficits related to cachexia. Lastly, we discuss differ- ent strategies currently under consideration to protect muscle tissue from chemotherapy- related toxicities, including nutritional interventions, mitochondria-targeted molecules, ghrelin, bisphosphonates, ACVR2B antagonists, and physical exercise.</ce:para>
</abstract>
</abstracts>
<source type="book" country="USA">
<sourcetitle>The Systemic Effects of Advanced Cancer A Textbook on Cancer-Associated Cachexia</sourcetitle>
<sourcetitle-abbrev>The Systemic Effects of Advanced Cancer A Textbook on Cancer-Associated Cachexia</sourcetitle-abbrev>
<isbn type="print" length="13">978-3-031-07272-7</isbn>
<isbn type="electronic" length="13">978-3-031-09518-4</isbn>
<volisspag>
<page-information>
<pages>
<first-page>139</first-page>
<last-page>153</last-page>
</pages>
</page-information>
</volisspag>
<publicationyear first="2022" />
<publicationdate>
<year>2022</year>
<month>01</month>
<day>01</day>
</publicationdate>
<website type="item">
<ce:e-address type="url">https://link.springer.com</ce:e-address>
</website>
<publisher>
<publishername>Springer International Publishing</publishername>
</publisher>
</source>
<enhancement>
<classificationgroup>
<classifications type="ASJC">
<classification>
<classification-code>2700</classification-code>
<classification-code>2400</classification-code>
<classification-code>1300</classification-code>
</classification>
</classifications>
</classificationgroup>
</enhancement>
</head>
<tail>
<bibliography refcount="">
<reference seq="1">
<ref-info>
<ref-title>
<ref-titletext-english> Cancer statistics, </ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials> R.L.</ce:initials>
<ce:surname>Siegel</ce:surname>
<ce:given-name> R.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle> CA Cancer J. Clin.</ref-sourcetitle>
<ref-publicationyear first="2022"/>
<volisspag>
<volume-issue-number>
<vol-first>72</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>7</first-page>
<last-page>33</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Siegel, R.L., et al.: Cancer statistics, 2022. CA Cancer J. Clin. 72(1), 7–33 (2022)</ref-fulltext>
<ce:source-text>Siegel, R.L., et al.: Cancer statistics, 2022. CA Cancer J. Clin. 72(1), 7–33 (2022)</ce:source-text>
</reference>
<reference seq="2">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer epidemiology: a survey of modifiable risk factors for prevention and survivorship.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Arem</ce:surname>
</author>
<author seq="2">
<ce:initials>E.</ce:initials>
<ce:surname>Loftfield</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Lifestyle Med</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>200</first-page>
<last-page>210</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Arem, H., Loftfield, E.: Cancer epidemiology: a survey of modifiable risk factors for prevention and survivorship. Am. J. Lifestyle Med. 12(3), 200–210 (2018)</ref-fulltext>
<ce:source-text>Arem, H., Loftfield, E.: Cancer epidemiology: a survey of modifiable risk factors for prevention and survivorship. Am. J. Lifestyle Med. 12(3), 200–210 (2018)</ce:source-text>
</reference>
<reference seq="3">
<ref-info>
<ref-title>
<ref-titletext-english>Evolution of cancer pharmacological treatments at the turn of the third millennium</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Falzone</ce:surname>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Salomone</ce:surname>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Libra</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Front. Pharmacol</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1300</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>. Falzone, L., Salomone, S., Libra, M.: Evolution of cancer pharmacological treatments at the turn of the third millennium. Front. Pharmacol. 9, 1300 (2018) </ref-fulltext>
<ce:source-text>. Falzone, L., Salomone, S., Libra, M.: Evolution of cancer pharmacological treatments at the turn of the third millennium. Front. Pharmacol. 9, 1300 (2018) </ce:source-text>
</reference>
<reference seq="4">
<ref-info>
<ref-title>
<ref-titletext-english></ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.A.</ce:initials>
<ce:surname>Khan</ce:surname>
<ce:given-name>F.A.</ce:given-name>
</author>
<author seq="2">
<ce:initials>S.S.</ce:initials>
<ce:surname>Akhtar</ce:surname>
<ce:given-name>S.S.</ce:given-name>
</author>
<author seq="3">
<ce:initials>M.K.</ce:initials>
<ce:surname>Sheikh</ce:surname>
<ce:given-name>M.K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer treatment – objectives and quality of life issues.</ref-sourcetitle>
<ref-publicationyear first="2005"/>
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3</first-page>
<last-page>5</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Khan, F.A., Akhtar, S.S., Sheikh, M.K.: Cancer treatment – objectives and quality of life issues. Malays. J. Med. Sci. 12(1), 3–5 (2005)</ref-fulltext>
<ce:source-text>Khan, F.A., Akhtar, S.S., Sheikh, M.K.: Cancer treatment – objectives and quality of life issues. Malays. J. Med. Sci. 12(1), 3–5 (2005)</ce:source-text>
</reference>
<reference seq="5">
<ref-info>
<ref-title>
<ref-titletext-english>Assessment of the evolution of cancer treatment therapies. </ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Arruebo</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cancers (Basel).</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>3</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3279</first-page>
<last-page>3330</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Arruebo, M., et al.: Assessment of the evolution of cancer treatment therapies. Cancers (Basel). 3(3), 3279–3330 (2011) </ref-fulltext>
<ce:source-text>Arruebo, M., et al.: Assessment of the evolution of cancer treatment therapies. Cancers (Basel). 3(3), 3279–3330 (2011) </ce:source-text>
</reference>
<reference seq="6">
<ref-info>
<ref-title>
<ref-titletext-english>Improving radiotherapy in cancer treatment: Promises and challenges. </ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.H.W.</ce:initials>
<ce:surname>Chen</ce:surname>
<ce:given-name>H.H.W.</ce:given-name>
</author>
<author seq="2">
<ce:initials>M.T.</ce:initials>
<ce:surname>Kuo</ce:surname>
<ce:given-name>M.T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncotarget</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>37</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>62742</first-page>
<last-page>62758</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Chen, H.H.W., Kuo, M.T.: Improving radiotherapy in cancer treatment: Promises and challenges. Oncotarget. 8(37), 62742–62758 (2017)</ref-fulltext>
<ce:source-text>Chen, H.H.W., Kuo, M.T.: Improving radiotherapy in cancer treatment: Promises and challenges. Oncotarget. 8(37), 62742–62758 (2017)</ce:source-text>
</reference>
<reference seq="7">
<ref-info>
<ref-title>
<ref-titletext-english>: Radiation oncology in the era of precision medicine.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Baumann</ce:surname>
<ce:given-name>M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Cancer.</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>16</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>234</first-page>
<last-page>249</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Baumann, M., et al.: Radiation oncology in the era of precision medicine. Nat. Rev. Cancer. 16(4), 234–249 (2016) </ref-fulltext>
<ce:source-text>Baumann, M., et al.: Radiation oncology in the era of precision medicine. Nat. Rev. Cancer. 16(4), 234–249 (2016) </ce:source-text>
</reference>
<reference seq="8">
<ref-info>
<ref-title>
<ref-titletext-english>Hormonal therapy for cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.S.</ce:initials>
<ce:surname>Jacinta Abraham</ce:surname>
<ce:given-name>J.S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Medicine</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>44</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>30</first-page>
<last-page>33</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Jacinta Abraham, J.S.: Hormonal therapy for cancer. Medicine. 44(1), 30–33 (2016)</ref-fulltext>
<ce:source-text>Jacinta Abraham, J.S.: Hormonal therapy for cancer. Medicine. 44(1), 30–33 (2016)</ce:source-text>
</reference>
<reference seq="9">
<ref-info>
<ref-title>
<ref-titletext-english>Current status and future directions of cancer immunotherapy.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Zhang</ce:surname>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Chen</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Cancer.</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
<iss-first>10</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1773</first-page>
<last-page>1781</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zhang, H., Chen, J.: Current status and future directions of cancer immunotherapy. J. Cancer. 9(10), 1773–1781 (2018)</ref-fulltext>
<ce:source-text>Zhang, H., Chen, J.: Current status and future directions of cancer immunotherapy. J. Cancer. 9(10), 1773–1781 (2018)</ce:source-text>
</reference>
<reference seq="10">
<ref-info>
<ref-title>
<ref-titletext-english>Delivery strategies of cancer immunotherapy: recent advances and future perspectives</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Z.</ce:initials>
<ce:surname>Zhao</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Hematol. Oncol.</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>126</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zhao, Z., et al.: Delivery strategies of cancer immunotherapy: recent advances and future perspectives. J. Hematol. Oncol. 12(1), 126 (2019)</ref-fulltext>
<ce:source-text>Zhao, Z., et al.: Delivery strategies of cancer immunotherapy: recent advances and future perspectives. J. Hematol. Oncol. 12(1), 126 (2019)</ce:source-text>
</reference>
<reference seq="11">
<ref-info>
<ref-title>
<ref-titletext-english>in LiverTox clinical and research information on drug-induced liver injury</ref-titletext-english>
</ref-title>
<collaboration seq="1">
<ce:text>Alkylating Agents</ce:text>
</collaboration>
<ref-sourcetitle>Bethesda (MD)</ref-sourcetitle>
<ref-publicationyear first="2012"/>
</ref-info>
<ref-fulltext>Alkylating Agents, in LiverTox: clinical and research information on drug-induced liver injury. 2012: Bethesda (MD)</ref-fulltext>
<ce:source-text>Alkylating Agents, in LiverTox: clinical and research information on drug-induced liver injury. 2012: Bethesda (MD)</ce:source-text>
</reference>
<reference seq="12">
<ref-info>
<ref-title>
<ref-titletext-english>Antimetabolites.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Lansiaux</ce:surname>
<ce:given-name></ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Bull</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<ref-text>Cancer</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>98</vol-first>
<iss-first>11</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1263</first-page>
<last-page>1274</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Lansiaux, A.: Antimetabolites. Bull. Cancer. 98(11), 1263–1274 (2011)</ref-fulltext>
<ce:source-text>Lansiaux, A.: Antimetabolites. Bull. Cancer. 98(11), 1263–1274 (2011)</ce:source-text>
</reference>
<reference seq="13">
<ref-info>
<ref-title>
<ref-titletext-english>Topoisomerase I inhibitors: camptothecins and beyond.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Pommier</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Cancer</ref-sourcetitle>
<ref-publicationyear first="2006"/>
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
<iss-first>10</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>789</first-page>
<last-page>802</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Pommier, Y.: Topoisomerase I inhibitors: camptothecins and beyond. Nat. Rev. Cancer. 6(10), 789–802 (2006)</ref-fulltext>
<ce:source-text>Pommier, Y.: Topoisomerase I inhibitors: camptothecins and beyond. Nat. Rev. Cancer. 6(10), 789–802 (2006)</ce:source-text>
</reference>
<reference seq="14">
<ref-info>
<ref-title>
<ref-titletext-english>Vinca alkaloids</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Moudi</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Prev. Med.</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<volisspag>
<volume-issue-number>
<vol-first>4</vol-first>
<iss-first>11</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1231</first-page>
<last-page>1235</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Moudi, M., et al.: Vinca alkaloids. Int. J. Prev. Med. 4(11), 1231–1235 (2013)</ref-fulltext>
<ce:source-text>Moudi, M., et al.: Vinca alkaloids. Int. J. Prev. Med. 4(11), 1231–1235 (2013)</ce:source-text>
</reference>
<reference seq="15">
<ref-info>
<ref-title>
<ref-titletext-english>Taxane pathway. </ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Oshiro</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Pharmacogenet</ref-sourcetitle>
<ref-publicationyear first="2009"/>
<ref-text>Genomics</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>19</vol-first>
<iss-first>12</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>979</first-page>
<last-page>983</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Oshiro, C., et al.: Taxane pathway. Pharmacogenet. Genomics. 19(12), 979–983 (2009)</ref-fulltext>
<ce:source-text>Oshiro, C., et al.: Taxane pathway. Pharmacogenet. Genomics. 19(12), 979–983 (2009)</ce:source-text>
</reference>
<reference seq="16">
<ref-info>
<ref-title>
<ref-titletext-english>Editorial: adverse effects of cancer chemotherapy: anything new to improve tolerance and reduce sequelae? Front. </ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Nurgali</ce:surname>
</author>
<author seq="2">
<ce:initials>R.T.</ce:initials>
<ce:surname>Jagoe</ce:surname>
<ce:given-name>R.T.</ce:given-name>
</author>
<author seq="2">
<ce:initials>R.</ce:initials>
<ce:surname>Abalo</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Pharmacol.</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>245</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Nurgali, K., Jagoe, R.T., Abalo, R.: Editorial: adverse effects of cancer chemotherapy: anything new to improve tolerance and reduce sequelae? Front. Pharmacol. 9, 245 (2018)</ref-fulltext>
<ce:source-text>Nurgali, K., Jagoe, R.T., Abalo, R.: Editorial: adverse effects of cancer chemotherapy: anything new to improve tolerance and reduce sequelae? Front. Pharmacol. 9, 245 (2018)</ce:source-text>
</reference>
<reference seq="17">
<ref-info>
<ref-title>
<ref-titletext-english> Experiences and consequences of altered taste, flavour and food hedonics during chemotherapy treatment.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Boltong</ce:surname>
</author>
<author seq="2">
<ce:initials>R.</ce:initials>
<ce:surname>Keast</ce:surname>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Aranda</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Support Care Cancer.</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<volisspag>
<volume-issue-number>
<vol-first>20</vol-first>
<iss-first>11</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2765</first-page>
<last-page>2774</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Boltong, A., Keast, R., Aranda, S.: Experiences and consequences of altered taste, flavour and food hedonics during chemotherapy treatment. Support Care Cancer. 20(11), 2765–2774 (2012)</ref-fulltext>
<ce:source-text>Boltong, A., Keast, R., Aranda, S.: Experiences and consequences of altered taste, flavour and food hedonics during chemotherapy treatment. Support Care Cancer. 20(11), 2765–2774 (2012)</ce:source-text>
</reference>
<reference seq="18">
<ref-info>
<ref-title>
<ref-titletext-english>Drug-induced myelosuppression: diagnosis and management. </ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.J.</ce:initials>
<ce:surname>Carey</ce:surname>
<ce:given-name>P.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Drug Saf.</ref-sourcetitle>
<ref-publicationyear first="2003"/>
<volisspag>
<volume-issue-number>
<vol-first>26</vol-first>
<iss-first>10</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>691</first-page>
<last-page>706</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Carey, P.J.: Drug-induced myelosuppression: diagnosis and management. Drug Saf. 26(10), 691–706 (2003)</ref-fulltext>
<ce:source-text>Carey, P.J.: Drug-induced myelosuppression: diagnosis and management. Drug Saf. 26(10), 691–706 (2003)</ce:source-text>
</reference>
<reference seq="19">
<ref-info>
<ref-title>
<ref-titletext-english>Delayed chemotherapy-induced nausea and vomiting: pathogenesis, incidence, and current management</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.L.</ce:initials>
<ce:surname>Rapoport</ce:surname>
<ce:given-name>B.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Front. Pharmacol.</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>19</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Rapoport, B.L.: Delayed chemotherapy-induced nausea and vomiting: pathogenesis, incidence, and current management. Front. Pharmacol. 8, 19 (2017)</ref-fulltext>
<ce:source-text>Rapoport, B.L.: Delayed chemotherapy-induced nausea and vomiting: pathogenesis, incidence, and current management. Front. Pharmacol. 8, 19 (2017)</ce:source-text>
</reference>
<reference seq="20">
<ref-info>
<ref-title>
<ref-titletext-english>The role of vagal neurocircuits in the regulation of nausea and vomiting. </ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Babic</ce:surname>
</author>
<author seq="2">
<ce:initials>K.N.</ce:initials>
<ce:surname>Browning</ce:surname>
<ce:given-name>K.N.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Eur. J. Pharmacol.</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>722</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>38</first-page>
<last-page>47</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Babic, T., Browning, K.N.: The role of vagal neurocircuits in the regulation of nausea and vomiting. Eur. J. Pharmacol. 722, 38–47 (2014)</ref-fulltext>
<ce:source-text>Babic, T., Browning, K.N.: The role of vagal neurocircuits in the regulation of nausea and vomiting. Eur. J. Pharmacol. 722, 38–47 (2014)</ce:source-text>
</reference>
<reference seq="21">
<ref-info>
<ref-title>
<ref-titletext-english>GDF15 Induces Anorexia through Nausea and Emesis.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Borner</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cell Metab</ref-sourcetitle>
<ref-publicationyear first="2020"/>
</ref-info>
<ref-fulltext>Borner, T., et al.: GDF15 Induces Anorexia through Nausea and Emesis. Cell Metab. (2020)</ref-fulltext>
<ce:source-text>Borner, T., et al.: GDF15 Induces Anorexia through Nausea and Emesis. Cell Metab. (2020)</ce:source-text>
</reference>
<reference seq="22">
<ref-info>
<ref-title>
<ref-titletext-english>The MIC-1/GDF15-GFRAL pathway in energy homeostasis: implications for obesity, cachexia, and other associated diseases.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>V.W.W.</ce:initials>
<ce:surname>Tsai</ce:surname>
<ce:given-name>V.W.W.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Metab. </ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>28</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>353</first-page>
<last-page>368</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Tsai, V.W.W., et al.: The MIC-1/GDF15-GFRAL pathway in energy homeostasis: implications for obesity, cachexia, and other associated diseases. Cell Metab. 28(3), 353–368 (2018) </ref-fulltext>
<ce:source-text>Tsai, V.W.W., et al.: The MIC-1/GDF15-GFRAL pathway in energy homeostasis: implications for obesity, cachexia, and other associated diseases. Cell Metab. 28(3), 353–368 (2018) </ce:source-text>
</reference>
<reference seq="23">
<ref-info>
<ref-title>
<ref-titletext-english>New frontiers in the pathobiology and treatment of cancer regimen-related mucosal injury</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Cinausero</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Front. Pharmacol. </ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>354</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Cinausero, M., et al.: New frontiers in the pathobiology and treatment of cancer regimen-related mucosal injury. Front. Pharmacol. 8, 354 (2017) </ref-fulltext>
<ce:source-text>Cinausero, M., et al.: New frontiers in the pathobiology and treatment of cancer regimen-related mucosal injury. Front. Pharmacol. 8, 354 (2017) </ce:source-text>
</reference>
<reference seq="24">
<ref-info>
<ref-title>
<ref-titletext-english>Treatment of oral mucositis due to chemotherapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.</ce:initials>
<ce:surname>Chaveli-Lopez</ce:surname>
</author>
<author seq="2">
<ce:initials>J.V.</ce:initials>
<ce:surname>Bagan-Sebastian</ce:surname>
<ce:given-name>J.V.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J Clin Exp Dent</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Chaveli-Lopez, B., Bagan-Sebastian, J.V.: Treatment of oral mucositis due to chemotherapy. J Clin Exp Dent. 8(2), e201–e209 (2016)</ref-fulltext>
<ce:source-text>Chaveli-Lopez, B., Bagan-Sebastian, J.V.: Treatment of oral mucositis due to chemotherapy. J Clin Exp Dent. 8(2), e201–e209 (2016)</ce:source-text>
</reference>
<reference seq="25">
<ref-info>
<ref-title>
<ref-titletext-english>Mechanisms of chemotherapy-induced peripheral neuropathy.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Zajaczkowska</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2019"/>
<ref-text>Int. J. Mol. Sci.</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>20</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Zajaczkowska, R., et al.: Mechanisms of chemotherapy-induced peripheral neuropathy. Int. J. Mol. Sci. 20(6) (2019)</ref-fulltext>
<ce:source-text>Zajaczkowska, R., et al.: Mechanisms of chemotherapy-induced peripheral neuropathy. Int. J. Mol. Sci. 20(6) (2019)</ce:source-text>
</reference>
<reference seq="26">
<ref-info>
<ref-title>
<ref-titletext-english>The association of chemotherapyinduced peripheral neuropathy symptoms and the risk of falling</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.A.</ce:initials>
<ce:surname>Kolb</ce:surname>
<ce:given-name>N.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>JAMA Neurol</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>73</vol-first>
<iss-first>7</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>860</first-page>
<last-page>866</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kolb, N.A., et al.: The association of chemotherapyinduced peripheral neuropathy symptoms and the risk of falling. JAMA Neurol. 73(7), 860–866 (2016)</ref-fulltext>
<ce:source-text>Kolb, N.A., et al.: The association of chemotherapyinduced peripheral neuropathy symptoms and the risk of falling. JAMA Neurol. 73(7), 860–866 (2016)</ce:source-text>
</reference>
<reference seq="27">
<ref-info>
<ref-title>
<ref-titletext-english>Chemotherapy, cognitive impairment and hippocampal toxicity</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Dietrich</ce:surname>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Prus</ce:surname>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Kaiser</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Neuroscience</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>309</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>224</first-page>
<last-page>232</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Dietrich, J., Prust, M., Kaiser, J.: Chemotherapy, cognitive impairment and hippocampal toxicity. Neuroscience. 309, 224–232 (2015)</ref-fulltext>
<ce:source-text>Dietrich, J., Prust, M., Kaiser, J.: Chemotherapy, cognitive impairment and hippocampal toxicity. Neuroscience. 309, 224–232 (2015)</ce:source-text>
</reference>
<reference seq="28">
<ref-info>
<ref-title>
<ref-titletext-english>Longitudinal assessment of chemotherapy-induced changes in brain and cognitive functioning: a systematic review</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Li</ce:surname>
</author>
<author seq="2">
<ce:initials>K.</ce:initials>
<ce:surname>Caeyenberghs</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Neurosci. Biobehav. Rev.</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>92</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>304</first-page>
<last-page>317</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Li, M., Caeyenberghs, K.: Longitudinal assessment of chemotherapy-induced changes in brain and cognitive functioning: a systematic review. Neurosci. Biobehav. Rev. 92, 304–317 (2018)</ref-fulltext>
<ce:source-text>Li, M., Caeyenberghs, K.: Longitudinal assessment of chemotherapy-induced changes in brain and cognitive functioning: a systematic review. Neurosci. Biobehav. Rev. 92, 304–317 (2018)</ce:source-text>
</reference>
<reference seq="29">
<ref-info>
<ref-title>
<ref-titletext-english> Cancer- and chemotherapyinduced musculoskeletal degradation.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.M.</ce:initials>
<ce:surname>Sturgeon</ce:surname>
<ce:given-name>K.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>JBMR Plus.</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>3</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Sturgeon, K.M., et al.: Cancer- and chemotherapyinduced musculoskeletal degradation. JBMR Plus. 3(3), e10187 (2019)</ref-fulltext>
<ce:source-text>Sturgeon, K.M., et al.: Cancer- and chemotherapyinduced musculoskeletal degradation. JBMR Plus. 3(3), e10187 (2019)</ce:source-text>
</reference>
<reference seq="30">
<ref-info>
<ref-title>
<ref-titletext-english>Glucocorticoid-induced osteoporosis.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.J.</ce:initials>
<ce:surname>Baylink</ce:surname>
<ce:given-name>D.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>N. Engl. J. Med.</ref-sourcetitle>
<ref-publicationyear first="1983"/>
<volisspag>
<volume-issue-number>
<vol-first>309</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>306</first-page>
<last-page>308</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Baylink, D.J.: Glucocorticoid-induced osteoporosis. N. Engl. J. Med. 309(5), 306–308 (1983)</ref-fulltext>
<ce:source-text>Baylink, D.J.: Glucocorticoid-induced osteoporosis. N. Engl. J. Med. 309(5), 306–308 (1983)</ce:source-text>
</reference>
<reference seq="31">
<ref-info>
<ref-title>
<ref-titletext-english>Myelosuppressive therapies significantly increase pro-inflammatory cytokines and directly cause bone loss</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.M.</ce:initials>
<ce:surname>Quach</ce:surname>
<ce:given-name>J.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Bone Miner. Res.</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>30</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>886</first-page>
<last-page>897</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Quach, J.M., et al.: Myelosuppressive therapies significantly increase pro-inflammatory cytokines and directly cause bone loss. J. Bone Miner. Res. 30(5), 886–897 (2015) </ref-fulltext>
<ce:source-text>Quach, J.M., et al.: Myelosuppressive therapies significantly increase pro-inflammatory cytokines and directly cause bone loss. J. Bone Miner. Res. 30(5), 886–897 (2015) </ce:source-text>
</reference>
<reference seq="32">
<ref-info>
<ref-title>
<ref-titletext-english>Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. </ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Saarto</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle> J. Clin. Oncol.</ref-sourcetitle>
<ref-publicationyear first="1997"/>
<volisspag>
<volume-issue-number>
<vol-first>15</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1341</first-page>
<last-page>1347</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Saarto, T., et al.: Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. J. Clin. Oncol. 15(4), 1341–1347 (1997)</ref-fulltext>
<ce:source-text>Saarto, T., et al.: Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. J. Clin. Oncol. 15(4), 1341–1347 (1997)</ce:source-text>
</reference>
<reference seq="33">
<ref-info>
<ref-title>
<ref-titletext-english>ACVR2B/Fc counteracts chemotherapy-induced loss of muscle and bone mass.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Barreto</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Sci. Rep.</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>14470</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Barreto, R., et al.: ACVR2B/Fc counteracts chemotherapy-induced loss of muscle and bone mass. Sci. Rep. 7(1), 14470 (2017)</ref-fulltext>
<ce:source-text>Barreto, R., et al.: ACVR2B/Fc counteracts chemotherapy-induced loss of muscle and bone mass. Sci. Rep. 7(1), 14470 (2017)</ce:source-text>
</reference>
<reference seq="34">
<ref-info>
<ref-title>
<ref-titletext-english>Chemotherapy-induced loss of bone and muscle mass in a mouse model of breastcancer bone metastases and cachexia.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.A.</ce:initials>
<ce:surname>Hain</ce:surname>
<ce:given-name>B.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>JCSM Rapid Commun</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>2</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Hain, B.A., et al.: Chemotherapy-induced loss of bone and muscle mass in a mouse model of breastcancer bone metastases and cachexia. JCSM Rapid Commun. 2(1) (2019)</ref-fulltext>
<ce:source-text>Hain, B.A., et al.: Chemotherapy-induced loss of bone and muscle mass in a mouse model of breastcancer bone metastases and cachexia. JCSM Rapid Commun. 2(1) (2019)</ce:source-text>
</reference>
<reference seq="35">
<ref-info>
<ref-title>
<ref-titletext-english>Bisphosphonate treatment ameliorates chemotherapy-induced bone and muscle abnormalities in young mice. </ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.L.</ce:initials>
<ce:surname>Essex</ce:surname>
<ce:given-name>A.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle> Front. Endocrinol. (Lausanne)</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>809</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Essex, A.L., et al.: Bisphosphonate treatment ameliorates chemotherapy-induced bone and muscle abnormalities in young mice. Front. Endocrinol. (Lausanne). 10, 809 (2019)</ref-fulltext>
<ce:source-text>Essex, A.L., et al.: Bisphosphonate treatment ameliorates chemotherapy-induced bone and muscle abnormalities in young mice. Front. Endocrinol. (Lausanne). 10, 809 (2019)</ce:source-text>
</reference>
<reference seq="36">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer and chemotherapy contribute to muscle loss by activating common signaling pathways</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Barreto</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Front. Physiol. </ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>472</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Barreto, R., et al.: Cancer and chemotherapy contribute to muscle loss by activating common signaling pathways. Front. Physiol. 7, 472 (2016) </ref-fulltext>
<ce:source-text>Barreto, R., et al.: Cancer and chemotherapy contribute to muscle loss by activating common signaling pathways. Front. Physiol. 7, 472 (2016) </ce:source-text>
</reference>
<reference seq="37">
<ref-info>
<ref-title>
<ref-titletext-english>Fatigue and quality of life outcomes of exercise during cancer treatment.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>V.</ce:initials>
<ce:surname>Mock</ce:surname>
<ce:given-name>V.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Pract.</ref-sourcetitle>
<ref-publicationyear first="2001"/>
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>119</first-page>
<last-page>127</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mock, V., et al.: Fatigue and quality of life outcomes of exercise during cancer treatment. Cancer Pract. 9(3), 119–127 (2001) </ref-fulltext>
<ce:source-text>Mock, V., et al.: Fatigue and quality of life outcomes of exercise during cancer treatment. Cancer Pract. 9(3), 119–127 (2001) </ce:source-text>
</reference>
<reference seq="38">
<ref-info>
<ref-title>
<ref-titletext-english>Chemotherapy-induced muscle wasting: association with NF-kappaB and cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.S.</ce:initials>
<ce:surname>Damrauer</ce:surname>
<ce:given-name>J.S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Eur. J. Transl. Myol. </ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>28</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>7590</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Damrauer, J.S., et al.: Chemotherapy-induced muscle wasting: association with NF-kappaB and cancer cachexia. Eur. J. Transl. Myol. 28(2), 7590 (2018)</ref-fulltext>
<ce:source-text>Damrauer, J.S., et al.: Chemotherapy-induced muscle wasting: association with NF-kappaB and cancer cachexia. Eur. J. Transl. Myol. 28(2), 7590 (2018)</ce:source-text>
</reference>
<reference seq="39">
<ref-info>
<ref-title>
<ref-titletext-english>Preservation of muscle mass as a strategy to reduce the toxic effects of cancer chemotherapy on body composition.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Pin</ce:surname>
</author>
<author seq="2">
<ce:initials>M.E.</ce:initials>
<ce:surname>Couch</ce:surname>
<ce:given-name>M.E.</ce:given-name>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Bonetto</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle> Curr. Opin. Support. Palliat. Care.</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>420</first-page>
<last-page>426</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Pin, F., Couch, M.E., Bonetto, A.: Preservation of muscle mass as a strategy to reduce the toxic effects of cancer chemotherapy on body composition. Curr. Opin. Support. Palliat. Care. 12(4), 420–426 (2018)</ref-fulltext>
<ce:source-text>Pin, F., Couch, M.E., Bonetto, A.: Preservation of muscle mass as a strategy to reduce the toxic effects of cancer chemotherapy on body composition. Curr. Opin. Support. Palliat. Care. 12(4), 420–426 (2018)</ce:source-text>
</reference>
<reference seq="40">
<ref-info>
<ref-title>
<ref-titletext-english>Negative impact of cancer chemotherapy on protein metabolism in healthy and tumor-bearing rats.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Le Bricon</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Metabolism</ref-sourcetitle>
<ref-publicationyear first="1995"/>
<volisspag>
<volume-issue-number>
<vol-first>44</vol-first>
<iss-first>10</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1340</first-page>
<last-page>1348</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Le Bricon, T., et al.: Negative impact of cancer chemotherapy on protein metabolism in healthy and tumor-bearing rats. Metabolism. 44(10), 1340–1348 (1995)</ref-fulltext>
<ce:source-text>Le Bricon, T., et al.: Negative impact of cancer chemotherapy on protein metabolism in healthy and tumor-bearing rats. Metabolism. 44(10), 1340–1348 (1995)</ce:source-text>
</reference>
<reference seq="41">
<ref-info>
<ref-title>
<ref-titletext-english>Is it time for a new paradigm for systemic cancer treatment? Lessons from a century of cancer chemotherapy. </ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Crawford</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Front. Pharmacol.</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<volisspag>
<volume-issue-number>
<vol-first>4</vol-first>
<iss-first>68</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Crawford, S.: Is it time for a new paradigm for systemic cancer treatment? Lessons from a century of cancer chemotherapy. Front. Pharmacol. 4, 68 (2013)</ref-fulltext>
<ce:source-text>Crawford, S.: Is it time for a new paradigm for systemic cancer treatment? Lessons from a century of cancer chemotherapy. Front. Pharmacol. 4, 68 (2013)</ce:source-text>
</reference>
<reference seq="42">
<ref-info>
<ref-title>
<ref-titletext-english>Definition and classification of cancer cachexia: an international consensus. </ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Fearon</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Lancet Oncol.</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>489</first-page>
<last-page>495</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Fearon, K., et al.: Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 12(5), 489–495 (2011)</ref-fulltext>
<ce:source-text>Fearon, K., et al.: Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 12(5), 489–495 (2011)</ce:source-text>
</reference>
<reference seq="43">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer statistics, </ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Siegel</ce:surname>
</author>
<author seq="2">
<ce:initials>D.</ce:initials>
<ce:surname>Naishadham</ce:surname>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Jemal</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>CA Cancer J. Clin</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<volisspag>
<volume-issue-number>
<vol-first>62</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>10</first-page>
<last-page>29</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Siegel, R., Naishadham, D., Jemal, A.: Cancer statistics, 2012. CA Cancer J. Clin. 62(1), 10–29 (2012)</ref-fulltext>
<ce:source-text>Siegel, R., Naishadham, D., Jemal, A.: Cancer statistics, 2012. CA Cancer J. Clin. 62(1), 10–29 (2012)</ce:source-text>
</reference>
<reference seq="44">
<ref-info>
<ref-title>
<ref-titletext-english>Nutritional status, cachexia and survival in patients with advanced colorectal carcinoma. Different assessment criteria for nutritional status provide unequal results.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Thoresen</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Clin. Nutr.</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<ref-text></ref-text>
<volisspag>
<volume-issue-number>
<vol-first>32</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>65</first-page>
<last-page>72</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Thoresen, L., et al.: Nutritional status, cachexia and survival in patients with advanced colorectal carcinoma. Different assessment criteria for nutritional status provide unequal results. Clin. Nutr. 32(1), 65–72 (2013)</ref-fulltext>
<ce:source-text>Thoresen, L., et al.: Nutritional status, cachexia and survival in patients with advanced colorectal carcinoma. Different assessment criteria for nutritional status provide unequal results. Clin. Nutr. 32(1), 65–72 (2013)</ce:source-text>
</reference>
<reference seq="45">
<ref-info>
<ref-title>
<ref-titletext-english>Chemotherapy-related cachexia is associated with mitochondrial depletion and the activation of ERK1/2 and p38 MAPKs.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Barreto</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Oncotarget.</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<ref-text></ref-text>
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
<iss-first>28</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>43442</first-page>
<last-page>43460</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Barreto, R., et al.: Chemotherapy-related cachexia is associated with mitochondrial depletion and the activation of ERK1/2 and p38 MAPKs. Oncotarget. 7(28), 43442–43460 (2016)</ref-fulltext>
<ce:source-text>Barreto, R., et al.: Chemotherapy-related cachexia is associated with mitochondrial depletion and the activation of ERK1/2 and p38 MAPKs. Oncotarget. 7(28), 43442–43460 (2016)</ce:source-text>
</reference>
<reference seq="46">
<ref-info>
<ref-title>
<ref-titletext-english>Chronic treatment with multi-kinase inhibitors causes differential toxicities on skeletal and cardiac muscles. </ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.R.</ce:initials>
<ce:surname>Huot</ce:surname>
<ce:given-name>J.R.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cancers (Basel). </ref-sourcetitle>
<ref-publicationyear first="2019"/>
<ref-text></ref-text>
<volisspag>
<volume-issue-number>
<vol-first>11</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Huot, J.R., et al.: Chronic treatment with multi-kinase inhibitors causes differential toxicities on skeletal and cardiac muscles. Cancers (Basel). 11(4) (2019)</ref-fulltext>
<ce:source-text>Huot, J.R., et al.: Chronic treatment with multi-kinase inhibitors causes differential toxicities on skeletal and cardiac muscles. Cancers (Basel). 11(4) (2019)</ce:source-text>
</reference>
<reference seq="47">
<ref-info>
<ref-title>
<ref-titletext-english>Cachexia induced by cancer and chemotherapy yield distinct perturbations to energy metabolism.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Pin</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle. </ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>140</first-page>
<last-page>154</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Pin, F., et al.: Cachexia induced by cancer and chemotherapy yield distinct perturbations to energy metabolism. J. Cachexia. Sarcopenia Muscle. 10(1), 140–154 (2019)</ref-fulltext>
<ce:source-text>Pin, F., et al.: Cachexia induced by cancer and chemotherapy yield distinct perturbations to energy metabolism. J. Cachexia. Sarcopenia Muscle. 10(1), 140–154 (2019)</ce:source-text>
</reference>
<reference seq="48">
<ref-info>
<ref-title>
<ref-titletext-english>Skeletal muscle depletion during chemotherapy has a large impact on physical function in elderly Japanese patients with advanced nonsmall-cell lung cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Naito</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>BMC Cancer.</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>17</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>571</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Naito, T., et al.: Skeletal muscle depletion during chemotherapy has a large impact on physical function in elderly Japanese patients with advanced nonsmall-cell lung cancer. BMC Cancer. 17(1), 571 (2017)</ref-fulltext>
<ce:source-text>Naito, T., et al.: Skeletal muscle depletion during chemotherapy has a large impact on physical function in elderly Japanese patients with advanced nonsmall-cell lung cancer. BMC Cancer. 17(1), 571 (2017)</ce:source-text>
</reference>
<reference seq="49">
<ref-info>
<ref-title>
<ref-titletext-english>Prognostic value of the six-minute walk in advanced non-small cell lung cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Kasymjanova</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Thorac. Oncol.</ref-sourcetitle>
<ref-publicationyear first="2009"/>
<volisspag>
<volume-issue-number>
<vol-first>4</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>602</first-page>
<last-page>607</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kasymjanova, G., et al.: Prognostic value of the six-minute walk in advanced non-small cell lung cancer. J. Thorac. Oncol. 4(5), 602–607 (2009)</ref-fulltext>
<ce:source-text>Kasymjanova, G., et al.: Prognostic value of the six-minute walk in advanced non-small cell lung cancer. J. Thorac. Oncol. 4(5), 602–607 (2009)</ce:source-text>
</reference>
<reference seq="50">
<ref-info>
<ref-title>
<ref-titletext-english>Impact of different palliative systemic treatments on skeletal muscle mass in metastatic colorectal cancer patients.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.A.</ce:initials>
<ce:surname>Kurk</ce:surname>
<ce:given-name>S.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle.</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>909</first-page>
<last-page>919</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kurk, S.A., et al.: Impact of different palliative systemic treatments on skeletal muscle mass in metastatic colorectal cancer patients. J. Cachexia. Sarcopenia Muscle. 9(5), 909–919 (2018)</ref-fulltext>
<ce:source-text>Kurk, S.A., et al.: Impact of different palliative systemic treatments on skeletal muscle mass in metastatic colorectal cancer patients. J. Cachexia. Sarcopenia Muscle. 9(5), 909–919 (2018)</ce:source-text>
</reference>
<reference seq="51">
<ref-info>
<ref-title>
<ref-titletext-english>Muscle strength in breast cancer patients receiving different treatment regimes</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>O.</ce:initials>
<ce:surname>Klassen</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle. </ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>305</first-page>
<last-page>316</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Klassen, O., et al.: Muscle strength in breast cancer patients receiving different treatment regimes. J. Cachexia. Sarcopenia Muscle. 8(2), 305–316 (2017)</ref-fulltext>
<ce:source-text>Klassen, O., et al.: Muscle strength in breast cancer patients receiving different treatment regimes. J. Cachexia. Sarcopenia Muscle. 8(2), 305–316 (2017)</ce:source-text>
</reference>
<reference seq="52">
<ref-info>
<ref-title>
<ref-titletext-english>Weight and body composition changes during and after adjuvant chemotherapy in women with breast cancer.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.J.</ce:initials>
<ce:surname>Freedman</ce:surname>
<ce:given-name>R.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Endocrinol. Metab.</ref-sourcetitle>
<ref-publicationyear first="2004"/>
<volisspag>
<volume-issue-number>
<vol-first>89</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2248</first-page>
<last-page>2253</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Freedman, R.J., et al.: Weight and body composition changes during and after adjuvant chemotherapy in women with breast cancer. J. Clin. Endocrinol. Metab. 89(5), 2248–2253 (2004)</ref-fulltext>
<ce:source-text>Freedman, R.J., et al.: Weight and body composition changes during and after adjuvant chemotherapy in women with breast cancer. J. Clin. Endocrinol. Metab. 89(5), 2248–2253 (2004)</ce:source-text>
</reference>
<reference seq="53">
<ref-info>
<ref-title>
<ref-titletext-english>Marked changes in body composition following neoadjuvant chemotherapy for oesophagogastric cancer.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Awad</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Clin. Nutr.</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<volisspag>
<volume-issue-number>
<vol-first>31</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>74</first-page>
<last-page>77</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Awad, S., et al.: Marked changes in body composition following neoadjuvant chemotherapy for oesophagogastric cancer. Clin. Nutr. 31(1), 74–77 (2012)</ref-fulltext>
<ce:source-text>Awad, S., et al.: Marked changes in body composition following neoadjuvant chemotherapy for oesophagogastric cancer. Clin. Nutr. 31(1), 74–77 (2012)</ce:source-text>
</reference>
<reference seq="54">
<ref-info>
<ref-title>
<ref-titletext-english>A decline in weight and attrition of muscle in colorectal cancer patients receiving chemotherapy with bevacizumab</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Poterucha</ce:surname>
</author>
<author seq="2">
<ce:initials>B.</ce:initials>
<ce:surname>Burnette</ce:surname>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Jatoi</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Med. Oncol</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<volisspag>
<volume-issue-number>
<vol-first>29</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1005</first-page>
<last-page>1009</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Poterucha, T., Burnette, B., Jatoi, A.: A decline in weight and attrition of muscle in colorectal cancer patients receiving chemotherapy with bevacizumab. Med. Oncol. 29(2), 1005–1009 (2012)</ref-fulltext>
<ce:source-text>Poterucha, T., Burnette, B., Jatoi, A.: A decline in weight and attrition of muscle in colorectal cancer patients receiving chemotherapy with bevacizumab. Med. Oncol. 29(2), 1005–1009 (2012)</ce:source-text>
</reference>
<reference seq="55">
<ref-info>
<ref-title>
<ref-titletext-english>Mechanisms of cisplatin-induced muscle atrophy. </ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Sakai</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2014"/>
<ref-text>Toxicol. Appl. Pharmacol. </ref-text>
<volisspag>
<volume-issue-number>
<vol-first>278</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>190</first-page>
<last-page>199</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sakai, H., et al.: Mechanisms of cisplatin-induced muscle atrophy. Toxicol. Appl. Pharmacol. 278(2), 190–199 (2014)</ref-fulltext>
<ce:source-text>Sakai, H., et al.: Mechanisms of cisplatin-induced muscle atrophy. Toxicol. Appl. Pharmacol. 278(2), 190–199 (2014)</ce:source-text>
</reference>
<reference seq="56">
<ref-info>
<ref-title>
<ref-titletext-english>Taurine rescues cisplatininduced muscle atrophy in vitro: a morphological study.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Stacchiotti</ce:surname>
<ce:given-name></ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oxidative Med.  </ref-sourcetitle>
<ref-publicationyear first="2014"/>
<ref-text>Cell. Longev.</ref-text>
</ref-info>
<ref-fulltext>Stacchiotti, A., et al.: Taurine rescues cisplatininduced muscle atrophy in vitro: a morphological study. Oxidative Med. Cell. Longev. 2014, 840951 (2014)</ref-fulltext>
<ce:source-text>Stacchiotti, A., et al.: Taurine rescues cisplatininduced muscle atrophy in vitro: a morphological study. Oxidative Med. Cell. Longev. 2014, 840951 (2014)</ce:source-text>
</reference>
<reference seq="57">
<ref-info>
<ref-title>
<ref-titletext-english>Oxaliplatin induces muscle loss and muscle-specific molecular changes in Mice.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.E.</ce:initials>
<ce:surname>Feather</ce:surname>
<ce:given-name>C.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Muscle Nerve.</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>57</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>650</first-page>
<last-page>658</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Feather, C.E., et al.: Oxaliplatin induces muscle loss and muscle-specific molecular changes in Mice. Muscle Nerve. 57(4), 650–658 (2018)</ref-fulltext>
<ce:source-text>Feather, C.E., et al.: Oxaliplatin induces muscle loss and muscle-specific molecular changes in Mice. Muscle Nerve. 57(4), 650–658 (2018)</ce:source-text>
</reference>
<reference seq="58">
<ref-info>
<ref-title>
<ref-titletext-english>BGP-15 protects against oxaliplatin-induced skeletal myopathy and mitochondrial reactive oxygen species production in mice.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.C.</ce:initials>
<ce:surname>Sorensen</ce:surname>
<ce:given-name>J.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Front. Pharmacol.</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>137</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sorensen, J.C., et al.: BGP-15 protects against oxaliplatin-induced skeletal myopathy and mitochondrial reactive oxygen species production in mice. Front. Pharmacol. 8, 137 (2017)</ref-fulltext>
<ce:source-text>Sorensen, J.C., et al.: BGP-15 protects against oxaliplatin-induced skeletal myopathy and mitochondrial reactive oxygen species production in mice. Front. Pharmacol. 8, 137 (2017)</ce:source-text>
</reference>
<reference seq="59">
<ref-info>
<ref-title>
<ref-titletext-english>Zoledronic acid improves muscle function in healthy mice treated with chemotherapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.A.</ce:initials>
<ce:surname>Hain</ce:surname>
<ce:given-name>B.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Bone Miner. Res.</ref-sourcetitle>
<ref-publicationyear first="2019"/>
</ref-info>
<ref-fulltext>Hain, B.A., et al.: Zoledronic acid improves muscle function in healthy mice treated with chemotherapy. J. Bone Miner. Res. (2019)</ref-fulltext>
<ce:source-text>Hain, B.A., et al.: Zoledronic acid improves muscle function in healthy mice treated with chemotherapy. J. Bone Miner. Res. (2019)</ce:source-text>
</reference>
<reference seq="60">
<ref-info>
<ref-title>
<ref-titletext-english>Aerobic exercise, but not metformin, prevents reduction of muscular performance by AMPk activation in mice on doxorubicin chemotherapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.A.</ce:initials>
<ce:surname>de Lima</ce:surname>
<ce:given-name>E.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cell. Physiol.</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>233</vol-first>
<iss-first>12</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>9652</first-page>
<last-page>9662</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>de Lima, E.A., et al.: Aerobic exercise, but not metformin, prevents reduction of muscular performance by AMPk activation in mice on doxorubicin chemotherapy. J. Cell. Physiol. 233(12), 9652–9662 (2018)</ref-fulltext>
<ce:source-text>de Lima, E.A., et al.: Aerobic exercise, but not metformin, prevents reduction of muscular performance by AMPk activation in mice on doxorubicin chemotherapy. J. Cell. Physiol. 233(12), 9652–9662 (2018)</ce:source-text>
</reference>
<reference seq="61">
<ref-info>
<ref-title>
<ref-titletext-english>Prevention of chemotherapyinduced cachexia by ACVR2B ligand blocking has different effects on heart and skeletal muscle.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.J.</ce:initials>
<ce:surname>Hulmi</ce:surname>
<ce:given-name>J.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle.</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>417</first-page>
<last-page>432</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hulmi, J.J., et al.: Prevention of chemotherapyinduced cachexia by ACVR2B ligand blocking has different effects on heart and skeletal muscle. J. Cachexia. Sarcopenia Muscle. 9(2), 417–432 (2018)</ref-fulltext>
<ce:source-text>Hulmi, J.J., et al.: Prevention of chemotherapyinduced cachexia by ACVR2B ligand blocking has different effects on heart and skeletal muscle. J. Cachexia. Sarcopenia Muscle. 9(2), 417–432 (2018)</ce:source-text>
</reference>
<reference seq="62">
<ref-info>
<ref-title>
<ref-titletext-english>Systemic blockade of ACVR2B ligands prevents chemotherapy-induced muscle wasting by restoring muscle protein synthesis without affecting oxidative capacity or atrogenes.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.A.</ce:initials>
<ce:surname>Nissinen</ce:surname>
<ce:given-name>T.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Sci. Rep.</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>32695</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Nissinen, T.A., et al.: Systemic blockade of ACVR2B ligands prevents chemotherapy-induced muscle wasting by restoring muscle protein synthesis without affecting oxidative capacity or atrogenes. Sci. Rep. 6, 32695 (2016)</ref-fulltext>
<ce:source-text>Nissinen, T.A., et al.: Systemic blockade of ACVR2B ligands prevents chemotherapy-induced muscle wasting by restoring muscle protein synthesis without affecting oxidative capacity or atrogenes. Sci. Rep. 6, 32695 (2016)</ce:source-text>
</reference>
<reference seq="63">
<ref-info>
<ref-title>
<ref-titletext-english>Endurance exercise protects skeletal muscle against both doxorubicin-induced and inactivity-induced muscle wasting. </ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.K.</ce:initials>
<ce:surname>Powers</ce:surname>
<ce:given-name>S.K.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Pflugers Arch. </ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>471</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>441</first-page>
<last-page>453</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Powers, S.K., et al.: Endurance exercise protects skeletal muscle against both doxorubicin-induced and inactivity-induced muscle wasting. Pflugers Arch. 471(3), 441–453 (2019)</ref-fulltext>
<ce:source-text>Powers, S.K., et al.: Endurance exercise protects skeletal muscle against both doxorubicin-induced and inactivity-induced muscle wasting. Pflugers Arch. 471(3), 441–453 (2019)</ce:source-text>
</reference>
<reference seq="64">
<ref-info>
<ref-title>
<ref-titletext-english> Ibudilast attenuates doxorubicin-induced cytotoxicity by suppressing formation of TRPC3 channel and NADPH oxidase 2 protein complexes.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Nishiyama</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Br. J. Pharmacol</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>176</vol-first>
<iss-first>18</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3723</first-page>
<last-page>3738</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Nishiyama, K., et al.: Ibudilast attenuates doxorubicin-induced cytotoxicity by suppressing formation of TRPC3 channel and NADPH oxidase 2 protein complexes. Br. J. Pharmacol. 176(18), 3723–3738 (2019)</ref-fulltext>
<ce:source-text>Nishiyama, K., et al.: Ibudilast attenuates doxorubicin-induced cytotoxicity by suppressing formation of TRPC3 channel and NADPH oxidase 2 protein complexes. Br. J. Pharmacol. 176(18), 3723–3738 (2019)</ce:source-text>
</reference>
<reference seq="65">
<ref-info>
<ref-title>
<ref-titletext-english>Prognostic effect of weight loss prior to chemotherapy in cancer patients. EasternCooperative Oncology Group.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>W.D.</ce:initials>
<ce:surname>Dewys</ce:surname>
<ce:given-name>W.D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Med</ref-sourcetitle>
<ref-publicationyear first="1980"/>
<volisspag>
<volume-issue-number>
<vol-first>69</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>491</first-page>
<last-page>497</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Dewys, W.D., et al.: Prognostic effect of weight loss prior to chemotherapy in cancer patients. EasternCooperative Oncology Group. Am. J. Med. 69(4), 491–497 (1980)</ref-fulltext>
<ce:source-text>Dewys, W.D., et al.: Prognostic effect of weight loss prior to chemotherapy in cancer patients. EasternCooperative Oncology Group. Am. J. Med. 69(4), 491–497 (1980)</ce:source-text>
</reference>
<reference seq="66">
<ref-info>
<ref-title>
<ref-titletext-english>Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Grothey</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Lancet.</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<volisspag>
<volume-issue-number>
<vol-first>381</vol-first>
<iss-first>9863</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>303</first-page>
<last-page>312</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Grothey, A., et al.: Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 381(9863), 303–312 (2013)</ref-fulltext>
<ce:source-text>Grothey, A., et al.: Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 381(9863), 303–312 (2013)</ce:source-text>
</reference>
<reference seq="67">
<ref-info>
<ref-title>
<ref-titletext-english>In a ‘real-world’, clinic-based community setting, sorafenib dose of 400 mg/day is as effective as standard dose of 800 mg/day in patients with advanced hepatocellular carcimona, with better tolerance and similar survival.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Shingina</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Can. J. Gastroenterol</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<volisspag>
<volume-issue-number>
<vol-first>27</vol-first>
<iss-first>7</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>393</first-page>
<last-page>396</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Shingina, A., et al.: In a ‘real-world’, clinic-based community setting, sorafenib dose of 400 mg/day is as effective as standard dose of 800 mg/day in patients with advanced hepatocellular carcimona, with better tolerance and similar survival. Can. J. Gastroenterol. 27(7), 393–396 (2013)</ref-fulltext>
<ce:source-text>Shingina, A., et al.: In a ‘real-world’, clinic-based community setting, sorafenib dose of 400 mg/day is as effective as standard dose of 800 mg/day in patients with advanced hepatocellular carcimona, with better tolerance and similar survival. Can. J. Gastroenterol. 27(7), 393–396 (2013)</ce:source-text>
</reference>
<reference seq="68">
<ref-info>
<ref-title>
<ref-titletext-english>Growth hormone secretagogues hexarelin and JMV2894 protect skeletal muscle from mitochondrial damages in a rat model of cisplatin-induced cachexia.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Sirago</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Sci. Rep.</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>13017</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sirago, G., et al.: Growth hormone secretagogues hexarelin and JMV2894 protect skeletal muscle from mitochondrial damages in a rat model of cisplatin-induced cachexia. Sci. Rep. 7(1), 13017 (2017)</ref-fulltext>
<ce:source-text>Sirago, G., et al.: Growth hormone secretagogues hexarelin and JMV2894 protect skeletal muscle from mitochondrial damages in a rat model of cisplatin-induced cachexia. Sci. Rep. 7(1), 13017 (2017)</ce:source-text>
</reference>
<reference seq="69">
<ref-info>
<ref-title>
<ref-titletext-english>Doxorubicin causes lesions in the electron transport system of skeletal muscle mitochondria that are associated with a loss of contractile function.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.D.</ce:initials>
<ce:surname>Tarpey</ce:surname>
<ce:given-name>M.D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Biol. Chem.</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>294</vol-first>
<iss-first>51</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>19709</first-page>
<last-page>19722</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Tarpey, M.D., et al.: Doxorubicin causes lesions in the electron transport system of skeletal muscle mitochondria that are associated with a loss of contractile function. J. Biol. Chem. 294(51), 19709–19722 (2019)</ref-fulltext>
<ce:source-text>Tarpey, M.D., et al.: Doxorubicin causes lesions in the electron transport system of skeletal muscle mitochondria that are associated with a loss of contractile function. J. Biol. Chem. 294(51), 19709–19722 (2019)</ce:source-text>
</reference>
<reference seq="70">
<ref-info>
<ref-title>
<ref-titletext-english>Muscle weakness and neuromuscular junctions in aging and disease.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Shigemoto</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Geriatr Gerontol Int.</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
<suppl>Suppl 1</suppl>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Shigemoto, K., et al.: Muscle weakness and neuromuscular junctions in aging and disease. Geriatr Gerontol Int. 10(Suppl 1), S137–S147 (2010) </ref-fulltext>
<ce:source-text>Shigemoto, K., et al.: Muscle weakness and neuromuscular junctions in aging and disease. Geriatr Gerontol Int. 10(Suppl 1), S137–S147 (2010) </ce:source-text>
</reference>
<reference seq="71">
<ref-info>
<ref-title>
<ref-titletext-english>Familial amyotrophic lateral sclerosis-linked SOD1 mutants perturb fast axonal transport to reduce axonal mitochondria content.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.J.</ce:initials>
<ce:surname>De Vos</ce:surname>
<ce:given-name>K.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Hum. Mol. Genet.</ref-sourcetitle>
<ref-publicationyear first="2007"/>
<volisspag>
<volume-issue-number>
<vol-first>16</vol-first>
<iss-first>22</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2720</first-page>
<last-page>2728</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>De Vos, K.J., et al.: Familial amyotrophic lateral sclerosis-linked SOD1 mutants perturb fast axonal transport to reduce axonal mitochondria content. Hum. Mol. Genet. 16(22), 2720–2728 (2007)</ref-fulltext>
<ce:source-text>De Vos, K.J., et al.: Familial amyotrophic lateral sclerosis-linked SOD1 mutants perturb fast axonal transport to reduce axonal mitochondria content. Hum. Mol. Genet. 16(22), 2720–2728 (2007)</ce:source-text>
</reference>
<reference seq="72">
<ref-info>
<ref-title>
<ref-titletext-english>Mitochondrial dynamics and bioenergetic dysfunction is associated with synaptic alterations in mutant SOD1 motor neurons</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Magrane</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Neurosci.</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<volisspag>
<volume-issue-number>
<vol-first>32</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>229</first-page>
<last-page>242</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Magrane, J., et al.: Mitochondrial dynamics and bioenergetic dysfunction is associated with synaptic alterations in mutant SOD1 motor neurons. J. Neurosci. 32(1), 229–242 (2012)</ref-fulltext>
<ce:source-text>Magrane, J., et al.: Mitochondrial dynamics and bioenergetic dysfunction is associated with synaptic alterations in mutant SOD1 motor neurons. J. Neurosci. 32(1), 229–242 (2012)</ce:source-text>
</reference>
<reference seq="73">
<ref-info>
<ref-title>
<ref-titletext-english>Neuromuscular disease: mitochondrial dysfunction could precipitate motor neuron loss in spinal muscular atrophy.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Malkki</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Neurol.</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
<iss-first>10</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>556</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Malkki, H.: Neuromuscular disease: mitochondrial dysfunction could precipitate motor neuron loss in spinal muscular atrophy. Nat. Rev. Neurol. 12(10), 556 (2016)</ref-fulltext>
<ce:source-text>Malkki, H.: Neuromuscular disease: mitochondrial dysfunction could precipitate motor neuron loss in spinal muscular atrophy. Nat. Rev. Neurol. 12(10), 556 (2016)</ce:source-text>
</reference>
<reference seq="74">
<ref-info>
<ref-title>
<ref-titletext-english>Mitochondrial oxidative stress impairs contractile function but paradoxically increases muscle mass via fibre branching</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.</ce:initials>
<ce:surname>Ahn</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle. </ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>411</first-page>
<last-page>428</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ahn, B., et al.: Mitochondrial oxidative stress impairs contractile function but paradoxically increases muscle mass via fibre branching. J. Cachexia. Sarcopenia Muscle. 10(2), 411–428 (2019)</ref-fulltext>
<ce:source-text>Ahn, B., et al.: Mitochondrial oxidative stress impairs contractile function but paradoxically increases muscle mass via fibre branching. J. Cachexia. Sarcopenia Muscle. 10(2), 411–428 (2019)</ce:source-text>
</reference>
<reference seq="75">
<ref-info>
<ref-title>
<ref-titletext-english>Regulation of nicotinic acetylcholine receptor turnover by MuRF1 connects muscle activity to endo/lysosomal and atrophy pathways.Age (Dordr.).</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Rudolf</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Age (Dordr.).</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<volisspag>
<volume-issue-number>
<vol-first>35</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1663</first-page>
<last-page>1674</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Rudolf, R., et al.: Regulation of nicotinic acetylcholine receptor turnover by MuRF1 connects muscle activity to endo/lysosomal and atrophy pathways. Age (Dordr.). 35(5), 1663–1674 (2013) </ref-fulltext>
<ce:source-text>Rudolf, R., et al.: Regulation of nicotinic acetylcholine receptor turnover by MuRF1 connects muscle activity to endo/lysosomal and atrophy pathways. Age (Dordr.). 35(5), 1663–1674 (2013)</ce:source-text>
</reference>
<reference seq="76">
<ref-info>
<ref-title>
<ref-titletext-english>D-methionine ameliorates cisplatin-induced muscle atrophy via inhibition of muscle degradation pathway</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.T.</ce:initials>
<ce:surname>Wu</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Integr. Cancer Ther</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>18</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Wu, C.T., et al.: D-methionine ameliorates cisplatin-induced muscle atrophy via inhibition of muscle degradation pathway. Integr. Cancer Ther. 18, 1534735419828832 (2019)</ref-fulltext>
<ce:source-text>Wu, C.T., et al.: D-methionine ameliorates cisplatin-induced muscle atrophy via inhibition of muscle degradation pathway. Integr. Cancer Ther. 18, 1534735419828832 (2019)</ce:source-text>
</reference>
<reference seq="77">
<ref-info>
<ref-title>
<ref-titletext-english>Role of oxidative stress in oxaliplatin-induced enteric neuropathy and colonic dysmotility in mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.M.</ce:initials>
<ce:surname>McQuade</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Br. J. Pharmacol</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>173</vol-first>
<iss-first>24</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3502</first-page>
<last-page>3521</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>McQuade, R.M., et al.: Role of oxidative stress in oxaliplatin-induced enteric neuropathy and colonic dysmotility in mice. Br. J. Pharmacol. 173(24), 3502–3521 (2016)</ref-fulltext>
<ce:source-text>McQuade, R.M., et al.: Role of oxidative stress in oxaliplatin-induced enteric neuropathy and colonic dysmotility in mice. Br. J. Pharmacol. 173(24), 3502–3521 (2016)</ce:source-text>
</reference>
<reference seq="78">
<ref-info>
<ref-title>
<ref-titletext-english>Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.G.</ce:initials>
<ce:surname>Webster</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Br. J. Pharmacol</ref-sourcetitle>
<ref-publicationyear first="2005"/>
<volisspag>
<volume-issue-number>
<vol-first>146</vol-first>
<iss-first>7</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1027</first-page>
<last-page>1039</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Webster, R.G., et al.: Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels. Br. J. Pharmacol. 146(7), 1027–1039 (2005)</ref-fulltext>
<ce:source-text>Webster, R.G., et al.: Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels. Br. J. Pharmacol. 146(7), 1027–1039 (2005)</ce:source-text>
</reference>
<reference seq="79">
<ref-info>
<ref-title>
<ref-titletext-english>Modification of neuromuscular junction protein expression by exercise and doxorubicin</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.M.</ce:initials>
<ce:surname>Huertas</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Med. Sci. Sports Exerc</ref-sourcetitle>
<ref-publicationyear first="2020"/>
</ref-info>
<ref-fulltext>Huertas,A.M.,etal.:Modificationofneuromuscularjunctionproteinexpressionbyexerciseanddoxoru-bicin.Med.Sci.SportsExerc.(2020)</ref-fulltext>
<ce:source-text>Huertas,A.M.,etal.:Modificationofneuromuscularjunctionproteinexpressionbyexerciseanddoxoru-bicin.Med.Sci.SportsExerc.(2020)</ce:source-text>
</reference>
<reference seq="80">
<ref-info>
<ref-title>
<ref-titletext-english>Neuromuscular junctions are stable in patients with cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>I.</ce:initials>
<ce:surname>Boehm</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>J. Clin. Invest</ref-sourcetitle>
<ref-publicationyear first="2019"/>
</ref-info>
<ref-fulltext>Boehm, I., et al.: Neuromuscular junctions are stable in patients with cancer cachexia. J. Clin. Invest. (2019)</ref-fulltext>
<ce:source-text>Boehm, I., et al.: Neuromuscular junctions are stable in patients with cancer cachexia. J. Clin. Invest. (2019)</ce:source-text>
</reference>
<reference seq="81">
<ref-info>
<ref-title>
<ref-titletext-english>Muscle wasting and impaired myogenesis in tumor bearing mice are prevented by ERK inhibition</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Penna</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Plos One</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<volisspag>
<volume-issue-number>
<vol-first>5</vol-first>
<iss-first>10</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Penna, F., et al.: Muscle wasting and impaired myogenesis in tumor bearing mice are prevented by ERK inhibition. PLoS One. 5(10), e13604 (2010)</ref-fulltext>
<ce:source-text>Penna, F., et al.: Muscle wasting and impaired myogenesis in tumor bearing mice are prevented by ERK inhibition. PLoS One. 5(10), e13604 (2010)</ce:source-text>
</reference>
<reference seq="82">
<ref-info>
<ref-title>
<ref-titletext-english>p38beta MAPK mediates ULK1-dependent induction of autophagy in skeletal muscle of tumor-bearing mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Z.</ce:initials>
<ce:surname>Liu</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Cell Stress</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>2</vol-first>
<iss-first>11</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>311</first-page>
<last-page>324</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Liu, Z., et al.: P38beta MAPK mediates ULK1-dependent induction of autophagy in skeletal muscle of tumor-bearing mice. Cell Stress. 2(11), 311–324 (2018)</ref-fulltext>
<ce:source-text>Liu, Z., et al.: P38beta MAPK mediates ULK1-dependent induction of autophagy in skeletal muscle of tumor-bearing mice. Cell Stress. 2(11), 311–324 (2018)</ce:source-text>
</reference>
<reference seq="83">
<ref-info>
<ref-title>
<ref-titletext-english>Selumetinib attenuates skeletal muscle wasting in murine cachexia model through ERK inhibition and AKT activation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Quan-Jun</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Mol. Cancer Ther</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>16</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>334</first-page>
<last-page>343</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Quan-Jun, Y., et al.: Selumetinib attenuates skeletal muscle wasting in murine cachexia model through ERK inhibition and AKT activation. Mol. Cancer Ther. 16(2), 334–343 (2017)</ref-fulltext>
<ce:source-text>Quan-Jun, Y., et al.: Selumetinib attenuates skeletal muscle wasting in murine cachexia model through ERK inhibition and AKT activation. Mol. Cancer Ther. 16(2), 334–343 (2017)</ce:source-text>
</reference>
<reference seq="84">
<ref-info>
<ref-title>
<ref-titletext-english>Ghrelin prevents tumour- and cisplatin-induced muscle wasting: Characterization of multiple mechanisms involved</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.A.</ce:initials>
<ce:surname>Chen</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>132</first-page>
<last-page>143</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Chen, J.A., et al.: Ghrelin prevents tumour- and cisplatin-induced muscle wasting: Characterization of multiple mechanisms involved. J. Cachexia. Sarcopenia Muscle. 6(2), 132–143 (2015)</ref-fulltext>
<ce:source-text>Chen, J.A., et al.: Ghrelin prevents tumour- and cisplatin-induced muscle wasting: Characterization of multiple mechanisms involved. J. Cachexia. Sarcopenia Muscle. 6(2), 132–143 (2015)</ce:source-text>
</reference>
<reference seq="85">
<ref-info>
<ref-title>
<ref-titletext-english>Dexamethasone exacerbates cisplatin-induced muscle atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Sakai</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Clin. Exp. Pharmacol. Physiol</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>46</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>19</first-page>
<last-page>28</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sakai, H., et al.: Dexamethasone exacerbates cisplatin-induced muscle atrophy. Clin. Exp. Pharmacol. Physiol. 46(1), 19–28 (2019)</ref-fulltext>
<ce:source-text>Sakai, H., et al.: Dexamethasone exacerbates cisplatin-induced muscle atrophy. Clin. Exp. Pharmacol. Physiol. 46(1), 19–28 (2019)</ce:source-text>
</reference>
<reference seq="86">
<ref-info>
<ref-title>
<ref-titletext-english>Systemic blockade of ACVR2B ligands protects myocardium from acute ischemia-reperfusion injury</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Magga</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Mol. Ther</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>27</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>600</first-page>
<last-page>610</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Magga, J., et al.: Systemic blockade of ACVR2B ligands protects myocardium from acute ischemia-reperfusion injury. Mol. Ther. 27(3), 600–610 (2019)</ref-fulltext>
<ce:source-text>Magga, J., et al.: Systemic blockade of ACVR2B ligands protects myocardium from acute ischemia-reperfusion injury. Mol. Ther. 27(3), 600–610 (2019)</ce:source-text>
</reference>
<reference seq="87">
<ref-info>
<ref-title>
<ref-titletext-english>Accelerated cardiomyocyte senescence contributes to late-onset doxorubicin-induced cardiotoxicity</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.A.</ce:initials>
<ce:surname>Mitry</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Am. J. Physiol. Cell Physiol</ref-sourcetitle>
<ref-publicationyear first="2020"/>
</ref-info>
<ref-fulltext>Mitry, M.A., et al.: Accelerated cardiomyocyte senescence contributes to late-onset doxorubicin-induced cardiotoxicity. Am. J. Physiol. Cell Physiol. (2020)</ref-fulltext>
<ce:source-text>Mitry, M.A., et al.: Accelerated cardiomyocyte senescence contributes to late-onset doxorubicin-induced cardiotoxicity. Am. J. Physiol. Cell Physiol. (2020)</ce:source-text>
</reference>
<reference seq="88">
<ref-info>
<ref-title>
<ref-titletext-english>Dexrazoxane ameliorates doxorubicin-induced cardiotoxicity by inhibiting both apoptosis and necroptosis in cardiomyocytes</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.</ce:initials>
<ce:surname>Yu</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Biochem. Biophys. Res. Commun</ref-sourcetitle>
<ref-publicationyear first="2019"/>
</ref-info>
<ref-fulltext>Yu, X., et al.: Dexrazoxane ameliorates doxorubicin-induced cardiotoxicity by inhibiting both apoptosis and necroptosis in cardiomyocytes. Biochem. Biophys. Res. Commun. (2019)</ref-fulltext>
<ce:source-text>Yu, X., et al.: Dexrazoxane ameliorates doxorubicin-induced cardiotoxicity by inhibiting both apoptosis and necroptosis in cardiomyocytes. Biochem. Biophys. Res. Commun. (2019)</ce:source-text>
</reference>
<reference seq="89">
<ref-info>
<ref-title>
<ref-titletext-english>Pravastatin attenuates carboplatin-induced cardiotoxicity via inhibition of oxidative stress associated apoptosis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.F.</ce:initials>
<ce:surname>Cheng</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Apoptosis</ref-sourcetitle>
<ref-publicationyear first="2008"/>
<volisspag>
<volume-issue-number>
<vol-first>13</vol-first>
<iss-first>7</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>883</first-page>
<last-page>894</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Cheng, C.F., et al.: Pravastatin attenuates carboplatin-induced cardiotoxicity via inhibition of oxidative stress associated apoptosis. Apoptosis. 13(7), 883–894 (2008)</ref-fulltext>
<ce:source-text>Cheng, C.F., et al.: Pravastatin attenuates carboplatin-induced cardiotoxicity via inhibition of oxidative stress associated apoptosis. Apoptosis. 13(7), 883–894 (2008)</ce:source-text>
</reference>
<reference seq="90">
<ref-info>
<ref-title>
<ref-titletext-english>The effect of rutin on cisplatin-induced oxidative cardiac damage in rats</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>I.</ce:initials>
<ce:surname>Topal</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Anatol. J. Cardiol</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>20</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>136</first-page>
<last-page>142</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Topal, I., et al.: The effect of rutin on cisplatin-induced oxidative cardiac damage in rats. Anatol. J. Cardiol. 20(3), 136–142 (2018)</ref-fulltext>
<ce:source-text>Topal, I., et al.: The effect of rutin on cisplatin-induced oxidative cardiac damage in rats. Anatol. J. Cardiol. 20(3), 136–142 (2018)</ce:source-text>
</reference>
<reference seq="91">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer cachexia: Understanding the molecular basis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.M.</ce:initials>
<ce:surname>Argiles</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Cancer</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>14</vol-first>
<iss-first>11</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>754</first-page>
<last-page>762</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Argiles, J.M., et al.: Cancer cachexia: understanding the molecular basis. Nat. Rev. Cancer. 14(11), 754–762 (2014)</ref-fulltext>
<ce:source-text>Argiles, J.M., et al.: Cancer cachexia: understanding the molecular basis. Nat. Rev. Cancer. 14(11), 754–762 (2014)</ce:source-text>
</reference>
<reference seq="92">
<ref-info>
<ref-title>
<ref-titletext-english>Nuclear magnetic resonance in conjunction with functional genomics suggests mitochondrial dysfunction in a murine model of cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Constantinou</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Int. J. Mol. Med</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>27</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>15</first-page>
<last-page>24</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Constantinou, C., et al.: Nuclear magnetic resonance in conjunction with functional genomics suggests mitochondrial dysfunction in a murine model of cancer cachexia. Int. J. Mol. Med. 27(1), 15–24 (2011)</ref-fulltext>
<ce:source-text>Constantinou, C., et al.: Nuclear magnetic resonance in conjunction with functional genomics suggests mitochondrial dysfunction in a murine model of cancer cachexia. Int. J. Mol. Med. 27(1), 15–24 (2011)</ce:source-text>
</reference>
<reference seq="93">
<ref-info>
<ref-title>
<ref-titletext-english>On the origin of cancer cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>O.</ce:initials>
<ce:surname>Warburg</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Science</ref-sourcetitle>
<ref-publicationyear first="1956"/>
<volisspag>
<volume-issue-number>
<vol-first>123</vol-first>
<iss-first>3191</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>309</first-page>
<last-page>314</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Warburg, O.: On the origin of cancer cells. Science. 123(3191), 309–314 (1956)</ref-fulltext>
<ce:source-text>Warburg, O.: On the origin of cancer cells. Science. 123(3191), 309–314 (1956)</ce:source-text>
</reference>
<reference seq="94">
<ref-info>
<ref-title>
<ref-titletext-english>Understanding the Warburg effect: The metabolic requirements of cell proliferation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.G.</ce:initials>
<ce:surname>Vander Heiden</ce:surname>
</author>
<author seq="2">
<ce:initials>L.C.</ce:initials>
<ce:surname>Cantley</ce:surname>
</author>
<author seq="3">
<ce:initials>C.B.</ce:initials>
<ce:surname>Thompson</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Science</ref-sourcetitle>
<ref-publicationyear first="2009"/>
<volisspag>
<volume-issue-number>
<vol-first>324</vol-first>
<iss-first>5930</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1029</first-page>
<last-page>1033</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Vander Heiden, M.G., Cantley, L.C., Thompson, C.B.: Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science. 324(5930), 1029–1033 (2009)</ref-fulltext>
<ce:source-text>Vander Heiden, M.G., Cantley, L.C., Thompson, C.B.: Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science. 324(5930), 1029–1033 (2009)</ce:source-text>
</reference>
<reference seq="95">
<ref-info>
<ref-title>
<ref-titletext-english>Energy metabolism in cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Rohm</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>EMBO Rep</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>20</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>4</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Rohm, M., et al.: Energy metabolism in cachexia. EMBO Rep. 20, 4 (2019)</ref-fulltext>
<ce:source-text>Rohm, M., et al.: Energy metabolism in cachexia. EMBO Rep. 20, 4 (2019)</ce:source-text>
</reference>
<reference seq="96">
<ref-info>
<ref-title>
<ref-titletext-english>Cachexia: A problem of energetic inefficiency</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.M.</ce:initials>
<ce:surname>Argiles</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>5</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>279</first-page>
<last-page>286</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Argiles, J.M., et al.: Cachexia: A problem of energetic inefficiency. J. Cachexia. Sarcopenia Muscle. 5(4), 279–286 (2014)</ref-fulltext>
<ce:source-text>Argiles, J.M., et al.: Cachexia: A problem of energetic inefficiency. J. Cachexia. Sarcopenia Muscle. 5(4), 279–286 (2014)</ce:source-text>
</reference>
<reference seq="97">
<ref-info>
<ref-title>
<ref-titletext-english>A creatine-driven substrate cycle enhances energy expenditure and thermogenesis in beige fat</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Kazak</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>163</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>643</first-page>
<last-page>655</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kazak, L., et al.: A creatine-driven substrate cycle enhances energy expenditure and thermogenesis in beige fat. Cell. 163(3), 643–655 (2015)</ref-fulltext>
<ce:source-text>Kazak, L., et al.: A creatine-driven substrate cycle enhances energy expenditure and thermogenesis in beige fat. Cell. 163(3), 643–655 (2015)</ce:source-text>
</reference>
<reference seq="98">
<ref-info>
<ref-title>
<ref-titletext-english>Lipid metabolism in cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.D.</ce:initials>
<ce:surname>Mulligan</ce:surname>
</author>
<author seq="2">
<ce:initials>S.A.</ce:initials>
<ce:surname>Beck</ce:surname>
</author>
<author seq="3">
<ce:initials>M.J.</ce:initials>
<ce:surname>Tisdale</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Br. J. Cancer</ref-sourcetitle>
<ref-publicationyear first="1992"/>
<volisspag>
<volume-issue-number>
<vol-first>66</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>57</first-page>
<last-page>61</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mulligan, H.D., Beck, S.A., Tisdale, M.J.: Lipid metabolism in cancer cachexia. Br. J. Cancer. 66(1), 57–61 (1992)</ref-fulltext>
<ce:source-text>Mulligan, H.D., Beck, S.A., Tisdale, M.J.: Lipid metabolism in cancer cachexia. Br. J. Cancer. 66(1), 57–61 (1992)</ce:source-text>
</reference>
<reference seq="99">
<ref-info>
<ref-title>
<ref-titletext-english>Insulin resistance and body composition in cancer patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Dev</ce:surname>
</author>
<author seq="2">
<ce:initials>E.</ce:initials>
<ce:surname>Bruera</ce:surname>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Dalal</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Ann. Oncol</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>29</vol-first>
<suppl>Supplement _2</suppl>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Dev, R., Bruera, E., Dalal, S.: Insulin resistance and body composition in cancer patients. Ann. Oncol. 29(suppl_2), ii18–ii26 (2018)</ref-fulltext>
<ce:source-text>Dev, R., Bruera, E., Dalal, S.: Insulin resistance and body composition in cancer patients. Ann. Oncol. 29(suppl_2), ii18–ii26 (2018)</ce:source-text>
</reference>
<reference seq="100">
<ref-info>
<ref-title>
<ref-titletext-english>Hyperglycemia and insulin resistance: Possible mechanisms</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.</ce:initials>
<ce:surname>Tomas</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Ann. N. Y. Acad. Sci</ref-sourcetitle>
<ref-publicationyear first="2002"/>
<volisspag>
<volume-issue-number>
<vol-first>967</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>43</first-page>
<last-page>51</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Tomas, E., et al.: Hyperglycemia and insulin resistance: Possible mechanisms. Ann. N. Y. Acad. Sci. 967, 43–51 (2002)</ref-fulltext>
<ce:source-text>Tomas, E., et al.: Hyperglycemia and insulin resistance: Possible mechanisms. Ann. N. Y. Acad. Sci. 967, 43–51 (2002)</ce:source-text>
</reference>
<reference seq="101">
<ref-info>
<ref-title>
<ref-titletext-english>Acute hyperglycemia associated with anti-cancer medication</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Hwangbo</ce:surname>
</author>
<author seq="2">
<ce:initials>E.K.</ce:initials>
<ce:surname>Lee</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Endocrinol. Metab. (Seoul).</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>32</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>23</first-page>
<last-page>29</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hwangbo, Y., Lee, E.K.: Acute hyperglycemia associated with anti-cancer medication. Endocrinol. Metab. (Seoul). 32(1), 23–29 (2017)</ref-fulltext>
<ce:source-text>Hwangbo, Y., Lee, E.K.: Acute hyperglycemia associated with anti-cancer medication. Endocrinol. Metab. (Seoul). 32(1), 23–29 (2017)</ce:source-text>
</reference>
<reference seq="102">
<ref-info>
<ref-title>
<ref-titletext-english>Pathophysiology of cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.N.</ce:initials>
<ce:surname>Younes</ce:surname>
</author>
<author seq="2">
<ce:initials>Y.</ce:initials>
<ce:surname>Noguchi</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Rev. Hosp. Clin. Fac. Med. Sao Paulo</ref-sourcetitle>
<ref-publicationyear first="2000"/>
<volisspag>
<volume-issue-number>
<vol-first>55</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>181</first-page>
<last-page>193</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Younes, R.N., Noguchi, Y.: Pathophysiology of cancer cachexia. Rev. Hosp. Clin. Fac. Med. Sao Paulo. 55(5), 181–193 (2000)</ref-fulltext>
<ce:source-text>Younes, R.N., Noguchi, Y.: Pathophysiology of cancer cachexia. Rev. Hosp. Clin. Fac. Med. Sao Paulo. 55(5), 181–193 (2000)</ce:source-text>
</reference>
<reference seq="103">
<ref-info>
<ref-title>
<ref-titletext-english>Severe recurrent nocturnal hypoglycemia during chemotherapy with 6-mercaptopurine in a child with acute lymphoblastic leukemia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.M.</ce:initials>
<ce:surname>Cho</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Ann. Pediatr. Endocrinol. Metab</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>23</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>226</first-page>
<last-page>228</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Cho, E.M., et al.: Severe recurrent nocturnal hypoglycemia during chemotherapy with 6-mercaptopurine in a child with acute lymphoblastic leukemia. Ann. Pediatr. Endocrinol. Metab. 23(4), 226–228 (2018)</ref-fulltext>
<ce:source-text>Cho, E.M., et al.: Severe recurrent nocturnal hypoglycemia during chemotherapy with 6-mercaptopurine in a child with acute lymphoblastic leukemia. Ann. Pediatr. Endocrinol. Metab. 23(4), 226–228 (2018)</ce:source-text>
</reference>
<reference seq="104">
<ref-info>
<ref-title>
<ref-titletext-english>Regulation of the activity of the pyruvate dehydrogenase complex</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.A.</ce:initials>
<ce:surname>Harris</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Adv. Enzym. Regul</ref-sourcetitle>
<ref-publicationyear first="2002"/>
<volisspag>
<volume-issue-number>
<vol-first>42</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>249</first-page>
<last-page>259</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Harris, R.A., et al.: Regulation of the activity of the pyruvate dehydrogenase complex. Adv. Enzym. Regul. 42, 249–259 (2002)</ref-fulltext>
<ce:source-text>Harris, R.A., et al.: Regulation of the activity of the pyruvate dehydrogenase complex. Adv. Enzym. Regul. 42, 249–259 (2002)</ce:source-text>
</reference>
<reference seq="105">
<ref-info>
<ref-title>
<ref-titletext-english>PDK4 drives metabolic alterations and muscle atrophy in cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Pin</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>FASEB J</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>33</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>7778</first-page>
<last-page>7790</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Pin, F., et al.: PDK4 drives metabolic alterations and muscle atrophy in cancer cachexia. FASEB J. 33(6), 7778–7790 (2019)</ref-fulltext>
<ce:source-text>Pin, F., et al.: PDK4 drives metabolic alterations and muscle atrophy in cancer cachexia. FASEB J. 33(6), 7778–7790 (2019)</ce:source-text>
</reference>
<reference seq="106">
<ref-info>
<ref-title>
<ref-titletext-english>Combination of exercise training and erythropoietin prevents cancer-induced muscle alterations</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Pin</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Oncotarget</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
<iss-first>41</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>43202</first-page>
<last-page>43215</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Pin, F., et al.: Combination of exercise training and erythropoietin prevents cancer-induced muscle alterations. Oncotarget. 6(41), 43202–43215 (2015)</ref-fulltext>
<ce:source-text>Pin, F., et al.: Combination of exercise training and erythropoietin prevents cancer-induced muscle alterations. Oncotarget. 6(41), 43202–43215 (2015)</ce:source-text>
</reference>
<reference seq="107">
<ref-info>
<ref-title>
<ref-titletext-english>Disruption of MEF2C signaling and loss of sarcomeric and mitochondrial integrity in cancer-induced skeletal muscle wasting</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.M.</ce:initials>
<ce:surname>Shum</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Aging (Albany NY)</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<volisspag>
<volume-issue-number>
<vol-first>4</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>133</first-page>
<last-page>143</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Shum,A.M.,etal.:DisruptionofMEF2Csignalingandlossofsarcomericandmitochondrialintegrityincancer-inducedskeletalmusclewasting.Aging(AlbanyNY).4(2),133–143(2012)</ref-fulltext>
<ce:source-text>Shum,A.M.,etal.:DisruptionofMEF2Csignalingandlossofsarcomericandmitochondrialintegrityincancer-inducedskeletalmusclewasting.Aging(AlbanyNY).4(2),133–143(2012)</ce:source-text>
</reference>
<reference seq="108">
<ref-info>
<ref-title>
<ref-titletext-english>Skeletal muscle atrophy and dysfunction in breast cancer patients: Role for chemotherapy-derived oxidant stress</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.A.</ce:initials>
<ce:surname>Guigni</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Physiol. Cell Physiol</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>315</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Guigni, B.A., et al.: Skeletal muscle atrophy and dysfunction in breast cancer patients: role for chemotherapy-derived oxidant stress. Am. J. Physiol. Cell Physiol. 315(5), C744–C756 (2018)</ref-fulltext>
<ce:source-text>Guigni, B.A., et al.: Skeletal muscle atrophy and dysfunction in breast cancer patients: role for chemotherapy-derived oxidant stress. Am. J. Physiol. Cell Physiol. 315(5), C744–C756 (2018)</ce:source-text>
</reference>
<reference seq="109">
<ref-info>
<ref-title>
<ref-titletext-english>Mechanisms for fiber-type specificity of skeletal muscle atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Wang</ce:surname>
</author>
<author seq="2">
<ce:initials>J.E.</ce:initials>
<ce:surname>Pessin</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Curr. Opin. Clin. Nutr. Metab. Care</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<volisspag>
<volume-issue-number>
<vol-first>16</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>243</first-page>
<last-page>250</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wang, Y., Pessin, J.E.: Mechanisms for fiber-type specificity of skeletal muscle atrophy. Curr. Opin. Clin. Nutr. Metab. Care. 16(3), 243–250 (2013)</ref-fulltext>
<ce:source-text>Wang, Y., Pessin, J.E.: Mechanisms for fiber-type specificity of skeletal muscle atrophy. Curr. Opin. Clin. Nutr. Metab. Care. 16(3), 243–250 (2013)</ce:source-text>
</reference>
<reference seq="110">
<ref-info>
<ref-title>
<ref-titletext-english>Role of oxidative stress as key regulator of muscle wasting during cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Abrigo</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Oxidative Med. Cell. Longev</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>2018</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Abrigo, J., et al.: Role of oxidative stress as key regulator of muscle wasting during cachexia. Oxidative Med. Cell. Longev. 2018, 2063179 (2018)</ref-fulltext>
<ce:source-text>Abrigo, J., et al.: Role of oxidative stress as key regulator of muscle wasting during cachexia. Oxidative Med. Cell. Longev. 2018, 2063179 (2018)</ce:source-text>
</reference>
<reference seq="111">
<ref-info>
<ref-title>
<ref-titletext-english>Skeletal muscle atrophy, a link between depression of protein synthesis and increase in degradation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.L.</ce:initials>
<ce:surname>Eley</ce:surname>
</author>
<author seq="2">
<ce:initials>M.J.</ce:initials>
<ce:surname>Tisdale</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Biol. Chem</ref-sourcetitle>
<ref-publicationyear first="2007"/>
<volisspag>
<volume-issue-number>
<vol-first>282</vol-first>
<iss-first>10</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>7087</first-page>
<last-page>7097</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Eley, H.L., Tisdale, M.J.: Skeletal muscle atrophy, a link between depression of protein synthesis and increase in degradation. J. Biol. Chem. 282(10), 7087–7097 (2007)</ref-fulltext>
<ce:source-text>Eley, H.L., Tisdale, M.J.: Skeletal muscle atrophy, a link between depression of protein synthesis and increase in degradation. J. Biol. Chem. 282(10), 7087–7097 (2007)</ce:source-text>
</reference>
<reference seq="112">
<ref-info>
<ref-title>
<ref-titletext-english>Impact of antioxidant supplementation on chemotherapeutic toxicity: A systematic review of the evidence from randomized controlled trials</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.I.</ce:initials>
<ce:surname>Block</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Cancer</ref-sourcetitle>
<ref-publicationyear first="2008"/>
<volisspag>
<volume-issue-number>
<vol-first>123</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1227</first-page>
<last-page>1239</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Block, K.I., et al.: Impact of antioxidant supplementation on chemotherapeutic toxicity: A systematic review of the evidence from randomized controlled trials. Int. J. Cancer. 123(6), 1227–1239 (2008)</ref-fulltext>
<ce:source-text>Block, K.I., et al.: Impact of antioxidant supplementation on chemotherapeutic toxicity: A systematic review of the evidence from randomized controlled trials. Int. J. Cancer. 123(6), 1227–1239 (2008)</ce:source-text>
</reference>
<reference seq="113">
<ref-info>
<ref-title>
<ref-titletext-english>PGC1-alpha over-expression prevents metabolic alterations and soleus muscle atrophy in hindlimb unloaded mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Cannavino</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Physiol</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>592</vol-first>
<iss-first>20</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>4575</first-page>
<last-page>4589</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Cannavino, J., et al.: PGC1-alpha over-expression prevents metabolic alterations and soleus muscle atrophy in hindlimb unloaded mice. J. Physiol. 592(20), 4575–4589 (2014)</ref-fulltext>
<ce:source-text>Cannavino, J., et al.: PGC1-alpha over-expression prevents metabolic alterations and soleus muscle atrophy in hindlimb unloaded mice. J. Physiol. 592(20), 4575–4589 (2014)</ce:source-text>
</reference>
<reference seq="114">
<ref-info>
<ref-title>
<ref-titletext-english>PGC-1alpha protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Sandri</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Proc. Natl. Acad. Sci. USA</ref-sourcetitle>
<ref-publicationyear first="2006"/>
<volisspag>
<volume-issue-number>
<vol-first>103</vol-first>
<iss-first>44</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>16260</first-page>
<last-page>16265</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sandri, M., et al.: PGC-1alpha protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription. Proc. Natl. Acad. Sci. USA. 103(44), 16260–16265 (2006)</ref-fulltext>
<ce:source-text>Sandri, M., et al.: PGC-1alpha protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription. Proc. Natl. Acad. Sci. USA. 103(44), 16260–16265 (2006)</ce:source-text>
</reference>
<reference seq="115">
<ref-info>
<ref-title>
<ref-titletext-english>Increase in muscle mitochondrial biogenesis does not prevent muscle loss but increased tumor size in a mouse model of acute cancer-induced cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.</ce:initials>
<ce:surname>Wang</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Plos One</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Wang, X., et al.: Increase in muscle mitochondrial biogenesis does not prevent muscle loss but increased tumor size in a mouse model of acute cancer-induced cachexia. PLoS One. 7(3), e33426 (2012)</ref-fulltext>
<ce:source-text>Wang, X., et al.: Increase in muscle mitochondrial biogenesis does not prevent muscle loss but increased tumor size in a mouse model of acute cancer-induced cachexia. PLoS One. 7(3), e33426 (2012)</ce:source-text>
</reference>
<reference seq="116">
<ref-info>
<ref-title>
<ref-titletext-english>Mitofusin-2 prevents skeletal muscle wasting in cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Q.L.</ce:initials>
<ce:surname>Xi</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Oncol. Lett</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>4013</first-page>
<last-page>4020</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Xi, Q.L., et al.: Mitofusin-2 prevents skeletal muscle wasting in cancer cachexia. Oncol. Lett. 12(5), 4013–4020 (2016)</ref-fulltext>
<ce:source-text>Xi, Q.L., et al.: Mitofusin-2 prevents skeletal muscle wasting in cancer cachexia. Oncol. Lett. 12(5), 4013–4020 (2016)</ce:source-text>
</reference>
<reference seq="117">
<ref-info>
<ref-title>
<ref-titletext-english>The mitochondrial metabolic reprogramming agent trimetazidine as an ‘exercise mimetic’ in cachectic C26-bearing mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Molinari</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>954</first-page>
<last-page>973</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Molinari, F., et al.: The mitochondrial metabolic reprogramming agent trimetazidine as an ‘exercise mimetic’ in cachectic C26-bearing mice. J. Cachexia. Sarcopenia Muscle. 8(6), 954–973 (2017)</ref-fulltext>
<ce:source-text>Molinari, F., et al.: The mitochondrial metabolic reprogramming agent trimetazidine as an ‘exercise mimetic’ in cachectic C26-bearing mice. J. Cachexia. Sarcopenia Muscle. 8(6), 954–973 (2017)</ce:source-text>
</reference>
<reference seq="118">
<ref-info>
<ref-title>
<ref-titletext-english>Moderate exercise improves experimental cancer cachexia by modulating the redox homeostasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Ballaro</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cancers (Basel)</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>11</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Ballaro, R., et al.: Moderate exercise improves experimental cancer cachexia by modulating the redox homeostasis. Cancers (Basel). 11(3) (2019)</ref-fulltext>
<ce:source-text>Ballaro, R., et al.: Moderate exercise improves experimental cancer cachexia by modulating the redox homeostasis. Cancers (Basel). 11(3) (2019)</ce:source-text>
</reference>
<reference seq="119">
<ref-info>
<ref-title>
<ref-titletext-english>Resistance exercise attenuates skeletal muscle oxidative stress, systemic pro-inflammatory state, and cachexia in Walker-256 tumor-bearing rats</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.S.</ce:initials>
<ce:surname>Padilha</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Appl. Physiol. Nutr. Metab</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>42</vol-first>
<iss-first>9</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>916</first-page>
<last-page>923</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Padilha, C.S., et al.: Resistance exercise attenuates skeletal muscle oxidative stress, systemic pro-inflammatory state, and cachexia in Walker-256 tumor-bearing rats. Appl. Physiol. Nutr. Metab. 42(9), 916–923 (2017)</ref-fulltext>
<ce:source-text>Padilha, C.S., et al.: Resistance exercise attenuates skeletal muscle oxidative stress, systemic pro-inflammatory state, and cachexia in Walker-256 tumor-bearing rats. Appl. Physiol. Nutr. Metab. 42(9), 916–923 (2017)</ce:source-text>
</reference>
<reference seq="120">
<ref-info>
<ref-title>
<ref-titletext-english>Combined exercise training positively affects muscle wasting in tumor-bearing mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Ranjbar</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Med. Sci. Sports Exerc</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>51</vol-first>
<iss-first>7</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1387</first-page>
<last-page>1395</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ranjbar, K., et al.: Combined exercise training positively affects muscle wasting in tumor-bearing mice. Med. Sci. Sports Exerc. 51(7), 1387–1395 (2019)</ref-fulltext>
<ce:source-text>Ranjbar, K., et al.: Combined exercise training positively affects muscle wasting in tumor-bearing mice. Med. Sci. Sports Exerc. 51(7), 1387–1395 (2019)</ce:source-text>
</reference>
<reference seq="121">
<ref-info>
<ref-title>
<ref-titletext-english>Moderate exercise in mice improves cancer plus chemotherapy-induced muscle wasting and mitochondrial alterations</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Ballaro</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>FASEB J</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>33</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>5482</first-page>
<last-page>5494</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ballaro, R., et al.: Moderate exercise in mice improves cancer plus chemotherapy-induced muscle wasting and mitochondrial alterations. FASEB J. 33(4), 5482–5494 (2019)</ref-fulltext>
<ce:source-text>Ballaro, R., et al.: Moderate exercise in mice improves cancer plus chemotherapy-induced muscle wasting and mitochondrial alterations. FASEB J. 33(4), 5482–5494 (2019)</ce:source-text>
</reference>
<reference seq="122">
<ref-info>
<ref-title>
<ref-titletext-english>Effect of acute treadmill exercise on cisplatin-induced muscle atrophy in the mouse</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Sakai</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Pflugers Arch</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>469</vol-first>
<iss-first>11</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1495</first-page>
<last-page>1505</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sakai, H., et al.: Effect of acute treadmill exercise on cisplatin-induced muscle atrophy in the mouse. Pflugers Arch. 469(11), 1495–1505 (2017)</ref-fulltext>
<ce:source-text>Sakai, H., et al.: Effect of acute treadmill exercise on cisplatin-induced muscle atrophy in the mouse. Pflugers Arch. 469(11), 1495–1505 (2017)</ce:source-text>
</reference>
<reference seq="123">
<ref-info>
<ref-title>
<ref-titletext-english>A systematic review of the safety and efficacy of aerobic exercise during cytotoxic chemotherapy treatment</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Cave</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Support Care Cancer</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>26</vol-first>
<iss-first>10</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3337</first-page>
<last-page>3351</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Cave, J., et al.: A systematic review of the safety and efficacy of aerobic exercise during cytotoxic chemotherapy treatment. Support Care Cancer. 26(10), 3337–3351 (2018)</ref-fulltext>
<ce:source-text>Cave, J., et al.: A systematic review of the safety and efficacy of aerobic exercise during cytotoxic chemotherapy treatment. Support Care Cancer. 26(10), 3337–3351 (2018)</ce:source-text>
</reference>
<reference seq="124">
<ref-info>
<ref-title>
<ref-titletext-english>Highly favorable physiological responses to concurrent resistance and high-intensity interval training during chemotherapy: The OptiTrain breast cancer trial</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Mijwel</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Breast Cancer Res. Treat</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>169</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>93</first-page>
<last-page>103</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mijwel, S., et al.: Highly favorable physiological responses to concurrent resistance and high-intensity interval training during chemotherapy: The OptiTrain breast cancer trial. Breast Cancer Res. Treat. 169(1), 93–103 (2018)</ref-fulltext>
<ce:source-text>Mijwel, S., et al.: Highly favorable physiological responses to concurrent resistance and high-intensity interval training during chemotherapy: The OptiTrain breast cancer trial. Breast Cancer Res. Treat. 169(1), 93–103 (2018)</ce:source-text>
</reference>
<reference seq="125">
<ref-info>
<ref-title>
<ref-titletext-english>Regulation of muscle growth by multiple ligands signaling through activin type II receptors</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.J.</ce:initials>
<ce:surname>Lee</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Proc. Natl. Acad. Sci. USA</ref-sourcetitle>
<ref-publicationyear first="2005"/>
<volisspag>
<volume-issue-number>
<vol-first>102</vol-first>
<iss-first>50</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>18117</first-page>
<last-page>18122</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Lee, S.J., et al.: Regulation of muscle growth by multiple ligands signaling through activin type II receptors. Proc. Natl. Acad. Sci. USA. 102(50), 18117–18122 (2005)</ref-fulltext>
<ce:source-text>Lee, S.J., et al.: Regulation of muscle growth by multiple ligands signaling through activin type II receptors. Proc. Natl. Acad. Sci. USA. 102(50), 18117–18122 (2005)</ce:source-text>
</reference>
<reference seq="126">
<ref-info>
<ref-title>
<ref-titletext-english>Activin signaling as an emerging target for therapeutic interventions</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Tsuchida</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cell Commun. Signal</ref-sourcetitle>
<ref-publicationyear first="2009"/>
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>15</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Tsuchida, K., et al.: Activin signaling as an emerging target for therapeutic interventions. Cell Commun. Signal. 7, 15 (2009)</ref-fulltext>
<ce:source-text>Tsuchida, K., et al.: Activin signaling as an emerging target for therapeutic interventions. Cell Commun. Signal. 7, 15 (2009)</ce:source-text>
</reference>
<reference seq="127">
<ref-info>
<ref-title>
<ref-titletext-english>ActRII blockade protects mice from cancer cachexia and prolongs survival in the presence of anti-cancer treatments</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Hatakeyama</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Skelet. Muscle</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>26</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hatakeyama, S., et al.: ActRII blockade protects mice from cancer cachexia and prolongs survival in the presence of anti-cancer treatments. Skelet. Muscle. 6, 26 (2016)</ref-fulltext>
<ce:source-text>Hatakeyama, S., et al.: ActRII blockade protects mice from cancer cachexia and prolongs survival in the presence of anti-cancer treatments. Skelet. Muscle. 6, 26 (2016)</ce:source-text>
</reference>
<reference seq="128">
<ref-info>
<ref-title>
<ref-titletext-english>Treating cachexia using soluble ACVR2B improves survival, alters mTOR localization, and attenuates liver and spleen responses</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.A.</ce:initials>
<ce:surname>Nissinen</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>514</first-page>
<last-page>529</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Nissinen, T.A., et al.: Treating cachexia using soluble ACVR2B improves survival, alters mTOR localization, and attenuates liver and spleen responses. J. Cachexia. Sarcopenia Muscle. 9(3), 514–529 (2018)</ref-fulltext>
<ce:source-text>Nissinen, T.A., et al.: Treating cachexia using soluble ACVR2B improves survival, alters mTOR localization, and attenuates liver and spleen responses. J. Cachexia. Sarcopenia Muscle. 9(3), 514–529 (2018)</ce:source-text>
</reference>
<reference seq="129">
<ref-info>
<ref-title>
<ref-titletext-english>The systemic activin response to pancreatic cancer: Implications for effective cancer cachexia therapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.</ce:initials>
<ce:surname>Zhong</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1083</first-page>
<last-page>1101</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zhong, X., et al.: The systemic activin response to pancreatic cancer: implications for effective cancer cachexia therapy. J. Cachexia. Sarcopenia Muscle. 10(5), 1083–1101 (2019)</ref-fulltext>
<ce:source-text>Zhong, X., et al.: The systemic activin response to pancreatic cancer: implications for effective cancer cachexia therapy. J. Cachexia. Sarcopenia Muscle. 10(5), 1083–1101 (2019)</ce:source-text>
</reference>
<reference seq="130">
<ref-info>
<ref-title>
<ref-titletext-english>Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.E.</ce:initials>
<ce:surname>Benny Klimek</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Biochem. Biophys. Res. Commun</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<volisspag>
<volume-issue-number>
<vol-first>391</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1548</first-page>
<last-page>1554</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Benny Klimek, M.E., et al.: Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia. Biochem. Biophys. Res. Commun. 391(3), 1548–1554 (2010)</ref-fulltext>
<ce:source-text>Benny Klimek, M.E., et al.: Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia. Biochem. Biophys. Res. Commun. 391(3), 1548–1554 (2010)</ce:source-text>
</reference>
<reference seq="131">
<ref-info>
<ref-title>
<ref-titletext-english>Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.</ce:initials>
<ce:surname>Zhou</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<volisspag>
<volume-issue-number>
<vol-first>142</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>531</first-page>
<last-page>543</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zhou, X., et al.: Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell. 142(4), 531–543 (2010)</ref-fulltext>
<ce:source-text>Zhou, X., et al.: Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell. 142(4), 531–543 (2010)</ce:source-text>
</reference>
<reference seq="132">
<ref-info>
<ref-title>
<ref-titletext-english>Bone and muscle: Interactions beyond mechanical</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Brotto</ce:surname>
</author>
<author seq="2">
<ce:initials>L.</ce:initials>
<ce:surname>Bonewald</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Bone</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>80</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>109</first-page>
<last-page>114</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Brotto,M.,Bonewald,L.:Boneandmuscle:Interactionsbeyondmechanical.Bone.80,109–114(2015)</ref-fulltext>
<ce:source-text>Brotto,M.,Bonewald,L.:Boneandmuscle:Interactionsbeyondmechanical.Bone.80,109–114(2015)</ce:source-text>
</reference>
<reference seq="133">
<ref-info>
<ref-title>
<ref-titletext-english>Differential bone loss in mouse models of colon cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Bonetto</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Front. Physiol</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>679</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Bonetto, A., et al.: Differential bone loss in mouse models of colon cancer cachexia. Front. Physiol. 7, 679 (2016)</ref-fulltext>
<ce:source-text>Bonetto, A., et al.: Differential bone loss in mouse models of colon cancer cachexia. Front. Physiol. 7, 679 (2016)</ce:source-text>
</reference>
<reference seq="134">
<ref-info>
<ref-title>
<ref-titletext-english>Growth of ovarian cancer xenografts causes loss of muscle and bone mass: A new model for the study of cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Pin</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>685</first-page>
<last-page>700</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Pin, F., et al.: Growth of ovarian cancer xenografts causes loss of muscle and bone mass: A new model for the study of cancer cachexia. J. Cachexia. Sarcopenia Muscle. 9(4), 685–700 (2018)</ref-fulltext>
<ce:source-text>Pin, F., et al.: Growth of ovarian cancer xenografts causes loss of muscle and bone mass: A new model for the study of cancer cachexia. J. Cachexia. Sarcopenia Muscle. 9(4), 685–700 (2018)</ce:source-text>
</reference>
<reference seq="135">
<ref-info>
<ref-title>
<ref-titletext-english>Excess TGF-beta mediates muscle weakness associated with bone metastases in mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.L.</ce:initials>
<ce:surname>Waning</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Med</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>21</vol-first>
<iss-first>11</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1262</first-page>
<last-page>1271</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Waning, D.L., et al.: Excess TGF-beta mediates muscle weakness associated with bone metastases in mice. Nat. Med. 21(11), 1262–1271 (2015)</ref-fulltext>
<ce:source-text>Waning, D.L., et al.: Excess TGF-beta mediates muscle weakness associated with bone metastases in mice. Nat. Med. 21(11), 1262–1271 (2015)</ce:source-text>
</reference>
<reference seq="136">
<ref-info>
<ref-title>
<ref-titletext-english>Pamidronate attenuates muscle loss after pediatric burn injury</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.</ce:initials>
<ce:surname>Borsheim</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Bone Miner. Res</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>29</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1369</first-page>
<last-page>1372</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Borsheim, E., et al.: Pamidronate attenuates muscle loss after pediatric burn injury. J. Bone Miner. Res. 29(6), 1369–1372 (2014)</ref-fulltext>
<ce:source-text>Borsheim, E., et al.: Pamidronate attenuates muscle loss after pediatric burn injury. J. Bone Miner. Res. 29(6), 1369–1372 (2014)</ce:source-text>
</reference>
<reference seq="137">
<ref-info>
<ref-title>
<ref-titletext-english>Molecular mechanisms responsible for the rescue effects of pamidronate on muscle atrophy in pediatric burn patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Pin</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Front. Endocrinol. (Lausanne).</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>543</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Pin, F., et al.: Molecular mechanisms responsible for the rescue effects of pamidronate on muscle atrophy in pediatric burn patients. Front. Endocrinol. (Lausanne). 10, 543 (2019)</ref-fulltext>
<ce:source-text>Pin, F., et al.: Molecular mechanisms responsible for the rescue effects of pamidronate on muscle atrophy in pediatric burn patients. Front. Endocrinol. (Lausanne). 10, 543 (2019)</ce:source-text>
</reference>
<reference seq="138">
<ref-info>
<ref-title>
<ref-titletext-english>RANKL inhibition improves muscle strength and insulin sensitivity and restores bone mass</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.</ce:initials>
<ce:surname>Bonnet</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Invest</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>129</vol-first>
<iss-first>8</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3214</first-page>
<last-page>3223</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Bonnet, N., et al.: RANKL inhibition improves muscle strength and insulin sensitivity and restores bone mass. J. Clin. Invest. 129(8), 3214–3223 (2019)</ref-fulltext>
<ce:source-text>Bonnet, N., et al.: RANKL inhibition improves muscle strength and insulin sensitivity and restores bone mass. J. Clin. Invest. 129(8), 3214–3223 (2019)</ce:source-text>
</reference>
<reference seq="139">
<ref-info>
<ref-title>
<ref-titletext-english>Nutrition interventions to treat low muscle mass in cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.M.</ce:initials>
<ce:surname>Prado</ce:surname>
</author>
<author seq="2">
<ce:initials>S.A.</ce:initials>
<ce:surname>Purcell</ce:surname>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Laviano</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2020"/>
</ref-info>
<ref-fulltext>Prado, C.M., Purcell, S.A., Laviano, A.: Nutrition interventions to treat low muscle mass in cancer. J. Cachexia. Sarcopenia Muscle. (2020)</ref-fulltext>
<ce:source-text>Prado, C.M., Purcell, S.A., Laviano, A.: Nutrition interventions to treat low muscle mass in cancer. J. Cachexia. Sarcopenia Muscle. (2020)</ce:source-text>
</reference>
<reference seq="140">
<ref-info>
<ref-title>
<ref-titletext-english>Alterations of protein turnover underlying disuse atrophy in human skeletal muscle</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.M.</ce:initials>
<ce:surname>Phillips</ce:surname>
</author>
<author seq="2">
<ce:initials>E.I.</ce:initials>
<ce:surname>Glover</ce:surname>
</author>
<author seq="3">
<ce:initials>M.J.</ce:initials>
<ce:surname>Rennie</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Appl. Physiol. 2009.</ref-sourcetitle>
<ref-publicationyear first="1985"/>
<volisspag>
<volume-issue-number>
<vol-first>107</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>645</first-page>
<last-page>654</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Phillips, S.M., Glover, E.I., Rennie, M.J.: Alterations of protein turnover underlying disuse atrophy in human skeletal muscle. J. Appl. Physiol. 2009. 107(3), 645–654 (1985)</ref-fulltext>
<ce:source-text>Phillips, S.M., Glover, E.I., Rennie, M.J.: Alterations of protein turnover underlying disuse atrophy in human skeletal muscle. J. Appl. Physiol. 2009. 107(3), 645–654 (1985)</ce:source-text>
</reference>
<reference seq="141">
<ref-info>
<ref-title>
<ref-titletext-english>Increased amino acid turnover and myofibrillar protein breakdown in advanced cancer are associated with muscle weakness and impaired physical function</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.S.</ce:initials>
<ce:surname>Van der Meij</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Clin. Nutr</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>38</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2399</first-page>
<last-page>2407</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>van der Meij, B.S., et al.: Increased amino acid turnover and myofibrillar protein breakdown in advanced cancer are associated with muscle weakness and impaired physical function. Clin. Nutr. 38(5), 2399–2407 (2019)</ref-fulltext>
<ce:source-text>van der Meij, B.S., et al.: Increased amino acid turnover and myofibrillar protein breakdown in advanced cancer are associated with muscle weakness and impaired physical function. Clin. Nutr. 38(5), 2399–2407 (2019)</ce:source-text>
</reference>
<reference seq="142">
<ref-info>
<ref-title>
<ref-titletext-english>ESPEN guidelines on nutrition in cancer patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Arends</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Clin. Nutr</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>36</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>11</first-page>
<last-page>48</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Arends, J., et al.: ESPEN guidelines on nutrition in cancer patients. Clin. Nutr. 36(1), 11–48 (2017)</ref-fulltext>
<ce:source-text>Arends, J., et al.: ESPEN guidelines on nutrition in cancer patients. Clin. Nutr. 36(1), 11–48 (2017)</ce:source-text>
</reference>
<reference seq="143">
<ref-info>
<ref-title>
<ref-titletext-english>Whey protein isolate supplementation improves body composition, muscle strength, and treatment tolerance in malnourished advanced cancer patients undergoing chemotherapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.</ce:initials>
<ce:surname>Cereda</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Cancer Med</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>16</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>6923</first-page>
<last-page>6932</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Cereda, E., et al.: Whey protein isolate supplementation improves body composition, muscle strength, and treatment tolerance in malnourished advanced cancer patients undergoing chemotherapy. Cancer Med. 8(16), 6923–6932 (2019)</ref-fulltext>
<ce:source-text>Cereda, E., et al.: Whey protein isolate supplementation improves body composition, muscle strength, and treatment tolerance in malnourished advanced cancer patients undergoing chemotherapy. Cancer Med. 8(16), 6923–6932 (2019)</ce:source-text>
</reference>
<reference seq="144">
<ref-info>
<ref-title>
<ref-titletext-english>Whey protein supplementation improves nutritional status, glutathione levels, and immune function in cancer patients: A randomized, double-blind controlled trial</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Bumrungpert</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>J. Med. Food</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>21</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>612</first-page>
<last-page>616</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Bumrungpert, A., et al.: Whey protein supplementation improves nutritional status, glutathione levels, and immune function in cancer patients: A randomized, double-blind controlled trial. J. Med. Food. 21(6), 612–616 (2018)</ref-fulltext>
<ce:source-text>Bumrungpert, A., et al.: Whey protein supplementation improves nutritional status, glutathione levels, and immune function in cancer patients: A randomized, double-blind controlled trial. J. Med. Food. 21(6), 612–616 (2018)</ce:source-text>
</reference>
<reference seq="145">
<ref-info>
<ref-title>
<ref-titletext-english>Cysteine-rich protein reverses weight loss in lung cancer patients receiving chemotherapy or radiotherapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.G.</ce:initials>
<ce:surname>Tozer</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Antioxid. Redox Signal</ref-sourcetitle>
<ref-publicationyear first="2008"/>
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>395</first-page>
<last-page>402</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Tozer, R.G., et al.: Cysteine-rich protein reverses weight loss in lung cancer patients receiving chemotherapy or radiotherapy. Antioxid. Redox Signal. 10(2), 395–402 (2008)</ref-fulltext>
<ce:source-text>Tozer, R.G., et al.: Cysteine-rich protein reverses weight loss in lung cancer patients receiving chemotherapy or radiotherapy. Antioxid. Redox Signal. 10(2), 395–402 (2008)</ce:source-text>
</reference>
<reference seq="146">
<ref-info>
<ref-title>
<ref-titletext-english>L-leucine dietary supplementation modulates muscle protein degradation and increases pro-inflammatory cytokines in tumour-bearing rats</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.</ce:initials>
<ce:surname>Cruz</ce:surname>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Oliveira</ce:surname>
</author>
<author seq="3">
<ce:initials>M.C.C.</ce:initials>
<ce:surname>Gomes-Marcondes</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cytokine</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>96</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>253</first-page>
<last-page>260</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Cruz, B., Oliveira, A., Gomes-Marcondes, M.C.C.: L-leucine dietary supplementation modulates muscle protein degradation and increases pro-inflammatory cytokines in tumour-bearing rats. Cytokine. 96, 253–260 (2017)</ref-fulltext>
<ce:source-text>Cruz, B., Oliveira, A., Gomes-Marcondes, M.C.C.: L-leucine dietary supplementation modulates muscle protein degradation and increases pro-inflammatory cytokines in tumour-bearing rats. Cytokine. 96, 253–260 (2017)</ce:source-text>
</reference>
<reference seq="147">
<ref-info>
<ref-title>
<ref-titletext-english>Nutritional leucine supplementation attenuates cardiac failure in tumour-bearing cachectic animals</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.T.</ce:initials>
<ce:surname>Toneto</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>577</first-page>
<last-page>586</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Toneto, A.T., et al.: Nutritional leucine supplementation attenuates cardiac failure in tumour-bearing cachectic animals. J. Cachexia. Sarcopenia Muscle. 7(5), 577–586 (2016)</ref-fulltext>
<ce:source-text>Toneto, A.T., et al.: Nutritional leucine supplementation attenuates cardiac failure in tumour-bearing cachectic animals. J. Cachexia. Sarcopenia Muscle. 7(5), 577–586 (2016)</ce:source-text>
</reference>
<reference seq="148">
<ref-info>
<ref-title>
<ref-titletext-english>beta-hydroxy-beta-methylbutyrate (HMB) attenuates muscle and body weight loss in experimental cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Z.</ce:initials>
<ce:surname>Aversa</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Int. J. Oncol</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>38</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>713</first-page>
<last-page>720</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Aversa, Z., et al.: beta-hydroxy-beta-methylbutyrate (HMB) attenuates muscle and body weight loss in experimental cancer cachexia. Int. J. Oncol. 38(3), 713–720 (2011)</ref-fulltext>
<ce:source-text>Aversa, Z., et al.: beta-hydroxy-beta-methylbutyrate (HMB) attenuates muscle and body weight loss in experimental cancer cachexia. Int. J. Oncol. 38(3), 713–720 (2011)</ce:source-text>
</reference>
<reference seq="149">
<ref-info>
<ref-title>
<ref-titletext-english>Reversal of cancer-related wasting using oral supplementation with a combination of beta-hydroxy-beta-methylbutyrate, arginine, and glutamine</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.E.</ce:initials>
<ce:surname>May</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Am. J. Surg</ref-sourcetitle>
<ref-publicationyear first="2002"/>
<volisspag>
<volume-issue-number>
<vol-first>183</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>471</first-page>
<last-page>479</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>May, P.E., et al.: Reversal of cancer-related wasting using oral supplementation with a combination of beta-hydroxy-beta-methylbutyrate, arginine, and glutamine. Am. J. Surg. 183(4), 471–479 (2002)</ref-fulltext>
<ce:source-text>May, P.E., et al.: Reversal of cancer-related wasting using oral supplementation with a combination of beta-hydroxy-beta-methylbutyrate, arginine, and glutamine. Am. J. Surg. 183(4), 471–479 (2002)</ce:source-text>
</reference>
<reference seq="150">
<ref-info>
<ref-title>
<ref-titletext-english>Efficacy of l-carnitine administration on fatigue, nutritional status, oxidative stress, and related quality of life in 12 advanced cancer patients undergoing anticancer therapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Gramignano</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Nutrition</ref-sourcetitle>
<ref-publicationyear first="2006"/>
<volisspag>
<volume-issue-number>
<vol-first>22</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>136</first-page>
<last-page>145</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Gramignano, G., et al.: Efficacy of l-carnitine administration on fatigue, nutritional status, oxidative stress, and related quality of life in 12 advanced cancer patients undergoing anticancer therapy. Nutrition. 22(2), 136–145 (2006)</ref-fulltext>
<ce:source-text>Gramignano, G., et al.: Efficacy of l-carnitine administration on fatigue, nutritional status, oxidative stress, and related quality of life in 12 advanced cancer patients undergoing anticancer therapy. Nutrition. 22(2), 136–145 (2006)</ce:source-text>
</reference>
<reference seq="151">
<ref-info>
<ref-title>
<ref-titletext-english>Nutritional intervention with fish oil provides a benefit over standard of care for weight and skeletal muscle mass in patients with nonsmall cell lung cancer receiving chemotherapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.A.</ce:initials>
<ce:surname>Murphy</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Cancer</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>117</vol-first>
<iss-first>8</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1775</first-page>
<last-page>1782</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Murphy, R.A., et al.: Nutritional intervention with fish oil provides a benefit over standard of care for weight and skeletal muscle mass in patients with nonsmall cell lung cancer receiving chemotherapy. Cancer. 117(8), 1775–1782 (2011)</ref-fulltext>
<ce:source-text>Murphy, R.A., et al.: Nutritional intervention with fish oil provides a benefit over standard of care for weight and skeletal muscle mass in patients with nonsmall cell lung cancer receiving chemotherapy. Cancer. 117(8), 1775–1782 (2011)</ce:source-text>
</reference>
<reference seq="152">
<ref-info>
<ref-title>
<ref-titletext-english>The ghrelin receptor agonist HM01 mimics the neuronal effects of ghrelin in the arcuate nucleus and attenuates anorexia-cachexia syndrome in tumor-bearing rats</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Borner</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Physiol. Regul. Integr. Comp. Physiol</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>311</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Borner, T., et al.: The ghrelin receptor agonist HM01 mimics the neuronal effects of ghrelin in the arcuate nucleus and attenuates anorexia-cachexia syndrome in tumor-bearing rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 311(1), R89–R96 (2016)</ref-fulltext>
<ce:source-text>Borner, T., et al.: The ghrelin receptor agonist HM01 mimics the neuronal effects of ghrelin in the arcuate nucleus and attenuates anorexia-cachexia syndrome in tumor-bearing rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 311(1), R89–R96 (2016)</ce:source-text>
</reference>
<reference seq="153">
<ref-info>
<ref-title>
<ref-titletext-english>Potentiation of ghrelin signaling attenuates cancer anorexia-cachexia and prolongs survival</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.</ce:initials>
<ce:surname>Fujitsuka</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Transl. Psychiatry</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>1</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Fujitsuka, N., et al.: Potentiation of ghrelin signaling attenuates cancer anorexia-cachexia and prolongs survival. Transl. Psychiatry. 1, e23 (2011)</ref-fulltext>
<ce:source-text>Fujitsuka, N., et al.: Potentiation of ghrelin signaling attenuates cancer anorexia-cachexia and prolongs survival. Transl. Psychiatry. 1, e23 (2011)</ce:source-text>
</reference>
<reference seq="154">
<ref-info>
<ref-title>
<ref-titletext-english>Oral treatment with the ghrelin receptor agonist HM01 attenuates cachexia in mice bearing Colon-26 (C26) tumors</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.O.</ce:initials>
<ce:surname>Villars</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Mol. Sci</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>18</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Villars, F.O., et al.: Oral treatment with the ghrelin receptor agonist HM01 attenuates cachexia in mice bearing Colon-26 (C26) tumors. Int. J. Mol. Sci. 18(5) (2017)</ref-fulltext>
<ce:source-text>Villars, F.O., et al.: Oral treatment with the ghrelin receptor agonist HM01 attenuates cachexia in mice bearing Colon-26 (C26) tumors. Int. J. Mol. Sci. 18(5) (2017)</ce:source-text>
</reference>
<reference seq="155">
<ref-info>
<ref-title>
<ref-titletext-english>Z-505 hydrochloride, an orally active ghrelin agonist, attenuates the progression of cancer cachexia via anabolic hormones in Colon 26 tumor-bearing mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Yoshimura</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Eur. J. Pharmacol</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>811</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>30</first-page>
<last-page>37</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Yoshimura, M., et al.: Z-505 hydrochloride, an orally active ghrelin agonist, attenuates the progression of cancer cachexia via anabolic hormones in Colon 26 tumor-bearing mice. Eur. J. Pharmacol. 811, 30–37 (2017)</ref-fulltext>
<ce:source-text>Yoshimura, M., et al.: Z-505 hydrochloride, an orally active ghrelin agonist, attenuates the progression of cancer cachexia via anabolic hormones in Colon 26 tumor-bearing mice. Eur. J. Pharmacol. 811, 30–37 (2017)</ce:source-text>
</reference>
<reference seq="156">
<ref-info>
<ref-title>
<ref-titletext-english>Z-505 hydrochloride ameliorates chemotherapy-induced anorexia in rodents via activation of the ghrelin receptor, GHSR1a</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Shiomi</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Eur. J. Pharmacol</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>818</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>148</first-page>
<last-page>157</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Shiomi, Y., et al.: Z-505 hydrochloride ameliorates chemotherapy-induced anorexia in rodents via activation of the ghrelin receptor, GHSR1a. Eur. J. Pharmacol. 818, 148–157 (2018)</ref-fulltext>
<ce:source-text>Shiomi, Y., et al.: Z-505 hydrochloride ameliorates chemotherapy-induced anorexia in rodents via activation of the ghrelin receptor, GHSR1a. Eur. J. Pharmacol. 818, 148–157 (2018)</ce:source-text>
</reference>
<reference seq="157">
<ref-info>
<ref-title>
<ref-titletext-english>Effects of ghrelin administration during chemotherapy with advanced esophageal cancer patients: A prospective, randomized, placebo-controlled phase 2 study</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Hiura</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cancer</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<volisspag>
<volume-issue-number>
<vol-first>118</vol-first>
<iss-first>19</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>4785</first-page>
<last-page>4794</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hiura, Y., et al.: Effects of ghrelin administration during chemotherapy with advanced esophageal cancer patients: A prospective, randomized, placebo-controlled phase 2 study. Cancer. 118(19), 4785–4794 (2012)</ref-fulltext>
<ce:source-text>Hiura, Y., et al.: Effects of ghrelin administration during chemotherapy with advanced esophageal cancer patients: A prospective, randomized, placebo-controlled phase 2 study. Cancer. 118(19), 4785–4794 (2012)</ce:source-text>
</reference>
</bibliography>
</tail>
</bibrecord>
<reference seq="161">
<ref-info>
<ref-title>
<ref-titletext-english>Muscle wasting in disease: Molecular mechanisms and promising therapies</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>S.</ce:initials>
<ce:surname>Cohen</ce:surname>
</author>
<author seq="">
<ce:initials>J.A.</ce:initials>
<ce:surname>Nathan</ce:surname>
<ce:given-name>J.A.</ce:given-name>
</author>
<author seq="">
<ce:initials>A.L.</ce:initials>
<ce:surname>Goldberg</ce:surname>
<ce:given-name>A.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Drug Discov</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>14</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>58</first-page>
<last-page>74</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1038/nrd4467</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Cohen, S., Nathan, J.A., Goldberg, A.L.: Muscle wasting in disease: molecular mechanisms and promising therapies. Nat. Rev. Drug Discov. 14, 58–74 (2015). https://doi.org/10.1038/nrd4467</ref-fulltext>
<ce:source-text>Cohen, S., Nathan, J.A., Goldberg, A.L.: Muscle wasting in disease: molecular mechanisms and promising therapies. Nat. Rev. Drug Discov. 14, 58–74 (2015). https://doi.org/10.1038/nrd4467</ce:source-text>
</reference>
<reference seq="162">
<ref-info>
<ref-title>
<ref-titletext-english>Bortezomib induced reversible left ventricular systolic dysfunction: A case report and review of literature</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>R.</ce:initials>
<ce:surname>Chakraborty</ce:surname>
</author>
<author seq="">
<ce:initials>S.K.R.</ce:initials>
<ce:surname>Mukkamalla</ce:surname>
<ce:given-name>S.K.R.</ce:given-name>
</author>
<author seq="">
<ce:initials>N.</ce:initials>
<ce:surname>Calderon</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Br. J. Med. Pract</ref-sourcetitle>
<ref-publicationyear first="2013"/>
</ref-info>
<ref-fulltext>Chakraborty, R., Mukkamalla, S.K.R., Calderon, N.: Bortezomib induced reversible left ventricular systolic dysfunction: A case report and review of literature. Br. J. Med. Pract. (2013)</ref-fulltext>
<ce:source-text>Chakraborty, R., Mukkamalla, S.K.R., Calderon, N.: Bortezomib induced reversible left ventricular systolic dysfunction: A case report and review of literature. Br. J. Med. Pract. (2013)</ce:source-text>
</reference>
<reference seq="163">
<ref-info>
<ref-title>
<ref-titletext-english>Patterns of cardiac toxicity associated with irreversible proteasome inhibition in the treatment of multiple myeloma</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>E.W.</ce:initials>
<ce:surname>Grandin</ce:surname>
<ce:given-name>E.W.</ce:given-name>
</author>
<author seq="">
<ce:initials>B.</ce:initials>
<ce:surname>Ky</ce:surname>
</author>
<author seq="">
<ce:initials>R.F.</ce:initials>
<ce:surname>Cornell</ce:surname>
<ce:given-name>R.F.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Card. Fail</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.cardfail.2014.11.008</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Grandin, E.W., Ky, B., Cornell, R.F., et al.: Patterns of cardiac toxicity associated with irreversible proteasome inhibition in the treatment of multiple myeloma. J. Card. Fail. (2015). https://doi.org/10.1016/j.cardfail.2014.11.008</ref-fulltext>
<ce:source-text>Grandin, E.W., Ky, B., Cornell, R.F., et al.: Patterns of cardiac toxicity associated with irreversible proteasome inhibition in the treatment of multiple myeloma. J. Card. Fail. (2015). https://doi.org/10.1016/j.cardfail.2014.11.008</ce:source-text>
</reference>
<reference seq="164">
<ref-info>
<ref-title>
<ref-titletext-english>Acute severe cardiac failure in a myeloma patient due to proteasome inhibitor bortezomib</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>A.</ce:initials>
<ce:surname>Hacihanefioglu</ce:surname>
</author>
<author seq="">
<ce:initials>P.</ce:initials>
<ce:surname>Tarkun</ce:surname>
</author>
<author seq="">
<ce:initials>E.</ce:initials>
<ce:surname>Gonullu</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Hematol</ref-sourcetitle>
<ref-publicationyear first="2008"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1007/s12185-008-0139-7</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Hacihanefioglu, A., Tarkun, P., Gonullu, E.: Acute severe cardiac failure in a myeloma patient due to proteasome inhibitor bortezomib. Int. J. Hematol. (2008). https://doi.org/10.1007/s12185-008-0139-7</ref-fulltext>
<ce:source-text>Hacihanefioglu, A., Tarkun, P., Gonullu, E.: Acute severe cardiac failure in a myeloma patient due to proteasome inhibitor bortezomib. Int. J. Hematol. (2008). https://doi.org/10.1007/s12185-008-0139-7</ce:source-text>
</reference>
<reference seq="165">
<ref-info>
<ref-title>
<ref-titletext-english>Primary proteasome inhibition results in cardiac dysfunction. Eur. J</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>J.</ce:initials>
<ce:surname>Herrmann</ce:surname>
</author>
<author seq="">
<ce:initials>C.</ce:initials>
<ce:surname>Wohlert</ce:surname>
</author>
<author seq="">
<ce:initials>A.M.</ce:initials>
<ce:surname>Saguner</ce:surname>
<ce:given-name>A.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Heart Fail</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1093/eurjhf/hft034</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Herrmann, J., Wohlert, C., Saguner, A.M., et al.: Primary proteasome inhibition results in cardiac dysfunction. Eur. J. Heart Fail. (2013). https://doi.org/10.1093/eurjhf/hft034</ref-fulltext>
<ce:source-text>Herrmann, J., Wohlert, C., Saguner, A.M., et al.: Primary proteasome inhibition results in cardiac dysfunction. Eur. J. Heart Fail. (2013). https://doi.org/10.1093/eurjhf/hft034</ce:source-text>
</reference>
<reference seq="166">
<ref-info>
<ref-title>
<ref-titletext-english>Left ventricular dysfunction development after bortezomib treatment in patients with oncologic diagnoses</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>R.</ce:initials>
<ce:surname>Jorge</ce:surname>
</author>
<author seq="">
<ce:initials>C.</ce:initials>
<ce:surname>Patricia</ce:surname>
</author>
<author seq="">
<ce:initials>R.</ce:initials>
<ce:surname>Asaf</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Circulation</ref-sourcetitle>
<ref-publicationyear first="2013"/>
</ref-info>
<ref-fulltext>Jorge, R., Patricia, C., Asaf, R., et al.: Left ventricular dysfunction development after bortezomib treatment in patients with oncologic diagnoses. Circulation. (2013)</ref-fulltext>
<ce:source-text>Jorge, R., Patricia, C., Asaf, R., et al.: Left ventricular dysfunction development after bortezomib treatment in patients with oncologic diagnoses. Circulation. (2013)</ce:source-text>
</reference>
<reference seq="167">
<ref-info>
<ref-title>
<ref-titletext-english>Bortezomib-induced severe congestive heart failure</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>J.</ce:initials>
<ce:surname>Jerkins</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cardiol. Res</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.4021/cr105e</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Jerkins, J.: Bortezomib-induced severe congestive heart failure. Cardiol. Res. (2010). https://doi.org/10.4021/cr105e</ref-fulltext>
<ce:source-text>Jerkins, J.: Bortezomib-induced severe congestive heart failure. Cardiol. Res. (2010). https://doi.org/10.4021/cr105e</ce:source-text>
</reference>
<reference seq="168">
<ref-info>
<ref-title>
<ref-titletext-english>Unexpected cardiotoxicity in haematological bortezomib treated patients [1]</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>E.</ce:initials>
<ce:surname>Orciuolo</ce:surname>
</author>
<author seq="">
<ce:initials>B.</ce:initials>
<ce:surname>Gabriele</ce:surname>
</author>
<author seq="">
<ce:initials>N.</ce:initials>
<ce:surname>Cecconi</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Br. J. Haematol</ref-sourcetitle>
<ref-publicationyear first="2007"/>
</ref-info>
<ref-fulltext>Orciuolo, E., Gabriele, B., Cecconi, N., et al.: Unexpected cardiotoxicity in haematological bortezomib treated patients [1]. Br. J. Haematol. (2007)</ref-fulltext>
<ce:source-text>Orciuolo, E., Gabriele, B., Cecconi, N., et al.: Unexpected cardiotoxicity in haematological bortezomib treated patients [1]. Br. J. Haematol. (2007)</ce:source-text>
</reference>
<reference seq="169">
<ref-info>
<ref-title>
<ref-titletext-english>The first autopsy case of fatal acute cardiac failure after administration of carfilzomib in a patient with multiple myeloma</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>T.</ce:initials>
<ce:surname>Takakuwa</ce:surname>
</author>
<author seq="">
<ce:initials>I.</ce:initials>
<ce:surname>Otomaru</ce:surname>
</author>
<author seq="">
<ce:initials>T.</ce:initials>
<ce:surname>Araki</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Case Reports Hematol</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1155/2019/1816287</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Takakuwa, T., Otomaru, I., Araki, T., et al.: The first autopsy case of fatal acute cardiac failure after administration of carfilzomib in a patient with multiple myeloma. Case Reports Hematol. (2019). https://doi.org/10.1155/2019/1816287</ref-fulltext>
<ce:source-text>Takakuwa, T., Otomaru, I., Araki, T., et al.: The first autopsy case of fatal acute cardiac failure after administration of carfilzomib in a patient with multiple myeloma. Case Reports Hematol. (2019). https://doi.org/10.1155/2019/1816287</ce:source-text>
</reference>
<reference seq="170">
<ref-info>
<ref-title>
<ref-titletext-english>Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: A case report</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>J.</ce:initials>
<ce:surname>Voortman</ce:surname>
</author>
<author seq="">
<ce:initials>G.</ce:initials>
<ce:surname>Giaccone</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>BMC Cancer</ref-sourcetitle>
<ref-publicationyear first="2006"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1186/1471-2407-6-129</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Voortman, J., Giaccone, G.: Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: A case report. BMC Cancer. (2006). https://doi.org/10.1186/1471-2407-6-129</ref-fulltext>
<ce:source-text>Voortman, J., Giaccone, G.: Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: A case report. BMC Cancer. (2006). https://doi.org/10.1186/1471-2407-6-129</ce:source-text>
</reference>
<reference seq="171">
<ref-info>
<ref-title>
<ref-titletext-english>Effect of the specific proteasome inhibitor bortezomib on cancer-related muscle wasting</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>F.</ce:initials>
<ce:surname>Penna</ce:surname>
</author>
<author seq="">
<ce:initials>A.</ce:initials>
<ce:surname>Bonetto</ce:surname>
</author>
<author seq="">
<ce:initials>Z.</ce:initials>
<ce:surname>Aversa</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1002/jcsm.12050</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Penna, F., Bonetto, A., Aversa, Z., et al.: Effect of the specific proteasome inhibitor bortezomib on cancer-related muscle wasting. J. Cachexia. Sarcopenia Muscle. (2016). https://doi.org/10.1002/jcsm.12050</ref-fulltext>
<ce:source-text>Penna, F., Bonetto, A., Aversa, Z., et al.: Effect of the specific proteasome inhibitor bortezomib on cancer-related muscle wasting. J. Cachexia. Sarcopenia Muscle. (2016). https://doi.org/10.1002/jcsm.12050</ce:source-text>
</reference>
<reference seq="172">
<ref-info>
<ref-title>
<ref-titletext-english>MG132-mediated inhibition of the ubiquitin-proteasome pathway ameliorates cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>L.</ce:initials>
<ce:surname>Zhang</ce:surname>
</author>
<author seq="">
<ce:initials>H.</ce:initials>
<ce:surname>Tang</ce:surname>
</author>
<author seq="">
<ce:initials>Y.</ce:initials>
<ce:surname>Kou</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Cancer Res. Clin. Oncol</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1007/s00432-013-1412-6</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Zhang, L., Tang, H., Kou, Y., et al.: MG132-mediated inhibition of the ubiquitin-proteasome pathway ameliorates cancer cachexia. J. Cancer Res. Clin. Oncol. (2013b). https://doi.org/10.1007/s00432-013-1412-6</ref-fulltext>
<ce:source-text>Zhang, L., Tang, H., Kou, Y., et al.: MG132-mediated inhibition of the ubiquitin-proteasome pathway ameliorates cancer cachexia. J. Cancer Res. Clin. Oncol. (2013b). https://doi.org/10.1007/s00432-013-1412-6</ce:source-text>
</reference>
<reference seq="173">
<ref-info>
<ref-title>
<ref-titletext-english>Small-molecule inhibition of MuRF1 attenuates skeletal muscle atrophy and dysfunction in cardiac cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>T.S.</ce:initials>
<ce:surname>Bowen</ce:surname>
<ce:given-name>T.S.</ce:given-name>
</author>
<author seq="">
<ce:initials>V.</ce:initials>
<ce:surname>Adams</ce:surname>
</author>
<author seq="">
<ce:initials>S.</ce:initials>
<ce:surname>Werner</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1002/jcsm.12233</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Bowen, T.S., Adams, V., Werner, S., et al.: Small-molecule inhibition of MuRF1 attenuates skeletal muscle atrophy and dysfunction in cardiac cachexia. J. Cachexia. Sarcopenia Muscle. (2017). https://doi.org/10.1002/jcsm.12233</ref-fulltext>
<ce:source-text>Bowen, T.S., Adams, V., Werner, S., et al.: Small-molecule inhibition of MuRF1 attenuates skeletal muscle atrophy and dysfunction in cardiac cachexia. J. Cachexia. Sarcopenia Muscle. (2017). https://doi.org/10.1002/jcsm.12233</ce:source-text>
</reference>
<reference seq="174">
<ref-info>
<ref-title>
<ref-titletext-english>Inhibition of atrogin-1/MAFbx expression by adenovirus-delivered small hairpin RNAs attenuates muscle atrophy in fasting mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>H.</ce:initials>
<ce:surname>Cong</ce:surname>
</author>
<author seq="">
<ce:initials>L.</ce:initials>
<ce:surname>Sun</ce:surname>
</author>
<author seq="">
<ce:initials>C.</ce:initials>
<ce:surname>Liu</ce:surname>
</author>
<author seq="">
<ce:initials>P.</ce:initials>
<ce:surname>Tien</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Hum. Gene Ther</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1089/hum.2010.057</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Cong, H., Sun, L., Liu, C., Tien, P.: Inhibition of atrogin-1/MAFbx expression by adenovirus-delivered small hairpin RNAs attenuates muscle atrophy in fasting mice. Hum. Gene Ther. (2011). https://doi.org/10.1089/hum.2010.057</ref-fulltext>
<ce:source-text>Cong, H., Sun, L., Liu, C., Tien, P.: Inhibition of atrogin-1/MAFbx expression by adenovirus-delivered small hairpin RNAs attenuates muscle atrophy in fasting mice. Hum. Gene Ther. (2011). https://doi.org/10.1089/hum.2010.057</ce:source-text>
</reference>
<reference seq="175">
<ref-info>
<ref-title>
<ref-titletext-english>Translational suppression of atrophic regulators by Micro RNA-23a integrates resistance to skeletal muscle atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>S.</ce:initials>
<ce:surname>Wada</ce:surname>
</author>
<author seq="">
<ce:initials>Y.</ce:initials>
<ce:surname>Kato</ce:surname>
</author>
<author seq="">
<ce:initials>M.</ce:initials>
<ce:surname>Okutsu</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Biol. Chem</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1074/jbc.M111.271270</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Wada, S., Kato, Y., Okutsu, M., et al.: Translational suppression of atrophic regulators by Micro RNA-23a integrates resistance to skeletal muscle atrophy. J. Biol. Chem. (2011). https://doi.org/10.1074/jbc.M111.271270</ref-fulltext>
<ce:source-text>Wada, S., Kato, Y., Okutsu, M., et al.: Translational suppression of atrophic regulators by Micro RNA-23a integrates resistance to skeletal muscle atrophy. J. Biol. Chem. (2011). https://doi.org/10.1074/jbc.M111.271270</ce:source-text>
</reference>
<reference seq="176">
<ref-info>
<ref-title>
<ref-titletext-english>Proteasome proteolytic activity in skeletal muscle is increased in patients with sepsis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>M.</ce:initials>
<ce:surname>Klaude</ce:surname>
</author>
<author seq="">
<ce:initials>K.</ce:initials>
<ce:surname>Fredriksson</ce:surname>
</author>
<author seq="">
<ce:initials>I.</ce:initials>
<ce:surname>Tjäder</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Clin. Sci</ref-sourcetitle>
<ref-publicationyear first="2007"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1042/CS20060265</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Klaude, M., Fredriksson, K., Tjäder, I., et al.: Proteasome proteolytic activity in skeletal muscle is increased in patients with sepsis. Clin. Sci. (2007). https://doi.org/10.1042/CS20060265</ref-fulltext>
<ce:source-text>Klaude, M., Fredriksson, K., Tjäder, I., et al.: Proteasome proteolytic activity in skeletal muscle is increased in patients with sepsis. Clin. Sci. (2007). https://doi.org/10.1042/CS20060265</ce:source-text>
</reference>
<reference seq="177">
<ref-info>
<ref-title>
<ref-titletext-english>Sepsis is associated with increased mRNAs of the ubiquitin-proteasome proteolytic pathway in human skeletal muscle</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>G.</ce:initials>
<ce:surname>Tiao</ce:surname>
</author>
<author seq="">
<ce:initials>S.</ce:initials>
<ce:surname>Hobler</ce:surname>
</author>
<author seq="">
<ce:initials>J.J.</ce:initials>
<ce:surname>Wang</ce:surname>
<ce:given-name>J.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Investig</ref-sourcetitle>
<ref-publicationyear first="1997"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1172/JCI119143</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Tiao, G., Hobler, S., Wang, J.J., et al.: Sepsis is associated with increased mRNAs of the ubiquitin-proteasome proteolytic pathway in human skeletal muscle. J. Clin. Investig. (1997). https://doi.org/10.1172/JCI119143</ref-fulltext>
<ce:source-text>Tiao, G., Hobler, S., Wang, J.J., et al.: Sepsis is associated with increased mRNAs of the ubiquitin-proteasome proteolytic pathway in human skeletal muscle. J. Clin. Investig. (1997). https://doi.org/10.1172/JCI119143</ce:source-text>
</reference>
<reference seq="178">
<ref-info>
<ref-title>
<ref-titletext-english>Ubiquitin and proteasome gene expression is increased in skeletal muscle of slim AIDS patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>M.</ce:initials>
<ce:surname>Llovera</ce:surname>
</author>
<author seq="">
<ce:initials>C.</ce:initials>
<ce:surname>Garcia-Martinez</ce:surname>
</author>
<author seq="">
<ce:initials>N.</ce:initials>
<ce:surname>Agell</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Mol. Med</ref-sourcetitle>
<ref-publicationyear first="1998"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.3892/ijmm.2.1.69</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Llovera, M., Garcia-Martinez, C., Agell, N., et al.: Ubiquitin and proteasome gene expression is increased in skeletal muscle of slim AIDS patients. Int. J. Mol. Med. (1998). https://doi.org/10.3892/ijmm.2.1.69</ref-fulltext>
<ce:source-text>Llovera, M., Garcia-Martinez, C., Agell, N., et al.: Ubiquitin and proteasome gene expression is increased in skeletal muscle of slim AIDS patients. Int. J. Mol. Med. (1998). https://doi.org/10.3892/ijmm.2.1.69</ce:source-text>
</reference>
<reference seq="179">
<ref-info>
<ref-title>
<ref-titletext-english>Proteasome inhibition in skeletal muscle cells unmasks metabolic derangements in type 2 diabetes</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>L.</ce:initials>
<ce:surname>Al-Khalili</ce:surname>
</author>
<author seq="">
<ce:initials>B.T.</ce:initials>
<ce:surname>de Castro</ce:surname>
<ce:given-name>B.T.</ce:given-name>
</author>
<author seq="">
<ce:initials>J.</ce:initials>
<ce:surname>Östling</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Physiol. Cell Physiol</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1152/ajpcell.00110.2014</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Al-Khalili, L., de Castro, B.T., Östling, J., et al.: Proteasome inhibition in skeletal muscle cells unmasks metabolic derangements in type 2 diabetes. Am. J. Physiol. Cell Physiol. (2014). https://doi.org/10.1152/ajpcell.00110.2014</ref-fulltext>
<ce:source-text>Al-Khalili, L., de Castro, B.T., Östling, J., et al.: Proteasome inhibition in skeletal muscle cells unmasks metabolic derangements in type 2 diabetes. Am. J. Physiol. Cell Physiol. (2014). https://doi.org/10.1152/ajpcell.00110.2014</ce:source-text>
</reference>
<reference seq="180">
<ref-info>
<ref-title>
<ref-titletext-english>Aging affects the transcriptional regulation of human skeletal muscle disuse atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>C.</ce:initials>
<ce:surname>Suetta</ce:surname>
</author>
<author seq="">
<ce:initials>U.</ce:initials>
<ce:surname>Frandsen</ce:surname>
</author>
<author seq="">
<ce:initials>L.</ce:initials>
<ce:surname>Jensen</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Plos One</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1371/journal.pone.0051238</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Suetta, C., Frandsen, U., Jensen, L., et al.: Aging affects the transcriptional regulation of human skeletal muscle disuse atrophy. PLoS One. (2012). https://doi.org/10.1371/journal.pone.0051238</ref-fulltext>
<ce:source-text>Suetta, C., Frandsen, U., Jensen, L., et al.: Aging affects the transcriptional regulation of human skeletal muscle disuse atrophy. PLoS One. (2012). https://doi.org/10.1371/journal.pone.0051238</ce:source-text>
</reference>
<reference seq="181">
<ref-info>
<ref-title>
<ref-titletext-english>Muscle atrophy due to nerve damage is accompanied by elevated myofibrillar protein synthesis rates</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>H.T.</ce:initials>
<ce:surname>Langer</ce:surname>
<ce:given-name>H.T.</ce:given-name>
</author>
<author seq="">
<ce:initials>J.M.G.</ce:initials>
<ce:surname>Senden</ce:surname>
<ce:given-name>J.M.G.</ce:given-name>
</author>
<author seq="">
<ce:initials>A.P.</ce:initials>
<ce:surname>Gijsen</ce:surname>
<ce:given-name>A.P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Front. Physiol</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.3389/fphys.2018.01220</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Langer, H.T., Senden, J.M.G., Gijsen, A.P., et al.: Muscle atrophy due to nerve damage is accompanied by elevated myofibrillar protein synthesis rates. Front. Physiol. (2018). https://doi.org/10.3389/fphys.2018.01220</ref-fulltext>
<ce:source-text>Langer, H.T., Senden, J.M.G., Gijsen, A.P., et al.: Muscle atrophy due to nerve damage is accompanied by elevated myofibrillar protein synthesis rates. Front. Physiol. (2018). https://doi.org/10.3389/fphys.2018.01220</ce:source-text>
</reference>
<reference seq="182">
<ref-info>
<ref-title>
<ref-titletext-english>Increased muscle proteasome activity correlates with disease severity in gastric cancer patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>M.</ce:initials>
<ce:surname>Bossola</ce:surname>
</author>
<author seq="">
<ce:initials>M.</ce:initials>
<ce:surname>Muscaritoli</ce:surname>
</author>
<author seq="">
<ce:initials>P.</ce:initials>
<ce:surname>Costelli</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Ann. Surg</ref-sourcetitle>
<ref-publicationyear first="2003"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1097/01.SLA.0000055225.96357.71</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Bossola, M., Muscaritoli, M., Costelli, P., et al.: Increased muscle proteasome activity correlates with disease severity in gastric cancer patients. Ann. Surg. (2003). https://doi.org/10.1097/01.SLA.0000055225.96357.71</ref-fulltext>
<ce:source-text>Bossola, M., Muscaritoli, M., Costelli, P., et al.: Increased muscle proteasome activity correlates with disease severity in gastric cancer patients. Ann. Surg. (2003). https://doi.org/10.1097/01.SLA.0000055225.96357.71</ce:source-text>
</reference>
<reference seq="183">
<ref-info>
<ref-title>
<ref-titletext-english>Increased muscle ubiquitin mrna levels in gastric cancer patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>M.</ce:initials>
<ce:surname>Bossola</ce:surname>
</author>
<author seq="">
<ce:initials>M.</ce:initials>
<ce:surname>Muscaritoli</ce:surname>
</author>
<author seq="">
<ce:initials>P.</ce:initials>
<ce:surname>Costelli</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Physiol. Regul. Integr. Comp. Physiol</ref-sourcetitle>
<ref-publicationyear first="2001"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1152/ajpregu.2001.280.5.r1518</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Bossola, M., Muscaritoli, M., Costelli, P., et al.: Increased muscle ubiquitin mrna levels in gastric cancer patients. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2001). https://doi.org/10.1152/ajpregu.2001.280.5.r1518</ref-fulltext>
<ce:source-text>Bossola, M., Muscaritoli, M., Costelli, P., et al.: Increased muscle ubiquitin mrna levels in gastric cancer patients. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2001). https://doi.org/10.1152/ajpregu.2001.280.5.r1518</ce:source-text>
</reference>
<reference seq="184">
<ref-info>
<ref-title>
<ref-titletext-english>Systemic inflammation correlates with increased expression of skeletal muscle ubiquitin but not uncoupling proteins in cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>C.H.C.</ce:initials>
<ce:surname>Dejong</ce:surname>
<ce:given-name>C.H.C.</ce:given-name>
</author>
<author seq="">
<ce:initials>S.</ce:initials>
<ce:surname>Busquets</ce:surname>
</author>
<author seq="">
<ce:initials>A.G.W.</ce:initials>
<ce:surname>Moses</ce:surname>
<ce:given-name>A.G.W.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncol. Rep</ref-sourcetitle>
<ref-publicationyear first="2005"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.3892/or.14.1.257</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Dejong, C.H.C., Busquets, S., Moses, A.G.W., et al.: Systemic inflammation correlates with increased expression of skeletal muscle ubiquitin but not uncoupling proteins in cancer cachexia. Oncol. Rep. (2005). https://doi.org/10.3892/or.14.1.257</ref-fulltext>
<ce:source-text>Dejong, C.H.C., Busquets, S., Moses, A.G.W., et al.: Systemic inflammation correlates with increased expression of skeletal muscle ubiquitin but not uncoupling proteins in cancer cachexia. Oncol. Rep. (2005). https://doi.org/10.3892/or.14.1.257</ce:source-text>
</reference>
<reference seq="185">
<ref-info>
<ref-title>
<ref-titletext-english>Increased expression of proteasome subunits in skeletal muscle of cancer patients with weight loss</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>J.</ce:initials>
<ce:surname>Khal</ce:surname>
</author>
<author seq="">
<ce:initials>A.V.</ce:initials>
<ce:surname>Hine</ce:surname>
<ce:given-name>A.V.</ce:given-name>
</author>
<author seq="">
<ce:initials>K.C.H.</ce:initials>
<ce:surname>Fearon</ce:surname>
<ce:given-name>K.C.H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Biochem. Cell Biol</ref-sourcetitle>
<ref-publicationyear first="2005"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.biocel.2004.10.017</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Khal, J., Hine, A.V., Fearon, K.C.H., et al.: Increased expression of proteasome subunits in skeletal muscle of cancer patients with weight loss. Int. J. Biochem. Cell Biol. (2005a). https://doi.org/10.1016/j.biocel.2004.10.017</ref-fulltext>
<ce:source-text>Khal, J., Hine, A.V., Fearon, K.C.H., et al.: Increased expression of proteasome subunits in skeletal muscle of cancer patients with weight loss. Int. J. Biochem. Cell Biol. (2005a). https://doi.org/10.1016/j.biocel.2004.10.017</ce:source-text>
</reference>
<reference seq="186">
<ref-info>
<ref-title>
<ref-titletext-english>Expression of TRAF6 and ubiquitin mRNA in skeletal muscle of gastric cancer patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>Y.S.</ce:initials>
<ce:surname>Sun</ce:surname>
<ce:given-name>Y.S.</ce:given-name>
</author>
<author seq="">
<ce:initials>Z.Y.</ce:initials>
<ce:surname>Ye</ce:surname>
<ce:given-name>Z.Y.</ce:given-name>
</author>
<author seq="">
<ce:initials>Z.Y.</ce:initials>
<ce:surname>Qian</ce:surname>
<ce:given-name>Z.Y.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Exp. Clin. Can</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1186/1756-9966-31-81</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Sun, Y.S., Ye, Z.Y., Qian, Z.Y., et al.: Expression of TRAF6 and ubiquitin mRNA in skeletal muscle of gastric cancer patients. J. Exp. Clin. Cancer Res. (2012). https://doi.org/10.1186/1756-9966-31-81</ref-fulltext>
<ce:source-text>Sun, Y.S., Ye, Z.Y., Qian, Z.Y., et al.: Expression of TRAF6 and ubiquitin mRNA in skeletal muscle of gastric cancer patients. J. Exp. Clin. Cancer Res. (2012). https://doi.org/10.1186/1756-9966-31-81</ce:source-text>
</reference>
<reference seq="187">
<ref-info>
<ref-title>
<ref-titletext-english>The expression of genes in the ubiquitin-proteasome proteolytic pathway is increased in skeletal muscle from patients with cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>A.</ce:initials>
<ce:surname>Williams</ce:surname>
</author>
<author seq="">
<ce:initials>X.</ce:initials>
<ce:surname>Sun</ce:surname>
</author>
<author seq="">
<ce:initials>J.E.</ce:initials>
<ce:surname>Fischer</ce:surname>
<ce:given-name>J.E.</ce:given-name>
</author>
<author seq="">
<ce:initials>P.O.</ce:initials>
<ce:surname>Hasselgren</ce:surname>
<ce:given-name>P.O.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Surgery</ref-sourcetitle>
<ref-publicationyear first="1999"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/S0039-6060(99)70131-5</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Williams, A., Sun, X., Fischer, J.E., Hasselgren, P.O.: The expression of genes in the ubiquitin-proteasome proteolytic pathway is increased in skeletal muscle from patients with cancer. Surgery. (1999). https://doi.org/10.1016/S0039-6060(99)70131-5</ref-fulltext>
<ce:source-text>Williams, A., Sun, X., Fischer, J.E., Hasselgren, P.O.: The expression of genes in the ubiquitin-proteasome proteolytic pathway is increased in skeletal muscle from patients with cancer. Surgery. (1999). https://doi.org/10.1016/S0039-6060(99)70131-5</ce:source-text>
</reference>
<reference seq="188">
<ref-info>
<ref-title>
<ref-titletext-english>Muscle wasting in patients with end-stage renal disease or early-stage lung cancer: Common mechanisms at work</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>J.</ce:initials>
<ce:surname>Aniort</ce:surname>
</author>
<author seq="">
<ce:initials>A.</ce:initials>
<ce:surname>Stella</ce:surname>
</author>
<author seq="">
<ce:initials>C.</ce:initials>
<ce:surname>Philipponnet</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1002/jcsm.12376</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Aniort, J., Stella, A., Philipponnet, C., et al.: Muscle wasting in patients with end-stage renal disease or early-stage lung cancer: Common mechanisms at work. J. Cachexia. Sarcopenia Muscle. (2019). https://doi.org/10.1002/jcsm.12376</ref-fulltext>
<ce:source-text>Aniort, J., Stella, A., Philipponnet, C., et al.: Muscle wasting in patients with end-stage renal disease or early-stage lung cancer: Common mechanisms at work. J. Cachexia. Sarcopenia Muscle. (2019). https://doi.org/10.1002/jcsm.12376</ce:source-text>
</reference>
<reference seq="189">
<ref-info>
<ref-title>
<ref-titletext-english>Skeletal muscle mRNA levels for cathepsin B, but not components of the ubiquitin-proteasome pathway, are increased in patients with lung cancer referred for thoracotomy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>R.T.</ce:initials>
<ce:surname>Jagoe</ce:surname>
<ce:given-name>R.T.</ce:given-name>
</author>
<author seq="">
<ce:initials>C.P.F.</ce:initials>
<ce:surname>Redfern</ce:surname>
<ce:given-name>C.P.F.</ce:given-name>
</author>
<author seq="">
<ce:initials>R.G.</ce:initials>
<ce:surname>Roberts</ce:surname>
<ce:given-name>R.G.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Clin. Sci</ref-sourcetitle>
<ref-publicationyear first="2002"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1042/CS20010270</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Jagoe, R.T., Redfern, C.P.F., Roberts, R.G., et al.: Skeletal muscle mRNA levels for cathepsin B, but not components of the ubiquitin-proteasome pathway, are increased in patients with lung cancer referred for thoracotomy. Clin. Sci. (2002). https://doi.org/10.1042/CS20010270</ref-fulltext>
<ce:source-text>Jagoe, R.T., Redfern, C.P.F., Roberts, R.G., et al.: Skeletal muscle mRNA levels for cathepsin B, but not components of the ubiquitin-proteasome pathway, are increased in patients with lung cancer referred for thoracotomy. Clin. Sci. (2002). https://doi.org/10.1042/CS20010270</ce:source-text>
</reference>
<reference seq="190">
<ref-info>
<ref-title>
<ref-titletext-english>Pre-cachexia in patients with stages I-III non-small cell lung cancer: Systemic inflammation and functional impairment without activation of skeletal muscle ubiquitin proteasome system</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>C.M.</ce:initials>
<ce:surname>Op Den Kamp</ce:surname>
<ce:given-name>C.M.</ce:given-name>
</author>
<author seq="">
<ce:initials>R.C.</ce:initials>
<ce:surname>Langen</ce:surname>
<ce:given-name>R.C.</ce:given-name>
</author>
<author seq="">
<ce:initials>R.</ce:initials>
<ce:surname>Minnaard</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Lung Cancer</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.lungcan.2011.09.012</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Op den Kamp, C.M., Langen, R.C., Minnaard, R., et al.: Pre-cachexia in patients with stages I-III non-small cell lung cancer: systemic inflammation and functional impairment without activation of skeletal muscle ubiquitin proteasome system. Lung Cancer. (2012). https://doi.org/10.1016/j.lungcan.2011.09.012</ref-fulltext>
<ce:source-text>Op den Kamp, C.M., Langen, R.C., Minnaard, R., et al.: Pre-cachexia in patients with stages I-III non-small cell lung cancer: systemic inflammation and functional impairment without activation of skeletal muscle ubiquitin proteasome system. Lung Cancer. (2012). https://doi.org/10.1016/j.lungcan.2011.09.012</ce:source-text>
</reference>
<reference seq="191">
<ref-info>
<ref-title>
<ref-titletext-english>Consequences of late-stage non-small-cell lung cancer cachexia on muscle metabolic processes</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>A.J.</ce:initials>
<ce:surname>Murton</ce:surname>
<ce:given-name>A.J.</ce:given-name>
</author>
<author seq="">
<ce:initials>M.</ce:initials>
<ce:surname>Maddocks</ce:surname>
</author>
<author seq="">
<ce:initials>F.B.</ce:initials>
<ce:surname>Stephens</ce:surname>
<ce:given-name>F.B.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Clin. Lung Cancer</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.cllc.2016.06.003</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Murton, A.J., Maddocks, M., Stephens, F.B., et al.: Consequences of late-stage non-small-cell lung cancer cachexia on muscle metabolic processes. Clin. Lung Cancer. (2017). https://doi.org/10.1016/j.cllc.2016.06.003</ref-fulltext>
<ce:source-text>Murton, A.J., Maddocks, M., Stephens, F.B., et al.: Consequences of late-stage non-small-cell lung cancer cachexia on muscle metabolic processes. Clin. Lung Cancer. (2017). https://doi.org/10.1016/j.cllc.2016.06.003</ce:source-text>
</reference>
<reference seq="192">
<ref-info>
<ref-title>
<ref-titletext-english>Differential gene expression of muscle-specific ubiquitin ligase MAFbx/Atrogin-1 and MuRF1 in response to immobilization-induced atrophy of slow-twitch and fast-twitch muscles</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>T.</ce:initials>
<ce:surname>Okamoto</ce:surname>
</author>
<author seq="">
<ce:initials>S.</ce:initials>
<ce:surname>Torii</ce:surname>
</author>
<author seq="">
<ce:initials>S.</ce:initials>
<ce:surname>Machida</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Physiol. Sci</ref-sourcetitle>
<ref-publicationyear first="2011"/>
</ref-info>
<ref-fulltext>Okamoto, T., Torii, S., Machida, S.: Differential gene expression of muscle-specific ubiquitin ligase MAFbx/Atrogin-1 and MuRF1 in response to immobilization-induced atrophy of slow-twitch and fast-twitch muscles. J. Physiol. Sci. (2011)</ref-fulltext>
<ce:source-text>Okamoto, T., Torii, S., Machida, S.: Differential gene expression of muscle-specific ubiquitin ligase MAFbx/Atrogin-1 and MuRF1 in response to immobilization-induced atrophy of slow-twitch and fast-twitch muscles. J. Physiol. Sci. (2011)</ce:source-text>
</reference>
<reference seq="193">
<ref-info>
<ref-title>
<ref-titletext-english>Breakdown of filamentous myofibrils by the UPS-step by step</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>D.</ce:initials>
<ce:surname>Aweida</ce:surname>
</author>
<author seq="">
<ce:initials>S.</ce:initials>
<ce:surname>Cohen</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Biomol. Ther</ref-sourcetitle>
<ref-publicationyear first="2021"/>
<volisspag>
<page-information>
<pages>
<first-page>11</first-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.3390/biom11010110</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Aweida, D., Cohen, S.: Breakdown of filamentous myofibrils by the UPS-step by step. Biomol. Ther. 11 (2021). https://doi.org/10.3390/biom11010110</ref-fulltext>
<ce:source-text>Aweida, D., Cohen, S.: Breakdown of filamentous myofibrils by the UPS-step by step. Biomol. Ther. 11 (2021). https://doi.org/10.3390/biom11010110</ce:source-text>
</reference>
<reference seq="194">
<ref-info>
<ref-title>
<ref-titletext-english>GSK3-β promotes calpain-1-mediated desmin filament depolymerization and myofibril loss in atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>D.</ce:initials>
<ce:surname>Aweida</ce:surname>
</author>
<author seq="">
<ce:initials>I.</ce:initials>
<ce:surname>Rudesky</ce:surname>
</author>
<author seq="">
<ce:initials>A.</ce:initials>
<ce:surname>Volodin</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Cell Biol</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>217</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3698</first-page>
<last-page>3714</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1083/jcb.201802018</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Aweida, D., Rudesky, I., Volodin, A., et al.: GSK3-β promotes calpain-1-mediated desmin filament depolymerization and myofibril loss in atrophy. J. Cell Biol. 217, 3698–3714 (2018). https://doi.org/10.1083/jcb.201802018</ref-fulltext>
<ce:source-text>Aweida, D., Rudesky, I., Volodin, A., et al.: GSK3-β promotes calpain-1-mediated desmin filament depolymerization and myofibril loss in atrophy. J. Cell Biol. 217, 3698–3714 (2018). https://doi.org/10.1083/jcb.201802018</ce:source-text>
</reference>
<reference seq="195">
<ref-info>
<ref-title>
<ref-titletext-english>During muscle atrophy, thick, but not thin, filament components are degraded by MuRF1-dependent ubiquitylation. J</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>S.</ce:initials>
<ce:surname>Cohen</ce:surname>
</author>
<author seq="">
<ce:initials>J.J.</ce:initials>
<ce:surname>Brault</ce:surname>
<ce:given-name>J.J.</ce:given-name>
</author>
<author seq="">
<ce:initials>S.P.</ce:initials>
<ce:surname>Gygi</ce:surname>
<ce:given-name>S.P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Biol</ref-sourcetitle>
<ref-publicationyear first="2009"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1083/jcb.200901052</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Cohen, S., Brault, J.J., Gygi, S.P., et al.: During muscle atrophy, thick, but not thin, filament components are degraded by MuRF1-dependent ubiquitylation. J. Cell Biol. (2009). https://doi.org/10.1083/jcb.200901052</ref-fulltext>
<ce:source-text>Cohen, S., Brault, J.J., Gygi, S.P., et al.: During muscle atrophy, thick, but not thin, filament components are degraded by MuRF1-dependent ubiquitylation. J. Cell Biol. (2009). https://doi.org/10.1083/jcb.200901052</ce:source-text>
</reference>
<reference seq="196">
<ref-info>
<ref-title>
<ref-titletext-english>Ubiquitylation by Trim32 causes coupled loss of desmin, Z-bands, and thin filaments in muscle atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>S.</ce:initials>
<ce:surname>Cohen</ce:surname>
</author>
<author seq="">
<ce:initials>B.</ce:initials>
<ce:surname>Zhai</ce:surname>
</author>
<author seq="">
<ce:initials>S.P.</ce:initials>
<ce:surname>Gygi</ce:surname>
<ce:given-name>S.P.</ce:given-name>
</author>
<author seq="">
<ce:initials>A.L.</ce:initials>
<ce:surname>Goldberg</ce:surname>
<ce:given-name>A.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Cell Biol</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<volisspag>
<volume-issue-number>
<vol-first>198</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>575</first-page>
<last-page>589</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1083/jcb.201110067</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Cohen, S., Zhai, B., Gygi, S.P., Goldberg, A.L.: Ubiquitylation by Trim32 causes coupled loss of desmin, Z-bands, and thin filaments in muscle atrophy. J. Cell Biol. 198, 575–589 (2012). https://doi.org/10.1083/jcb.201110067</ref-fulltext>
<ce:source-text>Cohen, S., Zhai, B., Gygi, S.P., Goldberg, A.L.: Ubiquitylation by Trim32 causes coupled loss of desmin, Z-bands, and thin filaments in muscle atrophy. J. Cell Biol. 198, 575–589 (2012). https://doi.org/10.1083/jcb.201110067</ce:source-text>
</reference>
<reference seq="197">
<ref-info>
<ref-title>
<ref-titletext-english>Myofibril breakdown during atrophy is a delayed response requiring the transcription factor PAX4 and desmin depolymerization</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>A.</ce:initials>
<ce:surname>Volodin</ce:surname>
</author>
<author seq="">
<ce:initials>I.</ce:initials>
<ce:surname>Kosti</ce:surname>
</author>
<author seq="">
<ce:initials>A.L.</ce:initials>
<ce:surname>Goldberg</ce:surname>
<ce:given-name>A.L.</ce:given-name>
</author>
<author seq="">
<ce:initials>S.</ce:initials>
<ce:surname>Cohen</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Proc. Natl. Acad. Sci. USA</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1073/pnas.1612988114</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Volodin, A., Kosti, I., Goldberg, A.L., Cohen, S.: Myofibril breakdown during atrophy is a delayed response requiring the transcription factor PAX4 and desmin depolymerization. Proc. Natl. Acad. Sci. USA. (2017). https://doi.org/10.1073/pnas.1612988114</ref-fulltext>
<ce:source-text>Volodin, A., Kosti, I., Goldberg, A.L., Cohen, S.: Myofibril breakdown during atrophy is a delayed response requiring the transcription factor PAX4 and desmin depolymerization. Proc. Natl. Acad. Sci. USA. (2017). https://doi.org/10.1073/pnas.1612988114</ce:source-text>
</reference>
<reference seq="198">
<ref-info>
<ref-title>
<ref-titletext-english>Autophagic degradation contributes to muscle wasting in cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>F.</ce:initials>
<ce:surname>Penna</ce:surname>
</author>
<author seq="">
<ce:initials>D.</ce:initials>
<ce:surname>Costamagna</ce:surname>
</author>
<author seq="">
<ce:initials>F.</ce:initials>
<ce:surname>Pin</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Pathol.</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.ajpath.2012.12.023</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Penna, F., Costamagna, D., Pin, F., et al.: Autophagic degradation contributes to muscle wasting in cancer cachexia. Am. J. Pathol. (2013). https://doi.org/10.1016/j.ajpath.2012.12.023</ref-fulltext>
<ce:source-text>Penna, F., Costamagna, D., Pin, F., et al.: Autophagic degradation contributes to muscle wasting in cancer cachexia. Am. J. Pathol. (2013). https://doi.org/10.1016/j.ajpath.2012.12.023</ce:source-text>
</reference>
<reference seq="199">
<ref-info>
<ref-title>
<ref-titletext-english>Autophagy is induced in the skeletal muscle of cachectic cancer patients. Sci</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>Z.</ce:initials>
<ce:surname>Aversa</ce:surname>
</author>
<author seq="">
<ce:initials>F.</ce:initials>
<ce:surname>Pin</ce:surname>
</author>
<author seq="">
<ce:initials>S.</ce:initials>
<ce:surname>Lucia</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Rep</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1038/srep30340</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Aversa, Z., Pin, F., Lucia, S., et al.: Autophagy is induced in the skeletal muscle of cachectic cancer patients. Sci. Rep. (2016). https://doi.org/10.1038/srep30340</ref-fulltext>
<ce:source-text>Aversa, Z., Pin, F., Lucia, S., et al.: Autophagy is induced in the skeletal muscle of cachectic cancer patients. Sci. Rep. (2016). https://doi.org/10.1038/srep30340</ce:source-text>
</reference>
<reference seq="200">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer cachexia associates with a systemic autophagy-inducing activity mimicked by cancer cell-derived IL-6 trans-signaling</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>K.</ce:initials>
<ce:surname>Pettersen</ce:surname>
</author>
<author seq="">
<ce:initials>S.</ce:initials>
<ce:surname>Andersen</ce:surname>
</author>
<author seq="">
<ce:initials>S.</ce:initials>
<ce:surname>Degen</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Sci. Rep</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1038/s41598-017-02088-2</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Pettersen, K., Andersen, S., Degen, S., et al.: Cancer cachexia associates with a systemic autophagy-inducing activity mimicked by cancer cell-derived IL-6 trans-signaling. Sci. Rep. (2017). https://doi.org/10.1038/s41598-017-02088-2</ref-fulltext>
<ce:source-text>Pettersen, K., Andersen, S., Degen, S., et al.: Cancer cachexia associates with a systemic autophagy-inducing activity mimicked by cancer cell-derived IL-6 trans-signaling. Sci. Rep. (2017). https://doi.org/10.1038/s41598-017-02088-2</ce:source-text>
</reference>
<reference seq="201">
<ref-info>
<ref-title>
<ref-titletext-english>Striated muscle cytoarchitecture: An intricate web of form and function</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>K.A.</ce:initials>
<ce:surname>Clark</ce:surname>
<ce:given-name>K.A.</ce:given-name>
</author>
<author seq="">
<ce:initials>A.S.</ce:initials>
<ce:surname>McElhinny</ce:surname>
<ce:given-name>A.S.</ce:given-name>
</author>
<author seq="">
<ce:initials>M.C.</ce:initials>
<ce:surname>Beckerle</ce:surname>
<ce:given-name>M.C.</ce:given-name>
</author>
<author seq="">
<ce:initials>C.C.</ce:initials>
<ce:surname>Gregorio</ce:surname>
<ce:given-name>C.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Annu. Rev. Cell Dev. Biol</ref-sourcetitle>
<ref-publicationyear first="2002"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1146/annurev.cellbio.18.012502.105840</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Clark, K.A., McElhinny, A.S., Beckerle, M.C., Gregorio, C.C.: Striated muscle cytoarchitecture: An intricate web of form and function. Annu. Rev. Cell Dev. Biol. (2002). https://doi.org/10.1146/annurev.cellbio.18.012502.105840</ref-fulltext>
<ce:source-text>Clark, K.A., McElhinny, A.S., Beckerle, M.C., Gregorio, C.C.: Striated muscle cytoarchitecture: An intricate web of form and function. Annu. Rev. Cell Dev. Biol. (2002). https://doi.org/10.1146/annurev.cellbio.18.012502.105840</ce:source-text>
</reference>
<reference seq="202">
<ref-info>
<ref-title>
<ref-titletext-english>Depletion of zebrafish essential and regulatory myosin light chains reduces cardiac function through distinct mechanisms</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>Z.</ce:initials>
<ce:surname>Chen</ce:surname>
</author>
<author seq="">
<ce:initials>W.</ce:initials>
<ce:surname>Huang</ce:surname>
</author>
<author seq="">
<ce:initials>T.</ce:initials>
<ce:surname>Dahme</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cardiovasc. Res</ref-sourcetitle>
<ref-publicationyear first="2008"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1093/cvr/cvn073</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Chen, Z., Huang, W., Dahme, T., et al.: Depletion of zebrafish essential and regulatory myosin light chains reduces cardiac function through distinct mechanisms. Cardiovasc. Res. (2008). https://doi.org/10.1093/cvr/cvn073</ref-fulltext>
<ce:source-text>Chen, Z., Huang, W., Dahme, T., et al.: Depletion of zebrafish essential and regulatory myosin light chains reduces cardiac function through distinct mechanisms. Cardiovasc. Res. (2008). https://doi.org/10.1093/cvr/cvn073</ce:source-text>
</reference>
<reference seq="203">
<ref-info>
<ref-title>
<ref-titletext-english>Cardiac myosin light chain-2: A novel essential component of thick-myofilament assembly and contractility of the heart</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>W.</ce:initials>
<ce:surname>Rottbauer</ce:surname>
</author>
<author seq="">
<ce:initials>G.</ce:initials>
<ce:surname>Wessels</ce:surname>
</author>
<author seq="">
<ce:initials>T.</ce:initials>
<ce:surname>Dahme</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Circ. Res</ref-sourcetitle>
<ref-publicationyear first="2006"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1161/01.RES.0000234807.16034.fe</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Rottbauer, W., Wessels, G., Dahme, T., et al.: Cardiac myosin light chain-2: A novel essential component of thick-myofilament assembly and contractility of the heart. Circ. Res. (2006). https://doi.org/10.1161/01.RES.0000234807.16034.fe</ref-fulltext>
<ce:source-text>Rottbauer, W., Wessels, G., Dahme, T., et al.: Cardiac myosin light chain-2: A novel essential component of thick-myofilament assembly and contractility of the heart. Circ. Res. (2006). https://doi.org/10.1161/01.RES.0000234807.16034.fe</ce:source-text>
</reference>
<reference seq="204">
<ref-info>
<ref-title>
<ref-titletext-english>Skeletal muscle myosin light chains are essential for physiological speeds of shortening</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>S.</ce:initials>
<ce:surname>Lowey</ce:surname>
</author>
<author seq="">
<ce:initials>G.S.</ce:initials>
<ce:surname>Waller</ce:surname>
<ce:given-name>G.S.</ce:given-name>
</author>
<author seq="">
<ce:initials>K.M.</ce:initials>
<ce:surname>Trybus</ce:surname>
<ce:given-name>K.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="1993"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1038/365454a0</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Lowey, S., Waller, G.S., Trybus, K.M.: Skeletal muscle myosin light chains are essential for physiological speeds of shortening. Nature. (1993). https://doi.org/10.1038/365454a0</ref-fulltext>
<ce:source-text>Lowey, S., Waller, G.S., Trybus, K.M.: Skeletal muscle myosin light chains are essential for physiological speeds of shortening. Nature. (1993). https://doi.org/10.1038/365454a0</ce:source-text>
</reference>
<reference seq="205">
<ref-info>
<ref-title>
<ref-titletext-english>Interaction of monomeric and polymeric actin with myosin subfragment 1</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>G.</ce:initials>
<ce:surname>Offer</ce:surname>
</author>
<author seq="">
<ce:initials>H.</ce:initials>
<ce:surname>Baker</ce:surname>
</author>
<author seq="">
<ce:initials>L.</ce:initials>
<ce:surname>Baker</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Mol. Biol</ref-sourcetitle>
<ref-publicationyear first="1972"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/0022-2836(72)90425-1</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Offer, G., Baker, H., Baker, L.: Interaction of monomeric and polymeric actin with myosin subfragment 1. J. Mol. Biol. (1972). https://doi.org/10.1016/0022-2836(72)90425-1</ref-fulltext>
<ce:source-text>Offer, G., Baker, H., Baker, L.: Interaction of monomeric and polymeric actin with myosin subfragment 1. J. Mol. Biol. (1972). https://doi.org/10.1016/0022-2836(72)90425-1</ce:source-text>
</reference>
<reference seq="206">
<ref-info>
<ref-title>
<ref-titletext-english>A mouse model of myosin binding protein C human familial hypertrophic cardiomyopathy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>Q.</ce:initials>
<ce:surname>Yang</ce:surname>
</author>
<author seq="">
<ce:initials>A.</ce:initials>
<ce:surname>Sanbe</ce:surname>
</author>
<author seq="">
<ce:initials>H.</ce:initials>
<ce:surname>Osinska</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Investig</ref-sourcetitle>
<ref-publicationyear first="1998"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1172/JCI3880</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Yang, Q., Sanbe, A., Osinska, H., et al.: A mouse model of myosin binding protein C human familial hypertrophic cardiomyopathy. J. Clin. Investig. (1998). https://doi.org/10.1172/JCI3880</ref-fulltext>
<ce:source-text>Yang, Q., Sanbe, A., Osinska, H., et al.: A mouse model of myosin binding protein C human familial hypertrophic cardiomyopathy. J. Clin. Investig. (1998). https://doi.org/10.1172/JCI3880</ce:source-text>
</reference>
<reference seq="207">
<ref-info>
<ref-title>
<ref-titletext-english>Desmin: A major intermediate filament protein essential for the structural integrity and function of muscle</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>D.</ce:initials>
<ce:surname>Paulin</ce:surname>
</author>
<author seq="">
<ce:initials>Z.</ce:initials>
<ce:surname>Li</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Exp. Cell Res</ref-sourcetitle>
<ref-publicationyear first="2004"/>
</ref-info>
<ref-fulltext>Paulin, D., Li, Z.: Desmin: A major intermediate filament protein essential for the structural integrity and function of muscle. Exp. Cell Res. (2004)</ref-fulltext>
<ce:source-text>Paulin, D., Li, Z.: Desmin: A major intermediate filament protein essential for the structural integrity and function of muscle. Exp. Cell Res. (2004)</ce:source-text>
</reference>
<reference seq="208">
<ref-info>
<ref-title>
<ref-titletext-english>The E3 Ligase MuRF1 degrades myosin heavy chain protein in dexamethasone-treated skeletal muscle</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>B.A.</ce:initials>
<ce:surname>Clarke</ce:surname>
<ce:given-name>B.A.</ce:given-name>
</author>
<author seq="">
<ce:initials>D.</ce:initials>
<ce:surname>Drujan</ce:surname>
</author>
<author seq="">
<ce:initials>M.S.</ce:initials>
<ce:surname>Willis</ce:surname>
<ce:given-name>M.S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell Metab</ref-sourcetitle>
<ref-publicationyear first="2007"/>
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>376</first-page>
<last-page>385</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.cmet.2007.09.009</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Clarke, B.A., Drujan, D., Willis, M.S., et al.: The E3 Ligase MuRF1 degrades myosin heavy chain protein in dexamethasone-treated skeletal muscle. Cell Metab. 6, 376–385 (2007). https://doi.org/10.1016/j.cmet.2007.09.009</ref-fulltext>
<ce:source-text>Clarke, B.A., Drujan, D., Willis, M.S., et al.: The E3 Ligase MuRF1 degrades myosin heavy chain protein in dexamethasone-treated skeletal muscle. Cell Metab. 6, 376–385 (2007). https://doi.org/10.1016/j.cmet.2007.09.009</ce:source-text>
</reference>
<reference seq="209">
<ref-info>
<ref-title>
<ref-titletext-english>Novel TRIM32 mutation in sarcotubular myopathy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>C.</ce:initials>
<ce:surname>Panicucci</ce:surname>
</author>
<author seq="">
<ce:initials>M.</ce:initials>
<ce:surname>Traverso</ce:surname>
</author>
<author seq="">
<ce:initials>S.</ce:initials>
<ce:surname>Baratto</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Acta Myologica</ref-sourcetitle>
<ref-publicationyear first="2019"/>
</ref-info>
<ref-fulltext>Panicucci, C., Traverso, M., Baratto, S., et al.: Novel TRIM32 mutation in sarcotubular myopathy. Acta Myologica. (2019)</ref-fulltext>
<ce:source-text>Panicucci, C., Traverso, M., Baratto, S., et al.: Novel TRIM32 mutation in sarcotubular myopathy. Acta Myologica. (2019)</ce:source-text>
</reference>
<reference seq="210">
<ref-info>
<ref-title>
<ref-titletext-english>Muscle actin is polyubiquitinylated in vitro and in vivo and targeted for breakdown by the E3 ligase MuRF1</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>P.</ce:initials>
<ce:surname>Cécile</ce:surname>
</author>
<author seq="">
<ce:initials>H.</ce:initials>
<ce:surname>Anne-Elisabeth</ce:surname>
</author>
<author seq="">
<ce:initials>J.</ce:initials>
<ce:surname>Marianne</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>FASEB J</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>25</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3790</first-page>
<last-page>3802</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1096/FJ.11-180968</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Cécile, P., Anne-Elisabeth, H., Marianne, J., et al.: Muscle actin is polyubiquitinylated in vitro and in vivo and targeted for breakdown by the E3 ligase MuRF1. FASEB J. 25, 3790–3802 (2011). https://doi.org/10.1096/FJ.11-180968</ref-fulltext>
<ce:source-text>Cécile, P., Anne-Elisabeth, H., Marianne, J., et al.: Muscle actin is polyubiquitinylated in vitro and in vivo and targeted for breakdown by the E3 ligase MuRF1. FASEB J. 25, 3790–3802 (2011). https://doi.org/10.1096/FJ.11-180968</ce:source-text>
</reference>
<reference seq="211">
<ref-info>
<ref-title>
<ref-titletext-english>UBE2L3, a partner of MuRF1/TRIM63, is involved in the degradation of myofibrillar actin and myosin</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>P.-M.</ce:initials>
<ce:surname>Dulce</ce:surname>
<ce:given-name>P.-M.</ce:given-name>
</author>
<author seq="">
<ce:initials>M.</ce:initials>
<ce:surname>Mélodie</ce:surname>
</author>
<author seq="">
<ce:initials>C.</ce:initials>
<ce:surname>Agnès</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2021"/>
<volisspag>
<page-information>
<pages>
<first-page>10</first-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.3390/CELLS10081974</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Dulce, P.-M., Mélodie, M., Agnès, C., et al.: UBE2L3, a partner of MuRF1/TRIM63, is involved in the degradation of myofibrillar actin and myosin. Cell. 10 (2021). https://doi.org/10.3390/CELLS10081974</ref-fulltext>
<ce:source-text>Dulce, P.-M., Mélodie, M., Agnès, C., et al.: UBE2L3, a partner of MuRF1/TRIM63, is involved in the degradation of myofibrillar actin and myosin. Cell. 10 (2021). https://doi.org/10.3390/CELLS10081974</ce:source-text>
</reference>
<reference seq="212">
<ref-info>
<ref-title>
<ref-titletext-english>Autophagy induction in atrophic muscle cells requires ULK1 activation by TRIM32 through unanchored K63-linked polyubiquitin chains</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>M.</ce:initials>
<ce:surname>Di Rienzo</ce:surname>
</author>
<author seq="">
<ce:initials>M.</ce:initials>
<ce:surname>Antonioli</ce:surname>
</author>
<author seq="">
<ce:initials>C.</ce:initials>
<ce:surname>Fusco</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Sci. Adv</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1126/sciadv.aau8857</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Di Rienzo, M., Antonioli, M., Fusco, C., et al.: Autophagy induction in atrophic muscle cells requires ULK1 activation by TRIM32 through unanchored K63-linked polyubiquitin chains. Sci. Adv. (2019a). https://doi.org/10.1126/sciadv.aau8857</ref-fulltext>
<ce:source-text>Di Rienzo, M., Antonioli, M., Fusco, C., et al.: Autophagy induction in atrophic muscle cells requires ULK1 activation by TRIM32 through unanchored K63-linked polyubiquitin chains. Sci. Adv. (2019a). https://doi.org/10.1126/sciadv.aau8857</ce:source-text>
</reference>
<reference seq="213">
<ref-info>
<ref-title>
<ref-titletext-english>A TRIM32-AMBRA1-ULK1 complex initiates the autophagy response in atrophic muscle cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>M.</ce:initials>
<ce:surname>Di Rienzo</ce:surname>
</author>
<author seq="">
<ce:initials>M.</ce:initials>
<ce:surname>Piacentini</ce:surname>
</author>
<author seq="">
<ce:initials>G.M.</ce:initials>
<ce:surname>Fimia</ce:surname>
<ce:given-name>G.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Autophagy</ref-sourcetitle>
<ref-publicationyear first="2019"/>
</ref-info>
<ref-fulltext>Di Rienzo, M., Piacentini, M., Fimia, G.M.: A TRIM32-AMBRA1-ULK1 complex initiates the autophagy response in atrophic muscle cells. Autophagy. (2019b)</ref-fulltext>
<ce:source-text>Di Rienzo, M., Piacentini, M., Fimia, G.M.: A TRIM32-AMBRA1-ULK1 complex initiates the autophagy response in atrophic muscle cells. Autophagy. (2019b)</ce:source-text>
</reference>
<reference seq="214">
<ref-info>
<ref-title>
<ref-titletext-english>Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>M.</ce:initials>
<ce:surname>Sandri</ce:surname>
</author>
<author seq="">
<ce:initials>C.</ce:initials>
<ce:surname>Sandri</ce:surname>
</author>
<author seq="">
<ce:initials>A.</ce:initials>
<ce:surname>Gilbert</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2004"/>
<volisspag>
<volume-issue-number>
<vol-first>117</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>399</first-page>
<last-page>412</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/S0092867404004003</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Sandri, M., Sandri, C., Gilbert, A., et al.: Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell. 117, 399–412 (2004) https://doi.org/S0092867404004003</ref-fulltext>
<ce:source-text>Sandri, M., Sandri, C., Gilbert, A., et al.: Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell. 117, 399–412 (2004) https://doi.org/S0092867404004003</ce:source-text>
</reference>
<reference seq="215">
<ref-info>
<ref-title>
<ref-titletext-english>The p97/VCP ATPase is critical in muscle atrophy and the accelerated degradation of muscle proteins</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>R.</ce:initials>
<ce:surname>Piccirillo</ce:surname>
</author>
<author seq="">
<ce:initials>A.L.</ce:initials>
<ce:surname>Goldberg</ce:surname>
<ce:given-name>A.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>EMBO J</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1038/emboj.2012.178</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Piccirillo, R., Goldberg, A.L.: The p97/VCP ATPase is critical in muscle atrophy and the accelerated degradation of muscle proteins. EMBO J. (2012). https://doi.org/10.1038/emboj.2012.178</ref-fulltext>
<ce:source-text>Piccirillo, R., Goldberg, A.L.: The p97/VCP ATPase is critical in muscle atrophy and the accelerated degradation of muscle proteins. EMBO J. (2012). https://doi.org/10.1038/emboj.2012.178</ce:source-text>
</reference>
<reference seq="216">
<ref-info>
<ref-title>
<ref-titletext-english>Remodeling of the cytoskeletal lattice in denervated skeletal muscle</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>S.</ce:initials>
<ce:surname>Boudriau</ce:surname>
</author>
<author seq="">
<ce:initials>C.H.</ce:initials>
<ce:surname>Côté</ce:surname>
<ce:given-name>C.H.</ce:given-name>
</author>
<author seq="">
<ce:initials>M.</ce:initials>
<ce:surname>Vincent</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Muscle Nerve</ref-sourcetitle>
<ref-publicationyear first="1996"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1002/(SICI)1097-4598(199611)19:11&lt;1383::AID-MUS2&gt;3.0.CO;2-8</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Boudriau, S., Côté, C.H., Vincent, M., et al.: Remodeling of the cytoskeletal lattice in denervated skeletal muscle. Muscle Nerve. (1996). https://doi.org/10.1002/(SICI)1097-4598(199611)19:11&lt;1383::AID-MUS2&gt;3.0.CO;2-8</ref-fulltext>
<ce:source-text>Boudriau, S., Côté, C.H., Vincent, M., et al.: Remodeling of the cytoskeletal lattice in denervated skeletal muscle. Muscle Nerve. (1996). https://doi.org/10.1002/(SICI)1097-4598(199611)19:11&lt;1383::AID-MUS2&gt;3.0.CO;2-8</ce:source-text>
</reference>
<reference seq="217">
<ref-info>
<ref-title>
<ref-titletext-english>Role of calpains in promoting desmin filaments depolymerization and muscle atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>S.</ce:initials>
<ce:surname>Cohen</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Biochim. Biophys. Acta Mol. Cell Res</ref-sourcetitle>
<ref-publicationyear first="2020"/>
<volisspag>
<volume-issue-number>
<vol-first>1867</vol-first>
</volume-issue-number>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.bbamcr.2020.118788</ce:e-address>
</ref-website>
<ref-text>118788</ref-text>
</ref-info>
<ref-fulltext>Cohen, S.: Role of calpains in promoting desmin filaments depolymerization and muscle atrophy. Biochim. Biophys. Acta Mol. Cell Res. 1867, 118788 (2020). https://doi.org/10.1016/j.bbamcr.2020.118788</ref-fulltext>
<ce:source-text>Cohen, S.: Role of calpains in promoting desmin filaments depolymerization and muscle atrophy. Biochim. Biophys. Acta Mol. Cell Res. 1867, 118788 (2020). https://doi.org/10.1016/j.bbamcr.2020.118788</ce:source-text>
</reference>
<reference seq="218">
<ref-info>
<ref-title>
<ref-titletext-english>The distribution of desmin (100 Å) filaments in primary cultures of embryonic chick cardiac cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>E.</ce:initials>
<ce:surname>Lazarides</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Exp. Cell Res</ref-sourcetitle>
<ref-publicationyear first="1978"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/0014-4827(78)90209-4</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Lazarides, E.: The distribution of desmin (100 Å) filaments in primary cultures of embryonic chick cardiac cells. Exp. Cell Res. (1978). https://doi.org/10.1016/0014-4827(78)90209-4</ref-fulltext>
<ce:source-text>Lazarides, E.: The distribution of desmin (100 Å) filaments in primary cultures of embryonic chick cardiac cells. Exp. Cell Res. (1978). https://doi.org/10.1016/0014-4827(78)90209-4</ce:source-text>
</reference>
<reference seq="219">
<ref-info>
<ref-title>
<ref-titletext-english>Immunological characterization of the subunit of the 100 Å filaments from muscle cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>E.</ce:initials>
<ce:surname>Lazarides</ce:surname>
</author>
<author seq="">
<ce:initials>B.D.</ce:initials>
<ce:surname>Hubbard</ce:surname>
<ce:given-name>B.D.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Proc. Natl. Acad. Sci. USA</ref-sourcetitle>
<ref-publicationyear first="1976"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1073/pnas.73.12.4344</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Lazarides, E., Hubbard, B.D.: Immunological characterization of the subunit of the 100 Å filaments from muscle cells. Proc. Natl. Acad. Sci. USA. (1976). https://doi.org/10.1073/pnas.73.12.4344</ref-fulltext>
<ce:source-text>Lazarides, E., Hubbard, B.D.: Immunological characterization of the subunit of the 100 Å filaments from muscle cells. Proc. Natl. Acad. Sci. USA. (1976). https://doi.org/10.1073/pnas.73.12.4344</ce:source-text>
</reference>
<reference seq="220">
<ref-info>
<ref-title>
<ref-titletext-english>Disruption of muscle architecture and myocardial degeneration in mice lacking desmin</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>D.J.</ce:initials>
<ce:surname>Milner</ce:surname>
<ce:given-name>D.J.</ce:given-name>
</author>
<author seq="">
<ce:initials>G.</ce:initials>
<ce:surname>Weitzer</ce:surname>
</author>
<author seq="">
<ce:initials>D.</ce:initials>
<ce:surname>Tran</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Cell Biol</ref-sourcetitle>
<ref-publicationyear first="1996"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1083/jcb.134.5.1255</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Milner, D.J., Weitzer, G., Tran, D., et al.: Disruption of muscle architecture and myocardial degeneration in mice lacking desmin. J. Cell Biol. (1996). https://doi.org/10.1083/jcb.134.5.1255</ref-fulltext>
<ce:source-text>Milner, D.J., Weitzer, G., Tran, D., et al.: Disruption of muscle architecture and myocardial degeneration in mice lacking desmin. J. Cell Biol. (1996). https://doi.org/10.1083/jcb.134.5.1255</ce:source-text>
</reference>
<reference seq="221">
<ref-info>
<ref-title>
<ref-titletext-english>A myopathy-linked desmin mutation perturbs striated muscle actin filament architecture</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>G.M.</ce:initials>
<ce:surname>Conover</ce:surname>
<ce:given-name>G.M.</ce:given-name>
</author>
<author seq="">
<ce:initials>S.N.</ce:initials>
<ce:surname>Henderson</ce:surname>
<ce:given-name>S.N.</ce:given-name>
</author>
<author seq="">
<ce:initials>C.C.</ce:initials>
<ce:surname>Gregorio</ce:surname>
<ce:given-name>C.C.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Mol. Biol. Cell</ref-sourcetitle>
<ref-publicationyear first="2009"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1091/mbc.E08-07-0753</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Conover, G.M., Henderson, S.N., Gregorio, C.C.: A myopathy-linked desmin mutation perturbs striated muscle actin filament architecture. Mol. Biol. Cell. (2009). https://doi.org/10.1091/mbc.E08-07-0753</ref-fulltext>
<ce:source-text>Conover, G.M., Henderson, S.N., Gregorio, C.C.: A myopathy-linked desmin mutation perturbs striated muscle actin filament architecture. Mol. Biol. Cell. (2009). https://doi.org/10.1091/mbc.E08-07-0753</ce:source-text>
</reference>
<reference seq="222">
<ref-info>
<ref-title>
<ref-titletext-english>Proteomic profiling of skeletal and cardiac muscle in cancer cachexia: Alterations in sarcomeric and mitochondrial protein expression</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>A.M.Y.</ce:initials>
<ce:surname>Shum</ce:surname>
<ce:given-name>A.M.Y.</ce:given-name>
</author>
<author seq="">
<ce:initials>A.</ce:initials>
<ce:surname>Poljak</ce:surname>
</author>
<author seq="">
<ce:initials>N.L.</ce:initials>
<ce:surname>Bentley</ce:surname>
<ce:given-name>N.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncotarget</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.18632/oncotarget.25146</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Shum, A.M.Y., Poljak, A., Bentley, N.L., et al.: Proteomic profiling of skeletal and cardiac muscle in cancer cachexia: Alterations in sarcomeric and mitochondrial protein expression. Oncotarget. (2018) https://doi.org/10.18632/oncotarget.25146</ref-fulltext>
<ce:source-text>Shum, A.M.Y., Poljak, A., Bentley, N.L., et al.: Proteomic profiling of skeletal and cardiac muscle in cancer cachexia: Alterations in sarcomeric and mitochondrial protein expression. Oncotarget. (2018) https://doi.org/10.18632/oncotarget.25146</ce:source-text>
</reference>
<reference seq="223">
<ref-info>
<ref-title>
<ref-titletext-english>Lectin binding and desmin expression during necrosis, regeneration, and neurogenic atrophy of human skeletal muscle</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>T.R.</ce:initials>
<ce:surname>Helliwell</ce:surname>
<ce:given-name>T.R.</ce:given-name>
</author>
<author seq="">
<ce:initials>O.</ce:initials>
<ce:surname>Gunhan</ce:surname>
</author>
<author seq="">
<ce:initials>R.H.T.</ce:initials>
<ce:surname>Edwards</ce:surname>
<ce:given-name>R.H.T.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Pathol</ref-sourcetitle>
<ref-publicationyear first="1989"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1002/path.1711590111</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Helliwell, T.R., Gunhan, O., Edwards, R.H.T.: Lectin binding and desmin expression during necrosis, regeneration, and neurogenic atrophy of human skeletal muscle. J. Pathol. (1989). https://doi.org/10.1002/path.1711590111</ref-fulltext>
<ce:source-text>Helliwell, T.R., Gunhan, O., Edwards, R.H.T.: Lectin binding and desmin expression during necrosis, regeneration, and neurogenic atrophy of human skeletal muscle. J. Pathol. (1989). https://doi.org/10.1002/path.1711590111</ce:source-text>
</reference>
<reference seq="224">
<ref-info>
<ref-title>
<ref-titletext-english>New roles for desmin in maintenance of muscle homeostasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>G.</ce:initials>
<ce:surname>Agnetti</ce:surname>
</author>
<author seq="">
<ce:initials>H.</ce:initials>
<ce:surname>Herrmann</ce:surname>
</author>
<author seq="">
<ce:initials>S.</ce:initials>
<ce:surname>Cohen</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>FEBS J</ref-sourcetitle>
<ref-publicationyear first="2021"/>
<volisspag>
<page-information>
<pages>
<first-page>15864</first-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1111/febs.15864</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Agnetti, G., Herrmann, H., Cohen, S.: New roles for desmin in maintenance of muscle homeostasis. FEBS J. 15864 (2021). https://doi.org/10.1111/febs.15864</ref-fulltext>
<ce:source-text>Agnetti, G., Herrmann, H., Cohen, S.: New roles for desmin in maintenance of muscle homeostasis. FEBS J. 15864 (2021). https://doi.org/10.1111/febs.15864</ce:source-text>
</reference>
<reference seq="225">
<ref-info>
<ref-title>
<ref-titletext-english>GSK-3β inhibitors reduce protein degradation in muscles from septic rats and in dexamethasone-treated myotubes</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>A.R.</ce:initials>
<ce:surname>Evenson</ce:surname>
<ce:given-name>A.R.</ce:given-name>
</author>
<author seq="">
<ce:initials>M.U.</ce:initials>
<ce:surname>Fareed</ce:surname>
<ce:given-name>M.U.</ce:given-name>
</author>
<author seq="">
<ce:initials>M.J.</ce:initials>
<ce:surname>Menconi</ce:surname>
<ce:given-name>M.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Biochem. Cell Biol</ref-sourcetitle>
<ref-publicationyear first="2005"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.biocel.2005.06.002</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Evenson, A.R., Fareed, M.U., Menconi, M.J., et al.: GSK-3β inhibitors reduce protein degradation in muscles from septic rats and in dexamethasone-treated myotubes. Int. J. Biochem. Cell Biol. (2005). https://doi.org/10.1016/j.biocel.2005.06.002</ref-fulltext>
<ce:source-text>Evenson, A.R., Fareed, M.U., Menconi, M.J., et al.: GSK-3β inhibitors reduce protein degradation in muscles from septic rats and in dexamethasone-treated myotubes. Int. J. Biochem. Cell Biol. (2005). https://doi.org/10.1016/j.biocel.2005.06.002</ce:source-text>
</reference>
<reference seq="226">
<ref-info>
<ref-title>
<ref-titletext-english>Glycogen synthase kinase-3β is required for the induction of skeletal muscle atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>K.J.P.</ce:initials>
<ce:surname>Verhees</ce:surname>
<ce:given-name>K.J.P.</ce:given-name>
</author>
<author seq="">
<ce:initials>A.M.W.J.</ce:initials>
<ce:surname>Schols</ce:surname>
<ce:given-name>A.M.W.J.</ce:given-name>
</author>
<author seq="">
<ce:initials>M.C.J.M.</ce:initials>
<ce:surname>Kelders</ce:surname>
<ce:given-name>M.C.J.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Physiol. Cell Physiol</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1152/ajpcell.00520.2010</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Verhees, K.J.P., Schols, A.M.W.J., Kelders, M.C.J.M., et al.: Glycogen synthase kinase-3β is required for the induction of skeletal muscle atrophy. Am. J. Physiol. Cell Physiol. (2011). https://doi.org/10.1152/ajpcell.00520.2010</ref-fulltext>
<ce:source-text>Verhees, K.J.P., Schols, A.M.W.J., Kelders, M.C.J.M., et al.: Glycogen synthase kinase-3β is required for the induction of skeletal muscle atrophy. Am. J. Physiol. Cell Physiol. (2011). https://doi.org/10.1152/ajpcell.00520.2010</ce:source-text>
</reference>
<reference seq="227">
<ref-info>
<ref-title>
<ref-titletext-english>Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>D.A.E.</ce:initials>
<ce:surname>Cross</ce:surname>
<ce:given-name>D.A.E.</ce:given-name>
</author>
<author seq="">
<ce:initials>D.R.</ce:initials>
<ce:surname>Alessi</ce:surname>
<ce:given-name>D.R.</ce:given-name>
</author>
<author seq="">
<ce:initials>P.</ce:initials>
<ce:surname>Cohen</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="1995"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1038/378785a0</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Cross, D.A.E., Alessi, D.R., Cohen, P., et al.: Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature. (1995). https://doi.org/10.1038/378785a0</ref-fulltext>
<ce:source-text>Cross, D.A.E., Alessi, D.R., Cohen, P., et al.: Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature. (1995). https://doi.org/10.1038/378785a0</ce:source-text>
</reference>
<reference seq="228">
<ref-info>
<ref-title>
<ref-titletext-english>Measuring GSK3 expression and activity in cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>A.R.</ce:initials>
<ce:surname>Cole</ce:surname>
<ce:given-name>A.R.</ce:given-name>
</author>
<author seq="">
<ce:initials>C.</ce:initials>
<ce:surname>Sutherland</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Methods Mol. Biol</ref-sourcetitle>
<ref-publicationyear first="2008"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1007/978-1-59745-249-6_4</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Cole, A.R., Sutherland, C.: Measuring GSK3 expression and activity in cells. Methods Mol. Biol. (2008). https://doi.org/10.1007/978-1-59745-249-6_4</ref-fulltext>
<ce:source-text>Cole, A.R., Sutherland, C.: Measuring GSK3 expression and activity in cells. Methods Mol. Biol. (2008). https://doi.org/10.1007/978-1-59745-249-6_4</ce:source-text>
</reference>
<reference seq="229">
<ref-info>
<ref-title>
<ref-titletext-english>What are the bona fide GSK3 substrates?</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>C.</ce:initials>
<ce:surname>Sutherland</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Alzheimer’s Dis</ref-sourcetitle>
<ref-publicationyear first="2011"/>
</ref-info>
<ref-fulltext>Sutherland, C.: What are the bona fide GSK3 substrates? Int. J. Alzheimer’s Dis. (2011)</ref-fulltext>
<ce:source-text>Sutherland, C.: What are the bona fide GSK3 substrates? Int. J. Alzheimer’s Dis. (2011)</ce:source-text>
</reference>
<reference seq="230">
<ref-info>
<ref-title>
<ref-titletext-english>Calpain inhibitors ameliorate muscle wasting in a cachectic mouse model bearing CT26 colorectal adenocarcinoma</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>X.Y.</ce:initials>
<ce:surname>Lin</ce:surname>
<ce:given-name>X.Y.</ce:given-name>
</author>
<author seq="">
<ce:initials>S.Z.</ce:initials>
<ce:surname>Chen</ce:surname>
<ce:given-name>S.Z.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Oncol. Rep</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.3892/or.2017.5396</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Lin, X.Y., Chen, S.Z.: Calpain inhibitors ameliorate muscle wasting in a cachectic mouse model bearing CT26 colorectal adenocarcinoma. Oncol. Rep. (2017). https://doi.org/10.3892/or.2017.5396</ref-fulltext>
<ce:source-text>Lin, X.Y., Chen, S.Z.: Calpain inhibitors ameliorate muscle wasting in a cachectic mouse model bearing CT26 colorectal adenocarcinoma. Oncol. Rep. (2017). https://doi.org/10.3892/or.2017.5396</ce:source-text>
</reference>
<reference seq="231">
<ref-info>
<ref-title>
<ref-titletext-english>Interference with Ca2+-dependent proteolysis does not alter the course of muscle wasting in experimental cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>F.</ce:initials>
<ce:surname>Pin</ce:surname>
</author>
<author seq="">
<ce:initials>V.G.</ce:initials>
<ce:surname>Minero</ce:surname>
<ce:given-name>V.G.</ce:given-name>
</author>
<author seq="">
<ce:initials>F.</ce:initials>
<ce:surname>Penna</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Front. Physiol</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.3389/fphys.2017.00213</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Pin, F., Minero, V.G., Penna, F., et al.: Interference with Ca2+-dependent proteolysis does not alter the course of muscle wasting in experimental cancer cachexia. Front. Physiol. (2017). https://doi.org/10.3389/fphys.2017.00213</ref-fulltext>
<ce:source-text>Pin, F., Minero, V.G., Penna, F., et al.: Interference with Ca2+-dependent proteolysis does not alter the course of muscle wasting in experimental cancer cachexia. Front. Physiol. (2017). https://doi.org/10.3389/fphys.2017.00213</ce:source-text>
</reference>
<reference seq="232">
<ref-info>
<ref-title>
<ref-titletext-english>A signaling hub of insulin receptor, dystrophin glycoprotein complex and plakoglobin regulates muscle size</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>Y.</ce:initials>
<ce:surname>Eid Mutlak</ce:surname>
</author>
<author seq="">
<ce:initials>D.</ce:initials>
<ce:surname>Aweida</ce:surname>
</author>
<author seq="">
<ce:initials>A.</ce:initials>
<ce:surname>Volodin</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Commun</ref-sourcetitle>
<ref-publicationyear first="2020"/>
<volisspag>
<volume-issue-number>
<vol-first>11</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1381</first-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1038/s41467-020-14895-9</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Eid Mutlak, Y., Aweida, D., Volodin, A., et al.: A signaling hub of insulin receptor, dystrophin glycoprotein complex and plakoglobin regulates muscle size. Nat. Commun. 11, 1381 (2020). https://doi.org/10.1038/s41467-020-14895-9</ref-fulltext>
<ce:source-text>Eid Mutlak, Y., Aweida, D., Volodin, A., et al.: A signaling hub of insulin receptor, dystrophin glycoprotein complex and plakoglobin regulates muscle size. Nat. Commun. 11, 1381 (2020). https://doi.org/10.1038/s41467-020-14895-9</ce:source-text>
</reference>
<reference seq="233">
<ref-info>
<ref-title>
<ref-titletext-english>The dystrophin glycoprotein complex</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>K.A.</ce:initials>
<ce:surname>Lapidos</ce:surname>
<ce:given-name>K.A.</ce:given-name>
</author>
<author seq="">
<ce:initials>R.</ce:initials>
<ce:surname>Kakkar</ce:surname>
</author>
<author seq="">
<ce:initials>E.M.</ce:initials>
<ce:surname>McNally</ce:surname>
<ce:given-name>E.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Circ. Res</ref-sourcetitle>
<ref-publicationyear first="2004"/>
<volisspag>
<volume-issue-number>
<vol-first>94</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1023</first-page>
<last-page>1031</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1161/01.RES.0000126574.61061.25</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Lapidos, K.A., Kakkar, R., McNally, E.M.: The dystrophin glycoprotein complex. Circ. Res. 94, 1023–1031 (2004). https://doi.org/10.1161/01.RES.0000126574.61061.25</ref-fulltext>
<ce:source-text>Lapidos, K.A., Kakkar, R., McNally, E.M.: The dystrophin glycoprotein complex. Circ. Res. 94, 1023–1031 (2004). https://doi.org/10.1161/01.RES.0000126574.61061.25</ce:source-text>
</reference>
<reference seq="234">
<ref-info>
<ref-title>
<ref-titletext-english>The costamere bridges sarcomeres to the sarcolemma in striated muscle</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>A.K.</ce:initials>
<ce:surname>Peter</ce:surname>
<ce:given-name>A.K.</ce:given-name>
</author>
<author seq="">
<ce:initials>H.</ce:initials>
<ce:surname>Cheng</ce:surname>
</author>
<author seq="">
<ce:initials>R.S.</ce:initials>
<ce:surname>Ross</ce:surname>
<ce:given-name>R.S.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Prog. Pediatr. Cardiol</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.ppedcard.2011.02.003</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Peter, A.K., Cheng, H., Ross, R.S., et al.: The costamere bridges sarcomeres to the sarcolemma in striated muscle. Prog. Pediatr. Cardiol. (2011). https://doi.org/10.1016/j.ppedcard.2011.02.003</ref-fulltext>
<ce:source-text>Peter, A.K., Cheng, H., Ross, R.S., et al.: The costamere bridges sarcomeres to the sarcolemma in striated muscle. Prog. Pediatr. Cardiol. (2011). https://doi.org/10.1016/j.ppedcard.2011.02.003</ce:source-text>
</reference>
<reference seq="235">
<ref-info>
<ref-title>
<ref-titletext-english>Membrane organization of the dystrophin-glycoprotein complex</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>J.M.</ce:initials>
<ce:surname>Ervasti</ce:surname>
<ce:given-name>J.M.</ce:given-name>
</author>
<author seq="">
<ce:initials>K.P.</ce:initials>
<ce:surname>Campbell</ce:surname>
<ce:given-name>K.P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="1991"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/0092-8674(91)90035-W</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Ervasti, J.M., Campbell, K.P.: Membrane organization of the dystrophin-glycoprotein complex. Cell. (1991). https://doi.org/10.1016/0092-8674(91)90035-W</ref-fulltext>
<ce:source-text>Ervasti, J.M., Campbell, K.P.: Membrane organization of the dystrophin-glycoprotein complex. Cell. (1991). https://doi.org/10.1016/0092-8674(91)90035-W</ce:source-text>
</reference>
<reference seq="236">
<ref-info>
<ref-title>
<ref-titletext-english>Calmodulin specifically binds three proteins of the dystrophin-glycoprotein complex</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>R.</ce:initials>
<ce:surname>Madhavan</ce:surname>
</author>
<author seq="">
<ce:initials>L.R.</ce:initials>
<ce:surname>Massom</ce:surname>
<ce:given-name>L.R.</ce:given-name>
</author>
<author seq="">
<ce:initials>H.W.</ce:initials>
<ce:surname>Jarrett</ce:surname>
<ce:given-name>H.W.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Biochem. Biophys. Res. Commun</ref-sourcetitle>
<ref-publicationyear first="1992"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/0006-291X(92)91690-R</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Madhavan, R., Massom, L.R., Jarrett, H.W.: Calmodulin specifically binds three proteins of the dystrophin-glycoprotein complex. Biochem. Biophys. Res. Commun. (1992). https://doi.org/10.1016/0006-291X(92)91690-R</ref-fulltext>
<ce:source-text>Madhavan, R., Massom, L.R., Jarrett, H.W.: Calmodulin specifically binds three proteins of the dystrophin-glycoprotein complex. Biochem. Biophys. Res. Commun. (1992). https://doi.org/10.1016/0006-291X(92)91690-R</ce:source-text>
</reference>
<reference seq="237">
<ref-info>
<ref-title>
<ref-titletext-english>The dystrophin-glycoprotein complex, cellular signaling, and the regulation of cell survival in the muscular dystrophies</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>T.A.</ce:initials>
<ce:surname>Rando</ce:surname>
<ce:given-name>T.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Muscle Nerve</ref-sourcetitle>
<ref-publicationyear first="2001"/>
<volisspag>
<volume-issue-number>
<vol-first>24</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1575</first-page>
<last-page>1594</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1002/mus.1192</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Rando, T.A.: The dystrophin-glycoprotein complex, cellular signaling, and the regulation of cell survival in the muscular dystrophies. Muscle Nerve. 24, 1575–1594 (2001). https://doi.org/10.1002/mus.1192</ref-fulltext>
<ce:source-text>Rando, T.A.: The dystrophin-glycoprotein complex, cellular signaling, and the regulation of cell survival in the muscular dystrophies. Muscle Nerve. 24, 1575–1594 (2001). https://doi.org/10.1002/mus.1192</ce:source-text>
</reference>
<reference seq="238">
<ref-info>
<ref-title>
<ref-titletext-english>Lateral transmission of force is impaired in skeletal muscles of dystrophic mice and very old rats</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>K.S.</ce:initials>
<ce:surname>Ramaswamy</ce:surname>
<ce:given-name>K.S.</ce:given-name>
</author>
<author seq="">
<ce:initials>M.L.</ce:initials>
<ce:surname>Palmer</ce:surname>
<ce:given-name>M.L.</ce:given-name>
</author>
<author seq="">
<ce:initials>J.H.</ce:initials>
<ce:surname>Van der Meulen</ce:surname>
<ce:given-name>J.H.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Physiol</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>589</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1195</first-page>
<last-page>1208</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1113/jphysiol.2010.201921</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Ramaswamy, K.S., Palmer, M.L., van der Meulen, J.H., et al.: Lateral transmission of force is impaired in skeletal muscles of dystrophic mice and very old rats. J. Physiol. 589, 1195–1208 (2011). https://doi.org/10.1113/jphysiol.2010.201921</ref-fulltext>
<ce:source-text>Ramaswamy, K.S., Palmer, M.L., van der Meulen, J.H., et al.: Lateral transmission of force is impaired in skeletal muscles of dystrophic mice and very old rats. J. Physiol. 589, 1195–1208 (2011). https://doi.org/10.1113/jphysiol.2010.201921</ce:source-text>
</reference>
<reference seq="239">
<ref-info>
<ref-title>
<ref-titletext-english>The dystrophin-glycoprotein complex in the prevention of muscle damage</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>J.D.</ce:initials>
<ce:surname>Gumerson</ce:surname>
<ce:given-name>J.D.</ce:given-name>
</author>
<author seq="">
<ce:initials>D.E.</ce:initials>
<ce:surname>Michele</ce:surname>
<ce:given-name>D.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Biomed. Biotechnol</ref-sourcetitle>
<ref-publicationyear first="2011"/>
</ref-info>
<ref-fulltext>Gumerson, J.D., Michele, D.E.: The dystrophin-glycoprotein complex in the prevention of muscle damage. J. Biomed. Biotechnol. (2011)</ref-fulltext>
<ce:source-text>Gumerson, J.D., Michele, D.E.: The dystrophin-glycoprotein complex in the prevention of muscle damage. J. Biomed. Biotechnol. (2011)</ce:source-text>
</reference>
<reference seq="240">
<ref-info>
<ref-title>
<ref-titletext-english>Direct observation of failing fibers in muscles of dystrophic mice provides mechanistic insight into muscular dystrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>D.R.</ce:initials>
<ce:surname>Claflin</ce:surname>
<ce:given-name>D.R.</ce:given-name>
</author>
<author seq="">
<ce:initials>S.V.</ce:initials>
<ce:surname>Brooks</ce:surname>
<ce:given-name>S.V.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Physiol. Cell Physiol</ref-sourcetitle>
<ref-publicationyear first="2008"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1152/ajpcell.00244.2007</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Claflin, D.R., Brooks, S.V.: Direct observation of failing fibers in muscles of dystrophic mice provides mechanistic insight into muscular dystrophy. Am. J. Physiol. Cell Physiol. (2008). https://doi.org/10.1152/ajpcell.00244.2007</ref-fulltext>
<ce:source-text>Claflin, D.R., Brooks, S.V.: Direct observation of failing fibers in muscles of dystrophic mice provides mechanistic insight into muscular dystrophy. Am. J. Physiol. Cell Physiol. (2008). https://doi.org/10.1152/ajpcell.00244.2007</ce:source-text>
</reference>
<reference seq="241">
<ref-info>
<ref-title>
<ref-titletext-english>Tibialis anterior muscles in mdx mice are highly susceptible to contraction-induced injury</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>C.</ce:initials>
<ce:surname>Dellorusso</ce:surname>
</author>
<author seq="">
<ce:initials>R.W.</ce:initials>
<ce:surname>Crawford</ce:surname>
<ce:given-name>R.W.</ce:given-name>
</author>
<author seq="">
<ce:initials>J.S.</ce:initials>
<ce:surname>Chamberlain</ce:surname>
<ce:given-name>J.S.</ce:given-name>
</author>
<author seq="">
<ce:initials>S.V.</ce:initials>
<ce:surname>Brooks</ce:surname>
<ce:given-name>S.V.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Muscle Res. Cell Motil</ref-sourcetitle>
<ref-publicationyear first="2001"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1023/A:1014587918367</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Dellorusso, C., Crawford, R.W., Chamberlain, J.S., Brooks, S.V.: Tibialis anterior muscles in mdx mice are highly susceptible to contraction-induced injury. J. Muscle Res. Cell Motil. (2001). https://doi.org/10.1023/A:1014587918367</ref-fulltext>
<ce:source-text>Dellorusso, C., Crawford, R.W., Chamberlain, J.S., Brooks, S.V.: Tibialis anterior muscles in mdx mice are highly susceptible to contraction-induced injury. J. Muscle Res. Cell Motil. (2001). https://doi.org/10.1023/A:1014587918367</ce:source-text>
</reference>
<reference seq="242">
<ref-info>
<ref-title>
<ref-titletext-english>A highly functional mini-dystrophin/GFP fusion gene for cell and gene therapy studies of Duchenne muscular dystrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>S.</ce:initials>
<ce:surname>Li</ce:surname>
</author>
<author seq="">
<ce:initials>E.</ce:initials>
<ce:surname>Kimura</ce:surname>
</author>
<author seq="">
<ce:initials>R.</ce:initials>
<ce:surname>Ng</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Hum. Mol. Genet</ref-sourcetitle>
<ref-publicationyear first="2006"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1093/hmg/ddl082</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Li, S., Kimura, E., Ng, R., et al.: A highly functional mini-dystrophin/GFP fusion gene for cell and gene therapy studies of Duchenne muscular dystrophy. Hum. Mol. Genet. (2006). https://doi.org/10.1093/hmg/ddl082</ref-fulltext>
<ce:source-text>Li, S., Kimura, E., Ng, R., et al.: A highly functional mini-dystrophin/GFP fusion gene for cell and gene therapy studies of Duchenne muscular dystrophy. Hum. Mol. Genet. (2006). https://doi.org/10.1093/hmg/ddl082</ce:source-text>
</reference>
<reference seq="243">
<ref-info>
<ref-title>
<ref-titletext-english>The extracellular matrix protein agrin promotes heart regeneration in mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>E.</ce:initials>
<ce:surname>Bassat</ce:surname>
</author>
<author seq="">
<ce:initials>Y.E.</ce:initials>
<ce:surname>Mutlak</ce:surname>
<ce:given-name>Y.E.</ce:given-name>
</author>
<author seq="">
<ce:initials>A.</ce:initials>
<ce:surname>Genzelinakh</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>547</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>179</first-page>
<last-page>184</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1038/nature22978</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Bassat, E., Mutlak, Y.E., Genzelinakh, A., et al.: The extracellular matrix protein agrin promotes heart regeneration in mice. Nature. 547, 179–184 (2017). https://doi.org/10.1038/nature22978</ref-fulltext>
<ce:source-text>Bassat, E., Mutlak, Y.E., Genzelinakh, A., et al.: The extracellular matrix protein agrin promotes heart regeneration in mice. Nature. 547, 179–184 (2017). https://doi.org/10.1038/nature22978</ce:source-text>
</reference>
<reference seq="244">
<ref-info>
<ref-title>
<ref-titletext-english>The molecular cross talk of the dystrophin–glycoprotein complex</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>M.</ce:initials>
<ce:surname>Gawor</ce:surname>
</author>
<author seq="">
<ce:initials>T.J.</ce:initials>
<ce:surname>Prószyński</ce:surname>
<ce:given-name>T.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Ann. NY Acad. Sci</ref-sourcetitle>
<ref-publicationyear first="2018"/>
</ref-info>
<ref-fulltext>Gawor, M., Prószyński, T.J.: The molecular cross talk of the dystrophin–glycoprotein complex. Ann. NY Acad. Sci. (2018)</ref-fulltext>
<ce:source-text>Gawor, M., Prószyński, T.J.: The molecular cross talk of the dystrophin–glycoprotein complex. Ann. NY Acad. Sci. (2018)</ce:source-text>
</reference>
<reference seq="245">
<ref-info>
<ref-title>
<ref-titletext-english>Profiling of the muscle-specific dystroglycan interactome reveals the role of Hippo signaling in muscular dystrophy and age-dependent muscle atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>A.S.</ce:initials>
<ce:surname>Yatsenko</ce:surname>
<ce:given-name>A.S.</ce:given-name>
</author>
<author seq="">
<ce:initials>M.M.</ce:initials>
<ce:surname>Kucherenko</ce:surname>
<ce:given-name>M.M.</ce:given-name>
</author>
<author seq="">
<ce:initials>Y.</ce:initials>
<ce:surname>Xie</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>BMC Med</ref-sourcetitle>
<ref-publicationyear first="2020"/>
<volisspag>
<volume-issue-number>
<vol-first>18</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>8</first-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1186/s12916-019-1478-3</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Yatsenko, A.S., Kucherenko, M.M., Xie, Y., et al.: Profiling of the muscle-specific dystroglycan interactome reveals the role of Hippo signaling in muscular dystrophy and age-dependent muscle atrophy. BMC Med. 18, 8 (2020). https://doi.org/10.1186/s12916-019-1478-3</ref-fulltext>
<ce:source-text>Yatsenko, A.S., Kucherenko, M.M., Xie, Y., et al.: Profiling of the muscle-specific dystroglycan interactome reveals the role of Hippo signaling in muscular dystrophy and age-dependent muscle atrophy. BMC Med. 18, 8 (2020). https://doi.org/10.1186/s12916-019-1478-3</ce:source-text>
</reference>
<reference seq="246">
<ref-info>
<ref-title>
<ref-titletext-english>Ca2+−calmodulin binds to the carboxyl-terminal domain of dystrophin</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>J.T.</ce:initials>
<ce:surname>Anderson</ce:surname>
<ce:given-name>J.T.</ce:given-name>
</author>
<author seq="">
<ce:initials>R.P.</ce:initials>
<ce:surname>Rogers</ce:surname>
<ce:given-name>R.P.</ce:given-name>
</author>
<author seq="">
<ce:initials>H.W.</ce:initials>
<ce:surname>Jarrett</ce:surname>
<ce:given-name>H.W.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Biol. Chem</ref-sourcetitle>
<ref-publicationyear first="1996"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1074/jbc.271.12.6605</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Anderson, J.T., Rogers, R.P., Jarrett, H.W.: Ca2+−calmodulin binds to the carboxyl-terminal domain of dystrophin. J. Biol. Chem. (1996). https://doi.org/10.1074/jbc.271.12.6605</ref-fulltext>
<ce:source-text>Anderson, J.T., Rogers, R.P., Jarrett, H.W.: Ca2+−calmodulin binds to the carboxyl-terminal domain of dystrophin. J. Biol. Chem. (1996). https://doi.org/10.1074/jbc.271.12.6605</ce:source-text>
</reference>
<reference seq="247">
<ref-info>
<ref-title>
<ref-titletext-english>Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>Y.</ce:initials>
<ce:surname>Lai</ce:surname>
</author>
<author seq="">
<ce:initials>G.D.</ce:initials>
<ce:surname>Thomas</ce:surname>
<ce:given-name>G.D.</ce:given-name>
</author>
<author seq="">
<ce:initials>Y.</ce:initials>
<ce:surname>Yue</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Investig</ref-sourcetitle>
<ref-publicationyear first="2009"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1172/JCI36612</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Lai, Y., Thomas, G.D., Yue, Y., et al.: Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy. J. Clin. Investig. (2009). https://doi.org/10.1172/JCI36612</ref-fulltext>
<ce:source-text>Lai, Y., Thomas, G.D., Yue, Y., et al.: Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy. J. Clin. Investig. (2009). https://doi.org/10.1172/JCI36612</ce:source-text>
</reference>
<reference seq="248">
<ref-info>
<ref-title>
<ref-titletext-english>Mouse α1-syntrophin binding to Grb2: Further evidence of a role for syntrophin in cell signaling</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>S.A.</ce:initials>
<ce:surname>Oak</ce:surname>
<ce:given-name>S.A.</ce:given-name>
</author>
<author seq="">
<ce:initials>K.</ce:initials>
<ce:surname>Russo</ce:surname>
</author>
<author seq="">
<ce:initials>T.C.</ce:initials>
<ce:surname>Petrucci</ce:surname>
<ce:given-name>T.C.</ce:given-name>
</author>
<author seq="">
<ce:initials>H.W.</ce:initials>
<ce:surname>Jarrett</ce:surname>
<ce:given-name>H.W.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Biochemistry</ref-sourcetitle>
<ref-publicationyear first="2001"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1021/bi010490n</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Oak, S.A., Russo, K., Petrucci, T.C., Jarrett, H.W.: Mouse α1-syntrophin binding to Grb2: further evidence of a role for syntrophin in cell signaling. Biochemistry. (2001). https://doi.org/10.1021/bi010490n</ref-fulltext>
<ce:source-text>Oak, S.A., Russo, K., Petrucci, T.C., Jarrett, H.W.: Mouse α1-syntrophin binding to Grb2: further evidence of a role for syntrophin in cell signaling. Biochemistry. (2001). https://doi.org/10.1021/bi010490n</ce:source-text>
</reference>
<reference seq="249">
<ref-info>
<ref-title>
<ref-titletext-english>SH3 domain-mediated interaction of dystroglycan and Grb2</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>B.</ce:initials>
<ce:surname>Yang</ce:surname>
</author>
<author seq="">
<ce:initials>D.</ce:initials>
<ce:surname>Jung</ce:surname>
</author>
<author seq="">
<ce:initials>D.</ce:initials>
<ce:surname>Motto</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Biol. Chem</ref-sourcetitle>
<ref-publicationyear first="1995"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1074/jbc.270.20.11711</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Yang, B., Jung, D., Motto, D., et al.: SH3 domain-mediated interaction of dystroglycan and Grb2. J. Biol. Chem. (1995). https://doi.org/10.1074/jbc.270.20.11711</ref-fulltext>
<ce:source-text>Yang, B., Jung, D., Motto, D., et al.: SH3 domain-mediated interaction of dystroglycan and Grb2. J. Biol. Chem. (1995). https://doi.org/10.1074/jbc.270.20.11711</ce:source-text>
</reference>
<reference seq="250">
<ref-info>
<ref-title>
<ref-titletext-english>Inhibition of dystroglycan binding to laminin disrupts the PI3K/AKT pathway and survival signaling in muscle cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>K.J.</ce:initials>
<ce:surname>Langenbach</ce:surname>
<ce:given-name>K.J.</ce:given-name>
</author>
<author seq="">
<ce:initials>T.A.</ce:initials>
<ce:surname>Rando</ce:surname>
<ce:given-name>T.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Muscle Nerve</ref-sourcetitle>
<ref-publicationyear first="2002"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1002/mus.10258</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Langenbach, K.J., Rando, T.A.: Inhibition of dystroglycan binding to laminin disrupts the PI3K/AKT pathway and survival signaling in muscle cells. Muscle Nerve. (2002). https://doi.org/10.1002/mus.10258</ref-fulltext>
<ce:source-text>Langenbach, K.J., Rando, T.A.: Inhibition of dystroglycan binding to laminin disrupts the PI3K/AKT pathway and survival signaling in muscle cells. Muscle Nerve. (2002). https://doi.org/10.1002/mus.10258</ce:source-text>
</reference>
<reference seq="251">
<ref-info>
<ref-title>
<ref-titletext-english>Trim32 reduces PI3K-Akt-FoxO signaling in muscle atrophy by promoting plakoglobin-PI3K dissociation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>S.</ce:initials>
<ce:surname>Cohen</ce:surname>
</author>
<author seq="">
<ce:initials>D.</ce:initials>
<ce:surname>Lee</ce:surname>
</author>
<author seq="">
<ce:initials>B.</ce:initials>
<ce:surname>Zhai</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Cell Biol</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>204</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>747</first-page>
<last-page>758</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1083/jcb.201304167</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Cohen, S., Lee, D., Zhai, B., et al.: Trim32 reduces PI3K-Akt-FoxO signaling in muscle atrophy by promoting plakoglobin-PI3K dissociation. J. Cell Biol. 204, 747–758 (2014). https://doi.org/10.1083/jcb.201304167</ref-fulltext>
<ce:source-text>Cohen, S., Lee, D., Zhai, B., et al.: Trim32 reduces PI3K-Akt-FoxO signaling in muscle atrophy by promoting plakoglobin-PI3K dissociation. J. Cell Biol. 204, 747–758 (2014). https://doi.org/10.1083/jcb.201304167</ce:source-text>
</reference>
<reference seq="252">
<ref-info>
<ref-title>
<ref-titletext-english>Muscular dystrophies at different ages: Metabolic and endocrine alterations</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>O.D.R.</ce:initials>
<ce:surname>Cruz Guzmán</ce:surname>
<ce:given-name>O.D.R.</ce:given-name>
</author>
<author seq="">
<ce:initials>A.L.</ce:initials>
<ce:surname>Chávez García</ce:surname>
<ce:given-name>A.L.</ce:given-name>
</author>
<author seq="">
<ce:initials>M.</ce:initials>
<ce:surname>Rodríguez-Cruz</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Endocrinol</ref-sourcetitle>
<ref-publicationyear first="2012"/>
</ref-info>
<ref-fulltext>Cruz Guzmán, O.D.R., Chávez García, A.L., Rodríguez-Cruz, M.: Muscular dystrophies at different ages: metabolic and endocrine alterations. Int. J. Endocrinol. (2012)</ref-fulltext>
<ce:source-text>Cruz Guzmán, O.D.R., Chávez García, A.L., Rodríguez-Cruz, M.: Muscular dystrophies at different ages: metabolic and endocrine alterations. Int. J. Endocrinol. (2012)</ce:source-text>
</reference>
<reference seq="253">
<ref-info>
<ref-title>
<ref-titletext-english>Dissociation of insulin resistance and decreased insulin receptor binding in duchenne muscular dystrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>G.R.</ce:initials>
<ce:surname>Freidenberg</ce:surname>
<ce:given-name>G.R.</ce:given-name>
</author>
<author seq="">
<ce:initials>J.M.</ce:initials>
<ce:surname>Olefsky</ce:surname>
<ce:given-name>J.M.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Endocrinol. Metab</ref-sourcetitle>
<ref-publicationyear first="1985"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1210/jcem-60-2-320</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Freidenberg, G.R., Olefsky, J.M.: Dissociation of insulin resistance and decreased insulin receptor binding in duchenne muscular dystrophy. J. Clin. Endocrinol. Metab. (1985). https://doi.org/10.1210/jcem-60-2-320</ref-fulltext>
<ce:source-text>Freidenberg, G.R., Olefsky, J.M.: Dissociation of insulin resistance and decreased insulin receptor binding in duchenne muscular dystrophy. J. Clin. Endocrinol. Metab. (1985). https://doi.org/10.1210/jcem-60-2-320</ce:source-text>
</reference>
<reference seq="254">
<ref-info>
<ref-title>
<ref-titletext-english>Evidence of insulin resistance and other metabolic alterations in boys with Duchenne or becker muscular dystrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>M.</ce:initials>
<ce:surname>Rodriguez-Cruz</ce:surname>
</author>
<author seq="">
<ce:initials>R.</ce:initials>
<ce:surname>Sanchez</ce:surname>
</author>
<author seq="">
<ce:initials>R.E.</ce:initials>
<ce:surname>Escobar</ce:surname>
<ce:given-name>R.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Endocrinol</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1155/2015/867273</ce:e-address>
</ref-website>
<ref-text>867273</ref-text>
</ref-info>
<ref-fulltext>Rodriguez-Cruz, M., Sanchez, R., Escobar, R.E., et al.: Evidence of insulin resistance and other metabolic alterations in boys with Duchenne or becker muscular dystrophy. Int. J. Endocrinol. 2015, 867273 (2015). https://doi.org/10.1155/2015/867273</ref-fulltext>
<ce:source-text>Rodriguez-Cruz, M., Sanchez, R., Escobar, R.E., et al.: Evidence of insulin resistance and other metabolic alterations in boys with Duchenne or becker muscular dystrophy. Int. J. Endocrinol. 2015, 867273 (2015). https://doi.org/10.1155/2015/867273</ce:source-text>
</reference>
<reference seq="255">
<ref-info>
<ref-title>
<ref-titletext-english>iLIR database: A web resource for LIR motif-containing proteins in eukaryotes</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>A.C.</ce:initials>
<ce:surname>Jacomin</ce:surname>
<ce:given-name>A.C.</ce:given-name>
</author>
<author seq="">
<ce:initials>S.</ce:initials>
<ce:surname>Samavedam</ce:surname>
</author>
<author seq="">
<ce:initials>V.</ce:initials>
<ce:surname>Promponas</ce:surname>
</author>
<author seq="">
<ce:initials>I.P.</ce:initials>
<ce:surname>Nezis</ce:surname>
<ce:given-name>I.P.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Autophagy</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1945</first-page>
<last-page>1953</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1080/15548627.2016.1207016</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Jacomin, A.C., Samavedam, S., Promponas, V., Nezis, I.P.: iLIR database: A web resource for LIR motif-containing proteins in eukaryotes. Autophagy. 12, 1945–1953 (2016). https://doi.org/10.1080/15548627.2016.1207016</ref-fulltext>
<ce:source-text>Jacomin, A.C., Samavedam, S., Promponas, V., Nezis, I.P.: iLIR database: A web resource for LIR motif-containing proteins in eukaryotes. Autophagy. 12, 1945–1953 (2016). https://doi.org/10.1080/15548627.2016.1207016</ce:source-text>
</reference>
<reference seq="256">
<ref-info>
<ref-title>
<ref-titletext-english>Skeletal muscle hypertrophy and atrophy signaling pathways</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>D.J.</ce:initials>
<ce:surname>Glass</ce:surname>
<ce:given-name>D.J.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Biochem. Cell Biol</ref-sourcetitle>
<ref-publicationyear first="2005"/>
<volisspag>
<volume-issue-number>
<vol-first>37</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1974</first-page>
<last-page>1984</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.biocel.2005.04.018</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Glass, D.J.: Skeletal muscle hypertrophy and atrophy signaling pathways. Int. J. Biochem. Cell Biol. 37, 1974–1984 (2005). https://doi.org/10.1016/j.biocel.2005.04.018</ref-fulltext>
<ce:source-text>Glass, D.J.: Skeletal muscle hypertrophy and atrophy signaling pathways. Int. J. Biochem. Cell Biol. 37, 1974–1984 (2005). https://doi.org/10.1016/j.biocel.2005.04.018</ce:source-text>
</reference>
<reference seq="257">
<ref-info>
<ref-title>
<ref-titletext-english>IGF-I stimulates muscle growth by suppressing protein breakdown and expression of atrophy-related ubiquitin ligases, atrogin-1 and MuRF1</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>J.M.</ce:initials>
<ce:surname>Sacheck</ce:surname>
<ce:given-name>J.M.</ce:given-name>
</author>
<author seq="">
<ce:initials>A.</ce:initials>
<ce:surname>Ohtsuka</ce:surname>
</author>
<author seq="">
<ce:initials>S.C.</ce:initials>
<ce:surname>McLary</ce:surname>
<ce:given-name>S.C.</ce:given-name>
</author>
<author seq="">
<ce:initials>A.L.</ce:initials>
<ce:surname>Goldberg</ce:surname>
<ce:given-name>A.L.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Am. J. Phys. Endocrinol. Metab</ref-sourcetitle>
<ref-publicationyear first="2004"/>
<volisspag>
<volume-issue-number>
<vol-first>287</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>E591</first-page>
<last-page>E601</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1152/ajpendo.00073.2004</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Sacheck, J.M., Ohtsuka, A., McLary, S.C., Goldberg, A.L.: IGF-I stimulates muscle growth by suppressing protein breakdown and expression of atrophy-related ubiquitin ligases, atrogin-1 and MuRF1. Am. J. Phys. Endocrinol. Metab. 287, E591–E601 (2004). https://doi.org/10.1152/ajpendo.00073.2004</ref-fulltext>
<ce:source-text>Sacheck, J.M., Ohtsuka, A., McLary, S.C., Goldberg, A.L.: IGF-I stimulates muscle growth by suppressing protein breakdown and expression of atrophy-related ubiquitin ligases, atrogin-1 and MuRF1. Am. J. Phys. Endocrinol. Metab. 287, E591–E601 (2004). https://doi.org/10.1152/ajpendo.00073.2004</ce:source-text>
</reference>
<reference seq="258">
<ref-info>
<ref-title>
<ref-titletext-english>The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>T.N.</ce:initials>
<ce:surname>Stitt</ce:surname>
<ce:given-name>T.N.</ce:given-name>
</author>
<author seq="">
<ce:initials>D.</ce:initials>
<ce:surname>Drujan</ce:surname>
</author>
<author seq="">
<ce:initials>B.A.</ce:initials>
<ce:surname>Clarke</ce:surname>
<ce:given-name>B.A.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>Mol. Cell</ref-sourcetitle>
<ref-publicationyear first="2004"/>
<volisspag>
<volume-issue-number>
<vol-first>14</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>395</first-page>
<last-page>403</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Stitt, T.N., Drujan, D., Clarke, B.A., et al.: The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol. Cell. 14, 395–403 (2004)</ref-fulltext>
<ce:source-text>Stitt, T.N., Drujan, D., Clarke, B.A., et al.: The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol. Cell. 14, 395–403 (2004)</ce:source-text>
</reference>
<reference seq="259">
<ref-info>
<ref-title>
<ref-titletext-english>The LIR motif – crucial for selective autophagy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>Å.B.</ce:initials>
<ce:surname>Birgisdottir</ce:surname>
<ce:given-name>Å.B.</ce:given-name>
</author>
<author seq="">
<ce:initials>T.</ce:initials>
<ce:surname>Lamark</ce:surname>
</author>
<author seq="">
<ce:initials>T.</ce:initials>
<ce:surname>Johansen</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Cell Sci</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1242/jcs.126128</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Birgisdottir, Å.B., Lamark, T., Johansen, T., et al.: The LIR motif – crucial for selective autophagy. J. Cell Sci. (2013). https://doi.org/10.1242/jcs.126128</ref-fulltext>
<ce:source-text>Birgisdottir, Å.B., Lamark, T., Johansen, T., et al.: The LIR motif – crucial for selective autophagy. J. Cell Sci. (2013). https://doi.org/10.1242/jcs.126128</ce:source-text>
</reference>
<reference seq="260">
<ref-info>
<ref-title>
<ref-titletext-english>Clinical trials of cancer cachexia therapy, now and hereafter</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>V.E.</ce:initials>
<ce:surname>Baracos</ce:surname>
<ce:given-name>V.E.</ce:given-name>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Oncol</ref-sourcetitle>
<ref-publicationyear first="2013"/>
</ref-info>
<ref-fulltext>Baracos, V.E.: Clinical trials of cancer cachexia therapy, now and hereafter. J. Clin. Oncol. (2013)</ref-fulltext>
<ce:source-text>Baracos, V.E.: Clinical trials of cancer cachexia therapy, now and hereafter. J. Clin. Oncol. (2013)</ce:source-text>
</reference>
<reference seq="261">
<ref-info>
<ref-title>
<ref-titletext-english>Molecular pathways leading to loss of skeletal muscle mass in cancer cachexia – can findings from animal models be translated to humans?</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="">
<ce:initials>T.C.</ce:initials>
<ce:surname>Mueller</ce:surname>
<ce:given-name>T.C.</ce:given-name>
</author>
<author seq="">
<ce:initials>J.</ce:initials>
<ce:surname>Bachmann</ce:surname>
</author>
<author seq="">
<ce:initials>O.</ce:initials>
<ce:surname>Prokopchuk</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>BMC Cancer</ref-sourcetitle>
<ref-publicationyear first="2016"/>
</ref-info>
<ref-fulltext>Mueller, T.C., Bachmann, J., Prokopchuk, O., et al.: Molecular pathways leading to loss of skeletal muscle mass in cancer cachexia – can findings from animal models be translated to humans? BMC Cancer. (2016)</ref-fulltext>
<ce:source-text>Mueller, T.C., Bachmann, J., Prokopchuk, O., et al.: Molecular pathways leading to loss of skeletal muscle mass in cancer cachexia – can findings from animal models be translated to humans? BMC Cancer. (2016)</ce:source-text>
</reference>